,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,7,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell line,Confirmatory,,
4,9,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
5,11,1,1,,67636,6167,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-18 Non-Small Cell Lung cell line,Confirmatory,,
6,13,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
7,15,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
8,17,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
9,19,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
10,21,1,1,,67636,6167,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
11,23,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
12,25,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
13,27,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
14,29,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
15,31,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
16,33,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
17,35,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
18,37,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
19,39,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
20,41,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the PC-3 Prostate cell line,Confirmatory,,
21,43,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DU-145 Prostate cell line,Confirmatory,,
22,45,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
23,47,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
24,49,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
25,51,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
26,53,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
27,55,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
28,57,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
29,59,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
30,61,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 273 Small Cell Lung cell line,Confirmatory,,
31,63,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
32,65,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
33,67,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
34,69,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
35,71,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
36,73,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
37,75,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
38,77,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCC-2998 Colon cell line,Confirmatory,,
39,79,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
40,81,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
41,83,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MCF7 Breast cell line,Confirmatory,,
42,85,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-435 Breast cell line,Confirmatory,,
43,87,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-N Breast cell line,Confirmatory,,
44,89,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the BT-549 Breast cell line,Confirmatory,,
45,91,1,1,,67636,6167,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the T-47D Breast cell line,Confirmatory,,
46,93,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI/ADR-RES Breast cell line,Confirmatory,,
47,95,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MDA-MB-231/ATCC Breast cell line,Confirmatory,,
48,99,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
49,101,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
50,103,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
51,105,1,1,,67636,6167,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
52,107,1,1,,67636,6167,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
53,109,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
54,111,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388 Leukemia cell line,Confirmatory,,
55,113,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
56,115,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
57,117,1,1,,67636,6167,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the P388/ADR Leukemia cell line,Confirmatory,,
58,119,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
59,121,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
60,123,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
61,125,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
62,127,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12K1 Renal cell line,Confirmatory,,
63,129,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line,Confirmatory,,
64,131,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
65,133,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF 393 Renal cell line,Confirmatory,,
66,135,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the RXF-631 Renal cell line,Confirmatory,,
67,137,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
68,139,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
69,141,1,1,,67636,6167,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
70,143,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
71,145,1,1,,67636,6167,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
72,155,1,1,,67636,6167,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
73,157,1,1,,67636,6167,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
74,161,1,1,,67636,6167,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
75,165,1,1,,67636,6167,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
76,167,1,1,,67636,6167,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
77,175,1,1,,67636,6167,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
78,179,1,1,,67636,6167,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
79,184,1,1,,67636,6167,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-6 (intraperitoneal) in BALB/cJ mice,Other,,
80,186,1,1,,67636,6167,Unspecified,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Nontumored Animals (Toxicity Test) in B6D2F1 (BDF1) mice,Other,,
81,192,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
82,194,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
83,200,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
84,206,1,1,,67636,6167,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
85,212,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
86,216,1,1,,67636,6167,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P288 Lymphocytic Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
87,220,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
88,222,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Ependymoblastoma (intracerebral) in C57BL/6 mice,Other,,
89,224,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P335 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
90,230,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphosarcoma Gardner 6C3HED (intraperitoneal) in C3H/He mice,Other,,
91,246,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1081 Chloroleukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
92,248,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
93,256,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
94,264,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
95,270,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
96,274,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6D2F1 (BDF1) mice,Other,,
97,276,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lewis Lung Carcinoma (intravenous) in B6C3F1 mice,Other,,
98,280,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Amelanotic Melanoma (LOX) (intraperitoneal) in NU/NU BALB/C (nude) mice,Other,,
99,290,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in unknown mice,Other,,
100,292,1,1,,67636,6167,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma M5076 (intraperitoneal) in B6C3F1 mice,Other,,
101,296,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
102,298,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
103,300,1,1,,67636,6167,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in unknown mice,Other,,
104,302,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Madison 109 Lung Carcinoma (intramuscular) in BALB/CM mice,Other,,
105,306,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia resistant to Methyl-GAG; NSC 32946 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
106,314,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1534 Leukemia (intraperitoneal) in DBA/2 mice,Other,,
107,316,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1534 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
108,328,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
109,330,1,1,,67636,6167,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
110,332,1,1,,67636,6167,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  ADJ-PC-20 Plasma Cell (subcutaneous) in unknown mice,Other,,
111,377,1,3,,10321652,6167,Inactive,42741659.0,5243.0,,,MDR-1,Other,,
112,410,1,5,,11114044,6167,Inconclusive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
113,411,2,1,,11114044,6167,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
114,421,1,3,,17389095,6167,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
115,421,1,3,,17389096,6167,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
116,422,1,5,,17404873,6167,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
117,426,1,2,,17389095,6167,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
118,426,1,2,,17389096,6167,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
119,427,1,1,,17389095,6167,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
120,427,1,1,,17389096,6167,Inconclusive,,,,,Cell Viability - Hek293,Confirmatory,,
121,429,1,5,,17404873,6167,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
122,429,1,5,,17404873,6167,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
123,433,1,1,,17389095,6167,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
124,433,1,1,,17389096,6167,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
125,434,1,2,,17389095,6167,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
126,434,1,2,,17389096,6167,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
127,435,1,2,,17389095,6167,Active,,,,,Cell Viability - SK-N-SH,Confirmatory,,
128,435,1,2,,17389096,6167,Active,,,,,Cell Viability - SK-N-SH,Confirmatory,,
129,436,2,1,,17404873,6167,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
130,445,3,1,,11114044,6167,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
131,445,3,1,,17389095,6167,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
132,445,3,1,,17389096,6167,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
133,447,1,1,,11114044,6167,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
134,448,1,2,,11114044,6167,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
135,450,1,2,,11114044,6167,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
136,451,1,2,,11114044,6167,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
137,526,1,1,,11114044,6167,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
138,530,1,1,,11114044,6167,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
139,530,1,1,,17389095,6167,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
140,530,1,1,,17389096,6167,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
141,540,1,1,,17389095,6167,Inconclusive,,,,,Cell Viability - N2a,Confirmatory,,
142,540,1,1,,17389096,6167,Active,,,,,Cell Viability - N2a,Confirmatory,,
143,541,1,1,,17389095,6167,Inactive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
144,541,1,1,,17389096,6167,Inconclusive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
145,542,1,1,,17389095,6167,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
146,542,1,1,,17389096,6167,Inconclusive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
147,543,1,1,,17389095,6167,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
148,543,1,1,,17389096,6167,Inconclusive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
149,544,2,1,,17389095,6167,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
150,544,2,1,,17389096,6167,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
151,545,1,1,,17389095,6167,Active,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
152,545,1,1,,17389096,6167,Active,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
153,546,1,1,,17389095,6167,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
154,546,1,1,,17389096,6167,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
155,547,1,4,,17404873,6167,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
156,584,1,3,,11114044,6167,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
157,584,1,3,,17389095,6167,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
158,584,1,3,,17389096,6167,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
159,585,1,4,,11114044,6167,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
160,585,1,4,,17389095,6167,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
161,585,1,4,,17389096,6167,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
162,595,1,3,,11114044,6167,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
163,595,1,3,,17389095,6167,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
164,595,1,3,,17389096,6167,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
165,596,1,2,,11114044,6167,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
166,596,1,2,,17389095,6167,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
167,596,1,2,,17389096,6167,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
168,597,1,3,,11114044,6167,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
169,603,1,2,,11114044,6167,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
170,603,1,2,,17389095,6167,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
171,603,1,2,,17389096,6167,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
172,605,1,2,,11114044,6167,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
173,605,1,2,,17389095,6167,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
174,605,1,2,,17389096,6167,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
175,607,1,3,,11114044,6167,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
176,608,1,6,,11537652,6167,Inactive,17149836.0,2280.0,,,NMR Based Screening Assay for FKBP12,Other,,
177,654,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
178,654,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
179,655,1,1,,17389095,6167,Active,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
180,655,1,1,,17389096,6167,Active,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
181,656,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
182,656,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
183,657,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
184,657,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
185,658,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
186,658,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
187,659,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
188,659,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
189,660,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
190,660,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
191,661,1,1,,17389095,6167,Active,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
192,661,1,1,,17389096,6167,Active,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
193,662,1,1,,11114044,6167,Active,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
194,662,1,1,,17389095,6167,Active,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
195,662,1,1,,17389096,6167,Active,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
196,663,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
197,663,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
198,664,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
199,664,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
200,665,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
201,665,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
202,666,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
203,666,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
204,667,1,1,,17389095,6167,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
205,667,1,1,,17389096,6167,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
206,694,1,1,,17404873,6167,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
207,732,1,2,,17404873,6167,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
208,875,1,2,,11114044,6167,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
209,875,1,2,,17389095,6167,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
210,875,1,2,,17389096,6167,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
211,879,1,2,,11114044,6167,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
212,879,1,2,,11114044,6167,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
213,880,2,1,,11114044,6167,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
214,880,2,1,,11114044,6167,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
215,880,2,1,,17389095,6167,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
216,880,2,1,,17389095,6167,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
217,880,2,1,,17389096,6167,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
218,880,2,1,,17389096,6167,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
219,880,2,1,,26752175,6167,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
220,880,2,1,,26752175,6167,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
221,880,2,1,,26752176,6167,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
222,880,2,1,,26752176,6167,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
223,880,2,1,,50104821,6167,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
224,880,2,1,,50104821,6167,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
225,881,2,2,,11114044,6167,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
226,881,2,2,,17389095,6167,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
227,881,2,2,,17389096,6167,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
228,881,2,2,,26752175,6167,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
229,883,1,3,,11114044,6167,Active,13699818.0,1559.0,3.1623,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
230,884,1,2,,11114044,6167,Inconclusive,13435386.0,1576.0,2.5119,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
231,884,1,2,,17389095,6167,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
232,884,1,2,,17389096,6167,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
233,885,1,2,,11114044,6167,Inactive,13435386.0,1576.0,2.5119,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
234,885,1,2,,17389095,6167,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
235,885,1,2,,17389096,6167,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
236,886,1,2,,11114044,6167,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
237,886,1,2,,11114044,6167,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
238,886,1,2,,17389095,6167,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
239,886,1,2,,17389095,6167,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
240,886,1,2,,17389096,6167,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
241,886,1,2,,17389096,6167,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
242,887,1,2,,11114044,6167,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
243,887,1,2,,17389095,6167,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
244,887,1,2,,17389096,6167,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
245,889,1,3,,11114044,6167,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
246,889,1,3,,17389095,6167,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
247,889,1,3,,17389096,6167,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
248,891,1,2,,11114044,6167,Active,40805836.0,1565.0,0.7943,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
249,892,1,2,,11114044,6167,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
250,892,1,2,,17389095,6167,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
251,892,1,2,,17389096,6167,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
252,893,1,2,,11114044,6167,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
253,893,1,2,,11114044,6167,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
254,893,1,2,,17389095,6167,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
255,893,1,2,,17389095,6167,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
256,893,1,2,,17389096,6167,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
257,893,1,2,,17389096,6167,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
258,894,2,1,,11114044,6167,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
259,894,2,1,,17389095,6167,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
260,894,2,1,,17389096,6167,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
261,894,2,1,,26752175,6167,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
262,894,2,1,,50104821,6167,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
263,895,1,2,,11114044,6167,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
264,899,1,2,,11114044,6167,Active,4503219.0,1557.0,12.5893,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
265,900,1,3,,11114044,6167,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
266,900,1,3,,17389095,6167,Inconclusive,15431328.0,834.0,39.8107,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
267,900,1,3,,17389096,6167,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
268,901,1,2,,11114044,6167,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
269,902,1,2,,11114044,6167,Inconclusive,120407068.0,7157.0,1.5849,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
270,902,1,2,,17389095,6167,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
271,902,1,2,,17389096,6167,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
272,905,1,2,,11114044,6167,Inactive,116241283.0,1387.0,,Potency,Cell Viability - CRE-beta lactamase CHO cell - 24 hr assay,Confirmatory,,
273,906,1,2,,11114044,6167,Inactive,116241283.0,1387.0,,Potency,Cell Viability - CRE-beta lactamase CHO cell - 40 hr assay,Confirmatory,,
274,907,1,2,,11114044,6167,Inconclusive,116241283.0,1387.0,5.0119,Potency,Confirmation Concentration-Response Assay for Cell signaling CRE-BLA (Fsk stim) - HEK293 CREB Luciferase,Confirmatory,,
275,912,1,2,,11114044,6167,Inconclusive,21392848.0,,31.6228,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
276,912,1,2,,17389095,6167,Inconclusive,21392848.0,,0.1,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
277,912,1,2,,17389096,6167,Inconclusive,21392848.0,,0.0501,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
278,916,1,2,,11114044,6167,Active,116241283.0,1387.0,5.0119,Potency,Confirmation Concentration-Response Assay for Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
279,917,1,3,,11114044,6167,Inconclusive,120660324.0,7066.0,0.5012,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
280,918,1,3,,11114044,6167,Inconclusive,120660324.0,7066.0,0.5012,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
281,921,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-001,Confirmatory,,
282,921,1,2,,17389096,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-001,Confirmatory,,
283,923,1,2,,11114044,6167,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
284,923,1,2,,17389095,6167,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
285,923,1,2,,17389096,6167,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
286,924,1,2,,11114044,6167,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
287,924,1,2,,17389095,6167,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
288,924,1,2,,17389096,6167,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
289,925,1,2,,17389095,6167,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
290,925,1,2,,17389096,6167,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
291,926,1,2,,11114044,6167,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
292,926,1,2,,17389095,6167,Inconclusive,38016895.0,7253.0,15.8489,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
293,926,1,2,,17389096,6167,Inconclusive,38016895.0,7253.0,1.9953,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
294,927,1,3,,11114044,6167,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
295,928,1,2,,11114044,6167,Inactive,21620132.0,4790.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
296,938,1,2,,11114044,6167,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
297,938,1,2,,17389095,6167,Inactive,38016895.0,7253.0,15.8489,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
298,938,1,2,,17389096,6167,Inactive,38016895.0,7253.0,1.9953,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
299,940,1,2,,17404873,6167,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
300,940,1,2,,26611671,6167,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
301,943,1,2,,11114044,6167,Inconclusive,18249941.0,25229.0,0.8913,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
302,944,1,2,,11114044,6167,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
303,945,1,4,,11114044,6167,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
304,946,1,2,,17389095,6167,Active,,,0.0631,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
305,946,1,2,,17389096,6167,Active,,,0.1,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
306,947,1,2,,17389095,6167,Inconclusive,,,0.1,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
307,947,1,2,,17389096,6167,Inconclusive,,,0.0251,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
308,948,1,2,,17389095,6167,Inconclusive,,,0.0794,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
309,948,1,2,,17389096,6167,Inconclusive,,,0.0794,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
310,954,1,2,,11114044,6167,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
311,955,1,2,,17389095,6167,Inconclusive,,,0.1259,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
312,955,1,2,,17389096,6167,Inconclusive,,,0.1,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
313,957,1,2,,11114044,6167,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
314,958,1,2,,11114044,6167,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
315,959,1,4,,11114044,6167,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
316,960,1,2,,17389095,6167,Active,,,0.0501,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
317,960,1,2,,17389096,6167,Active,,,0.0501,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
318,961,1,2,,17389095,6167,Active,,,0.631,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
319,961,1,2,,17389096,6167,Inconclusive,,,0.5012,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
320,962,1,2,,17389095,6167,Inconclusive,,,0.0631,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
321,962,1,2,,17389096,6167,Inconclusive,,,0.0794,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
322,963,1,2,,17389095,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
323,963,1,2,,17389096,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
324,964,1,2,,17389095,6167,Active,,,0.02,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
325,964,1,2,,17389096,6167,Inconclusive,,,0.02,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
326,965,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-003,Confirmatory,,
327,965,1,2,,17389096,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-003,Confirmatory,,
328,966,1,2,,17389095,6167,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
329,966,1,2,,17389096,6167,Inconclusive,,,0.1,Potency,Cell Viability - LYMP2-004,Confirmatory,,
330,967,1,2,,17389095,6167,Inconclusive,,,0.0126,Potency,Cell Viability - LYMP2-005,Confirmatory,,
331,967,1,2,,17389096,6167,Inconclusive,,,0.01,Potency,Cell Viability - LYMP2-005,Confirmatory,,
332,968,1,2,,17389095,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-009,Confirmatory,,
333,968,1,2,,17389096,6167,Inconclusive,,,0.1,Potency,Cell Viability - LYMP2-009,Confirmatory,,
334,969,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-011,Confirmatory,,
335,969,1,2,,17389096,6167,Inconclusive,,,0.0631,Potency,Cell Viability - LYMP2-011,Confirmatory,,
336,970,1,2,,17389095,6167,Inconclusive,,,0.1995,Potency,Cell Viability - LYMP2-013,Confirmatory,,
337,970,1,2,,17389096,6167,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
338,971,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-015,Confirmatory,,
339,971,1,2,,17389096,6167,Inconclusive,,,0.0316,Potency,Cell Viability - LYMP2-015,Confirmatory,,
340,972,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-017,Confirmatory,,
341,972,1,2,,17389096,6167,Inconclusive,,,0.0631,Potency,Cell Viability - LYMP2-017,Confirmatory,,
342,973,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-019,Confirmatory,,
343,973,1,2,,17389096,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-019,Confirmatory,,
344,974,1,2,,17389095,6167,Inconclusive,,,0.1259,Potency,Cell Viability - LYMP2-021,Confirmatory,,
345,974,1,2,,17389096,6167,Inconclusive,,,0.1,Potency,Cell Viability - LYMP2-021,Confirmatory,,
346,975,1,2,,17389095,6167,Inconclusive,,,0.0631,Potency,Cell Viability - LYMP2-023,Confirmatory,,
347,975,1,2,,17389096,6167,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
348,976,1,2,,17389095,6167,Inconclusive,,,100.0,Potency,Cell Viability - LYMP2-025,Confirmatory,,
349,976,1,2,,17389096,6167,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
350,977,1,2,,17389095,6167,Inconclusive,,,0.0316,Potency,Cell Viability - LYMP2-002,Confirmatory,,
351,977,1,2,,17389096,6167,Inconclusive,,,0.02,Potency,Cell Viability - LYMP2-002,Confirmatory,,
352,978,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-006,Confirmatory,,
353,978,1,2,,17389096,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-006,Confirmatory,,
354,979,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-007,Confirmatory,,
355,979,1,2,,17389096,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-007,Confirmatory,,
356,980,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-008,Confirmatory,,
357,980,1,2,,17389096,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-008,Confirmatory,,
358,981,1,2,,17389095,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-010,Confirmatory,,
359,981,1,2,,17389096,6167,Inconclusive,,,0.0631,Potency,Cell Viability - LYMP2-010,Confirmatory,,
360,982,1,2,,17389095,6167,Inconclusive,,,0.0251,Potency,Cell Viability - LYMP2-012,Confirmatory,,
361,982,1,2,,17389096,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-012,Confirmatory,,
362,983,1,2,,17389095,6167,Inconclusive,,,0.0794,Potency,Cell Viability - LYMP2-014,Confirmatory,,
363,983,1,2,,17389096,6167,Inconclusive,,,0.0631,Potency,Cell Viability - LYMP2-014,Confirmatory,,
364,984,1,2,,17389095,6167,Inconclusive,,,0.0794,Potency,Cell Viability - LYMP2-016,Confirmatory,,
365,984,1,2,,17389096,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-016,Confirmatory,,
366,985,1,2,,17389095,6167,Inconclusive,,,0.0251,Potency,Cell Viability - LYMP2-018,Confirmatory,,
367,985,1,2,,17389096,6167,Inconclusive,,,0.0316,Potency,Cell Viability - LYMP2-018,Confirmatory,,
368,986,1,2,,17389095,6167,Inconclusive,,,0.0316,Potency,Cell Viability - LYMP2-020,Confirmatory,,
369,986,1,2,,17389096,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-020,Confirmatory,,
370,987,1,2,,17389095,6167,Inconclusive,,,0.0501,Potency,Cell Viability - LYMP2-022,Confirmatory,,
371,987,1,2,,17389096,6167,Inconclusive,,,0.0316,Potency,Cell Viability - LYMP2-022,Confirmatory,,
372,988,1,2,,17389095,6167,Inconclusive,,,0.0398,Potency,Cell Viability - LYMP2-024,Confirmatory,,
373,988,1,2,,17389096,6167,Inconclusive,,,0.0251,Potency,Cell Viability - LYMP2-024,Confirmatory,,
374,989,1,2,,17389095,6167,Inconclusive,,,0.1585,Potency,Cell Viability - LYMP2-026,Confirmatory,,
375,989,1,2,,17389096,6167,Inconclusive,,,0.0316,Potency,Cell Viability - LYMP2-026,Confirmatory,,
376,992,1,3,,11114044,6167,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
377,993,1,2,,17389095,6167,Inconclusive,,,0.0631,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
378,993,1,2,,17389096,6167,Inconclusive,,,0.0631,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
379,994,1,2,,17389095,6167,Active,,,0.0316,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
380,994,1,2,,17389096,6167,Active,,,0.0316,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
381,995,1,2,,11114044,6167,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
382,995,1,2,,17389095,6167,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
383,995,1,2,,17389096,6167,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
384,997,1,2,,11114044,6167,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
385,998,1,2,,11114044,6167,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
386,999,1,1,,46487909,6167,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Cells with a Deletion of the PTEN Tumor Suppressor Using a Diverse Compound Set,Screening,,
387,1004,1,1,,46487909,6167,Inactive,,,,,A Validation Screen to Identify Compounds that Suppress the Growth of Human Colon Tumor Cells Lacking Oncogenic Beta Catenin Expression Using a Diverse Compound Set,Screening,,
388,1030,2,1,,11114044,6167,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
389,1030,2,1,,17389095,6167,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
390,1030,2,1,,17389096,6167,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
391,1030,2,1,,26752175,6167,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
392,1030,2,1,,50104821,6167,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
393,1033,2,2,,11537652,6167,Inactive,216546.0,,,,NMR Based Screening Assay for the substrate binding domain of the chaperone DnaK,Screening,,
394,1332,1,1,,49698458,6167,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
395,1379,1,2,,11114044,6167,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
396,1379,1,2,,26752175,6167,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
397,1379,1,2,,50104821,6167,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
398,1422,1,1,,17404873,6167,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
399,1422,1,1,,26611671,6167,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
400,1452,1,1,,11114044,6167,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
401,1452,1,1,,17389095,6167,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
402,1452,1,1,,17389096,6167,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
403,1452,1,1,,26752175,6167,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
404,1454,1,1,,11114044,6167,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
405,1454,1,1,,50104821,6167,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
406,1457,1,1,,11114044,6167,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
407,1457,1,1,,17389095,6167,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
408,1457,1,1,,17389096,6167,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
409,1457,1,1,,26752175,6167,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
410,1457,1,1,,50104821,6167,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
411,1458,1,1,,17389095,6167,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
412,1458,1,1,,17389096,6167,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
413,1458,1,1,,50104821,6167,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
414,1459,1,1,,50104821,6167,Inconclusive,27436948.0,4000.0,0.0708,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
415,1460,1,3,,11114044,6167,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
416,1460,1,3,,26752175,6167,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
417,1460,1,3,,50104821,6167,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
418,1461,1,2,,50104821,6167,Inconclusive,46395496.0,387129.0,2.5119,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
419,1463,1,1,,11114044,6167,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
420,1463,1,1,,26752175,6167,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
421,1463,1,1,,50104821,6167,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
422,1467,1,3,,11114044,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
423,1467,1,3,,26752175,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
424,1467,1,3,,50104821,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
425,1468,1,1,,11114044,6167,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
426,1468,1,1,,26752175,6167,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
427,1468,1,1,,50104821,6167,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
428,1469,1,1,,11114044,6167,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
429,1469,1,1,,17389095,6167,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
430,1469,1,1,,17389096,6167,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
431,1469,1,1,,26752175,6167,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
432,1469,1,1,,26752176,6167,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
433,1469,1,1,,50104821,6167,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
434,1471,2,1,,11114044,6167,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
435,1471,2,1,,17389095,6167,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
436,1471,2,1,,17389096,6167,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
437,1471,2,1,,26752175,6167,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
438,1471,2,1,,26752176,6167,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
439,1476,2,1,,11114044,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
440,1476,2,1,,17389095,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
441,1476,2,1,,17389096,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
442,1476,2,1,,26752175,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
443,1476,2,1,,50104821,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
444,1477,1,1,,11114044,6167,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
445,1477,1,1,,17389095,6167,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
446,1477,1,1,,17389096,6167,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
447,1477,1,1,,26752175,6167,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
448,1477,1,1,,50104821,6167,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
449,1478,2,1,,11114044,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
450,1478,2,1,,17389095,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
451,1478,2,1,,17389096,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
452,1478,2,1,,26752175,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
453,1478,2,1,,50104821,6167,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
454,1479,1,2,,11114044,6167,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
455,1479,1,2,,17389095,6167,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
456,1479,1,2,,17389096,6167,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
457,1479,1,2,,26752175,6167,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
458,1479,1,2,,26752176,6167,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
459,1479,1,2,,50104821,6167,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
460,1487,1,1,,26752176,6167,Inconclusive,27436948.0,4000.0,0.1259,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
461,1487,1,1,,50104821,6167,Inconclusive,27436948.0,4000.0,0.0089,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
462,1490,2,1,,11114044,6167,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
463,1490,2,1,,26752175,6167,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
464,1490,2,1,,26752176,6167,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
465,1490,2,1,,49718107,6167,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
466,1511,1,3,,49718107,6167,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
467,1519,1,3,,11114044,6167,Inconclusive,,,3.5481,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
468,1519,1,3,,50104821,6167,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
469,1527,1,3,,49718107,6167,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
470,1529,1,1,,49718107,6167,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
471,1530,1,1,,49718107,6167,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
472,1531,1,1,,49718107,6167,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
473,1549,1,2,,11537652,6167,Inactive,89033149.0,,,,NMR Based Screening Assay for Novel Chemotypes against influenza A virus,Other,,
474,1552,1,3,,11537652,6167,Inactive,4507793.0,7334.0,,,NMR assay targeting the ubiquitin-proteasome system to modulate protein folding and degradation,Other,,
475,1554,1,1,,49718107,6167,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
476,1556,1,4,,49718107,6167,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
477,1565,2,2,,49718107,6167,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
478,1566,2,3,,49718107,6167,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
479,1578,3,2,,49718107,6167,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
480,1580,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that inhibit mitochondrial permeability transition (MitoPT),Other,,
481,1581,1,1,,8149269,6167,Inconclusive,,,,,Screen of Compounds to Block PAR4 - aPKC Interaction for Treatment of Neurodegeneration (Par4_PKC),Other,,
482,1582,1,1,,8149269,6167,Inconclusive,,,,,Yeast cell-based screen for Novel HDAC inhibitors using a PHO84-LacZ reporter gene (PHO84),Other,,
483,1583,1,1,,8149269,6167,Unspecified,,,,,Assay to identify inhibitors of polyglutamine-induced caspase-3 activation (CASP3),Other,,
484,1584,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that inhibit in vitro mutant huntingtin aggregation (QA1),Other,,
485,1585,1,1,,8149269,6167,Inconclusive,,,,,"Screen for compounds that inhibit the ability of solid phase synthetic polyglutamine aggregates to elongate by incorporating solution-phase biotin-tagged, monomeric polyglutamine (QA3)",Other,,
486,1586,1,1,,8149269,6167,Inconclusive,,,,,A 2-Hybrid Test for Interactions Between Polyglutamine-Containing Proteins in the Yeast Nucleus  (Qn2Hy),Other,,
487,1587,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that increase the expression of EAAT-2 in rat spinal cord organotypic slice cultures (X4_EAAT2),Other,,
488,1588,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that reduce polyglutamine aggregation as measured by turbidity (QTHIO),Other,,
489,1589,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (SDS),Other,,
490,1590,1,1,,8149269,6167,Inconclusive,,,,,Cellular toxicity caused by inducible expressing of N-terminal huntingtin with expanded ployglutamine repeat (Htt-N63-148Q) in PC12 cells (ROSShtt),Other,,
491,1593,1,1,,8149269,6167,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU),Other,,
492,1594,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that decrease glutamate induced motor neuron death measured by TUNEL staining for DNA degradation (MNGlu),Other,,
493,1595,1,1,,8149269,6167,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYe),Other,,
494,1596,1,1,,8149269,6167,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH100),Other,,
495,1597,1,1,,8149269,6167,Inconclusive,,,,,Suppression of Polyglutamine Toxicity in Whole Organism Drosophila Model of SCA1 (SCA1FLYp),Other,,
496,1598,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that selectively increase SMN2 splicing relative to SMN1 splicing (SMNLUC),Other,,
497,1599,1,1,,8149269,6167,Unspecified,,,,,"Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU)",Other,,
498,1600,1,1,,8149269,6167,Inconclusive,,,,,Yeast Assay for Parkinson&apos;s Disease (YAPD),Other,,
499,1601,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that suppress mutant SOD1-mediated cell death (mSODtox),Other,,
500,1602,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that attenuate mutant SOD1 toxicity (mSOD1),Other,,
501,1603,1,1,,8149269,6167,Unspecified,,,,,Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel),Other,,
502,1604,1,1,,8149269,6167,Unspecified,,,,,Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG),Other,,
503,1605,1,1,,8149269,6167,Unspecified,,,,,Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1),Other,,
504,1606,1,1,,8149269,6167,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH20),Other,,
505,1607,1,1,,8149269,6167,Inconclusive,,,,,Screen for compounds that promote the turnover of an expanded polyglutamine androgen receptor (AR112GFP),Other,,
506,1608,1,1,,8149269,6167,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH016),Other,,
507,1609,1,1,,8149269,6167,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells (LDH08),Other,,
508,1610,1,1,,8149269,6167,Inconclusive,,,,,Protection from expanded polyglutamine huntingtin toxicity in PC12 cells,Other,,
509,1612,1,1,,8149269,6167,Unspecified,,,,,Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE),Other,,
510,1613,1,1,,8149269,6167,Unspecified,,,,,Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1),Other,,
511,1614,1,1,,8149269,6167,Unspecified,,,,,Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80),Other,,
512,1616,1,1,,8149269,6167,Unspecified,,,,,Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH),Other,,
513,1621,1,2,,49718107,6167,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
514,1631,3,1,,49718107,6167,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
515,1634,3,1,,49718107,6167,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
516,1637,1,2,,11537652,6167,Inactive,,,,,NMR Based Screening Assay for Influenza A RNA Promoter,Other,,
517,1648,1,2,,11537652,6167,Inactive,159164579.0,,,,NMR Based Screening Assay For Novel Chemical Probes Targeting The FRB Domain of mTOR,Other,,
518,1654,2,2,,49718107,6167,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
519,1656,2,2,,49718107,6167,Inconclusive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
520,1662,1,2,,49718107,6167,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
521,1663,1,2,,49718107,6167,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
522,1672,1,3,,49718107,6167,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
523,1688,1,1,,26752176,6167,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
524,1700,1,2,,49718107,6167,Active,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
525,1705,1,2,,50104821,6167,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
526,1706,1,2,,49718107,6167,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
527,1707,1,3,,50104821,6167,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
528,1708,1,3,,50104821,6167,Inactive,405898.0,,2.5119,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
529,1721,1,2,,49718107,6167,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
530,1722,1,2,,49718107,6167,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
531,1766,1,1,,11114044,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
532,1766,1,1,,11114044,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
533,1766,1,1,,26752175,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
534,1766,1,1,,26752175,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
535,1766,1,1,,26752176,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
536,1766,1,1,,26752176,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
537,1766,1,1,,49718107,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
538,1766,1,1,,49718107,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
539,1766,1,1,,50104821,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
540,1766,1,1,,50104821,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
541,1768,1,1,,11114044,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
542,1768,1,1,,11114044,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
543,1768,1,1,,26752175,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
544,1768,1,1,,26752175,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
545,1768,1,1,,26752176,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
546,1768,1,1,,26752176,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
547,1768,1,1,,49718107,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
548,1768,1,1,,49718107,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
549,1768,1,1,,50104821,6167,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
550,1768,1,1,,50104821,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
551,1777,3,2,,49718107,6167,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
552,1778,3,3,,49718107,6167,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
553,1779,2,2,,49718107,6167,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
554,1789,1,2,,49718107,6167,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
555,1800,1,2,,49718107,6167,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
556,1813,1,2,,49718107,6167,Active,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
557,1814,1,2,,49718107,6167,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
558,1815,1,1,,50104821,6167,Active,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
559,1816,1,1,,50104821,6167,Inconclusive,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
560,1817,2,2,,49718107,6167,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
561,1822,1,3,,49718107,6167,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
562,1825,1,1,,49718107,6167,Active,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
563,1828,2,1,,50104821,6167,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
564,1832,2,1,,49718107,6167,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
565,1834,1,2,,49718107,6167,Active,124263658.0,688.0,,,Luminescence-based confirmation cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
566,1845,1,2,,49718107,6167,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
567,1850,2,1,,49718107,6167,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
568,1851,1,2,,11114044,6167,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
569,1851,1,2,1.0,11114044,6167,Active,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
570,1851,1,2,2.0,11114044,6167,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
571,1851,1,2,3.0,11114044,6167,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
572,1851,1,2,4.0,11114044,6167,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
573,1851,1,2,5.0,11114044,6167,Active,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
574,1861,2,1,,49718107,6167,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
575,1863,2,1,,49718107,6167,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
576,1865,1,1,,11114044,6167,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
577,1865,1,1,,26752175,6167,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
578,1865,1,1,,50104821,6167,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
579,1875,2,1,,49718107,6167,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
580,1876,1,1,,50104821,6167,Active,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
581,1877,1,1,,50104821,6167,Inconclusive,,,14.1254,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
582,1882,1,1,,50104821,6167,Inconclusive,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
583,1883,1,1,,50104821,6167,Active,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
584,1885,2,1,,49718107,6167,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
585,1886,1,1,,50104821,6167,Inconclusive,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
586,1899,1,3,,49718107,6167,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
587,1903,2,3,,49718107,6167,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
588,1905,1,1,,49718107,6167,Active,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line in triplicate.,Screening,,
589,1906,1,3,,49718107,6167,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
590,1907,1,2,,49718107,6167,Active,,,,,Luminescence-based confirmation cell-based assay for cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
591,1910,1,2,,49718107,6167,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
592,1947,1,2,,49718107,6167,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
593,1948,1,1,,11114044,6167,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
594,1948,1,1,,17389095,6167,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
595,1948,1,1,,17389096,6167,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
596,1948,1,1,,26752175,6167,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
597,1948,1,1,,50104821,6167,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
598,1950,1,3,,49718107,6167,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
599,1961,2,2,,49718107,6167,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
600,1962,1,2,,49718107,6167,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
601,1967,1,1,,50104821,6167,Inactive,4505907.0,5376.0,,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
602,1972,1,1,,49718107,6167,Active,,,0.06279,IC50,Luminescence-based dose response cell-based high throughput screening assay for cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Confirmatory,,
603,1974,1,2,,49718107,6167,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
604,1979,1,1,,49718107,6167,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
605,1984,1,3,,49718107,6167,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
606,1986,1,2,,49718107,6167,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
607,1987,1,2,,49718107,6167,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
608,2006,3,2,,49718107,6167,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
609,2006,3,2,,49718107,6167,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
610,2006,3,2,,49718107,6167,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
611,2012,3,2,,49718107,6167,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
612,2013,2,2,,49718107,6167,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
613,2014,3,2,,49718107,6167,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
614,2016,1,3,,49718107,6167,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
615,2023,1,3,,49718107,6167,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
616,2025,1,3,,49718107,6167,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
617,2029,1,3,,49718107,6167,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
618,2052,2,1,,49718107,6167,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
619,2057,1,2,,49718107,6167,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
620,2058,3,2,,49718107,6167,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
621,2066,1,4,,49718107,6167,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
622,2071,2,2,,49718107,6167,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
623,2073,2,3,,49718107,6167,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
624,2073,2,3,,49718107,6167,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
625,2094,1,2,,49718107,6167,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
626,2094,1,2,,49718107,6167,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
627,2094,1,2,,49718107,6167,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
628,2097,1,2,,49718107,6167,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
629,2098,1,1,,49718107,6167,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
630,2099,1,1,,49718107,6167,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
631,2100,1,1,,49718107,6167,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
632,2101,1,1,,11114044,6167,Inconclusive,496369.0,2629.0,39.8107,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
633,2101,1,1,,17389095,6167,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
634,2101,1,1,,17389096,6167,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
635,2101,1,1,,26752175,6167,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
636,2101,1,1,,49718107,6167,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
637,2101,1,1,,50104821,6167,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
638,2107,1,1,,11114044,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
639,2107,1,1,,17389095,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
640,2107,1,1,,17389096,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
641,2107,1,1,,26752175,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
642,2107,1,1,,50104821,6167,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
643,2112,1,1,,11114044,6167,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
644,2112,1,1,,17389095,6167,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
645,2112,1,1,,17389096,6167,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
646,2112,1,1,,26752175,6167,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
647,2112,1,1,,50104821,6167,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
648,2120,1,1,,17389095,6167,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
649,2120,1,1,,17389096,6167,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
650,2129,1,2,,49718107,6167,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
651,2130,1,3,,49718107,6167,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
652,2147,1,1,,11114044,6167,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
653,2147,1,1,,50104821,6167,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
654,2156,2,2,,49718107,6167,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
655,2174,1,3,,49718107,6167,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
656,2177,1,3,,49718107,6167,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
657,2216,1,3,,49718107,6167,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
658,2221,1,2,,49718107,6167,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
659,2227,1,2,,49718107,6167,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
660,2234,1,2,,49718107,6167,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
661,2235,1,2,,49718107,6167,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
662,2237,1,2,,49718107,6167,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
663,2239,1,2,,49718107,6167,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
664,2240,1,1,,85788838,6167,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
665,2241,1,1,,85788838,6167,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
666,2247,1,2,,49718107,6167,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
667,2275,1,1,,85788838,6167,Active,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
668,2280,2,3,,49718107,6167,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
669,2288,1,1,,49718107,6167,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
670,2289,1,1,,49718107,6167,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
671,2300,1,3,,49718107,6167,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
672,2313,1,1,,85788838,6167,Active,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
673,2314,1,2,,26752175,6167,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
674,2314,1,2,,26752175,6167,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
675,2314,1,2,,49718107,6167,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
676,2314,1,2,,49718107,6167,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
677,2315,1,2,,26752175,6167,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
678,2315,1,2,,26752175,6167,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
679,2315,1,2,,49718107,6167,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
680,2315,1,2,,49718107,6167,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
681,2322,1,1,,85788838,6167,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
682,2323,1,1,,50104821,6167,Inconclusive,254220970.0,,35.4813,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
683,2326,1,1,,49718107,6167,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
684,2326,1,1,,50104821,6167,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
685,2330,1,1,,85788838,6167,Active,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
686,2353,1,3,,50104821,6167,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
687,2364,1,2,,50104821,6167,Inactive,4557365.0,641.0,,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
688,2380,1,2,,49718107,6167,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
689,2391,1,1,,49718107,6167,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
690,2435,1,2,,49718107,6167,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
691,2441,1,1,,50104821,6167,Active,,,0.02,Potency,Cell cycle validation with wells to cells screening paradigm,Confirmatory,,
692,2445,1,2,,49718107,6167,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
693,2451,1,2,,11114044,6167,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
694,2451,1,2,,26752175,6167,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
695,2451,1,2,,49718107,6167,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
696,2451,1,2,,50104821,6167,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
697,2462,1,1,,49718107,6167,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
698,2462,1,1,,49718107,6167,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
699,2472,1,2,,11114044,6167,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
700,2472,1,2,,26752175,6167,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
701,2472,1,2,,49718107,6167,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
702,2517,2,1,,11114044,6167,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
703,2517,2,1,,17389095,6167,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
704,2517,2,1,,17389096,6167,Inactive,6980812.0,,70.7946,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
705,2517,2,1,,26752175,6167,Inactive,6980812.0,,0.0056,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
706,2517,2,1,,49718107,6167,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
707,2517,2,1,,50104821,6167,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
708,2520,1,4,,49718107,6167,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
709,2521,1,3,,49718107,6167,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
710,2524,1,2,,49718107,6167,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
711,2528,1,2,,11114044,6167,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
712,2528,1,2,,26752175,6167,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
713,2528,1,2,,26752176,6167,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
714,2528,1,2,,49718107,6167,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
715,2528,1,2,,50104821,6167,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
716,2540,1,2,,49718107,6167,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
717,2544,1,2,,49718107,6167,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
718,2546,1,1,,11114044,6167,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
719,2546,1,1,,17389095,6167,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
720,2546,1,1,,17389096,6167,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
721,2546,1,1,,26752175,6167,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
722,2546,1,1,,26752176,6167,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
723,2546,1,1,,49718107,6167,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
724,2549,1,1,,11114044,6167,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
725,2549,1,1,,17389095,6167,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
726,2549,1,1,,17389096,6167,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
727,2549,1,1,,26752175,6167,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
728,2549,1,1,,50104821,6167,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
729,2550,1,3,,49718107,6167,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
730,2551,1,1,,11114044,6167,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
731,2551,1,1,,17389095,6167,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
732,2551,1,1,,17389096,6167,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
733,2551,1,1,,26752175,6167,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
734,2551,1,1,,26752176,6167,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
735,2551,1,1,,49718107,6167,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
736,2553,1,2,,49718107,6167,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
737,2557,1,3,,49718107,6167,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
738,2563,1,1,,49718107,6167,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
739,2599,1,2,,49718107,6167,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
740,2606,1,2,,49718107,6167,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
741,2629,1,1,,49718107,6167,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
742,2642,1,2,,49718107,6167,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
743,2648,1,2,,49718107,6167,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
744,2650,2,1,,49718107,6167,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
745,2660,1,1,,90340644,6167,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
746,2661,1,1,,49718107,6167,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
747,2662,2,1,,26752176,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
748,2662,2,1,,49718107,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
749,2662,2,1,,50104821,6167,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
750,2666,1,1,,90340644,6167,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
751,2667,1,1,,90340644,6167,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
752,2668,1,1,,90340644,6167,Inactive,4826730.0,2475.0,,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
753,2675,1,1,,49718107,6167,Inconclusive,41281591.0,4154.0,15.8489,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
754,2675,1,1,,50104821,6167,Inconclusive,41281591.0,4154.0,12.5893,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
755,2676,1,2,,49718107,6167,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
756,2685,1,1,,49718107,6167,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
757,2690,1,2,,49718107,6167,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
758,2716,1,1,,49718107,6167,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
759,2717,1,2,,49718107,6167,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
760,2718,1,1,,49718107,6167,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
761,2732,1,1,,17404873,6167,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
762,2751,2,2,,49718107,6167,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
763,2774,1,3,,92303527,6167,Inactive,,,,,LOPAC Circadian Assay,Screening,,
764,2796,1,4,,49718107,6167,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
765,2797,1,2,,49718107,6167,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
766,2805,2,2,,49718107,6167,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
767,2806,2,2,,49718107,6167,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
768,2825,1,2,,49718107,6167,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
769,2955,4,4,,103177124,6167,Active,,,0.0119,IC50,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Confirmatory,12270161.0,
770,2968,4,4,,103177124,6167,Unspecified,,,2.5,IC50,Inhibitory activity against Taxol resistant 1A9 cell lines,Confirmatory,10571149.0,
771,3279,4,5,,103177124,6167,Unspecified,,,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,Other,4032423.0,
772,3330,4,4,,103177124,6167,Unspecified,,,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,Other,4032423.0,
773,7783,3,4,,103177124,6167,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
774,7908,4,4,,103177124,6167,Active,,,0.013999999999999999,IC50,Inhibition of A431 cell proliferation,Confirmatory,7990108.0,
775,8002,5,2,,103177124,6167,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
776,8458,6,2,,103177124,6167,Unspecified,,,,,"In vitro growth inhibition of A549, lung carcinoma.",Other,9599244.0,
777,8461,8,1,,103177124,6167,Active,,,0.018000000000000002,ED50,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Confirmatory,8496935.0,
778,9014,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Other,9544215.0,
779,9282,6,1,,103177124,6167,Active,,,0.0631,GI50,In vitro cytotoxicity against A549/ATCC cell line.,Confirmatory,8496915.0,
780,9451,4,4,,103177124,6167,Active,,,0.0138,IC50,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Confirmatory,12270161.0,
781,19006,4,3,,103177124,6167,Unspecified,,,,,Calculated membrane partition coefficient (Kmemb),Other,15027870.0,
782,19468,3,3,,103177124,6167,Unspecified,,,,,Partition coefficient (logP),Other,12699389.0,
783,23271,4,4,,103177124,6167,Unspecified,,,,,Partition coefficient (logD7.4),Other,2362268.0,
784,23448,3,3,,103177124,6167,Unspecified,,,,,Partition coefficient (logP),Other,7241524.0,
785,23461,3,3,,103177124,6167,Unspecified,,,,,Partition coefficient (logP),Other,7265111.0,
786,23476,3,3,,103177124,6167,Unspecified,,,,,Partition coefficient (logP),Other,1956052.0,
787,24566,3,3,,103177124,6167,Unspecified,,,,,Retention time of the compound.,Other,1956052.0,
788,26380,3,3,,103177124,6167,Inactive,,,,,Dissociation constant (pKa),Other,14971904.0,
789,28233,3,3,,103177124,6167,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
790,28235,3,3,,103177124,6167,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
791,28236,3,3,,103177124,6167,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
792,29423,3,4,,103177124,6167,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
793,29925,5,2,,103177124,6167,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
794,41043,8,3,,103177124,6167,Inconclusive,,,,,Inhibition B16F1 cell proliferation (Not tested),Other,7990108.0,
795,42553,6,2,,103177124,6167,Active,,,15.0,IC50,Inhibits the growth of the human Burkitt lymphoma CA46 cell,Confirmatory,9083485.0,
796,42572,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human renal cancer cells (CAKI-1) using SRB assay.,Other,9544215.0,
797,42750,6,2,,103177124,6167,Unspecified,,,,,"In vitro growth inhibition of CAKI-1, Kidney carcinoma",Other,9599244.0,
798,43926,6,2,,103177124,6167,Active,,,0.05,IC50,Growth inhibition on human burkitt lymphoma cells after 36 h,Confirmatory,8496935.0,
799,44202,3,4,,103177124,6167,Unspecified,,,,,Effect on cross resistance of CCRF-CEM cells resistant to vincristine.,Other,2362268.0,
800,45400,3,4,,103177124,6167,Unspecified,,,,,Effect on cross resistance of CHO cells resistant to colchicine (CHRC5),Other,2362268.0,
801,52380,6,2,,103177124,6167,Active,,,0.03,IC50,Cytotoxic activity against cellular metabolic activity of Cervix KB/HeLa tumor cell line using XTT proliferation assay after incubation with the compound for 48 h,Confirmatory,12852768.0,
802,53918,6,2,,103177124,6167,Active,,,0.19,EC50,Tested for caspase activation activity in colorectal DLD-1 cell line,Confirmatory,12773051.0,
803,54102,6,1,,103177124,6167,Active,,,0.1122,GI50,In vitro cytotoxicity against DMS114 cell line.,Confirmatory,8496915.0,
804,54322,3,7,,103177124,6167,Unspecified,118573906.0,281555.0,,,Evaluated for the stimulation of GTP hydrolysis,Other,8496935.0,
805,54923,6,5,,103177124,6167,Unspecified,,,50.0,IC50,Inhibition of human cytochrome P450 3A4,Confirmatory,12699389.0,
806,57541,4,5,,103177124,6167,Active,,,0.2283,IC50,Inhibitory concentration required for cytotoxicity in DOX-resistant (DOX/R) cells,Confirmatory,,
807,75537,6,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxic activity against cellular metabolic activity of Glioma SF-268 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h,Confirmatory,12852768.0,
808,75538,3,3,,103177124,6167,Unspecified,,,,,"Ability to inhibit the dibutyryl-cAMP-induced change of an immature glioma cell to a mature, differentiated astrocyte by in vitro astrocytoma assay at 0.1 ug/mL dose (Experiment #1); value may range from 0 to 5",Other,2821258.0,
809,75539,3,3,,103177124,6167,Unspecified,,,,,"Ability to inhibit the dibutyryl-cAMP-induced change of an immature glioma cell to a mature, differentiated astrocyte by in vitro astrocytoma assay at 0.1 ug/mL dose (Experiment #2); value may range from 0 to 5",Other,2821258.0,
810,75546,3,3,,103177124,6167,Unspecified,,,,,"Ability to inhibit the dibutyryl-cAMP-induced change of an immature glioma cell to a mature, differentiated astrocyte by in vitro astrocytoma assay at 10 ug/mL dose (Experiment #1); value may range from 91 to up",Other,2821258.0,
811,75548,3,3,,103177124,6167,Unspecified,,,,,"Ability to inhibit the dibutyryl-cAMP-induced change of an immature glioma cell to a mature, differentiated astrocyte by in vitro astrocytoma assay at 10 ug/mL dose (Experiment #2); value may range from 91 to up",Other,2821258.0,
812,75554,3,3,,103177124,6167,Unspecified,,,,,"Ability to inhibit the dibutyryl-cAMP-induced change of an immature glioma cell to a mature, differentiated astrocyte by in vitro astrocytoma assay at 1 ug/mL dose (Experiment #1); value may range from 51 to 70",Other,2821258.0,
813,75556,3,3,,103177124,6167,Unspecified,,,,,"Ability to inhibit the dibutyryl-cAMP-induced change of an immature glioma cell to a mature, differentiated astrocyte by in vitro astrocytoma assay at 1 ug/mL dose (Experiment #2); value may range from 51 to 70",Other,2821258.0,
814,78620,5,3,,103177124,6167,Active,,,0.14,IC50,Antiproliferative activity against the MDR positive human colon adenocarcinoma cell line HCT-15,Confirmatory,11814821.0,
815,78790,6,1,,103177124,6167,Active,,,0.0631,GI50,In vitro cytotoxicity against HCT-15 cell line.,Confirmatory,8496915.0,
816,78822,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human ileocecal carcinoma cells (HCT-8) using SRB assay.,Other,9544215.0,
817,80245,6,2,,103177124,6167,Unspecified,,,,,In vitro cytotoxic activity (growth inhibition) of compound against HCT 116 cancer cell line was determined,Other,12372531.0,
818,80380,5,1,,103177124,6167,Active,,,0.175,ED50,Cytotoxicity against human solid tumor Colon carcinoma HCT-8 cell line,Confirmatory,8496935.0,
819,81367,4,4,,103177124,6167,Active,,,0.018000000000000002,IC50,Inhibition of HeLa cell proliferation,Confirmatory,7990108.0,
820,86838,7,1,,103177124,6167,Unspecified,,,,,In vitro antimitotic activity against HeLa cells after 6 hours exposure,Other,2362275.0,
821,87604,6,2,,103177124,6167,Active,,,0.023,IC50,In vitro inhibitory activity against HeLa/KB cells using XTT proliferation assay.,Confirmatory,11741473.0,
822,90441,6,2,,103177124,6167,Unspecified,,,10.0,IC50,Cytotoxic activity against human colon adenocarcinoma RKO cells with ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1,Confirmatory,12852768.0,
823,90442,6,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxic activity against human colon adenocarcinoma RKO cells without ectopic inducible expression of cyclin-dependent kinase inhibitor p27kip1,Confirmatory,12852768.0,
824,91688,6,4,,103177124,6167,Active,,,4.2,IC50,In vitro inhibition of tubulin polymerization.,Confirmatory,8496915.0,
825,91784,4,5,,103177124,6167,Active,,,0.0931,IC50,Inhibitory concentration required for cytotoxicity in J774.2 murine macrophage-like cells,Confirmatory,,
826,92127,5,2,,103177124,6167,Active,,,0.05754,GI50,in vitro antitumor activity against NCI 's human tumor cell lines,Confirmatory,9301667.0,
827,92128,5,2,,103177124,6167,Active,,,0.05754,GI50,"Cytotoxic effect in human tumor cell lines, tested by the National Cancer Institute",Confirmatory,9216846.0,
828,93939,4,4,,103177124,6167,Active,,,0.0064,IC50,The compound was tested in vitro for growth of inhibitory activity against lymphoid leukemia L1210 cells,Confirmatory,2795608.0,
829,94097,4,4,,103177124,6167,Active,,,,,Mitotic index (fraction of cells in mitosis divided by total cells ) for cultured lymphoid leukemia L1210 cells,Other,2795608.0,
830,94181,3,4,,103177124,6167,Unspecified,,,,,Cytotoxicity was evaluated against KB-C2 cells at 0.1 ug/mL; No cytotoxicity,Other,11086720.0,
831,94198,4,4,,103177124,6167,Unspecified,,,0.1,IC50,The compound was tested for its cytotoxic concentration required to inhibit the replication of human tumor nasopharynx (KB-VIN) cell lines which is drug resistant,Confirmatory,12270161.0,
832,94435,4,5,,103177124,6167,Active,,,0.0147,IC50,Inhibition of L1210 cell proliferation,Confirmatory,7990108.0,
833,95339,3,4,,103177124,6167,Unspecified,,,,,Cytotoxicity was evaluated against KB CV-60 cells at 0.1 ug/mL; No cytotoxicity,Other,11086720.0,
834,95485,6,1,,103177124,6167,Unspecified,,,,,In vitro effective dose to inhibit KB cell growth from a human epidermoid carcinoma.,Other,1992152.0,
835,95519,6,2,,103177124,6167,Unspecified,,,,,"In vitro growth inhibition of KB, epidermoid carcinoma of the nasopharynx.",Other,9599244.0,
836,95523,5,1,,103177124,6167,Active,,,0.002,ED50,Cytotoxicity against human solid tumor nasopharyngeal carcinoma KB cell line,Confirmatory,8496935.0,
837,95664,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human epidermoid carcinoma of the nasopharyngeal cells (KB) using SRB assay.,Other,9544215.0,
838,95875,4,4,,103177124,6167,Active,,,0.0119,IC50,The compound was tested for its cytotoxic concentration required to inhibit the replication of human tumor nasopharynx (KB) cell lines,Confirmatory,12270161.0,
839,95876,4,4,,103177124,6167,Active,,,0.0056,IC50,Inhibition of KB cell proliferation,Confirmatory,7990108.0,
840,96018,10,1,,103177124,6167,Unspecified,,,,,In vitro inhibitory activity against growth of KB cells derived from human epidermoid carcinoma of the mouth,Other,6502608.0,
841,96173,4,4,,103177124,6167,Active,,,0.0141,IC50,Inhibition of K562 cell proliferation,Confirmatory,7990108.0,
842,96598,4,4,,103177124,6167,Active,,,,,Concentration that causes a mitotic index (number of cells in mitosis divided by total cells) of 0.5 for cultured lymphoid leukemia L1210 cells during an exposure period of 12 h,Other,1479582.0,
843,98159,6,2,,103177124,6167,Active,,,0.0064,IC50,Concentration required to inhibit proliferation of cultured lymphoid leukemia L1210 cells to 50% growth over 48 hours,Confirmatory,1433180.0,
844,98163,4,4,,103177124,6167,Active,,,0.0064,IC50,Concentration that inhibits proliferation of cultured lymphoid leukemia L1210 cells to 50% control growth during 48 h,Confirmatory,1479582.0,
845,98510,4,4,,103177124,6167,Active,,,0.04,IC50,In vitro cytotoxicity against L1210 (murine leukemia) cells.,Confirmatory,2299625.0,
846,100329,4,5,,103177124,6167,Unspecified,,,,,In vivo antitumor activity against L1210 intraperitoneally implanted L1210 leukemia cells,Other,4032423.0,
847,101492,6,2,,103177124,6167,Active,,,0.02,IC50,In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth,Confirmatory,12852768.0,
848,101610,4,4,,103177124,6167,Active,,,0.0153,IC50,Inhibition of MCF-7 cell proliferation,Confirmatory,7990108.0,
849,101630,4,4,,103177124,6167,Active,,,0.0018,IC50,Anti tumor activity on human breast cancer cell line MDR-negative MDA-MB 231 after 72 hours of treatment,Confirmatory,10602712.0,
850,101632,6,2,,103177124,6167,Active,,,0.03,IC50,Inhibition of the growth of MDA-MB 231 human breast cancer cells,Confirmatory,9357519.0,
851,101821,4,4,,103177124,6167,Active,,,0.0205,IC50,Inhibition of MDA-MB-231 cell proliferation,Confirmatory,7990108.0,
852,102187,4,4,,103177124,6167,Active,,,0.006,IC50,Inhibition of LOVO cell proliferation,Confirmatory,7990108.0,
853,102444,6,2,,103177124,6167,Active,,,0.05,GI50,Compound was evaluated for growth inhibition against MCF-7 cells using cellular assay,Confirmatory,9871709.0,
854,102526,6,2,,103177124,6167,Active,,,0.07,IC50,Cytotoxic activity against cellular metabolic activity of Lung NCI-H460 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h,Confirmatory,12852768.0,
855,103260,6,2,,103177124,6167,Unspecified,,,,,"In vitro growth inhibition of MCF-7, breast adenocarcinoma.",Other,9599244.0,
856,103435,6,3,,103177124,6167,Active,,,0.05,GI50,In vivo growth inhibitory activity against human neoplastic MCF-7 cell line,Confirmatory,10091693.0,
857,103729,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human breast cancer cells (MCF-7) using SRB assay.,Other,9544215.0,
858,103890,4,4,,103177124,6167,Active,,,12.0,IC50,Anti tumor activity on human breast cancer cell line MDR-positive MCF-7 ADRr after 72 hours of treatment,Confirmatory,10602712.0,
859,105060,4,5,,103177124,6167,Active,,,0.0069,IC50,Inhibition of MDA-MB-468 cell proliferation,Confirmatory,7990108.0,
860,105067,3,5,,103177124,6167,Unspecified,,,,,In vitro growth inhibition in MDA-MB-231 cells by crystal violet staining,Other,9836614.0,
861,106133,4,4,,103177124,6167,Active,,,0.5,IC50,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Confirmatory,12431060.0,
862,106134,4,4,,103177124,6167,Active,,,0.025,IC50,Inhibitory concentration against the growth of HET-SR-2SC-LNM cell line after 72 hr of drug exposure by MTT test,Confirmatory,12431060.0,
863,109716,3,3,,103177124,6167,Unspecified,,,,,Antitumor activity against P388 lymphocytic leukemia in mice,Other,4032423.0,
864,115600,3,3,,103177124,6167,Unspecified,,,,,MED(minimum effective dose) against P388 lymphocytic leukemia in mice; this dose produced T/C greater than the threshold value of 125,Other,4032423.0,
865,116722,6,2,,103177124,6167,Unspecified,,,,,Acute toxicity as LD50 value was determined in mice administered intraperitoneally,Other,6218302.0,
866,116723,6,2,,103177124,6167,Unspecified,,,,,Acute toxicity as LD50 value was determined in mice administered orally,Other,6218302.0,
867,117073,6,2,,103177124,6167,Unspecified,,,,,Lethal dose after the intraperitoneal injection in a group of 10 mice,Other,4032423.0,
868,120593,3,3,,103177124,6167,Unspecified,,,,,Dose of compound which caused an average weight loss >3g in a set of mice or the death of one or more of the mice in the set in the P388 NCI screen.,Other,7265112.0,
869,120695,3,3,,103177124,6167,Unspecified,,,,,Compound was evaluated for the antitumor activity against P388 lymphocytic leukemia in mice,Other,4032423.0,
870,123247,3,3,,103177124,6167,Unspecified,,,,,Toxicity found after a single im injection. The total number of deaths were counted after 7 days and LD50 was determined by probit analysis; 2.5-4.0,Other,7265112.0,
871,123252,3,3,,103177124,6167,Unspecified,,,,,Toxicity found after a single intramuscular injection in mice,Other,6620299.0,
872,123253,3,3,,103177124,6167,Unspecified,,,,,Toxicity in the P388 NCI screen defined as the dose that caused an average wt. loss>3g in at least one out of set of mice or the death of one or more of mice,Other,6620299.0,
873,125974,8,2,,103177124,6167,Inconclusive,,,,,Inhibition of bovine brain microtubule polymerization; No data,Other,11814821.0,
874,126115,6,3,,103177124,6167,Active,,,7.5,IC50,Concentration was evaluated for its ability to inhibit microtubule assembly and protein polymerization by 50%,Confirmatory,,
875,130471,6,2,,103177124,6167,Unspecified,,,,,Carrageenan-induced edema was determined value for intraperitoneal administration,Other,6218302.0,
876,130472,6,2,,103177124,6167,Unspecified,,,,,Carrageenan-induced edema was determined value for oral administration,Other,6218302.0,
877,132741,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.06 mg/kg in trail 1,Other,7241524.0,
878,132742,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.06 mg/kg in trail 2,Other,7241524.0,
879,132743,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.12 mg/kg in trail 1,Other,7241524.0,
880,132744,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.12 mg/kg in trail 2,Other,7241524.0,
881,132745,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.25 mg/kg in trail 1,Other,7241524.0,
882,132746,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.25 mg/kg in trail 2,Other,7241524.0,
883,132879,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.5 mg/kg in trail 1,Other,7241524.0,
884,132880,3,3,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 0.5 mg/kg in trail 2,Other,7241524.0,
885,132883,5,2,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 1 mg/kg in trail 1; Toxic,Other,7241524.0,
886,132884,5,2,,103177124,6167,Unspecified,,,,,Percent increase in life-span against in vivo P388 murine leukemia at a dose 1 mg/kg in trail 2; Toxic,Other,7241524.0,
887,132966,3,3,,103177124,6167,Unspecified,,,,,In vivo antitumor activity against P388 mouse leukemia and minimum affective dose (MED) which produced a T/C greater than the threshold value of 125 was reported.,Other,3560165.0,
888,134555,6,2,,103177124,6167,Unspecified,,,,,Compound was tested for toxicity in P388 tumored mice,Other,7241524.0,
889,134556,6,2,,103177124,6167,Unspecified,,,,,Compound was tested for toxicity in non tumored mice,Other,7241524.0,
890,136915,3,3,,103177124,6167,Unspecified,,,,,In vivo antitumor activity against P388 mouse leukemia expressed as T/C (median survival time of treated animals / median survival time of untreated controls x 100) at a dose of 0.5 mg/kg,Other,3560165.0,
891,137219,3,3,,103177124,6167,Unspecified,,,,,In vivo antitumor activity was measured in mice (P388 leukemia) at dose 0.3 mg/kg after intraperitoneal administration,Other,6502608.0,
892,137220,3,3,,103177124,6167,Unspecified,,,,,In vivo antitumor activity was measured in mice (P388 leukemia) at dose 0.5 mg/kg after intraperitoneal administration,Other,6502608.0,
893,137225,3,3,,103177124,6167,Unspecified,,,,,In vivo antitumor activity was measured in mice (P388 leukemia) at dose 1 mg/kg after intraperitoneal administration,Other,6502608.0,
894,139239,3,3,,103177124,6167,Unspecified,,,,,Logarithm of toxic activity (1/lethal dose) in mice bearing P388 leukemia on chronic regimen (Q 1-9),Other,7241524.0,
895,140029,3,3,,103177124,6167,Unspecified,,,,,Acute toxicity after intramuscular injection in mice.,Other,2299625.0,
896,143034,5,3,,103177124,6167,Active,,,0.046,IC50,Antiproliferative activity against the human non small cell lung carcinoma cell line NCI-H460,Confirmatory,11814821.0,
897,143208,6,3,,103177124,6167,Active,,,0.05,GI50,In vivo growth inhibitory activity against human neoplastic NCI-H520 cell line,Confirmatory,10091693.0,
898,143209,6,2,,103177124,6167,Active,,,0.05,GI50,Compound was evaluated for growth inhibition against NCI-H520 cells using cellular assay,Confirmatory,9871709.0,
899,147804,6,1,,103177124,6167,Active,,,0.0631,GI50,In vitro cytotoxicity against OVCAR cell line.,Confirmatory,8496915.0,
900,150343,10,1,,103177124,6167,Active,,,0.012,ED50,Cytotoxic activity against P388 mouse lymphocytic leukemia cell line,Confirmatory,1956052.0,
901,150344,10,1,,103177124,6167,Active,,,0.47,ED50,Cytotoxic activity against P388 mouse lymphocytic leukemia cell line (doxorubicin resistant).,Confirmatory,1956052.0,
902,150751,7,1,,103177124,6167,Unspecified,,,,,Inhibition of P-glycoprotein using ATPase in MDR1 membranes,Other,12699389.0,
903,150752,6,3,,103177124,6167,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
904,150753,6,3,,103177124,6167,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
905,150754,6,3,,103177124,6167,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
906,150755,6,3,,103177124,6167,Unspecified,,,50.0,IC50,Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,Confirmatory,12699389.0,
907,150756,3,7,,103177124,6167,Unspecified,,,,,Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells,Other,12699389.0,
908,150757,3,7,,103177124,6167,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-MDR1 epithelial cells",Other,12699389.0,
909,150758,3,7,,103177124,6167,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-PK1 epithelial cells",Other,12699389.0,
910,150759,3,7,,103177124,6167,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-mdr1a epithelial cells",Other,12699389.0,
911,151506,6,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxic activity against cellular metabolic activity of Ovary SKOV3 tumor cell line using XTT proliferation assay after incubation with the compound for 48 h,Confirmatory,12852768.0,
912,152355,5,1,,103177124,6167,Active,,,0.1,ED50,Cytotoxicity against murine P388 leukemia cell line,Confirmatory,8496935.0,
913,152356,4,5,,103177124,6167,Active,,,0.0095,IC50,Inhibition of P388 cell proliferation,Confirmatory,7990108.0,
914,152691,4,1,,103177124,6167,Unspecified,,,,,Potency against lymphocytic leukemia P388 screen in mice.,Other,6620299.0,
915,152693,4,1,,103177124,6167,Unspecified,,,,,The compound was tested for its potency against lymphocytic leukemia P388 screen in mice.,Other,7265112.0,
916,153066,3,5,,103177124,6167,Unspecified,,,,,Compound was tested for % increase in life span of P388 tumor,Other,,
917,153067,4,3,,103177124,6167,Inconclusive,,,,,Compound was tested for % increase in life span of P388 tumor; No data,Other,,
918,153069,4,3,,103177124,6167,Inconclusive,,,,,Compound was tested for % increase in life span of adriamycin resistant P388 tumor; No data,Other,,
919,153070,2,5,,103177124,6167,Unspecified,,,,,Compound was tested for % increase in life span of vincristine resistant P388 tumor,Other,,
920,153197,4,5,,103177124,6167,Unspecified,,,,,In vivo antitumor activity against P388 lymphocytic leukemia cells implanted intraperitoneally; reproducible significant activity.,Other,4032423.0,
921,154376,3,4,,103177124,6167,Unspecified,,,,,Antitumor activity against murine lymphocytic leukemia P388 cells,Other,7265111.0,
922,155864,6,2,,103177124,6167,Unspecified,,,,,In vitro cytotoxic activity (growth inhibition) of compound against PC-12 human cancer cell line was determined,Other,12372531.0,
923,156331,6,2,,103177124,6167,Active,,,0.05,GI50,Compound was evaluated for growth inhibition against PC-3 cells using cellular assay,Confirmatory,9871709.0,
924,156646,6,3,,103177124,6167,Active,,,0.05,GI50,In vivo growth inhibitory activity against human neoplastic PC3 cell line,Confirmatory,10091693.0,
925,157341,4,4,,103177124,6167,Unspecified,,,2.5,IC50,Inhibitory activity against Taxol resistant PTX10 cell lines,Confirmatory,10571149.0,
926,157344,4,4,,103177124,6167,Unspecified,,,2.5,IC50,Inhibitory activity against Taxol resistant PTX22 cell lines,Confirmatory,10571149.0,
927,159533,6,7,,103177124,6167,Active,135435.0,100135051.0,1.4,IC50,In vitro inhibition of maximum porcine tubulin assembly rate after 20 min at 37 degrees C,Confirmatory,12852768.0,
928,159533,6,7,,103177124,6167,Active,135490.0,,1.4,IC50,In vitro inhibition of maximum porcine tubulin assembly rate after 20 min at 37 degrees C,Confirmatory,12852768.0,
929,159536,6,2,,103177124,6167,Active,,,1.4,IC50,In vitro inhibitory concentration against tubulin assembly,Confirmatory,12852768.0,
930,160673,6,8,,103177124,6167,Active,135435.0,100135051.0,29.3,IC50,Concentration of compound required to inhibit tubulin polymerization (Microtubule assembly) was determined by the turbidity formation after 20 min of incubation,Confirmatory,12372531.0,
931,160673,6,8,,103177124,6167,Active,135490.0,,29.3,IC50,Concentration of compound required to inhibit tubulin polymerization (Microtubule assembly) was determined by the turbidity formation after 20 min of incubation,Confirmatory,12372531.0,
932,167041,5,1,,103177124,6167,Active,,,0.001,ED50,Cytotoxicity against human melanoma RPMI-7951 cell line,Confirmatory,8496935.0,
933,169086,3,6,,103177124,6167,Unspecified,,,,,The ability to displace [3H]colchicine binding to rat brain tubulin protein,Other,6094813.0,
934,200619,8,2,,103177124,6167,Inconclusive,,,,,Inhibition of SCL-1 cell proliferation (Not tested),Other,7990108.0,
935,200637,6,1,,103177124,6167,Active,,,0.0631,GI50,In vitro cytotoxicity against SNB-19 cell line.,Confirmatory,8496915.0,
936,201634,4,4,,103177124,6167,Active,,,0.005,IC50,Inhibition of SK-BR-3 cell proliferation,Confirmatory,7990108.0,
937,201786,6,2,,103177124,6167,Unspecified,,,,,"In vitro growth inhibition of SK-MEL-2, malignant melanoma.",Other,9599244.0,
938,202313,6,1,,103177124,6167,Active,,,0.0631,GI50,In vitro cytotoxicity against SK-MEL-5 cell line.,Confirmatory,8496915.0,
939,202649,6,2,,103177124,6167,Active,,,0.02,IC50,In vitro inhibitory activity against SK-OV-3 cells using XTT proliferation assay.,Confirmatory,11741473.0,
940,202815,5,1,,103177124,6167,Unspecified,,,,,The compound was tested for the cytotoxicity for the cell lines of human melanoma cancer (SKMEL-2) using SRB assay.,Other,9544215.0,
941,208695,6,2,,103177124,6167,Active,,,0.013999999999999999,EC50,Tested for caspase activation activity in human breast cancer T47D cells,Confirmatory,12773051.0,
942,208873,5,1,,103177124,6167,Active,,,0.001,ED50,Cytotoxicity against human central nervous system carcinoma TE671 cell line,Confirmatory,8496935.0,
943,211307,8,4,,103177124,6167,Inactive,,,,,In vitro activity against mammalian topoisomerase II measured as ATP-dependent unknotting of P4 DNA compared to enzyme and DNA control; Inactive,Other,9599244.0,
944,212934,7,2,,103177124,6167,Unspecified,,,,,In vitro minimum inhibition concentration to inhibit the regeneration of cilia in Tetrahymena pyriformis W.,Other,1992152.0,
945,213841,6,2,,103177124,6167,Active,,,10.0,IC50,Compound was evaluated for its ability to inhibit polymerization of tubulin,Confirmatory,10743950.0,
946,213852,9,2,,103177124,6167,Active,,,3.5,IC50,Compound was evaluated for in vitro inhibitory activity against polymerization of tubulin into microtubules isolated from bovine brain at 1 mg/mL tubulin concentration,Confirmatory,,
947,213853,9,1,,103177124,6167,Active,,,0.78,Ki,Binding constant at colchicine site of bovine brain tubulin,Confirmatory,11814821.0,
948,213858,3,6,,103177124,6167,Unspecified,,,,,Percentage by which the binding of [3H]colchicine (2.5 uM) to tubulin from calf brain is reduced by 25 uM concentration of compound,Other,3560165.0,
949,213862,3,10,,103177124,6167,Unspecified,75053726.0,,,,Inhibition activity of colchicine for tubuline polymerization to that of compound,Other,9371249.0,
950,213862,3,10,,103177124,6167,Unspecified,75053735.0,,,,Inhibition activity of colchicine for tubuline polymerization to that of compound,Other,9371249.0,
951,213862,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,Inhibition activity of colchicine for tubuline polymerization to that of compound,Other,9371249.0,
952,213994,6,8,,103177124,6167,Active,75053726.0,,11.2,IC50,"Compound was evaluated for inhibition of tubulin polymerization using purified bovine brain tubulin, activity expressed as IC50",Confirmatory,,
953,213994,6,8,,103177124,6167,Active,75053735.0,,11.2,IC50,"Compound was evaluated for inhibition of tubulin polymerization using purified bovine brain tubulin, activity expressed as IC50",Confirmatory,,
954,213994,6,8,,103177124,6167,Active,118573906.0,281555.0,11.2,IC50,"Compound was evaluated for inhibition of tubulin polymerization using purified bovine brain tubulin, activity expressed as IC50",Confirmatory,,
955,213996,9,5,,103177124,6167,Active,75053726.0,,2.5,IC50,In vitro inhibition of purified bovine brain tubulin polymerisation in the absence of microtubule-associated proteins.,Confirmatory,,
956,213996,9,5,,103177124,6167,Active,75053735.0,,2.5,IC50,In vitro inhibition of purified bovine brain tubulin polymerisation in the absence of microtubule-associated proteins.,Confirmatory,,
957,213996,9,5,,103177124,6167,Active,118573906.0,281555.0,2.5,IC50,In vitro inhibition of purified bovine brain tubulin polymerisation in the absence of microtubule-associated proteins.,Confirmatory,,
958,214006,9,3,,103177124,6167,Active,,,1.4,IC50,In vitro inhibitory activity against tubulin polymerization (10 uM),Confirmatory,9632366.0,
959,214008,9,5,,103177124,6167,Active,75053726.0,,1.9,IC50,Inhibition of Tubulin polymerization by a 40 uM solution of compound; compound showed inhibition >50% at 40 uM,Confirmatory,9836614.0,
960,214008,9,5,,103177124,6167,Active,75053735.0,,1.9,IC50,Inhibition of Tubulin polymerization by a 40 uM solution of compound; compound showed inhibition >50% at 40 uM,Confirmatory,9836614.0,
961,214008,9,5,,103177124,6167,Active,118573906.0,281555.0,1.9,IC50,Inhibition of Tubulin polymerization by a 40 uM solution of compound; compound showed inhibition >50% at 40 uM,Confirmatory,9836614.0,
962,214010,6,8,,103177124,6167,Active,75053726.0,,1.7,IC50,Inhibition of tubulin polymerization using isolated calf brain at 26 degrees C,Confirmatory,9357519.0,
963,214010,6,8,,103177124,6167,Active,75053735.0,,1.7,IC50,Inhibition of tubulin polymerization using isolated calf brain at 26 degrees C,Confirmatory,9357519.0,
964,214010,6,8,,103177124,6167,Active,118573906.0,281555.0,1.7,IC50,Inhibition of tubulin polymerization using isolated calf brain at 26 degrees C,Confirmatory,9357519.0,
965,214011,6,8,,103177124,6167,Active,75053726.0,,2.1,IC50,Inhibition of tubulin polymerization using isolated calf brain at 37 degrees C,Confirmatory,9357519.0,
966,214011,6,8,,103177124,6167,Active,75053735.0,,2.1,IC50,Inhibition of tubulin polymerization using isolated calf brain at 37 degrees C,Confirmatory,9357519.0,
967,214011,6,8,,103177124,6167,Active,118573906.0,281555.0,2.1,IC50,Inhibition of tubulin polymerization using isolated calf brain at 37 degrees C,Confirmatory,9357519.0,
968,214012,11,1,,103177124,6167,Unspecified,,,11200.0,IC50,Inhibition of tubulin polymerization,Confirmatory,9371249.0,
969,214014,6,3,,103177124,6167,Active,,,0.8,IC50,Inhibition of tubulin polymerization,Confirmatory,8164254.0,
970,214015,6,8,,103177124,6167,Active,75053726.0,,0.8,IC50,Inhibition of tubulin polymerization,Confirmatory,9301667.0,
971,214015,6,8,,103177124,6167,Active,75053735.0,,0.8,IC50,Inhibition of tubulin polymerization,Confirmatory,9301667.0,
972,214015,6,8,,103177124,6167,Active,118573906.0,281555.0,0.8,IC50,Inhibition of tubulin polymerization,Confirmatory,9301667.0,
973,214021,6,8,,103177124,6167,Active,75053726.0,,4.2,IC50,Inhibition of tubulin polymerization with preincubation for 15 minutes at 37 degree Centigrade prior to addition of the GTP required for polymerization,Confirmatory,8496935.0,
974,214021,6,8,,103177124,6167,Active,75053735.0,,4.2,IC50,Inhibition of tubulin polymerization with preincubation for 15 minutes at 37 degree Centigrade prior to addition of the GTP required for polymerization,Confirmatory,8496935.0,
975,214021,6,8,,103177124,6167,Active,118573906.0,281555.0,4.2,IC50,Inhibition of tubulin polymerization with preincubation for 15 minutes at 37 degree Centigrade prior to addition of the GTP required for polymerization,Confirmatory,8496935.0,
976,214031,6,8,,103177124,6167,Active,75053726.0,,0.8,IC50,Tested for inhibition against tubulin polymerization,Confirmatory,11087572.0,
977,214031,6,8,,103177124,6167,Active,75053735.0,,0.8,IC50,Tested for inhibition against tubulin polymerization,Confirmatory,11087572.0,
978,214031,6,8,,103177124,6167,Active,118573906.0,281555.0,0.8,IC50,Tested for inhibition against tubulin polymerization,Confirmatory,11087572.0,
979,214033,6,7,,103177124,6167,Active,75053726.0,,0.8,IC50,Inhibition of bovine tubulin polymerization,Confirmatory,7932568.0,
980,214033,6,7,,103177124,6167,Active,75053735.0,,0.8,IC50,Inhibition of bovine tubulin polymerization,Confirmatory,7932568.0,
981,214033,6,7,,103177124,6167,Active,118573906.0,281555.0,0.8,IC50,Inhibition of bovine tubulin polymerization,Confirmatory,7932568.0,
982,214039,9,5,,103177124,6167,Active,75053726.0,,0.8,IC50,Inhibition of bovine brain tubulin polymerization (ITP).,Confirmatory,9544215.0,
983,214039,9,5,,103177124,6167,Active,75053735.0,,0.8,IC50,Inhibition of bovine brain tubulin polymerization (ITP).,Confirmatory,9544215.0,
984,214039,9,5,,103177124,6167,Active,118573906.0,281555.0,0.8,IC50,Inhibition of bovine brain tubulin polymerization (ITP).,Confirmatory,9544215.0,
985,214066,4,4,,103177124,6167,Active,,,0.0052,IC50,Inhibition of U937 cell proliferation,Confirmatory,7990108.0,
986,214174,3,10,,103177124,6167,Unspecified,75053726.0,,,,Inhibition of Tubulin polymerization by a 40 uM solution of compound,Other,9836614.0,
987,214174,3,10,,103177124,6167,Unspecified,75053735.0,,,,Inhibition of Tubulin polymerization by a 40 uM solution of compound,Other,9836614.0,
988,214174,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,Inhibition of Tubulin polymerization by a 40 uM solution of compound,Other,9836614.0,
989,214180,3,10,,103177124,6167,Unspecified,75053726.0,,,,Inhibition of tubulin polymerisation in calf brain,Other,9357519.0,
990,214180,3,10,,103177124,6167,Unspecified,75053735.0,,,,Inhibition of tubulin polymerisation in calf brain,Other,9357519.0,
991,214180,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,Inhibition of tubulin polymerisation in calf brain,Other,9357519.0,
992,214205,3,10,,103177124,6167,Unspecified,75053726.0,,,,"Inhibition of tubulin polymerization using purified bovine brain tubulin relative to estratropone, activity expressed as relative activity (IC50colchicine /IC50 estratropone).",Other,,
993,214205,3,10,,103177124,6167,Unspecified,75053735.0,,,,"Inhibition of tubulin polymerization using purified bovine brain tubulin relative to estratropone, activity expressed as relative activity (IC50colchicine /IC50 estratropone).",Other,,
994,214205,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,"Inhibition of tubulin polymerization using purified bovine brain tubulin relative to estratropone, activity expressed as relative activity (IC50colchicine /IC50 estratropone).",Other,,
995,214331,3,10,,103177124,6167,Unspecified,75053726.0,,,,Percentage inhibition of [3H]-colchicine binding at 5 uM,Other,8496935.0,
996,214331,3,10,,103177124,6167,Unspecified,75053735.0,,,,Percentage inhibition of [3H]-colchicine binding at 5 uM,Other,8496935.0,
997,214331,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,Percentage inhibition of [3H]-colchicine binding at 5 uM,Other,8496935.0,
998,214332,6,3,,103177124,6167,Active,,,2.4,IC50,Inhibitory effect on the polymerization of purified bovine brain tubulin.,Confirmatory,2299625.0,
999,214350,9,5,,103177124,6167,Active,135435.0,100135051.0,5.75,Ki,Binding affinity against tubulin usingf [3H]-colchicine as radioligand,Confirmatory,7381854.0,
1000,214350,9,5,,103177124,6167,Active,135490.0,,5.75,Ki,Binding affinity against tubulin usingf [3H]-colchicine as radioligand,Confirmatory,7381854.0,
1001,214361,6,8,,103177124,6167,Active,135435.0,100135051.0,2.5,IC50,Tested for the inhibition of polymerization rate of tubulin microtubule assembly.,Confirmatory,7381854.0,
1002,214361,6,8,,103177124,6167,Active,135490.0,,2.5,IC50,Tested for the inhibition of polymerization rate of tubulin microtubule assembly.,Confirmatory,7381854.0,
1003,214367,9,5,,103177124,6167,Active,135435.0,100135051.0,10.0,IC50,In vitro tubulin polymerization-inhibitory activity.,Confirmatory,9873473.0,
1004,214367,9,5,,103177124,6167,Active,135490.0,,10.0,IC50,In vitro tubulin polymerization-inhibitory activity.,Confirmatory,9873473.0,
1005,214373,9,5,,103177124,6167,Active,135435.0,100135051.0,1.26,IC50,In vitro inhibitory concentration required to displace [3H]colchicine from its binding site on tubulin,Confirmatory,12852768.0,
1006,214373,9,5,,103177124,6167,Active,135490.0,,1.26,IC50,In vitro inhibitory concentration required to displace [3H]colchicine from its binding site on tubulin,Confirmatory,12852768.0,
1007,214375,3,10,,103177124,6167,Unspecified,,,,,Inhibition of [3H]colchicine binding to microtubule protein tubulin,Other,7265112.0,
1008,214376,3,9,,103177124,6167,Unspecified,,,,,Percentage by which binding is reduced at 25 uM in rat brain microtubule protein,Other,6620299.0,
1009,214548,9,3,,103177124,6167,Active,,,1.5,IC50,In vitro inhibition of mammalian tubulin polymerization by 50%,Confirmatory,9599244.0,
1010,214550,6,4,,103177124,6167,Active,,,1.5,IC50,Inhibition of Tubulin polymerization after 20 minutes of administration at 30 degree Centigrade,Confirmatory,9083485.0,
1011,214555,6,3,,103177124,6167,Active,,,0.8,IC50,Inhibition of bovine tubulin polymerization,Confirmatory,9216846.0,
1012,214556,9,2,,103177124,6167,Active,,,0.8,IC50,Inhibition of tubulin polymerization (ITP),Confirmatory,11689079.0,
1013,214692,8,1,,103177124,6167,Unspecified,,,800.0,IC50,Inhibitory concentration required against tubulin polymerization in the antimicrotubule activity test,Confirmatory,11354375.0,
1014,214694,9,3,,103177124,6167,Active,,,1.9,IC50,Tested for 50 % inhibition of tubulin polymerization by turbidimetric assay,Confirmatory,,
1015,214696,6,4,,103177124,6167,Active,,,1.5,IC50,The compound was evaluated in vitro for the mammalian brain tubulin polymerization using standard assay.,Confirmatory,,
1016,214714,3,7,,103177124,6167,Unspecified,,,,,Inhibitory activity against tubulin polymerization at 0.25 mM concentration,Other,10571149.0,
1017,214715,3,7,,103177124,6167,Unspecified,,,,,Inhibitory activity against tubulin polymerization at 0.5 mM concentration,Other,10571149.0,
1018,214716,3,7,,103177124,6167,Unspecified,,,,,Inhibitory activity against tubulin polymerization at 1.0 mM concentration,Other,10571149.0,
1019,214717,3,7,,103177124,6167,Unspecified,,,,,Inhibitory activity against tubulin polymerization at 2.0 mM concentration,Other,10571149.0,
1020,214730,3,10,,103177124,6167,Unspecified,,,,,Inhibitory binding percentage of compound towards colchicine site in tubulin using tubulin-[3H]colchicine as radioligand at a concentration of 100 uM,Other,12372531.0,
1021,214731,3,10,,103177124,6167,Unspecified,,,,,Inhibitory binding percentage of compound towards colchicine site in tubulin using tubulin-[3H]colchicine as radioligand at a concentration of 200 uM,Other,12372531.0,
1022,214733,3,9,,103177124,6167,Unspecified,,,,,Compound was evaluated for its affinity to bind tubulin at 37 degree centigrade; value ranges from 10E3 - 10E4,Other,,
1023,214734,5,5,,103177124,6167,Unspecified,,,,,Compound was evaluated for its affinity to bind tubulin at 37 degree centigrade; value ranges from E6 to E7,Other,,
1024,214735,9,3,,103177124,6167,Active,,,2.5,Ki,Compound was evaluated for its ability to inhibit the binding of [3H]-colchicine to tubulin in competitive binding assay,Confirmatory,,
1025,214887,8,2,,103177124,6167,Active,,,4.16869,IC50,Inhibition of tubulin polymerization interacting at the colchicine binding site.,Confirmatory,10649972.0,
1026,214889,3,7,,103177124,6167,Unspecified,,,,,beta-Tubulin GTPase activity at 1 uM concentration.,Other,11741473.0,
1027,214891,3,7,,103177124,6167,Unspecified,,,,,beta-Tubulin GTPase activity at 10 uM concentration.,Other,11741473.0,
1028,214892,3,8,,103177124,6167,Unspecified,,,,,Binding affinity towards tubulin protein measured by their ability to displace [3H]colchicine from rat brain at the dose 2.5 M,Other,4032423.0,
1029,214893,3,8,,103177124,6167,Unspecified,,,,,Binding affinity towards tubulin protein measured by their ability to displace [3H]colchicine from rat brain at the dose 25 uM,Other,4032423.0,
1030,216262,4,5,,103177124,6167,Active,,,0.0515,IC50,Inhibitory concentration required for cytotoxicity in hydroxyrubicin-resistant (WP159/R) cells,Confirmatory,,
1031,218985,6,2,,103177124,6167,Active,,,11.8,IC50,Compound was evaluated for inhibition of tubulin polymerization in bovine brain tubulin,Confirmatory,9871709.0,
1032,220415,6,2,,103177124,6167,Active,,,0.006,EC50,Tested for caspase activation activity in human breast cancer ZR-75-1 cells,Confirmatory,12773051.0,
1033,221845,10,1,,103177124,6167,Unspecified,,,200.0,ED50,Cytotoxic activity against mouse macrophage cell line J7.COL-100.,Confirmatory,1956052.0,
1034,221848,10,1,,103177124,6167,Active,,,17.0,ED50,Cytotoxic activity against mouse macrophage cell line J7.VBL-1,Confirmatory,1956052.0,
1035,221849,8,1,,103177124,6167,Active,,,0.06,ED50,Cytotoxic activity against mouse macrophage cell line J774.2,Confirmatory,1956052.0,
1036,225069,6,3,,103177124,6167,Active,,,0.071,IC50,The compound was evaluated in vitro for the inhibition of P388D1 cell colony formation.,Confirmatory,,
1037,225070,6,3,,103177124,6167,Active,,,0.00062,IC50,The compound was evaluated in vitro for the inhibition of murine leukemia P388D1 cell proliferation.,Confirmatory,,
1038,225199,6,2,,103177124,6167,Active,,,5.1,IC50,Concentration required to effect a 50% reduction in microtubule polymerization,Confirmatory,8459402.0,
1039,225200,3,3,,103177124,6167,Unspecified,,,,,Percent inhibition of [3H]-colchicine binding to tubulin with molar ratio of 1:1 (inhibitor: [3H]-colchicine),Other,8459402.0,
1040,225315,3,4,,103177124,6167,Unspecified,,,,,Percent inhibition of [3H]colchicine binding to tubulin with molar ratio of 1:10 (inhibitor: [3H]colchicine),Other,8459402.0,
1041,228428,3,7,,103177124,6167,Inactive,,,,,Compound was evaluated for its ability to affect topoisomerase II inhibition; inactive,Other,9871709.0,
1042,228457,6,4,,103177124,6167,Active,,,1.9,IC50,Inhibition of tubulin polymerization,Confirmatory,8387598.0,
1043,228458,6,8,,103177124,6167,Active,75053726.0,,11.2,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 30 degree C,Confirmatory,10091693.0,
1044,228458,6,8,,103177124,6167,Active,75053735.0,,11.2,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 30 degree C,Confirmatory,10091693.0,
1045,228458,6,8,,103177124,6167,Active,118573906.0,281555.0,11.2,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 30 degree C,Confirmatory,10091693.0,
1046,228459,6,8,,103177124,6167,Active,75053726.0,,8.7,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 37 degree C,Confirmatory,10091693.0,
1047,228459,6,8,,103177124,6167,Active,75053735.0,,8.7,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 37 degree C,Confirmatory,10091693.0,
1048,228459,6,8,,103177124,6167,Active,118573906.0,281555.0,8.7,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 37 degree C,Confirmatory,10091693.0,
1049,228460,6,8,,103177124,6167,Active,75053726.0,,8.7,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 45 degree C,Confirmatory,10091693.0,
1050,228460,6,8,,103177124,6167,Active,75053735.0,,8.7,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 45 degree C,Confirmatory,10091693.0,
1051,228460,6,8,,103177124,6167,Active,118573906.0,281555.0,8.7,IC50,Inhibition of tubulin polymerization activity using homogenous bovine brain tubulin at 45 degree C,Confirmatory,10091693.0,
1052,228462,3,10,,103177124,6167,Unspecified,75053726.0,,,,"Inhibition of tubulin polymerization, induced by 10 mM taxol at a concentration of 2 uM.",Other,1956052.0,
1053,228462,3,10,,103177124,6167,Unspecified,75053735.0,,,,"Inhibition of tubulin polymerization, induced by 10 mM taxol at a concentration of 2 uM.",Other,1956052.0,
1054,228462,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,"Inhibition of tubulin polymerization, induced by 10 mM taxol at a concentration of 2 uM.",Other,1956052.0,
1055,228464,3,10,,103177124,6167,Unspecified,75053726.0,,,,"Inhibition of tubulin polymerization, induced by 10 mM taxol at a concentration of 5 uM.",Other,1956052.0,
1056,228464,3,10,,103177124,6167,Unspecified,75053735.0,,,,"Inhibition of tubulin polymerization, induced by 10 mM taxol at a concentration of 5 uM.",Other,1956052.0,
1057,228464,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,"Inhibition of tubulin polymerization, induced by 10 mM taxol at a concentration of 5 uM.",Other,1956052.0,
1058,228466,3,10,,103177124,6167,Unspecified,75053726.0,,,,"Inhibition of tubulin polymerization, induced by 1 mM GTP at a concentration of 2 uM.",Other,1956052.0,
1059,228466,3,10,,103177124,6167,Unspecified,75053735.0,,,,"Inhibition of tubulin polymerization, induced by 1 mM GTP at a concentration of 2 uM.",Other,1956052.0,
1060,228466,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,"Inhibition of tubulin polymerization, induced by 1 mM GTP at a concentration of 2 uM.",Other,1956052.0,
1061,228615,3,10,,103177124,6167,Unspecified,75053726.0,,,,"Inhibition of tubulin polymerization, induced by 1 mM GTP at a concentration of 5 uM.",Other,1956052.0,
1062,228615,3,10,,103177124,6167,Unspecified,75053735.0,,,,"Inhibition of tubulin polymerization, induced by 1 mM GTP at a concentration of 5 uM.",Other,1956052.0,
1063,228615,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,"Inhibition of tubulin polymerization, induced by 1 mM GTP at a concentration of 5 uM.",Other,1956052.0,
1064,231477,3,4,,103177124,6167,Unspecified,,,,,Ratio between IC50 value of DOX/R and WP159/R was determined,Other,,
1065,235165,3,3,,103177124,6167,Unspecified,,,,,Selectivity ratio expressed as temperature dependence at 45 Degree C to that of 30 Degree C in bovine brain tubulin,Other,10091693.0,
1066,235404,3,3,,103177124,6167,Unspecified,,,,,Therapeutic ratio was determined for intraperitoneal administration,Other,6218302.0,
1067,235405,3,3,,103177124,6167,Unspecified,,,,,Therapeutic ratio was determined for peroral administration,Other,6218302.0,
1068,236904,3,3,,103177124,6167,Unspecified,,,,,Partition coefficient (logP),Other,15925511.0,
1069,243422,3,10,,103177124,6167,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
1070,247402,8,1,,103177124,6167,Active,,,0.0017,GI50,Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program,Confirmatory,15743190.0,
1071,249634,3,4,,103177124,6167,Unspecified,,,,,Effect to arrest S-phase on HEK 293 cells at 10 uM was determined,Other,15828811.0,
1072,249637,3,4,,103177124,6167,Unspecified,,,,,Effect to arrest GI-phase on HEK 293 cells at 10 uM was determined,Other,15828811.0,
1073,249641,3,4,,103177124,6167,Unspecified,,,,,Effect to arrest G2/M-phase on HEK 293 cells at 10 uM was determined,Other,15828811.0,
1074,251661,3,3,,103177124,6167,Unspecified,,,,,Inhibitory activity against tubulin polymerization at 20 uM,Other,15603947.0,
1075,256879,3,10,,103177124,6167,Unspecified,75053726.0,,,,Inhibition of tubulin polymerization in bovine brain at 10 uM,Other,16198562.0,
1076,256879,3,10,,103177124,6167,Unspecified,75053735.0,,,,Inhibition of tubulin polymerization in bovine brain at 10 uM,Other,16198562.0,
1077,256879,3,10,,103177124,6167,Unspecified,118573906.0,281555.0,,,Inhibition of tubulin polymerization in bovine brain at 10 uM,Other,16198562.0,
1078,256880,5,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in A431 cells by accumulation at G2/M phase cell at 0.1uM,Other,16198562.0,
1079,256881,6,2,,103177124,6167,Active,,,0.0028,EC50,Cell cycle arrest in A431 cells by accumulation at G2/M phase cell,Confirmatory,16198562.0,
1080,261687,4,1,,103177124,6167,Unspecified,,,,,Antiproliferative activity against NCI60 cell line,Other,16539384.0,
1081,261688,3,3,,103177124,6167,Unspecified,,,,,Activity against NCI60 cell line xenograft in nude mouse by HF assay,Other,16539384.0,
1082,262911,9,5,,103177124,6167,Active,20455316.0,7278.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1083,262911,9,5,,103177124,6167,Active,20455316.0,113457.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1084,262911,9,5,,103177124,6167,Active,20455322.0,84790.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1085,262911,9,5,,103177124,6167,Active,20455526.0,10381.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1086,262911,9,5,,103177124,6167,Active,55977474.0,10376.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1087,262911,9,5,,103177124,6167,Active,55977476.0,7277.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1088,262911,9,5,,103177124,6167,Active,55977480.0,10383.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1089,262911,9,5,,103177124,6167,Active,55977864.0,7846.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1090,262911,9,5,,103177124,6167,Active,56757569.0,203068.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1091,262911,9,5,,103177124,6167,Active,62903515.0,81027.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1092,262911,9,5,,103177124,6167,Active,68776070.0,84617.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1093,262911,9,5,,103177124,6167,Active,74761283.0,347733.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1094,262911,9,5,,103177124,6167,Active,74762137.0,7280.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1095,262911,9,5,,103177124,6167,Active,93141323.0,10382.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1096,262911,9,5,,103177124,6167,Active,182705285.0,347688.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1097,262911,9,5,,103177124,6167,Active,224471855.0,112714.0,2.7,IC50,Inhibition of tubulin polymerization,Confirmatory,16570932.0,
1098,264021,6,7,,103177124,6167,Active,20455316.0,7278.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1099,264021,6,7,,103177124,6167,Active,20455316.0,113457.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1100,264021,6,7,,103177124,6167,Active,20455322.0,84790.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1101,264021,6,7,,103177124,6167,Active,20455526.0,10381.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1102,264021,6,7,,103177124,6167,Active,55977474.0,10376.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1103,264021,6,7,,103177124,6167,Active,55977476.0,7277.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1104,264021,6,7,,103177124,6167,Active,55977480.0,10383.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1105,264021,6,7,,103177124,6167,Active,55977864.0,7846.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1106,264021,6,7,,103177124,6167,Active,56757569.0,203068.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1107,264021,6,7,,103177124,6167,Active,62903515.0,81027.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1108,264021,6,7,,103177124,6167,Active,68776070.0,84617.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1109,264021,6,7,,103177124,6167,Active,74761283.0,347733.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1110,264021,6,7,,103177124,6167,Active,74762137.0,7280.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1111,264021,6,7,,103177124,6167,Active,93141323.0,10382.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1112,264021,6,7,,103177124,6167,Active,182705285.0,347688.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1113,264021,6,7,,103177124,6167,Active,224471855.0,112714.0,1.7,IC50,Inhibition of microtubule polymerization,Confirmatory,16504507.0,
1114,264024,4,4,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human PC3 cell line,Confirmatory,16504507.0,
1115,270729,3,11,,103177124,6167,Unspecified,135435.0,100135051.0,,,Inhibition of tubulin polymerization in porcine brain at 20 uM,Other,16870433.0,
1116,270729,3,11,,103177124,6167,Unspecified,135490.0,,,,Inhibition of tubulin polymerization in porcine brain at 20 uM,Other,16870433.0,
1117,270964,6,2,,103177124,6167,Active,,,0.016,IC50,Cytotoxicity against proliferating RKOp27 cells after 72 hrs by Alamar Blue assay,Confirmatory,16970401.0,
1118,270965,6,2,,103177124,6167,Unspecified,,,5.0,IC50,Cytotoxicity against cell cycle arrested RKOp27 cells after 72 hrs by alamar blue assay,Confirmatory,16970401.0,
1119,270966,9,5,,103177124,6167,Active,20455316.0,7278.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1120,270966,9,5,,103177124,6167,Active,20455316.0,113457.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1121,270966,9,5,,103177124,6167,Active,20455322.0,84790.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1122,270966,9,5,,103177124,6167,Active,20455526.0,10381.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1123,270966,9,5,,103177124,6167,Active,55977474.0,10376.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1124,270966,9,5,,103177124,6167,Active,55977476.0,7277.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1125,270966,9,5,,103177124,6167,Active,55977480.0,10383.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1126,270966,9,5,,103177124,6167,Active,55977864.0,7846.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1127,270966,9,5,,103177124,6167,Active,56757569.0,203068.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1128,270966,9,5,,103177124,6167,Active,62903515.0,81027.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1129,270966,9,5,,103177124,6167,Active,68776070.0,84617.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1130,270966,9,5,,103177124,6167,Active,74761283.0,347733.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1131,270966,9,5,,103177124,6167,Active,74762137.0,7280.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1132,270966,9,5,,103177124,6167,Active,93141323.0,10382.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1133,270966,9,5,,103177124,6167,Active,182705285.0,347688.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1134,270966,9,5,,103177124,6167,Active,224471855.0,112714.0,0.5,IC50,Inhibition of [3H]colchicine binding to beta tubulin,Confirmatory,16970401.0,
1135,271652,4,4,,103177124,6167,Active,,,0.015,IC50,Cytotoxicity against human MKN45 cell line by methylene blue dye assay,Confirmatory,17154496.0,
1136,271653,4,4,,103177124,6167,Active,,,0.0133,IC50,Cytotoxicity against human KB cell line by methylene blue dye assay,Confirmatory,17154496.0,
1137,271657,4,4,,103177124,6167,Active,,,0.11699999999999999,IC50,Cytotoxicity against KB-VIN 10 cell line by methylene blue dye assay,Confirmatory,17154496.0,
1138,271658,6,7,,103177124,6167,Active,20455316.0,7278.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1139,271658,6,7,,103177124,6167,Active,20455316.0,113457.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1140,271658,6,7,,103177124,6167,Active,20455322.0,84790.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1141,271658,6,7,,103177124,6167,Active,20455526.0,10381.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1142,271658,6,7,,103177124,6167,Active,55977474.0,10376.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1143,271658,6,7,,103177124,6167,Active,55977476.0,7277.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1144,271658,6,7,,103177124,6167,Active,55977480.0,10383.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1145,271658,6,7,,103177124,6167,Active,55977864.0,7846.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1146,271658,6,7,,103177124,6167,Active,56757569.0,203068.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1147,271658,6,7,,103177124,6167,Active,62903515.0,81027.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1148,271658,6,7,,103177124,6167,Active,68776070.0,84617.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1149,271658,6,7,,103177124,6167,Active,74761283.0,347733.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1150,271658,6,7,,103177124,6167,Active,74762137.0,7280.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1151,271658,6,7,,103177124,6167,Active,93141323.0,10382.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1152,271658,6,7,,103177124,6167,Active,182705285.0,347688.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1153,271658,6,7,,103177124,6167,Active,224471855.0,112714.0,3.3,IC50,Inhibition of tubulin polymerization,Confirmatory,17154496.0,
1154,273359,6,7,,103177124,6167,Active,20455316.0,7278.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1155,273359,6,7,,103177124,6167,Active,20455316.0,113457.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1156,273359,6,7,,103177124,6167,Active,20455322.0,84790.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1157,273359,6,7,,103177124,6167,Active,20455526.0,10381.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1158,273359,6,7,,103177124,6167,Active,55977474.0,10376.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1159,273359,6,7,,103177124,6167,Active,55977476.0,7277.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1160,273359,6,7,,103177124,6167,Active,55977480.0,10383.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1161,273359,6,7,,103177124,6167,Active,55977864.0,7846.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1162,273359,6,7,,103177124,6167,Active,56757569.0,203068.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1163,273359,6,7,,103177124,6167,Active,62903515.0,81027.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1164,273359,6,7,,103177124,6167,Active,68776070.0,84617.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1165,273359,6,7,,103177124,6167,Active,74761283.0,347733.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1166,273359,6,7,,103177124,6167,Active,74762137.0,7280.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1167,273359,6,7,,103177124,6167,Active,93141323.0,10382.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1168,273359,6,7,,103177124,6167,Active,182705285.0,347688.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1169,273359,6,7,,103177124,6167,Active,224471855.0,112714.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17034147.0,
1170,274784,6,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human K562 cell line,Confirmatory,17181164.0,
1171,274785,6,2,,103177124,6167,Active,,,1.4,IC50,Inhibition of tubulin polymerization in porcine brain,Confirmatory,17181164.0,
1172,274786,6,3,,103177124,6167,Active,,,0.03,IC50,Antiproliferative activity against KB/HeLa cells by XTT assay after 48 hrs,Confirmatory,17181164.0,
1173,274787,6,2,,103177124,6167,Active,,,0.05,IC50,Antiproliferative activity against SKOV3 cells by XTT assay after 48 hrs,Confirmatory,17181164.0,
1174,274788,6,2,,103177124,6167,Active,,,0.05,IC50,Antiproliferative activity against SF268 cells by XTT assay after 48 hrs,Confirmatory,17181164.0,
1175,274789,6,2,,103177124,6167,Active,,,0.07,IC50,Antiproliferative activity against NCI-H460 cells by XTT assay after 48 hrs,Confirmatory,17181164.0,
1176,274790,6,2,,103177124,6167,Unspecified,,,10.0,IC50,Antiproliferative activity against RKO cells with ectopic-induced p27kip1-expression by XTT assay after 48 hrs,Confirmatory,17181164.0,
1177,274791,6,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against RKO cells by XTT assay after 48 hrs,Confirmatory,17181164.0,
1178,274798,4,3,,103177124,6167,Active,,,0.013999999999999999,EC50,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase,Confirmatory,17181164.0,
1179,274802,7,1,,103177124,6167,Active,20455316.0,7278.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1180,274802,7,1,,103177124,6167,Active,20455316.0,113457.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1181,274802,7,1,,103177124,6167,Active,20455322.0,84790.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1182,274802,7,1,,103177124,6167,Active,20455526.0,10381.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1183,274802,7,1,,103177124,6167,Active,55977474.0,10376.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1184,274802,7,1,,103177124,6167,Active,55977476.0,7277.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1185,274802,7,1,,103177124,6167,Active,55977480.0,10383.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1186,274802,7,1,,103177124,6167,Active,55977864.0,7846.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1187,274802,7,1,,103177124,6167,Active,56757569.0,203068.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1188,274802,7,1,,103177124,6167,Active,62903515.0,81027.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1189,274802,7,1,,103177124,6167,Active,68776070.0,84617.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1190,274802,7,1,,103177124,6167,Active,74761283.0,347733.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1191,274802,7,1,,103177124,6167,Active,74762137.0,7280.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1192,274802,7,1,,103177124,6167,Active,93141323.0,10382.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1193,274802,7,1,,103177124,6167,Active,182705285.0,347688.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1194,274802,7,1,,103177124,6167,Active,224471855.0,112714.0,,,Displacement of [3H]colchicine from tubulin by SPA assay,Other,17181164.0,
1195,274810,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 0.3 nM,Other,17181164.0,
1196,274811,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 1 nM,Other,17181164.0,
1197,274812,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 3.16 nM,Other,17181164.0,
1198,274813,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 10 nM,Other,17181164.0,
1199,274814,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 31.6 nM,Other,17181164.0,
1200,274815,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 100 nM,Other,17181164.0,
1201,274816,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at S phase at 316 nM,Other,17181164.0,
1202,274818,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 0.3 nM,Other,17181164.0,
1203,274819,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 1 nM,Other,17181164.0,
1204,274820,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 3.16 nM,Other,17181164.0,
1205,274821,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 10 nM,Other,17181164.0,
1206,274822,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 31.6 nM,Other,17181164.0,
1207,274823,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 100 nM,Other,17181164.0,
1208,274824,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G2/M phase at 316 nM,Other,17181164.0,
1209,274826,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 0.3 nM,Other,17181164.0,
1210,274827,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 1 nM,Other,17181164.0,
1211,274828,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 3.16 nM,Other,17181164.0,
1212,274829,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 10 nM,Other,17181164.0,
1213,274830,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 31.6 nM,Other,17181164.0,
1214,274831,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 100 nM,Other,17181164.0,
1215,274832,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells by accumulation at G1 phase at 316 nM,Other,17181164.0,
1216,275870,3,4,,103177124,6167,Inactive,,,,,Induction of apoptosis in HeLa cells assessed as effect on sub-G1 population,Other,17228873.0,
1217,277278,4,4,,103177124,6167,Active,,,0.00275,IC50,Cytotoxicity against HCT116 cell line,Confirmatory,17249649.0,
1218,277279,4,4,,103177124,6167,Active,,,0.522,IC50,Cytotoxicity against ZR-75-1 cell line,Confirmatory,17249649.0,
1219,277280,4,4,,103177124,6167,Active,,,0.0018399999999999998,IC50,Cytotoxicity against HeLa cell line,Confirmatory,17249649.0,
1220,277281,4,3,,103177124,6167,Active,,,0.00399,IC50,Cytotoxicity against KB-3-1 cell line,Confirmatory,17249649.0,
1221,277282,4,3,,103177124,6167,Active,,,0.62,IC50,Cytotoxicity against P-glycoprotein-overexpressing KB-V1 cell line,Confirmatory,17249649.0,
1222,277283,7,1,,103177124,6167,Inconclusive,20455316.0,7278.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1223,277283,7,1,,103177124,6167,Inconclusive,20455316.0,113457.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1224,277283,7,1,,103177124,6167,Inconclusive,20455322.0,84790.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1225,277283,7,1,,103177124,6167,Inconclusive,20455526.0,10381.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1226,277283,7,1,,103177124,6167,Inconclusive,55977474.0,10376.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1227,277283,7,1,,103177124,6167,Inconclusive,55977476.0,7277.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1228,277283,7,1,,103177124,6167,Inconclusive,55977480.0,10383.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1229,277283,7,1,,103177124,6167,Inconclusive,55977864.0,7846.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1230,277283,7,1,,103177124,6167,Inconclusive,56757569.0,203068.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1231,277283,7,1,,103177124,6167,Inconclusive,62903515.0,81027.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1232,277283,7,1,,103177124,6167,Inconclusive,68776070.0,84617.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1233,277283,7,1,,103177124,6167,Inconclusive,74761283.0,347733.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1234,277283,7,1,,103177124,6167,Inconclusive,74762137.0,7280.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1235,277283,7,1,,103177124,6167,Inconclusive,93141323.0,10382.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1236,277283,7,1,,103177124,6167,Inconclusive,182705285.0,347688.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1237,277283,7,1,,103177124,6167,Inconclusive,224471855.0,112714.0,,IC50,Inhibition of tubulin polymerization,Confirmatory,17249649.0,
1238,280072,4,4,,103177124,6167,Active,,,0.0063,IC50,Antiproliferative activity against drug sensitive Messa cell line by Alamar Blue assay,Confirmatory,17286393.0,
1239,280073,4,4,,103177124,6167,Active,,,0.063,IC50,Antiproliferative activity against drug resistant Messa/DX5 cell line expressing MDR1 by Alamar Blue assay,Confirmatory,17286393.0,
1240,280074,4,5,,103177124,6167,Active,,,0.1,IC50,Antiproliferative activity against drug resistant HCT15 cell line expressing MDR1 by Alamar Blue assay,Confirmatory,17286393.0,
1241,280075,4,5,,103177124,6167,Active,,,0.0398,IC50,Antiproliferative activity against drug resistant ACHN cell line expressing MDR1 by Alamar Blue assay,Confirmatory,17286393.0,
1242,281503,7,1,,103177124,6167,Active,20455316.0,7278.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1243,281503,7,1,,103177124,6167,Active,20455316.0,113457.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1244,281503,7,1,,103177124,6167,Active,20455322.0,84790.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1245,281503,7,1,,103177124,6167,Active,20455526.0,10381.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1246,281503,7,1,,103177124,6167,Active,55977474.0,10376.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1247,281503,7,1,,103177124,6167,Active,55977476.0,7277.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1248,281503,7,1,,103177124,6167,Active,55977480.0,10383.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1249,281503,7,1,,103177124,6167,Active,55977864.0,7846.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1250,281503,7,1,,103177124,6167,Active,56757569.0,203068.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1251,281503,7,1,,103177124,6167,Active,62903515.0,81027.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1252,281503,7,1,,103177124,6167,Active,68776070.0,84617.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1253,281503,7,1,,103177124,6167,Active,74761283.0,347733.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1254,281503,7,1,,103177124,6167,Active,74762137.0,7280.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1255,281503,7,1,,103177124,6167,Active,93141323.0,10382.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1256,281503,7,1,,103177124,6167,Active,182705285.0,347688.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1257,281503,7,1,,103177124,6167,Active,224471855.0,112714.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,15566282.0,
1258,281505,4,4,,103177124,6167,Active,,,0.013000000000000001,IC50,Growth inhibition of human MCF7 cells assessed as G2/M DNA content after 48 hrs,Confirmatory,15566282.0,
1259,281698,6,2,,103177124,6167,Active,,,0.013999999999999999,EC50,Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs,Confirmatory,15566300.0,
1260,281699,6,2,,103177124,6167,Active,,,0.034,EC50,Induction of apoptosis in human H1299 cells assessed as caspase activation after 24 hrs,Confirmatory,15566300.0,
1261,281700,6,2,,103177124,6167,Active,,,0.19,EC50,Induction of apoptosis in human DLD1 cells assessed as caspase activation after 24 hrs,Confirmatory,15566300.0,
1262,282687,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in HEK293EBNA cells by accumulation at G1 phase cell at 10 uM relative to DMSO,Other,16279766.0,
1263,282688,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in HEK293EBNA cells by accumulation at S phase cell at 10 uM relative to DMSO,Other,16279766.0,
1264,282689,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in HEK293EBNA cells by accumulation at G2/M phase cell at 10 uM relative to DMSO,Other,16279766.0,
1265,287691,6,2,,103177124,6167,Active,,,0.018000000000000002,IC50,Cytotoxicity against human PC3 cells after 3 days by MTT assay,Confirmatory,17275318.0,
1266,288667,7,1,,103177124,6167,Active,20455316.0,7278.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1267,288667,7,1,,103177124,6167,Active,20455316.0,113457.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1268,288667,7,1,,103177124,6167,Active,20455322.0,84790.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1269,288667,7,1,,103177124,6167,Active,20455526.0,10381.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1270,288667,7,1,,103177124,6167,Active,55977474.0,10376.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1271,288667,7,1,,103177124,6167,Active,55977476.0,7277.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1272,288667,7,1,,103177124,6167,Active,55977480.0,10383.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1273,288667,7,1,,103177124,6167,Active,55977864.0,7846.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1274,288667,7,1,,103177124,6167,Active,56757569.0,203068.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1275,288667,7,1,,103177124,6167,Active,62903515.0,81027.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1276,288667,7,1,,103177124,6167,Active,68776070.0,84617.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1277,288667,7,1,,103177124,6167,Active,74761283.0,347733.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1278,288667,7,1,,103177124,6167,Active,74762137.0,7280.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1279,288667,7,1,,103177124,6167,Active,93141323.0,10382.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1280,288667,7,1,,103177124,6167,Active,182705285.0,347688.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1281,288667,7,1,,103177124,6167,Active,224471855.0,112714.0,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,17497841.0,
1282,288668,4,4,,103177124,6167,Active,,,0.013000000000000001,IC50,Growth inhibition of human MCF7 cells after 48 hrs,Confirmatory,17497841.0,
1283,288670,7,1,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1284,288670,7,1,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1285,288670,7,1,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1286,288670,7,1,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1287,288670,7,1,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1288,288670,7,1,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1289,288670,7,1,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1290,288670,7,1,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1291,288670,7,1,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1292,288670,7,1,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1293,288670,7,1,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1294,288670,7,1,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1295,288670,7,1,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1296,288670,7,1,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1297,288670,7,1,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1298,288670,7,1,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of MTC from tubulin,Other,17497841.0,
1299,288694,6,2,,103177124,6167,Active,,,0.004,GI50,Growth inhibition of human HT29 cells after 48 hrs,Confirmatory,17498960.0,
1300,288695,6,2,,103177124,6167,Active,,,0.015,GI50,Growth inhibition of human M21 cells after 48 hrs,Confirmatory,17498960.0,
1301,288696,6,2,,103177124,6167,Active,,,0.009000000000000001,GI50,Growth inhibition of human MCF7 cells after 48 hrs,Confirmatory,17498960.0,
1302,291499,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in HL60 cells assessed as accumulation in G0/G1 phase at 600 nM,Other,17567121.0,
1303,291503,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in HL60 cells assessed as accumulation in S phase at 600 nM,Other,17567121.0,
1304,291507,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in HL60 cells assessed as accumulation in G0/M phase at 600 nM,Other,17567121.0,
1305,296576,3,3,,103177124,6167,Unspecified,,,,,Effect on thrombin-induced human platelet aggregation assessed as lag time at 0.1 uM,Other,17602466.0,
1306,296580,3,3,,103177124,6167,Unspecified,,,,,Effect on rate of thrombin-induced human platelet aggregation at 0.1 uM,Other,17602466.0,
1307,296584,3,3,,103177124,6167,Unspecified,,,,,Effect on thrombin-induced human platelet aggregation at 0.1 uM,Other,17602466.0,
1308,296594,3,3,,103177124,6167,Unspecified,,,,,Effect on thrombin-induced microtubular reorganization at 10 uM after 30 mins,Other,17602466.0,
1309,297419,4,4,,103177124,6167,Active,,,0.012,IC50,Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay,Confirmatory,17685504.0,
1310,297420,4,3,,103177124,6167,Active,,,0.12,IC50,Growth inhibition of human KB-vin10 cells after 72 hrs by methylene blue dye assay,Confirmatory,17685504.0,
1311,297421,4,4,,103177124,6167,Active,,,0.019,IC50,Growth inhibition of human H460 cells after 72 hrs by methylene blue dye assay,Confirmatory,17685504.0,
1312,297424,4,4,,103177124,6167,Active,,,0.013000000000000001,IC50,Growth inhibition of human MKN45 cells after 72 hrs by methylene blue dye assay,Confirmatory,17685504.0,
1313,297425,7,1,,103177124,6167,Active,20455316.0,7278.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1314,297425,7,1,,103177124,6167,Active,20455316.0,113457.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1315,297425,7,1,,103177124,6167,Active,20455322.0,84790.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1316,297425,7,1,,103177124,6167,Active,20455526.0,10381.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1317,297425,7,1,,103177124,6167,Active,55977474.0,10376.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1318,297425,7,1,,103177124,6167,Active,55977476.0,7277.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1319,297425,7,1,,103177124,6167,Active,55977480.0,10383.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1320,297425,7,1,,103177124,6167,Active,55977864.0,7846.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1321,297425,7,1,,103177124,6167,Active,56757569.0,203068.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1322,297425,7,1,,103177124,6167,Active,62903515.0,81027.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1323,297425,7,1,,103177124,6167,Active,68776070.0,84617.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1324,297425,7,1,,103177124,6167,Active,74761283.0,347733.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1325,297425,7,1,,103177124,6167,Active,74762137.0,7280.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1326,297425,7,1,,103177124,6167,Active,93141323.0,10382.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1327,297425,7,1,,103177124,6167,Active,182705285.0,347688.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1328,297425,7,1,,103177124,6167,Active,224471855.0,112714.0,2.9,IC50,Inhibition of tubulin polymerization in presence of microtubule associated proteins after 30 mins,Confirmatory,17685504.0,
1329,298660,3,4,,103177124,6167,Active,,,,,Increase in caspase 3 activation in Jurkat cells at 5 uM,Other,17894480.0,
1330,299427,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in Jurkat cells assessed as accumulation at G0/G1 phase at 25 uM after 15 hrs relative to control,Other,17512729.0,
1331,299428,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in Jurkat cells assessed as accumulation at S phase at 25 uM after 15 hrs relative to control,Other,17512729.0,
1332,299429,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in Jurkat cells assessed as accumulation at G2/M phase at 25 uM after 15 hrs relative to control,Other,17512729.0,
1333,302074,6,2,,103177124,6167,Active,,,0.03,IC50,Antiproliferative activity against human MDA-MB-231 cells after 4 days by microplate assay,Confirmatory,17889547.0,
1334,302075,6,2,,103177124,6167,Inconclusive,,,,IC50,Antiproliferative activity against human MCF7 cells after 5 days by microplate assay,Confirmatory,17889547.0,
1335,302076,6,2,,103177124,6167,Inconclusive,,,,IC50,Inhibition of cell growth in human A431 cells after 3 days by microplate assay,Confirmatory,17889547.0,
1336,302077,3,3,,103177124,6167,Unspecified,,,,,Inhibition of temperature-induced tubulin polymerization of calf brain at 40 uM,Other,17889547.0,
1337,303684,6,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human K562 cells after 48 hrs,Confirmatory,17973361.0,
1338,303685,6,2,,103177124,6167,Active,,,1.4,IC50,Inhibition of porcine brain tubulin polymerization,Confirmatory,17973361.0,
1339,303686,7,1,,103177124,6167,Active,20455316.0,7278.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1340,303686,7,1,,103177124,6167,Active,20455316.0,113457.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1341,303686,7,1,,103177124,6167,Active,20455322.0,84790.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1342,303686,7,1,,103177124,6167,Active,20455526.0,10381.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1343,303686,7,1,,103177124,6167,Active,55977474.0,10376.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1344,303686,7,1,,103177124,6167,Active,55977476.0,7277.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1345,303686,7,1,,103177124,6167,Active,55977480.0,10383.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1346,303686,7,1,,103177124,6167,Active,55977864.0,7846.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1347,303686,7,1,,103177124,6167,Active,56757569.0,203068.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1348,303686,7,1,,103177124,6167,Active,62903515.0,81027.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1349,303686,7,1,,103177124,6167,Active,68776070.0,84617.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1350,303686,7,1,,103177124,6167,Active,74761283.0,347733.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1351,303686,7,1,,103177124,6167,Active,74762137.0,7280.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1352,303686,7,1,,103177124,6167,Active,93141323.0,10382.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1353,303686,7,1,,103177124,6167,Active,182705285.0,347688.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1354,303686,7,1,,103177124,6167,Active,224471855.0,112714.0,1.05,IC50,Displacement of [3H]colchicine from biotinylated tubulin by scintillation proximity assay,Confirmatory,17973361.0,
1355,303687,6,3,,103177124,6167,Active,,,0.03,IC50,Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay,Confirmatory,17973361.0,
1356,303688,6,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay,Confirmatory,17973361.0,
1357,303689,6,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human SF268 cells after 48 hrs by XTT assay,Confirmatory,17973361.0,
1358,303690,6,2,,103177124,6167,Active,,,0.07,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay,Confirmatory,17973361.0,
1359,303691,6,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human RKO cells after 48 hrs by XTT assay,Confirmatory,17973361.0,
1360,303692,6,2,,103177124,6167,Unspecified,,,14.0,IC50,Cytotoxicity against human RKO cells with ectopic-inducible expression of p27kip1 after 48 hrs by XTT assay,Confirmatory,17973361.0,
1361,303699,8,1,,103177124,6167,Active,,,0.013999999999999999,EC50,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometric analysis,Confirmatory,17973361.0,
1362,303701,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 0.3 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1363,303702,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 1 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1364,303703,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 3.16 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1365,303704,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 10 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1366,303705,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 31.6 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1367,303706,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 100 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1368,303707,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at S phase at 316 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1369,303710,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 0.3 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1370,303711,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 1 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1371,303712,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 3.16 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1372,303713,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 10 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1373,303714,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 31.6 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1374,303715,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 100 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1375,303716,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G2M phase at 316 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1376,303719,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 0.3 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1377,303720,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 1 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1378,303721,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 3.16 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1379,303722,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 10 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1380,303723,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 31.6 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1381,303724,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 100 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1382,303725,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in KB/HeLa cells assessed as accumulation at G1 phase at 316 nM after 24 hrs by flow cytometric analysis,Other,17973361.0,
1383,310118,5,3,,103177124,6167,Active,,,0.37154,IC50,Cytotoxicity against human A2780/ADR cells after 72 hrs by MTT assay,Confirmatory,17890094.0,
1384,310119,6,1,,103177124,6167,Active,,,0.02291,IC50,Cytotoxicity against human A2780 cells after 72 hrs by MTT assay,Confirmatory,17890094.0,
1385,311138,6,2,,103177124,6167,Inconclusive,,,,IC50,Antitrypanosomal activity against Trypanosoma brucei brucei bloodstream trypomastigotes by alamar blue assay,Confirmatory,17637068.0,
1386,311139,6,2,,103177124,6167,Active,,,0.21,IC50,Cytotoxicity against mouse J774 cells by alamar blue assay,Confirmatory,17637068.0,
1387,312971,6,2,,103177124,6167,Active,,,0.009000000000000001,EC50,Induction of apoptosis in human T47D cells assessed as caspase activation after 24 hrs by HTS assay,Confirmatory,18197614.0,
1388,312972,6,2,,103177124,6167,Active,,,0.015,EC50,Induction of apoptosis in human HCT116 cells assessed as caspase activation after 24 hrs by HTS assay,Confirmatory,18197614.0,
1389,312973,6,3,,103177124,6167,Active,,,0.004,EC50,Induction of apoptosis in human SNU398 cells assessed as caspase activation after 24 hrs by HTS assay,Confirmatory,18197614.0,
1390,312974,6,2,,103177124,6167,Active,,,0.006999999999999999,GI50,Growth inhibition of human T47D cells after 48 hrs,Confirmatory,18197614.0,
1391,312975,6,2,,103177124,6167,Inconclusive,,,,GI50,Growth inhibition of human HCT116 cells after 48 hrs,Confirmatory,18197614.0,
1392,312976,6,3,,103177124,6167,Inconclusive,,,,GI50,Growth inhibition of human SNU398 cells after 48 hrs,Confirmatory,18197614.0,
1393,317728,6,2,,103177124,6167,Inconclusive,,,,IC50,Inhibition of HIV1 reverse transcriptase,Confirmatory,18083556.0,
1394,317729,6,2,,103177124,6167,Inconclusive,,,,EC50,Antiviral activity against HIV1RF infected in human CEM-SS cells,Confirmatory,18083556.0,
1395,317730,6,2,,103177124,6167,Inconclusive,,,,EC50,Antiviral activity against HIV13B infected in human MT4 cells,Confirmatory,18083556.0,
1396,317731,6,2,,103177124,6167,Inconclusive,,,,EC50,Antiviral activity against HIV2ROD infected in human MT4 cells,Confirmatory,18083556.0,
1397,317732,6,2,,103177124,6167,Inconclusive,,,,CC50,Cytotoxicity against human HIV1RF infected CEM-SS cells by MTT assay,Confirmatory,18083556.0,
1398,317733,6,2,,103177124,6167,Inconclusive,,,,CC50,Cytotoxicity against mock-infected human MT4 cells by MTT assay,Confirmatory,18083556.0,
1399,317734,6,2,,103177124,6167,Active,,,3.8,IC50,Inhibition of tubulin polymerization after 20 mins,Confirmatory,18083556.0,
1400,326375,9,1,,103177124,6167,Active,,,2.0,IC50,Antiproliferative activity against human MDA-MB-435 cells after 48 hrs by SRB assay,Confirmatory,18083520.0,
1401,326376,8,1,,103177124,6167,Inconclusive,,,,EC50,Inhibition of tubulin polymerization in rat A10 cells after 18 hrs by indirect immunofluorescence technique,Confirmatory,18083520.0,
1402,327206,6,2,,103177124,6167,Active,,,44.9,IC50,Inhibition of tubulin polymerization in presence of microtubule-associated proteins,Confirmatory,18321710.0,
1403,328771,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human Jurkat cells at mitosis at 0.5 uM after 24 hrs,Other,18366178.0,
1404,328776,3,3,,103177124,6167,Active,,,,,Inhibition of pig brain tubulin polymerization at 3 uM,Other,18366178.0,
1405,331396,6,2,,103177124,6167,Active,,,0.004,GI50,Antiproliferative activity against human HT29 cells,Confirmatory,18502639.0,
1406,331397,6,2,,103177124,6167,Active,,,0.015,GI50,Antiproliferative activity against human M21 cells,Confirmatory,18502639.0,
1407,331398,6,2,,103177124,6167,Active,,,0.009000000000000001,GI50,Antiproliferative activity against human MCF7 cells,Confirmatory,18502639.0,
1408,331404,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as increase in G0/G1 phase accumulation at 0.1 uM after 16 hrs by FACS analysis,Other,18502639.0,
1409,331407,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as increase in S phase accumulation at 0.1 uM after 16 hrs by FACS analysis,Other,18502639.0,
1410,331410,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as increase in G2/M phase accumulation at 0.1 uM after 16 hrs by FACS analysis,Other,18502639.0,
1411,333738,6,2,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Other,15620246.0,
1412,333739,6,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against human PC-3MIE8 cells after 48 hrs by MTT assay,Other,15620246.0,
1413,333740,6,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay,Other,15620246.0,
1414,333741,6,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against human MDA-MB-423 cells after 48 hrs by MTT assay,Other,15620246.0,
1415,333742,6,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay,Other,15620246.0,
1416,333743,6,2,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Other,15620246.0,
1417,333842,6,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human KB cells,Other,7130986.0,
1418,335771,3,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 100 ug/mL,Other,8277312.0,
1419,335772,3,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 20 ug/mL,Other,8277312.0,
1420,335773,3,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 4 ug/mL,Other,8277312.0,
1421,335774,3,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.8 ug/mL,Other,8277312.0,
1422,335775,4,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.16 ug/mL,Other,8277312.0,
1423,335776,4,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.032 ug/mL,Other,8277312.0,
1424,335777,4,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.0064 ug/mL,Other,8277312.0,
1425,335778,4,4,,103177124,6167,Unspecified,,,,,Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.00128 ug/mL,Other,8277312.0,
1426,336336,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human LNCAP cells,Other,8133298.0,
1427,336337,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human Lu1 cells,Other,8133298.0,
1428,336338,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against multidrug-resistant human KBV1 cells,Other,8133298.0,
1429,336339,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human KB cells,Other,8133298.0,
1430,336340,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HT cells,Other,8133298.0,
1431,336341,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human BC1 cells,Other,8133298.0,
1432,336342,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human A431 cells,Other,8133298.0,
1433,336343,6,1,,103177124,6167,Unspecified,,,,,Inhibition of calf thymus tubulin polymerization by turbidimetric analysis,Other,8133298.0,
1434,336344,4,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 0.00128 ug/ml,Other,8133298.0,
1435,336345,4,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 0.032 ug/ml,Other,8133298.0,
1436,336346,4,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 0.16 ug/ml,Other,8133298.0,
1437,336347,4,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 0.8 ug/ml,Other,8133298.0,
1438,336348,3,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 4 ug/ml,Other,8133298.0,
1439,336349,3,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 20 ug/ml,Other,8133298.0,
1440,336350,3,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 100 ug/ml,Other,8133298.0,
1441,336351,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human Col2 cells,Other,8133298.0,
1442,336352,4,5,,103177124,6167,Unspecified,,,,,Antimitotic activity against rat ASK cells assessed as reversal of astrocyte morphology at 0.0064 ug/ml,Other,8133298.0,
1443,336353,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human SK-MEL-2 cells,Other,8133298.0,
1444,336354,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human U373 cells,Other,8133298.0,
1445,336355,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human ZR-75-1 cells,Other,8133298.0,
1446,337171,6,3,,103177124,6167,Active,,,0.018000000000000002,IC50,Antiviral activity against HIV1 HTLV-3B in human H9 cells after 3 days by p24 antigen capture assay,Confirmatory,1919593.0,
1447,337172,6,3,,103177124,6167,Active,,,0.01,EC50,Cytotoxicity against human H9 cells,Confirmatory,1919593.0,
1448,337648,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human Lu1 cells after 3 days by SRB assay,Other,7528785.0,
1449,337649,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human KB cells after 3 days by SRB assay,Other,7528785.0,
1450,337650,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human KBVIN cells in presence of 1 ug/ml vinblastine after 3 days by SRB assay,Other,7528785.0,
1451,337651,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human KBVIN cells after 3 days by SRB assay,Other,7528785.0,
1452,337652,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human LNCAP cells after 3 days by SRB assay,Other,7528785.0,
1453,337653,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human ZR-75-1 cells after 3 days by SRB assay,Other,7528785.0,
1454,337654,3,5,,103177124,6167,Active,,,,,Cytotoxicity against human ASK cells after 3 days by SRB assay,Other,7528785.0,
1455,337714,8,1,,103177124,6167,Active,,,6.0,ID50,Inhibition of microtubule assembly by turbidimetry,Confirmatory,3598594.0,
1456,340146,4,4,,103177124,6167,Active,,,0.0114,IC50,Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay,Confirmatory,18588280.0,
1457,340147,4,4,,103177124,6167,Active,,,0.0202,IC50,Growth inhibition of human H460 cells after 72 hrs by methylene blue dye assay,Confirmatory,18588280.0,
1458,340148,4,4,,103177124,6167,Active,,,0.011000000000000001,IC50,Growth inhibition of human MKN45 cells after 72 hrs by methylene blue dye assay,Confirmatory,18588280.0,
1459,340149,4,3,,103177124,6167,Active,,,0.125,IC50,Growth inhibition of P-gp 170/MDR overexpressing human KB-vin10 cells after 72 hrs by methylene blue dye assay,Confirmatory,18588280.0,
1460,340150,6,2,,103177124,6167,Active,,,3.0,IC50,Inhibition of microtubule associated protein rich tubulin polymerization,Confirmatory,18588280.0,
1461,342492,6,2,,103177124,6167,Active,,,0.004,GI50,Growth inhibition of human HT29 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18579387.0,
1462,342493,6,2,,103177124,6167,Active,,,0.015,GI50,Growth inhibition of human M21 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18579387.0,
1463,342494,6,2,,103177124,6167,Active,,,0.009000000000000001,GI50,Growth inhibition of human MCF7 cells after 48 hrs by sulforhodamine B assay,Confirmatory,18579387.0,
1464,342499,3,4,,103177124,6167,Inactive,,,,,Inhibition of nuclear translocation of thioredoxin 1 in human M21 cells at 0.1 uM after 18 hrs by immunocytochemistry,Other,18579387.0,
1465,342501,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as MG0/G1 phase accumulation at 2 times GI50 after 24 hrs by flow cytometry,Other,18579387.0,
1466,342502,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as S phase accumulation at 2 times GI50 after 24 hrs by flow cytometry,Other,18579387.0,
1467,342503,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as G2/M phase accumulation at 2 times GI50 after 24 hrs by flow cytometry,Other,18579387.0,
1468,342518,3,3,,103177124,6167,Unspecified,,,,,Ratio of IC50 of drug to IC50 of colchicine for calf brain tubulin polymerization,Other,18583138.0,
1469,342519,6,2,,103177124,6167,Active,,,0.031,IC50,Cytotoxicity against mouse B16 cells assessed as cell viability after 48 hrs by MTT test,Confirmatory,18583138.0,
1470,342520,7,1,,103177124,6167,Active,,,,,Induction of morphological changes in human EA.hy 926 cells assessed as rounding up after 2 hrs,Other,18583138.0,
1471,342589,6,2,,103177124,6167,Active,,,0.009000000000000001,GI50,Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B method,Confirmatory,18617414.0,
1472,342590,6,2,,103177124,6167,Active,,,0.015,GI50,Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method,Confirmatory,18617414.0,
1473,342591,6,2,,103177124,6167,Active,,,0.004,GI50,Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B method,Confirmatory,18617414.0,
1474,342592,4,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 2 times GI50 after 24 hrs by flow cytometry,Other,18617414.0,
1475,342593,4,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 times GI50 after 24 hrs by flow cytometry,Other,18617414.0,
1476,342594,4,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 times GI50 after 24 hrs by flow cytometry,Other,18617414.0,
1477,342597,3,4,,103177124,6167,Inactive,,,,,Induction of beta2-tubulin alkylation in human M21 cells at 2 times GI50 by Western blot analysis,Other,18617414.0,
1478,342598,3,4,,103177124,6167,Inactive,,,,,Induction of beta2-tubulin alkylation in human M21 cells at 50 nM by Western blot analysis,Other,18617414.0,
1479,342600,3,4,,103177124,6167,Inactive,,,,,Inhibition of nuclear translocation of thioredoxin-1 from cytosol in human M21 cells at 50 nM after 16 hrs by immunocytofluorescence,Other,18617414.0,
1480,347581,6,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human K562 cells after 48 hrs,Confirmatory,19220018.0,
1481,347582,6,2,,103177124,6167,Active,,,1.4,IC50,Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetric assay,Confirmatory,19220018.0,
1482,347971,6,3,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human KB/HeLa cells by XTT assay,Confirmatory,19220018.0,
1483,347972,6,2,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human SKOV3 cells by XTT assay,Confirmatory,19220018.0,
1484,347973,6,2,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human SF268 cells by XTT assay,Confirmatory,19220018.0,
1485,347974,6,2,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human NCI-H460 cells by XTT assay,Confirmatory,19220018.0,
1486,347975,6,2,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human RKO cells by XTT assay,Confirmatory,19220018.0,
1487,347976,6,2,,103177124,6167,Unspecified,,,3.0,IC50,Antiproliferative activity against human RKO cells containing ecdysone-inducible expression vector of p27kipl by XTT assay,Confirmatory,19220018.0,
1488,347983,4,3,,103177124,6167,Active,,,0.013999999999999999,EC50,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation after 24 hrs by FACS analysis,Confirmatory,19220018.0,
1489,347987,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 0.3 nM after 24 hrs by FACS analysis,Other,19220018.0,
1490,347988,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 0.3 nM after 24 hrs by FACS analysis,Other,19220018.0,
1491,347989,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 0.3 nM after 24 hrs by FACS analysis,Other,19220018.0,
1492,347990,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 1 nM after 24 hrs by FACS analysis,Other,19220018.0,
1493,347991,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 1 nM after 24 hrs by FACS analysis,Other,19220018.0,
1494,347992,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 1 nM after 24 hrs by FACS analysis,Other,19220018.0,
1495,347993,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 3.16 nM after 24 hrs by FACS analysis,Other,19220018.0,
1496,347994,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 3.16 nM after 24 hrs by FACS analysis,Other,19220018.0,
1497,347995,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 3.16 nM after 24 hrs by FACS analysis,Other,19220018.0,
1498,347996,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 10 nM after 24 hrs by FACS analysis,Other,19220018.0,
1499,347997,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 10 nM after 24 hrs by FACS analysis,Other,19220018.0,
1500,347998,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 10 nM after 24 hrs by FACS analysis,Other,19220018.0,
1501,347999,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 31.6 nM after 24 hrs by FACS analysis,Other,19220018.0,
1502,348000,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 31.6 nM after 24 hrs by FACS analysis,Other,19220018.0,
1503,348001,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 31.6 nM after 24 hrs by FACS analysis,Other,19220018.0,
1504,348002,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 100 nM after 24 hrs by FACS analysis,Other,19220018.0,
1505,348003,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 100 nM after 24 hrs by FACS analysis,Other,19220018.0,
1506,348004,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 100 nM after 24 hrs by FACS analysis,Other,19220018.0,
1507,348005,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as S phase accumulation at 316 nM after 24 hrs by FACS analysis,Other,19220018.0,
1508,348006,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G2/M phase accumulation at 316 nM after 24 hrs by FACS analysis,Other,19220018.0,
1509,348007,3,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human KB/HeLa cells assessed as G1 phase accumulation at 316 nM after 24 hrs by FACS analysis,Other,19220018.0,
1510,348011,6,2,,103177124,6167,Active,,,1.06,IC50,Displacement of [3H]Colchicine from pig biotinylated tubulin after 2 hrs by SPA,Confirmatory,19220018.0,
1511,348166,4,4,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human MDA-MB-231 cells after 48 hrs by alamar blue assay,Confirmatory,19117761.0,
1512,348167,4,4,,103177124,6167,Active,,,0.025,IC50,Cytotoxicity against human MIAPaCa2 cells after 48 hrs by alamar blue assay,Confirmatory,19117761.0,
1513,348168,4,4,,103177124,6167,Active,,,0.025,IC50,Cytotoxicity against human SNU423 cells after 48 hrs by alamar blue assay,Confirmatory,19117761.0,
1514,348169,4,4,,103177124,6167,Active,,,0.03,IC50,Cytotoxicity against human UCI101 cells after 48 hrs by alamar blue assay,Confirmatory,19117761.0,
1515,348171,3,3,,103177124,6167,Active,,,,,Inhibition of tubulin without microtubule associated protein polymerization at 5 uM after 60 mins,Other,19117761.0,
1516,351385,7,1,,103177124,6167,Active,,,,,Cell cycle arrest in human leukemic cells assessed as mitotic block by cytometry,Other,19394222.0,
1517,351391,3,3,,103177124,6167,Inactive,,,,,Binding affinity to purine-binding protein in human red blood cells,Other,19394222.0,
1518,351577,6,2,,103177124,6167,Active,,,0.5,IC50,Inhibition of tubulin polymerization by DAPI staining method,Confirmatory,19394823.0,
1519,354537,9,1,,103177124,6167,Active,,,0.2,LC50,Cytotoxicity against rat C6 cells after 3 days treated 4 hrs before db-cAMP challenge by MTT assay,Confirmatory,8988604.0,
1520,354541,9,1,,103177124,6167,Active,,,0.1,EC50,Inhibition of tubulin polymerization in rat C6 cells after 4 hrs,Confirmatory,8988604.0,
1521,354543,3,4,,103177124,6167,Inactive,,,,,Cytotoxicity against rat C6 cells assessed as cell release at 50 ug/mL to 2.5 mg/mL after 5 hrs by MTT assay in absence of db-cAMP,Other,8988604.0,
1522,355578,9,1,,103177124,6167,Active,,,0.018000000000000002,IC50,Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,2778449.0,
1523,355580,3,5,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1524,355581,3,5,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1525,355582,3,5,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1526,355583,9,1,,103177124,6167,Active,,,0.024,IC50,Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay,Confirmatory,2778449.0,
1527,355584,3,5,,103177124,6167,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1528,355585,3,5,,103177124,6167,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1529,355586,3,5,,103177124,6167,Unspecified,,,,,Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method,Other,2778449.0,
1530,357047,6,2,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HeLa cells after 72 hrs by MTT assay,Other,11473441.0,
1531,357845,4,4,,103177124,6167,Unspecified,,,,,Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method,Other,1812211.0,
1532,357846,4,4,,103177124,6167,Unspecified,,,,,Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method,Other,1812211.0,
1533,362356,6,2,,103177124,6167,Unspecified,,,,IC50,Binding affinity to pig brain tubulin at 10 uM after 15 mins relative to control,Confirmatory,18678497.0,
1534,366382,6,2,,103177124,6167,Active,,,0.009000000000000001,EC50,Induction of apoptosis in human T47D cells assessed as caspase 3 activation after 24 hrs,Confirmatory,18651728.0,
1535,366383,6,2,,103177124,6167,Active,,,0.015,EC50,Induction of apoptosis in human HCT116 cells assessed as caspase 3 activation after 24 hrs,Confirmatory,18651728.0,
1536,366389,4,3,,103177124,6167,Active,,,0.5,IC50,Inhibition of tubulin polymerization,Confirmatory,18651728.0,
1537,368327,9,1,,103177124,6167,Unspecified,,,,IC50,Cytotoxicity against human A549 cells after 24 hrs by YO-PRO-1 assay,Confirmatory,19138858.0,
1538,368408,9,1,,103177124,6167,Unspecified,,,,IC50,Cytotoxicity against human A549 cells after 24 hrs by propidium iodide assay,Confirmatory,19138858.0,
1539,374351,6,2,,103177124,6167,Active,,,0.022000000000000002,EC50,Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay,Confirmatory,17893158.0,
1540,374353,6,3,,103177124,6167,Active,,,0.0476,CC50,Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay,Confirmatory,17893158.0,
1541,374355,3,3,,103177124,6167,Unspecified,,,,,"Selectivity index, ratio of CC50 for human WI38 cells preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay to EC50 for BKV Gardner ATCC VR837",Other,17893158.0,
1542,375807,6,2,,103177124,6167,Active,,,0.009000000000000001,EC50,Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs by HTS assay,Confirmatory,19464890.0,
1543,375808,6,2,,103177124,6167,Active,,,0.05,EC50,Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs by HTS assay,Confirmatory,19464890.0,
1544,375809,6,2,,103177124,6167,Active,,,0.5,IC50,Inhibition of tubulin polymerization by high-throughput assay,Confirmatory,19464890.0,
1545,377072,6,2,,103177124,6167,Active,,,0.016,EC50,Cytotoxicity against human MCF7 after 3 days by SRB assay,Confirmatory,15730238.0,
1546,377073,6,2,,103177124,6167,Active,,,0.03,EC50,Cytotoxicity against human H460 after 3 days by SRB assay,Confirmatory,15730238.0,
1547,377074,6,2,,103177124,6167,Active,,,0.025,EC50,Cytotoxicity against human SF-268 after 3 days by SRB assay,Confirmatory,15730238.0,
1548,377075,7,2,,103177124,6167,Unspecified,,,,,Toxicity in brine shrimp,Other,15730238.0,
1549,377076,6,2,,103177124,6167,Unspecified,,,,,Antimicrobial activity against Micrococcus luteus after 3 days,Other,15730238.0,
1550,377077,6,2,,103177124,6167,Unspecified,,,,,Antimicrobial activity against Mycobacterium smegmatis after 3 days,Other,15730238.0,
1551,377078,6,2,,103177124,6167,Unspecified,,,,,Antimicrobial activity against Saccharomyces cerevisiae after 3 days,Other,15730238.0,
1552,377079,6,2,,103177124,6167,Unspecified,,,,,Antimicrobial activity against Aspergillus niger after 3 days,Other,15730238.0,
1553,379862,3,3,,103177124,6167,Unspecified,,,,,Inhibition of tubulin polymerization at 1 ug/mL by tubulin assembly assay,Other,10395506.0,
1554,383959,5,2,,103177124,6167,Active,,,0.01259,GI50,Cytotoxicity against human K562 cells,Confirmatory,18386884.0,
1555,383960,5,2,,103177124,6167,Active,,,0.12589,GI50,Cytotoxicity against human HCT15 cells,Confirmatory,18386884.0,
1556,383961,9,1,,103177124,6167,Active,,,0.02512,GI50,Cytotoxicity against human SNB75 cells,Confirmatory,18386884.0,
1557,383962,10,1,,103177124,6167,Active,,,0.02512,GI50,Cytotoxicity against human UACC62 cells,Confirmatory,18386884.0,
1558,383963,5,2,,103177124,6167,Active,,,0.01585,GI50,Cytotoxicity against human OVCAR-3 cells,Confirmatory,18386884.0,
1559,383964,5,2,,103177124,6167,Active,,,0.31623,GI50,Cytotoxicity against human MDA-MB-231 cells,Confirmatory,18386884.0,
1560,383965,5,2,,103177124,6167,Active,,,0.01,GI50,Cytotoxicity against human MDA-MB-435 cells,Confirmatory,18386884.0,
1561,383970,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of 2N cells at 2 uM after 24 hrs by flow cytometry,Other,18386884.0,
1562,383976,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at sub-G1 phase at 2 uM after 24 hrs by flow cytometry,Other,18386884.0,
1563,383982,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of 4N cells at 2 uM after 24 hrs by flow cytometry,Other,18386884.0,
1564,383988,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of >4N cells at 2 uM after 24 hrs by flow cytometry,Other,18386884.0,
1565,383994,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of 2N cells at 2 uM after 72 hrs by flow cytometry,Other,18386884.0,
1566,384000,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation at sub-G1 phase at 2 uM after 72 hrs by flow cytometry,Other,18386884.0,
1567,384006,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of 4N cells at 2 uM after 72 hrs by flow cytometry,Other,18386884.0,
1568,384012,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MDA-MB-231 cells assessed as accumulation of >4N cells at 2 uM after 72 hrs by flow cytometry,Other,18386884.0,
1569,386623,4,8,,103177124,6167,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
1570,388959,3,3,,103177124,6167,Unspecified,,,,,Toxicity in C57BL/J6 mouse assessed as liver aspartate aminotransferase level,Other,18835721.0,
1571,388960,3,3,,103177124,6167,Unspecified,,,,,Toxicity in C57BL/J6 mouse assessed as liver alanine aminotransferase level,Other,18835721.0,
1572,388961,3,3,,103177124,6167,Unspecified,,,,,Toxicity in C57BL/J6 mouse assessed as liver alkaline phosphatase level,Other,18835721.0,
1573,388962,3,3,,103177124,6167,Unspecified,,,,,Toxicity in C57BL/J6 mouse assessed as liver lactate dehydrogenase level,Other,18835721.0,
1574,388963,3,4,,103177124,6167,Unspecified,,,,,Toxicity in C57BL/J6 mouse assessed as creatinine level in serum,Other,18835721.0,
1575,390905,6,2,,103177124,6167,Active,,,2.2,IC50,Inhibition of tubulin polymerization,Confirmatory,18778046.0,
1576,390908,6,2,,103177124,6167,Active,,,0.99,IC50,Inhibition of tubulin polymerization assessed as effect on maximum propogation rate,Confirmatory,18778046.0,
1577,391282,4,3,,103177124,6167,Active,,,0.0017,IC50,Displacement of [3H]colchicine from tubulin by scintillation proximity assay,Confirmatory,18783207.0,
1578,393412,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation in G0/G1 phase at 10 uM after 24 hrs by flow cytometry analysis,Other,18440099.0,
1579,393413,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation in S phase at 10 uM after 24 hrs by flow cytometry analysis,Other,18440099.0,
1580,393414,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation in G2/M phase at 10 uM after 24 hrs by flow cytometry analysis,Other,18440099.0,
1581,393415,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation in Sub-G1 phase at 10 uM after 24 hrs by flow cytometry analysis,Other,18440099.0,
1582,394850,8,1,,103177124,6167,Active,,,0.028999999999999998,IC50,Cytotoxicity against mouse B16-F1 cells after 48 hrs by SRB assay,Confirmatory,19243174.0,
1583,394851,8,1,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human A375 cells after 48 hrs by SRB assay,Confirmatory,19243174.0,
1584,394852,8,1,,103177124,6167,Active,,,0.01,IC50,Cytotoxicity against human DU145 cells after 48 hrs by SRB assay,Confirmatory,19243174.0,
1585,394853,8,1,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,19243174.0,
1586,394854,8,1,,103177124,6167,Active,,,0.016,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by SRB assay,Confirmatory,19243174.0,
1587,394855,8,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human PPC1 cells after 48 hrs by SRB assay,Confirmatory,19243174.0,
1588,397098,6,3,,103177124,6167,Active,,,2.4,IC50,Inhibition of bovine brain tubulin polymerization,Confirmatory,2095370.0,
1589,397122,6,3,,103177124,6167,Unspecified,,,,,Inhibition of HIV1 RT,Other,1710653.0,
1590,397289,4,4,,103177124,6167,Active,,,0.032,IC50,Cytotoxicity against human HCT116 cells after 72 hrs,Confirmatory,19530698.0,
1591,397290,4,4,,103177124,6167,Active,,,0.028999999999999998,IC50,Cytotoxicity against human K562 cells after 72 hrs,Confirmatory,19530698.0,
1592,397291,4,4,,103177124,6167,Active,,,0.03,IC50,Cytotoxicity against human H1299 cells after 72 hrs,Confirmatory,19530698.0,
1593,397292,4,4,,103177124,6167,Active,,,0.026000000000000002,IC50,Cytotoxicity against human MDA-MB-231 cells after 72 hrs,Confirmatory,19530698.0,
1594,397293,6,2,,103177124,6167,Active,,,2.1,IC50,Inhibition of tubulin polymerization assessed as blockade of microtubule assembly,Confirmatory,19530698.0,
1595,397414,3,5,,103177124,6167,Active,,,,,Cytotoxicity against Spodoptera frugiperda Sf9 cells assessed as chromatin condensation at 0.14 ppm after 48 hrs by fluorescence microscopy,Other,19223182.0,
1596,397419,3,4,,103177124,6167,Unspecified,,,,,Cytotoxicity against CHO cells assessed as chromatin condensation after 24 hrs by fluorescence microscopy,Other,19223182.0,
1597,397420,3,4,,103177124,6167,Unspecified,,,,,Cytotoxicity against CHO cells assessed as chromatin condensation after 48 hrs by fluorescence microscopy,Other,19223182.0,
1598,397421,4,3,,103177124,6167,Active,,,,,Inhibition of bovine tubulin polymerization,Other,19223182.0,
1599,398312,6,3,,103177124,6167,Active,,,1.4,IC50,Inhibition of tubulin polymerization,Confirmatory,7623025.0,
1600,399881,6,2,,103177124,6167,Active,,,0.65,IC50,Inhibition of tubulin polymerization,Confirmatory,14987069.0,
1601,400573,6,2,,103177124,6167,Active,,,10.0,IC50,Inhibition of pig brain microtubule assembly,Confirmatory,15043436.0,
1602,401021,3,4,,103177124,6167,Unspecified,,,,,Displacement of [3H]colchicine from rat brain tubulin at 25 uM,Other,3879267.0,
1603,401022,8,3,,103177124,6167,Unspecified,,,,,Toxicity in intramuscular dosed mouse,Other,3879267.0,
1604,401548,6,2,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HL60 cells after 48 hrs by MTT assay,Other,15165134.0,
1605,401549,6,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay,Other,15165134.0,
1606,401550,6,2,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Other,15165134.0,
1607,401551,6,2,,103177124,6167,Unspecified,,,,,Cytotoxicity against human U937 cells after 48 hrs by MTT assay,Other,15165134.0,
1608,404304,3,10,,103177124,6167,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
1609,404608,6,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human KB cells after 72 hrs,Confirmatory,18503262.0,
1610,404609,6,2,,103177124,6167,Active,,,2.2,IC50,Inhibition of sheep brain tubulin polymerization,Confirmatory,18503262.0,
1611,404610,6,3,,103177124,6167,Active,,,0.028999999999999998,IC50,Antiproliferative activity against mouse B16F10 cells after 72 hrs,Confirmatory,18503262.0,
1612,404611,6,2,,103177124,6167,Active,,,0.045,IC50,Antiproliferative activity against human A549 cells after 72 hrs,Confirmatory,18503262.0,
1613,404612,6,2,,103177124,6167,Active,,,0.04,IC50,Antiproliferative activity against human MDA-MB-435 cells after 72 hrs,Confirmatory,18503262.0,
1614,404613,6,2,,103177124,6167,Active,,,0.07,IC50,Antiproliferative activity against human MDA-MB-231 cells after 72 hrs,Confirmatory,18503262.0,
1615,404615,6,2,,103177124,6167,Inconclusive,,,,IC50,Antiproliferative activity against mouse L1210 cells after 72 hrs,Confirmatory,18503262.0,
1616,404616,6,2,,103177124,6167,Inconclusive,,,,IC50,Antiproliferative activity against human K562 cells after 72 hrs,Confirmatory,18503262.0,
1617,404617,6,2,,103177124,6167,Inconclusive,,,,IC50,Antiproliferative activity against human HT29 cells after 72 hrs,Confirmatory,18503262.0,
1618,404618,6,2,,103177124,6167,Active,,,0.04,IC50,Antiproliferative activity against human HCT116 cells after 72 hrs,Confirmatory,18503262.0,
1619,404658,3,3,,103177124,6167,Unspecified,,,,,Antitumor activity against human U87 tumor transplanted in chick chorio-allantoic membrane assessed as reduction of tumor volume at 10 uM after 4 days,Other,18503262.0,
1620,404812,3,3,,103177124,6167,Active,,,,,Inhibition of tubulin polymerization at 5 uM by microplate assay,Other,18513974.0,
1621,404870,6,2,,103177124,6167,Inconclusive,,,,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs,Confirmatory,18503262.0,
1622,409671,3,3,,103177124,6167,Active,,,,,Inhibition of bovine tubulin polymerization at 5 uM,Other,18684625.0,
1623,409672,6,2,,103177124,6167,Active,,,0.039,EC50,Cytotoxicity against human HeLa cells after 48 hrs by luminescence cell viability assay,Confirmatory,18684625.0,
1624,409673,6,2,,103177124,6167,Active,,,0.031,EC50,Cytotoxicity against human HepG2 cells after 48 hrs by luminescence cell viability assay,Confirmatory,18684625.0,
1625,409674,6,2,,103177124,6167,Active,,,0.013999999999999999,EC50,Cytotoxicity against human Raji cells after 48 hrs by luminescence cell viability assay,Confirmatory,18684625.0,
1626,409675,6,2,,103177124,6167,Active,,,0.53,EC50,Cytotoxicity against african green monkey Vero cells after 48 hrs by luminescence cell viability assay,Confirmatory,18684625.0,
1627,409676,7,1,,103177124,6167,Unspecified,,,,,Membrane permeability by PAMPA,Other,18684625.0,
1628,409677,5,2,,103177124,6167,Unspecified,,,,,Solubility in phosphate buffer saline after 2 hrs,Other,18684625.0,
1629,409678,6,2,,103177124,6167,Active,,,0.39,EC50,Induction of apoptosis in african green monkey Vero cells assessed as caspase 3/7 activity after 18 hrs by flow cytometry using propidium iodide staining,Confirmatory,18684625.0,
1630,409679,6,2,,103177124,6167,Active,,,0.27,EC50,Cell cycle arrest in african green monkey Vero cells assessed as accumulation at G2/M phase after 18 hrs by flow cytometry using propidium iodide staining,Confirmatory,18684625.0,
1631,409954,4,9,,103177124,6167,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
1632,409956,4,9,,103177124,6167,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
1633,412960,8,1,,103177124,6167,Active,,,0.011000000000000001,IC50,Growth inhibition of human KB cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
1634,412961,8,1,,103177124,6167,Active,,,0.11599999999999999,IC50,Growth inhibition of human Pgp170 overexpressing multidrug resistant-KB-VIN10 cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
1635,412962,4,4,,103177124,6167,Active,,,0.018000000000000002,IC50,Growth inhibition of human H460 cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
1636,412963,4,4,,103177124,6167,Active,,,0.01,IC50,Growth inhibition of human HT-29 cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
1637,412964,4,4,,103177124,6167,Active,,,0.013000000000000001,IC50,Growth inhibition of human MKN45 cells after 72 hrs by methylene blue dye assay,Confirmatory,19053773.0,
1638,412968,6,2,,103177124,6167,Active,,,3.2,IC50,Inhibition of tubulin polymerization after 30 mins,Confirmatory,19053773.0,
1639,418789,6,2,,103177124,6167,Active,,,0.006999999999999999,GI50,Growth inhibition of human T47D cells after 48 hrs,Confirmatory,19282188.0,
1640,418790,6,2,,103177124,6167,Inconclusive,,,,GI50,Growth inhibition of human HCT116 cells after 48 hrs,Confirmatory,19282188.0,
1641,418791,6,3,,103177124,6167,Inconclusive,,,,GI50,Growth inhibition of human SNU398 cells after 48 hrs,Confirmatory,19282188.0,
1642,418797,6,2,,103177124,6167,Active,,,0.5,IC50,Inhibition of tubulin polymerization by DAPI fluorescence method,Confirmatory,19282188.0,
1643,422575,4,4,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human KB cells after 72 hrs by methylene blue dye assay,Confirmatory,19586033.0,
1644,422576,4,4,,103177124,6167,Active,,,0.018000000000000002,IC50,Cytotoxicity against human H460 cells after 72 hrs by methylene blue dye assay,Confirmatory,19586033.0,
1645,422577,4,4,,103177124,6167,Active,,,0.01,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue dye assay,Confirmatory,19586033.0,
1646,422578,3,3,,103177124,6167,Unspecified,,,,,Displacement of [3H]colchicine from tubulin at 1 uM after 1 hr by scintillation counter,Other,19586033.0,
1647,422579,3,3,,103177124,6167,Unspecified,,,,,Displacement of [3H]colchicine from tubulin at 5 uM after 1 hr by scintillation counter,Other,19586033.0,
1648,422580,6,2,,103177124,6167,Active,,,0.977,Ki,Displacement of [3H]colchicine from tubulin after 1 hr by scintillation counter,Confirmatory,19586033.0,
1649,422581,6,2,,103177124,6167,Active,,,3.2,IC50,Inhibition of tubulin polymerization,Confirmatory,19586033.0,
1650,424441,6,2,,103177124,6167,Active,,,0.5,IC50,Inhibition of tubulin polymerization,Confirmatory,19369076.0,
1651,427907,6,2,,103177124,6167,Active,,,0.013999999999999999,EC50,Induction of apoptosis in human T47D cells assessed as caspase activation after 48 hrs,Confirmatory,19500976.0,
1652,427908,6,2,,103177124,6167,Active,,,0.18,EC50,Induction of apoptosis in human DLD1 cells assessed as caspase activation after 48 hrs,Confirmatory,19500976.0,
1653,427909,6,2,,103177124,6167,Active,,,0.05,EC50,Induction of apoptosis in human H1299 cells assessed as caspase activation after 48 hrs,Confirmatory,19500976.0,
1654,427913,6,2,,103177124,6167,Active,,,0.14,GI50,Growth inhibition of human T47D cells after 48 hrs,Confirmatory,19500976.0,
1655,428001,6,2,,103177124,6167,Active,,,0.063,GI50,Growth inhibition of human H1299 cells after 48 hrs,Confirmatory,19500976.0,
1656,428053,6,3,,103177124,6167,Active,,,2.3,IC50,Immunosuppressive activity in mouse splenocytes assessed as inhibition of allogenic mixed lymphocyte reaction,Confirmatory,19502058.0,
1657,428054,4,3,,103177124,6167,Active,,,0.0073,IC50,Immunosuppressive activity in LPS-activated B lymphocyte assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting,Confirmatory,19502058.0,
1658,428055,4,3,,103177124,6167,Active,,,0.5479999999999999,IC50,Immunosuppressive activity in concanavalin A-activated T cell assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting,Confirmatory,19502058.0,
1659,434955,1,2,,49718107,6167,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
1660,434959,1,1,,85788838,6167,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
1661,434962,1,2,,49718107,6167,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
1662,434973,1,3,,49718107,6167,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
1663,434989,1,1,,49718107,6167,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1664,435003,1,3,,49718107,6167,Active,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1665,435005,1,1,,49718107,6167,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
1666,435020,1,2,,49718107,6167,Active,,,,,Single concentration confirmation of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
1667,435022,2,2,,49718107,6167,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1668,435030,1,2,,49718107,6167,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1669,435030,1,2,,49718107,6167,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
1670,449728,1,2,,49718107,6167,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
1671,449746,1,2,,49718107,6167,Inactive,,,,,Single concentration confirmation of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
1672,449762,1,2,,49718107,6167,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
1673,449763,1,3,,49718107,6167,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1674,452614,5,2,,103177124,6167,Active,,,2.6,IC50,Inhibition of tubulin assembly by immunofluorescence assay,Confirmatory,19837594.0,
1675,458390,5,3,,103177124,6167,Active,,,0.01,IC50,Anticancer activity against human NUGC3 cells after 72 hrs by MTS/PMS assay,Confirmatory,20170097.0,
1676,458392,5,2,,103177124,6167,Active,,,0.29,IC50,Inhibition of bovine brain tubulin polymerization by turbidity assay,Confirmatory,20170097.0,
1677,459397,3,4,,103177124,6167,Unspecified,,,,,Antiinvasive activity in human MDA-MB-231 cells assessed as cell invasion at 4 uM by BME cell invasion assay,Other,20034800.0,
1678,461782,3,4,,103177124,6167,Active,,,0.012,IC50,Antiproliferative activity against human KB cells after 72 hrs by methylene blue dye assay,Confirmatory,20148562.0,
1679,461783,3,4,,103177124,6167,Active,,,0.0201,IC50,Antiproliferative activity against human H460 cells after 72 hrs by methylene blue dye assay,Confirmatory,20148562.0,
1680,461784,3,4,,103177124,6167,Active,,,0.0132,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by methylene blue dye assay,Confirmatory,20148562.0,
1681,461785,3,4,,103177124,6167,Active,,,0.0124,IC50,Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue dye assay,Confirmatory,20148562.0,
1682,461786,3,3,,103177124,6167,Active,,,0.128,IC50,Antiproliferative activity against P-gp170/MDR expressing human KBVIN cells after 72 hrs by methylene blue dye assay,Confirmatory,20148562.0,
1683,461787,5,2,,103177124,6167,Active,,,4.2,IC50,Inhibition of tubulin polymerization by turbidimetric assay,Confirmatory,20148562.0,
1684,463079,1,2,,49718107,6167,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
1685,463082,1,1,,49718107,6167,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
1686,463096,1,1,,50104821,6167,Inactive,,,,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
1687,463097,1,1,,50104821,6167,Active,7705682.0,51053.0,0.0398,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
1688,463104,1,2,,49718107,6167,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
1689,463106,1,2,,90340644,6167,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1690,463111,1,1,,49718107,6167,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
1691,463141,1,2,,49718107,6167,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
1692,463165,1,1,,49718107,6167,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
1693,463189,1,1,,53777416,6167,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
1694,463190,1,2,,49718107,6167,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
1695,463195,1,2,,49718107,6167,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
1696,463210,1,2,,49718107,6167,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
1697,463212,1,1,,49718107,6167,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
1698,463254,1,1,,49718107,6167,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
1699,472409,5,2,,103177124,6167,Active,,,0.013000000000000001,IC50,Cytotoxicity against human KB cells after 48 hrs by MTT assay,Confirmatory,20363142.0,
1700,472410,5,3,,103177124,6167,Active,,,10.9,IC50,Cytotoxicity against human multidrug-resistant KB-C2 cells after 48 hrs by MTT assay,Confirmatory,20363142.0,
1701,473622,5,2,,103177124,6167,Active,,,0.0134,IC50,Antiproliferative activity against human MCF7 cells after 72 hrs by crystal violet biomass reduction assay,Confirmatory,20334421.0,
1702,473624,5,2,,103177124,6167,Active,,,0.008,IC50,Antiproliferative activity against human U937 cells by sulforhodamine B assay,Confirmatory,20334421.0,
1703,479353,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human HeLa cells by accumulation of cells at M phase at 100 nM after 9 hrs by propidium iodide staining based flow cytometry,Other,20411988.0,
1704,479354,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human HeLa cells by accumulation of cells at G2 phase at 100 nM after 9 hrs by propidium iodide staining based flow cytometry,Other,20411988.0,
1705,479366,5,2,,103177124,6167,Active,,,0.053,IC50,Cytotoxicity against human HL60 cells after 72 hrs MTS assay,Confirmatory,20411988.0,
1706,479367,5,2,,103177124,6167,Unspecified,,,100.0,IC50,Cytotoxicity against vincristine-resistant human HL60 cells after 72 hrs MTS assay,Confirmatory,20411988.0,
1707,479368,3,4,,103177124,6167,Unspecified,,,,,Selectivity ratio of IC50 for vincristine-resistant human HL60 cells to IC50 for human HL60 cells,Other,20411988.0,
1708,483367,3,3,,103177124,6167,Active,,,,,Inhibition of microtubule polymerization at 10 uM after 10 mins,Other,20529690.0,
1709,483368,3,4,,103177124,6167,Active,,,0.012,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by crystal violet staining,Confirmatory,20529690.0,
1710,483369,3,4,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human PC3 cells after 72 hrs by crystal violet staining,Confirmatory,20529690.0,
1711,485270,1,1,,49718107,6167,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
1712,485272,1,1,,49718107,6167,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
1713,485273,2,1,,49718107,6167,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
1714,485275,1,3,,49718107,6167,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
1715,485281,1,1,,26752175,6167,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1716,485281,1,1,,49718107,6167,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
1717,485290,1,1,,11114044,6167,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1718,485290,1,1,,17389095,6167,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1719,485290,1,1,,17389096,6167,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1720,485290,1,1,,26752175,6167,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1721,485290,1,1,,26752176,6167,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1722,485290,1,1,,50104821,6167,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
1723,485294,1,1,,49718107,6167,Inconclusive,119389684.0,,5.0119,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
1724,485295,1,2,,90340644,6167,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
1725,485297,1,1,,49718107,6167,Inactive,4759012.0,9367.0,1.9953,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1726,485297,1,1,,90340644,6167,Inactive,4759012.0,9367.0,580.479,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
1727,485298,1,1,,49718107,6167,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1728,485298,1,1,,90340644,6167,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
1729,485313,1,2,,49718107,6167,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1730,485313,1,2,,90340644,6167,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
1731,485314,1,1,,49718107,6167,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1732,485314,1,1,,50104821,6167,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
1733,485317,1,2,,49718107,6167,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
1734,485341,1,1,,49718107,6167,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
1735,485342,1,2,,90340644,6167,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1736,485345,1,2,,90340644,6167,Inconclusive,,,2.3109,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1737,485346,1,1,,49718107,6167,Active,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1738,485346,1,1,,49718107,6167,Active,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1739,485349,1,1,,49718107,6167,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
1740,485350,1,2,,92123932,6167,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1741,485350,1,2,,92125451,6167,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
1742,485353,2,1,,49718107,6167,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
1743,485364,1,1,,49718107,6167,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
1744,485366,1,2,,90340644,6167,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1745,485367,1,2,,49718107,6167,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1746,485368,1,2,,90340644,6167,Inconclusive,72386991.0,3656265.0,0.0379,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
1747,486600,5,2,,103177124,6167,Active,,,0.017,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,20493717.0,
1748,486601,5,2,,103177124,6167,Active,,,3.2,IC50,Inhibition of bovine brain tubulin polymerization after 20 mins,Confirmatory,20493717.0,
1749,486602,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 25 nM after 24 hrs by flow cytometry,Other,20493717.0,
1750,486603,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 25 nM after 24 hrs by flow cytometry,Other,20493717.0,
1751,486604,3,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 25 nM after 24 hrs by flow cytometry,Other,20493717.0,
1752,488745,1,4,,50104821,6167,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1753,488752,1,4,,50104821,6167,Inactive,,,,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1754,488772,1,1,,90340644,6167,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1755,488773,1,2,,90340644,6167,Inconclusive,8659577.0,58819.0,0.8437,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
1756,488816,1,1,,90340644,6167,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
1757,488837,1,1,,49718107,6167,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1758,488837,1,1,,90340644,6167,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
1759,488839,1,1,,50085974,6167,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1760,488839,1,1,,50085974,6167,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1761,488847,1,3,,49718107,6167,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
1762,488862,1,1,,50085974,6167,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1763,488890,1,2,,49718107,6167,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
1764,488895,1,2,,50085974,6167,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1765,488896,1,1,,50085974,6167,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1766,488899,1,1,,50085974,6167,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1767,488922,1,2,,49718107,6167,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
1768,488949,1,2,,50104821,6167,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1769,488949,1,2,,90340644,6167,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1770,488953,1,1,,90340644,6167,Inactive,187960037.0,10951.0,0.0038,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1771,488965,1,2,,50085974,6167,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1772,488966,1,1,,50085974,6167,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
1773,488975,1,2,,49718107,6167,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
1774,488977,1,2,,49718107,6167,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
1775,488978,1,1,,90340644,6167,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
1776,488979,1,1,,50104821,6167,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
1777,488980,1,1,,50104821,6167,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
1778,488981,1,1,,90340644,6167,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
1779,488982,1,1,,90340644,6167,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
1780,488983,1,1,,90340644,6167,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
1781,489026,1,2,,49718107,6167,Inactive,,,80.0,IC50_Mean,Dose response cytotoxicity of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay,Confirmatory,,
1782,489028,1,2,,49718107,6167,Active,88702791.0,4194.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1783,489028,1,2,,49718107,6167,Active,89993689.0,4193.0,,,Single concentration confirmation of uHTS for Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
1784,489030,2,1,,49718107,6167,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
1785,489031,2,1,,49718107,6167,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
1786,489033,1,2,,49718107,6167,Inactive,,,80.0,IC50_Mean,Dose Response selectivity of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a 697B cell line using a luminescence assay,Confirmatory,,
1787,489035,1,1,,49718107,6167,Inactive,,,80.0,IC50_Mean,Dose response confirmation of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a Jurkat cell line using a luminescence assay,Confirmatory,,
1788,489041,1,2,,49718107,6167,Active,,,0.16,IC50_Mean,Dose response counterscreen of uHTS chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay,Confirmatory,,
1789,492476,5,2,,103177124,6167,Active,,,1.5,IC50,Inhibition of tubulin polymerization,Confirmatory,20187635.0,
1790,492477,5,3,,103177124,6167,Active,,,0.8,IC50,Antitumor activity against human OVCAR-3 cells xenografted in mouse assessed as increase in mouse life span,Confirmatory,20187635.0,
1791,492947,1,1,,49718107,6167,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
1792,492953,1,1,,50085974,6167,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
1793,492956,1,1,,50085974,6167,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
1794,492961,1,1,,26752176,6167,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
1795,492967,1,2,,92125451,6167,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1796,492967,1,2,,99301841,6167,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
1797,492972,1,1,,50085974,6167,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
1798,493005,1,1,,49718107,6167,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
1799,493008,1,1,,50085974,6167,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1800,493008,1,1,,50085974,6167,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1801,493008,1,1,,50085974,6167,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1802,493008,1,1,,50085974,6167,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1803,493011,1,1,,49718107,6167,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1804,493012,1,1,,49718107,6167,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
1805,493014,1,1,,49718107,6167,Inconclusive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
1806,493033,1,2,,92123932,6167,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1807,493033,1,2,,92125451,6167,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
1808,493036,1,2,,49718107,6167,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
1809,493056,1,1,,49718107,6167,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
1810,493084,1,1,,49718107,6167,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
1811,493087,1,1,,50085974,6167,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
1812,493091,1,1,,49718107,6167,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
1813,493098,1,1,,49718107,6167,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
1814,493106,1,1,,90340644,6167,Active,116283940.0,79915.0,0.4609,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1815,493107,1,1,,90340644,6167,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1816,493127,1,1,,50104821,6167,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
1817,493131,1,1,,50085974,6167,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
1818,493140,1,1,,103914140,6167,Inactive,,,,,Screening small molecules to find regulators of human embryonic stem cell survival.,Screening,,
1819,493153,1,1,,90340644,6167,Inconclusive,,4780.0,0.0731,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1820,493153,1,1,,90340644,6167,Inconclusive,224028257.0,4780.0,0.0731,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
1821,493160,1,1,,49718107,6167,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
1822,493162,1,2,,99301841,6167,Inactive,335756.0,,,,A screen for compounds that inhibit processive DNA synthesis of vaccinia virus,Other,,
1823,493164,1,2,,90340644,6167,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1824,493164,1,2,,90340644,6167,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1825,493164,1,2,,90340644,6167,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
1826,493165,1,2,,50104821,6167,Active,,51053.0,0.0337,Potency,Retest of LOPAC molecules that induce DNA re-replication in SW480 adenocarcinoma cells.,Confirmatory,,
1827,493165,1,2,,50104821,6167,Active,7705682.0,51053.0,0.0337,Potency,Retest of LOPAC molecules that induce DNA re-replication in SW480 adenocarcinoma cells.,Confirmatory,,
1828,493166,1,2,,50104821,6167,Inactive,,51053.0,0.03,Potency,Retest of LOPAC molecules that induce DNA re-replication in MCF 10A normal breast cells.,Confirmatory,,
1829,493166,1,2,,50104821,6167,Inactive,7705682.0,51053.0,0.03,Potency,Retest of LOPAC molecules that induce DNA re-replication in MCF 10A normal breast cells.,Confirmatory,,
1830,493187,1,2,,49718107,6167,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
1831,493189,1,1,,50104821,6167,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
1832,493244,1,1,,50085974,6167,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1833,493244,1,1,,50085974,6167,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1834,493244,1,1,,50085974,6167,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1835,493244,1,1,,50085974,6167,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
1836,494501,4,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human K562 cells after 48 hrs,Confirmatory,20537765.0,
1837,494502,4,2,,103177124,6167,Active,,,1.4,IC50,Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetry,Confirmatory,20537765.0,
1838,494503,4,3,,103177124,6167,Active,,,0.03,IC50,Antiproliferative activity against human KB/HeLa cells after 48 hrs by XTT assay,Confirmatory,20537765.0,
1839,494504,4,2,,103177124,6167,Active,,,0.05,IC50,Antiproliferative activity against human SKOV3 cells after 48 hrs by XTT assay,Confirmatory,20537765.0,
1840,494505,4,2,,103177124,6167,Active,,,0.05,IC50,Antiproliferative activity against human SF268 cells after 48 hrs by XTT assay,Confirmatory,20537765.0,
1841,494506,4,2,,103177124,6167,Active,,,0.07,IC50,Antiproliferative activity against human NCI-H460 cells after 48 hrs by XTT assay,Confirmatory,20537765.0,
1842,494507,4,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human RKO cells after 48 hrs by XTT assay,Confirmatory,20537765.0,
1843,494509,4,2,,103177124,6167,Unspecified,,,10.0,IC50,Antiproliferative activity against human RKO cells expressing p27Kip1 after 48 hrs by XTT assay,Confirmatory,20537765.0,
1844,494515,2,3,,103177124,6167,Active,,,0.013999999999999999,EC50,Cell cycle arrest in human KB/HeLa cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,20537765.0,
1845,494520,4,2,,103177124,6167,Active,,,0.02,IC50,Cell growth inhibition of human K562 cells after 48 hrs,Confirmatory,20546980.0,
1846,494521,5,1,,103177124,6167,Active,20455316.0,7278.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1847,494521,5,1,,103177124,6167,Active,20455316.0,113457.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1848,494521,5,1,,103177124,6167,Active,20455322.0,84790.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1849,494521,5,1,,103177124,6167,Active,20455526.0,10381.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1850,494521,5,1,,103177124,6167,Active,55977474.0,10376.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1851,494521,5,1,,103177124,6167,Active,55977476.0,7277.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1852,494521,5,1,,103177124,6167,Active,55977480.0,10383.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1853,494521,5,1,,103177124,6167,Active,55977864.0,7846.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1854,494521,5,1,,103177124,6167,Active,56757569.0,203068.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1855,494521,5,1,,103177124,6167,Active,62903515.0,81027.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1856,494521,5,1,,103177124,6167,Active,68776070.0,84617.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1857,494521,5,1,,103177124,6167,Active,74761283.0,347733.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1858,494521,5,1,,103177124,6167,Active,74762137.0,7280.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1859,494521,5,1,,103177124,6167,Active,93141323.0,10382.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1860,494521,5,1,,103177124,6167,Active,182705285.0,347688.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1861,494521,5,1,,103177124,6167,Active,224471855.0,112714.0,1.4,IC50,Inhibition of tubulin polymerization in human K562 cells,Confirmatory,20546980.0,
1862,504326,1,2,,50085974,6167,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1863,504326,1,2,,50085974,6167,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1864,504327,1,1,,11114044,6167,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1865,504327,1,1,,26752175,6167,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1866,504327,1,1,,26752176,6167,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1867,504327,1,1,,49718107,6167,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1868,504327,1,1,,90340644,6167,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
1869,504329,1,1,,50085974,6167,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
1870,504332,1,1,,26752175,6167,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1871,504332,1,1,,26752176,6167,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1872,504332,1,1,,50104821,6167,Inactive,168985070.0,,10.0,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1873,504332,1,1,,90340644,6167,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
1874,504333,1,1,,49718107,6167,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
1875,504339,1,1,,49718107,6167,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
1876,504357,1,1,,50085974,6167,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1877,504357,1,1,,50085974,6167,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
1878,504364,1,1,,50104821,6167,Active,7705682.0,51053.0,0.057999999999999996,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
1879,504406,1,1,,49718107,6167,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
1880,504408,2,1,,49718107,6167,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
1881,504411,1,1,,50085974,6167,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
1882,504414,1,1,,50085974,6167,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1883,504414,1,1,,50085974,6167,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1884,504423,1,1,,50085974,6167,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1885,504441,1,1,,50085974,6167,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1886,504444,1,1,,49718107,6167,Inconclusive,224028257.0,4780.0,0.057999999999999996,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
1887,504454,1,3,,50085974,6167,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
1888,504462,1,1,,49718107,6167,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
1889,504466,1,1,,49718107,6167,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1890,504467,1,1,,49718107,6167,Inconclusive,116283940.0,79915.0,23.0999,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1891,504490,1,2,,50085974,6167,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1892,504523,1,1,,50085974,6167,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1893,504523,1,1,,50085974,6167,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1894,504536,1,1,,90340644,6167,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
1895,504547,1,1,,90340644,6167,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1896,504548,1,2,,90340644,6167,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
1897,504558,1,1,,50085974,6167,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1898,504577,2,2,,50085974,6167,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1899,504582,2,1,,50085974,6167,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1900,504607,1,1,,49718107,6167,Active,,,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Full-Length Luciferase Counterscreen assay,Screening,,
1901,504621,1,1,,50085974,6167,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1902,504634,1,1,,50085974,6167,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1903,504648,1,1,,49718107,6167,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1904,504651,1,1,,49718107,6167,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1905,504652,1,1,,49718107,6167,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1906,504660,1,1,,49718107,6167,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1907,504668,1,1,,49718107,6167,Active,728984.0,672.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1908,504668,1,1,,49718107,6167,Active,116241265.0,580.0,,,Single concentration confirmation of inhibitors of Mdm2/MdmX interaction using a Brca1/Bard1 BiLC Counterscreen assay.,Screening,,
1909,504690,1,3,,49718107,6167,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1910,504692,2,2,,50085974,6167,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1911,504700,1,1,,50085974,6167,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1912,504700,1,1,,50085974,6167,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1913,504706,1,1,,49718107,6167,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1914,504707,1,1,,50085974,6167,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1915,504707,1,1,,50085974,6167,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1916,504720,1,1,,49718107,6167,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1917,504734,1,1,,50085974,6167,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1918,504749,1,3,,26752176,6167,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1919,504749,1,3,1.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1920,504749,1,3,2.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1921,504749,1,3,3.0,26752176,6167,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1922,504749,1,3,4.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1923,504749,1,3,5.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1924,504749,1,3,6.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1925,504749,1,3,7.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1926,504749,1,3,8.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1927,504749,1,3,9.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1928,504749,1,3,10.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1929,504749,1,3,11.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1930,504749,1,3,12.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1931,504749,1,3,13.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1932,504749,1,3,14.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1933,504749,1,3,15.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1934,504749,1,3,16.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1935,504749,1,3,17.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1936,504749,1,3,18.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1937,504749,1,3,19.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1938,504749,1,3,20.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1939,504749,1,3,21.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1940,504749,1,3,22.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1941,504749,1,3,23.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1942,504749,1,3,24.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1943,504749,1,3,25.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1944,504749,1,3,26.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1945,504749,1,3,27.0,26752176,6167,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1946,504749,1,3,28.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1947,504749,1,3,29.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1948,504749,1,3,30.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1949,504749,1,3,31.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1950,504749,1,3,32.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1951,504749,1,3,33.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1952,504749,1,3,34.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1953,504749,1,3,35.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1954,504749,1,3,36.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1955,504749,1,3,37.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1956,504749,1,3,38.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1957,504749,1,3,39.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1958,504749,1,3,40.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1959,504749,1,3,41.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1960,504749,1,3,42.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1961,504749,1,3,43.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1962,504749,1,3,44.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1963,504749,1,3,45.0,26752176,6167,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1964,504749,1,3,46.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1965,504749,1,3,47.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1966,504749,1,3,48.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1967,504749,1,3,49.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1968,504749,1,3,50.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1969,504749,1,3,51.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1970,504749,1,3,52.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1971,504749,1,3,53.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1972,504749,1,3,54.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1973,504749,1,3,55.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1974,504749,1,3,56.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1975,504749,1,3,57.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1976,504749,1,3,58.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1977,504749,1,3,59.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1978,504749,1,3,60.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1979,504749,1,3,61.0,26752176,6167,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
1980,504766,2,1,,50085974,6167,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1981,504770,1,2,,92123932,6167,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
1982,504775,1,1,,50085974,6167,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1983,504803,1,1,,50085974,6167,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1984,504810,1,2,,49718107,6167,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1985,504810,1,2,,90340644,6167,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1986,504812,1,2,,49718107,6167,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1987,504812,1,2,,90340644,6167,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1988,504821,1,1,,50104821,6167,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
1989,504832,1,1,,26752176,6167,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1990,504832,1,1,,49718107,6167,Inconclusive,,,18.526,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1991,504834,1,1,,26752176,6167,Inconclusive,,,9.5283,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1992,504834,1,1,,49718107,6167,Inconclusive,,,9.285,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1993,504836,1,2,,90340644,6167,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
1994,504842,1,1,,49718107,6167,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1995,504845,1,1,,11114044,6167,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1996,504845,1,1,,49718107,6167,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1997,504845,1,1,,90340644,6167,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1998,504847,1,1,,11114044,6167,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1999,504847,1,1,,26752175,6167,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2000,504847,1,1,,26752176,6167,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2001,504847,1,1,,49718107,6167,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2002,504847,1,1,,90340644,6167,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
2003,504865,1,1,,11114044,6167,Inconclusive,118600387.0,7398.0,25.1189,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2004,504865,1,1,,26752176,6167,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2005,504865,1,1,,90340644,6167,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
2006,504884,1,2,,50085974,6167,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2007,504891,1,1,,49718107,6167,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
2008,504894,1,1,,49718107,6167,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
2009,504937,1,2,,49718107,6167,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
2010,511362,1,4,,103177124,6167,Unspecified,,,,,Cytotoxicity against MEF cells assessed as dead cells at 5 uM after 48 hrs by propidium iodide-based FACS flow cytometry,Other,20674369.0,
2011,511363,3,1,,103177124,6167,Active,,,0.02,LD50,Cytotoxicity against human Jurkat cells after 48 hrs,Confirmatory,20674369.0,
2012,511364,1,4,,103177124,6167,Unspecified,,,,,Cytotoxicity against human Jurkat cells assessed as dead cells at 5 uM after 48 hrs by propidium iodide-based FACS flow cytometry,Other,20674369.0,
2013,514407,6,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HCT8 cells after 2 days,Other,20542428.0,
2014,514408,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human A549 cells after 2 days,Other,20542428.0,
2015,514409,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human DU145 cells after 2 days,Other,20542428.0,
2016,514410,6,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human SKBR3 cells after 2 days,Other,20542428.0,
2017,514411,5,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human KB cells after 2 days,Other,20542428.0,
2018,514412,6,1,,103177124,6167,Unspecified,,,,,Cytotoxicity against human KBVIN cells expressing p-glycoprotein after 2 days,Other,20542428.0,
2019,518931,6,1,,103177124,6167,Unspecified,,,2500.0,IC50,Inhibition of tubulin in Acanthamoeba polyphaga by alamar blue assay,Confirmatory,18070965.0,
2020,518932,4,2,,103177124,6167,Active,,,2.5,IC50,Inhibition of tubulin in Acanthamoeba castellanii by alamar blue assay,Confirmatory,18070965.0,
2021,518933,6,2,,103177124,6167,Unspecified,,,2400.0,IC50,Inhibition of tubulin in rabbit corneal cells by alamar blue assay,Confirmatory,18070965.0,
2022,521220,3,3,,103177124,6167,Active,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
2023,524790,7,2,,103177124,6167,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2024,524791,7,2,,103177124,6167,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2025,524792,7,2,,103177124,6167,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2026,524794,7,1,,103177124,6167,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2027,524795,7,2,,103177124,6167,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2028,524796,7,1,,103177124,6167,Active,,,10.0,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
2029,526943,4,2,,103177124,6167,Active,,,1.8,IC50,Displacement of [3H]-Colchicine from tubulin alpha/beta after 45 mins by scintillation proximity assay,Confirmatory,20919720.0,
2030,526944,2,5,,103177124,6167,Active,,,0.01,IC50,Cytotoxicity against human multidrug-resistant MDA-MB-435/LCCMDR1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2031,526945,2,5,,103177124,6167,Active,,,0.6579999999999999,IC50,Cytotoxicity against human MDA-MB-435 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2032,526946,6,1,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human A375 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2033,526947,6,1,,103177124,6167,Active,,,0.028999999999999998,IC50,Cytotoxicity against mouse B16-F1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2034,526948,6,1,,103177124,6167,Inconclusive,,,,IC50,Cytotoxicity against human WM164 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2035,526949,6,1,,103177124,6167,Active,,,0.016,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2036,526950,6,1,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2037,526951,6,1,,103177124,6167,Active,,,0.01,IC50,Cytotoxicity against human DU145 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2038,526952,6,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human PPC1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,20919720.0,
2039,526953,2,5,,103177124,6167,Active,,,0.0658,IC50,"Resistance index, ratio of IC50 for human multidrug-resistant MDA-MB-435/LCCMDR1 cells to IC50 for human MDA-MB-435 cells",Confirmatory,20919720.0,
2040,536764,4,2,,103177124,6167,Active,,,1.0,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,20833451.0,
2041,536765,4,2,,103177124,6167,Active,,,1.0,IC50,Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay,Confirmatory,20833451.0,
2042,536766,4,2,,103177124,6167,Active,,,1.0,IC50,Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,20833451.0,
2043,536767,1,4,,103177124,6167,Unspecified,,,,,Inhibition of tubulin polymerization at 3 uM,Other,20833451.0,
2044,537733,2,3,,103177124,6167,Inactive,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
2045,537734,5,2,,103177124,6167,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
2046,537735,2,3,,103177124,6167,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
2047,537736,5,2,,103177124,6167,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
2048,538692,4,2,,103177124,6167,Active,,,0.017,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,21036623.0,
2049,538693,4,2,,103177124,6167,Active,,,3.2,IC50,Inhibition of bovine brain tubulin polymerization by turbidimetric analysis,Confirmatory,21036623.0,
2050,538695,1,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at sub-G1 phase after 24 hrs by flow cytometry relative to control,Other,21036623.0,
2051,538696,1,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase after 24 hrs by flow cytometry relative to control,Other,21036623.0,
2052,538697,1,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase after 24 hrs by flow cytometry relative to control,Other,21036623.0,
2053,538698,1,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometry relative to control,Other,21036623.0,
2054,540209,4,3,,103177124,6167,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
2055,540210,4,3,,103177124,6167,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
2056,540211,2,5,,103177124,6167,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
2057,540212,4,3,,103177124,6167,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
2058,540213,4,3,,103177124,6167,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
2059,540235,1,3,,103177124,6167,Inactive,,,,,Phospholipidosis-negative literature compound,Other,17428028.0,
2060,540253,1,1,,49718107,6167,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2061,540253,1,1,,49718107,6167,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2062,540253,1,1,,49718107,6167,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
2063,540256,1,2,,50104821,6167,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2064,540256,1,2,,90340644,6167,Inconclusive,,,0.073,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2065,540263,1,1,,49718107,6167,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2066,540263,1,1,,49718107,6167,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
2067,540267,1,1,,49718107,6167,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
2068,540275,1,1,,49718107,6167,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
2069,540276,1,2,,11114044,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2070,540276,1,2,,17389095,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2071,540276,1,2,,17389096,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2072,540276,1,2,,26752175,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2073,540276,1,2,,26752176,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2074,540276,1,2,,50104821,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2075,540276,1,2,,50104822,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2076,540276,1,2,,50113684,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2077,540276,1,2,,50113685,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2078,540276,1,2,,50113686,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2079,540276,1,2,,90340644,6167,Inconclusive,420597.0,,0.1635,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2080,540276,1,2,,104219585,6167,Inconclusive,420597.0,,1.4125,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2081,540277,1,1,,49718107,6167,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
2082,540295,1,1,,50085974,6167,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
2083,540299,1,2,,92123932,6167,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2084,540299,1,2,,92125451,6167,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
2085,540303,1,1,,49718107,6167,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2086,540303,1,1,,49718107,6167,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2087,540303,1,1,,49718107,6167,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
2088,540308,1,1,,50085974,6167,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
2089,540317,1,1,,49718107,6167,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
2090,540336,1,1,,50085974,6167,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2091,540336,1,1,,50085974,6167,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2092,540364,1,2,,50085974,6167,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
2093,551510,4,2,,103177124,6167,Active,,,3.7,Kd,Binding affinity to porcine tubulin after 1 hr by spectrofluorometric analysis,Confirmatory,21106379.0,
2094,551512,2,4,,103177124,6167,Active,,,0.0166,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by XTT/PMS method,Confirmatory,21106379.0,
2095,553906,4,2,,103177124,6167,Inconclusive,,,,IC50,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2096,553907,4,2,,103177124,6167,Active,,,0.017,IC50,Cell cycle arrest in human Jurkat cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2097,553908,4,3,,103177124,6167,Active,,,0.01,IC50,Cell cycle arrest in human U266 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2098,553909,4,2,,103177124,6167,Active,,,0.013999999999999999,IC50,Cell cycle arrest in human NCI-H522 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2099,553910,4,2,,103177124,6167,Active,,,0.013999999999999999,IC50,Cell cycle arrest in human SW620 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2100,553911,4,2,,103177124,6167,Active,,,0.013000000000000001,IC50,Cell cycle arrest in human NCI-H23 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2101,553912,4,3,,103177124,6167,Active,,,0.016,IC50,Cell cycle arrest in human BxPC3 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2102,553913,4,2,,103177124,6167,Active,,,0.033,IC50,Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase after 24 hrs using propidium iodide staining by FACS analysis,Confirmatory,21126027.0,
2103,553916,4,2,,103177124,6167,Active,,,2.0,EC50,Inhibition of tubulin polymerization after 60 mins,Confirmatory,21126027.0,
2104,553917,3,3,,103177124,6167,Unspecified,,,,,Displacement of [3H]colchicine from tubulin at 30 uM,Other,21126027.0,
2105,587610,3,4,,103177124,6167,Active,,,,,Inhibition of microtubule polymerization in human A549 cells after 24 hs by immunofluorescence staining,Other,21284385.0,
2106,587611,3,4,,103177124,6167,Active,,,,,Inhibition of spindle formation in human A549 cells after 24 hs by DAPI staining,Other,21284385.0,
2107,588208,2,3,,103177124,6167,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
2108,588209,2,3,,103177124,6167,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
2109,588210,2,4,,103177124,6167,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
2110,588211,2,3,,103177124,6167,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
2111,588212,2,3,,103177124,6167,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
2112,588213,2,3,,103177124,6167,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
2113,588334,1,1,,50085974,6167,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
2114,588335,1,1,,50085974,6167,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
2115,588342,1,1,,49718107,6167,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
2116,588349,1,1,,90340644,6167,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
2117,588352,1,2,,50085974,6167,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
2118,588354,1,1,,50085974,6167,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
2119,588358,1,2,,50085974,6167,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
2120,588378,1,1,,90340644,6167,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
2121,588379,1,2,,11114044,6167,Inactive,13399304.0,60489.0,,Potency,qHTS for inhibitors of Vif-A3G interactions: Validation,Confirmatory,,
2122,588391,1,1,,50085974,6167,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2123,588405,1,1,,50085974,6167,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
2124,588413,1,2,,49718107,6167,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
2125,588436,1,1,,50085974,6167,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
2126,588453,1,1,,49718107,6167,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2127,588453,1,1,,50104821,6167,Inconclusive,8659577.0,58819.0,29.9349,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2128,588453,1,1,,90340644,6167,Inconclusive,8659577.0,58819.0,0.8437,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2129,588456,1,1,,49718107,6167,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2130,588456,1,1,,90340644,6167,Inconclusive,8659577.0,58819.0,9.4662,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
2131,588458,1,1,,50085974,6167,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
2132,588473,1,1,,49718107,6167,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2133,588473,1,1,,49718107,6167,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2134,588475,1,2,,49718107,6167,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2135,588475,1,2,,49718107,6167,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
2136,588478,1,2,,124799683,6167,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
2137,588489,1,1,,50085974,6167,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
2138,588492,1,1,,50085974,6167,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
2139,588493,1,2,,50085974,6167,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
2140,588497,1,2,,50085974,6167,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
2141,588497,1,2,,50085974,6167,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
2142,588497,1,2,,50085974,6167,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
2143,588499,1,3,,50085974,6167,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
2144,588499,1,3,,50085974,6167,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
2145,588499,1,3,,50085974,6167,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
2146,588501,1,2,,50085974,6167,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
2147,588501,1,2,,50085974,6167,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
2148,588501,1,2,,50085974,6167,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
2149,588511,1,2,,49718107,6167,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
2150,588513,1,1,,17389095,6167,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2151,588513,1,1,,17389096,6167,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2152,588513,1,1,,26752176,6167,Inconclusive,348019627.0,2099.0,4.4668,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
2153,588514,1,1,,17389095,6167,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2154,588514,1,1,,17389096,6167,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2155,588514,1,1,,26752176,6167,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
2156,588515,1,1,,17389095,6167,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2157,588515,1,1,,17389096,6167,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2158,588515,1,1,,26752176,6167,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
2159,588516,1,1,,17389095,6167,Inconclusive,124375976.0,367.0,0.0355,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2160,588516,1,1,,17389096,6167,Inconclusive,124375976.0,367.0,0.0112,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2161,588516,1,1,,26752176,6167,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
2162,588519,1,2,,92123932,6167,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2163,588519,1,2,,92125451,6167,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
2164,588526,1,1,,17389095,6167,Inconclusive,325495553.0,9971.0,0.0316,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2165,588526,1,1,,17389096,6167,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2166,588526,1,1,,26752176,6167,Inconclusive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
2167,588527,1,1,,17389095,6167,Inconclusive,325495553.0,9971.0,0.0251,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2168,588527,1,1,,17389096,6167,Inconclusive,325495553.0,9971.0,0.0501,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2169,588527,1,1,,26752176,6167,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
2170,588532,1,1,,17389095,6167,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2171,588532,1,1,,17389096,6167,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2172,588532,1,1,,26752176,6167,Inconclusive,311348376.0,2908.0,4.4668,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
2173,588533,1,1,,17389095,6167,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2174,588533,1,1,,17389096,6167,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2175,588533,1,1,,26752176,6167,Inconclusive,311348376.0,2908.0,0.7079,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
2176,588534,1,1,,17389095,6167,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2177,588534,1,1,,17389096,6167,Inconclusive,216409690.0,5467.0,0.0178,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2178,588534,1,1,,26752176,6167,Inconclusive,216409690.0,5467.0,0.1122,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2179,588535,1,1,,17389095,6167,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2180,588535,1,1,,17389096,6167,Inconclusive,216409690.0,5467.0,0.0316,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2181,588535,1,1,,26752176,6167,Inconclusive,216409690.0,5467.0,7.9433,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
2182,588536,1,1,,17389095,6167,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2183,588536,1,1,,17389096,6167,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2184,588536,1,1,,26752176,6167,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2185,588537,1,1,,17389095,6167,Inconclusive,216409692.0,5468.0,0.0251,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2186,588537,1,1,,17389096,6167,Inconclusive,216409692.0,5468.0,0.01,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2187,588537,1,1,,26752176,6167,Inconclusive,216409692.0,5468.0,0.0708,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
2188,588541,1,1,,17389095,6167,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2189,588541,1,1,,17389096,6167,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2190,588541,1,1,,26752176,6167,Inconclusive,216409708.0,7421.0,0.0794,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
2191,588543,1,1,,17389095,6167,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2192,588543,1,1,,17389096,6167,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2193,588543,1,1,,26752176,6167,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
2194,588544,1,1,,17389095,6167,Inconclusive,325495497.0,6256.0,0.0316,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2195,588544,1,1,,17389096,6167,Inconclusive,325495497.0,6256.0,0.0251,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2196,588544,1,1,,26752176,6167,Inconclusive,325495497.0,6256.0,0.0251,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
2197,588545,1,1,,17389095,6167,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2198,588545,1,1,,17389096,6167,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2199,588545,1,1,,26752176,6167,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
2200,588546,1,1,,17389095,6167,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2201,588546,1,1,,17389096,6167,Inconclusive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2202,588546,1,1,,26752176,6167,Inconclusive,325495497.0,6256.0,0.0398,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
2203,588547,1,1,,17389095,6167,Inconclusive,189491771.0,7068.0,0.0013,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2204,588547,1,1,,17389096,6167,Inconclusive,189491771.0,7068.0,0.0447,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2205,588547,1,1,,26752176,6167,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
2206,588549,1,1,,50085974,6167,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2207,588579,1,1,,11114044,6167,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2208,588579,1,1,,26752175,6167,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2209,588579,1,1,,26752176,6167,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2210,588579,1,1,,49718107,6167,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2211,588579,1,1,,90340644,6167,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
2212,588590,1,1,,49718107,6167,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2213,588590,1,1,,50104821,6167,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
2214,588591,1,1,,49718107,6167,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2215,588591,1,1,,50104821,6167,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
2216,588621,1,1,,50085974,6167,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
2217,588627,1,1,,49718107,6167,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
2218,588664,1,2,,50085974,6167,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2219,588664,1,2,,50085974,6167,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
2220,588674,1,2,,50085974,6167,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2221,588675,1,1,,49718107,6167,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
2222,588676,1,1,,49718107,6167,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
2223,588689,1,1,,50085974,6167,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
2224,588692,2,1,,50085974,6167,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2225,588726,1,2,,50085974,6167,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
2226,588727,1,1,,50085974,6167,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
2227,588795,1,1,,49718107,6167,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2228,588795,1,1,,90340644,6167,Inconclusive,4758356.0,2237.0,6.7016,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
2229,588812,1,1,,17389095,6167,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2230,588812,1,1,,17389096,6167,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2231,588812,1,1,1.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2232,588812,1,1,1.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2233,588812,1,1,2.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2234,588812,1,1,2.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2235,588812,1,1,3.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2236,588812,1,1,3.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2237,588812,1,1,4.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2238,588812,1,1,4.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2239,588812,1,1,5.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2240,588812,1,1,5.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2241,588812,1,1,6.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2242,588812,1,1,6.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2243,588812,1,1,7.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2244,588812,1,1,7.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2245,588812,1,1,8.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2246,588812,1,1,8.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2247,588812,1,1,9.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2248,588812,1,1,9.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2249,588812,1,1,10.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2250,588812,1,1,10.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2251,588812,1,1,11.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2252,588812,1,1,11.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2253,588812,1,1,12.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2254,588812,1,1,12.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2255,588812,1,1,13.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2256,588812,1,1,13.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2257,588812,1,1,14.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2258,588812,1,1,14.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2259,588812,1,1,15.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2260,588812,1,1,15.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2261,588812,1,1,16.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2262,588812,1,1,16.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2263,588812,1,1,17.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2264,588812,1,1,17.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2265,588812,1,1,18.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2266,588812,1,1,18.0,17389096,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2267,588812,1,1,19.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2268,588812,1,1,19.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2269,588812,1,1,20.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2270,588812,1,1,20.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2271,588812,1,1,21.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2272,588812,1,1,21.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2273,588812,1,1,22.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2274,588812,1,1,22.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2275,588812,1,1,23.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2276,588812,1,1,23.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2277,588812,1,1,24.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2278,588812,1,1,24.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2279,588812,1,1,25.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2280,588812,1,1,25.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2281,588812,1,1,26.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2282,588812,1,1,26.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2283,588812,1,1,27.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2284,588812,1,1,27.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2285,588812,1,1,28.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2286,588812,1,1,28.0,17389096,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2287,588812,1,1,29.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2288,588812,1,1,29.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2289,588812,1,1,30.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2290,588812,1,1,30.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2291,588812,1,1,31.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2292,588812,1,1,31.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2293,588812,1,1,32.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2294,588812,1,1,32.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2295,588812,1,1,33.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2296,588812,1,1,33.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2297,588812,1,1,34.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2298,588812,1,1,34.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2299,588812,1,1,35.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2300,588812,1,1,35.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2301,588812,1,1,36.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2302,588812,1,1,36.0,17389096,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2303,588812,1,1,37.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2304,588812,1,1,37.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2305,588812,1,1,38.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2306,588812,1,1,38.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2307,588812,1,1,39.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2308,588812,1,1,39.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2309,588812,1,1,40.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2310,588812,1,1,40.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2311,588812,1,1,41.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2312,588812,1,1,41.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2313,588812,1,1,42.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2314,588812,1,1,42.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2315,588812,1,1,43.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2316,588812,1,1,43.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2317,588812,1,1,44.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2318,588812,1,1,44.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2319,588812,1,1,45.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2320,588812,1,1,45.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2321,588812,1,1,46.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2322,588812,1,1,46.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2323,588812,1,1,47.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2324,588812,1,1,47.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2325,588812,1,1,48.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2326,588812,1,1,48.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2327,588812,1,1,49.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2328,588812,1,1,49.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2329,588812,1,1,50.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2330,588812,1,1,50.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2331,588812,1,1,51.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2332,588812,1,1,51.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2333,588812,1,1,52.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2334,588812,1,1,52.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2335,588812,1,1,53.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2336,588812,1,1,53.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2337,588812,1,1,54.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2338,588812,1,1,54.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2339,588812,1,1,55.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2340,588812,1,1,55.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2341,588812,1,1,56.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2342,588812,1,1,56.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2343,588812,1,1,57.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2344,588812,1,1,57.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2345,588812,1,1,58.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2346,588812,1,1,58.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2347,588812,1,1,59.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2348,588812,1,1,59.0,17389096,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2349,588812,1,1,60.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2350,588812,1,1,60.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2351,588812,1,1,61.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2352,588812,1,1,61.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2353,588812,1,1,62.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2354,588812,1,1,62.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2355,588812,1,1,63.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2356,588812,1,1,63.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2357,588812,1,1,64.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2358,588812,1,1,64.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2359,588812,1,1,65.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2360,588812,1,1,65.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2361,588812,1,1,66.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2362,588812,1,1,66.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2363,588812,1,1,67.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2364,588812,1,1,67.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2365,588812,1,1,68.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2366,588812,1,1,68.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2367,588812,1,1,69.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2368,588812,1,1,69.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2369,588812,1,1,70.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2370,588812,1,1,70.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2371,588812,1,1,71.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2372,588812,1,1,71.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2373,588812,1,1,72.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2374,588812,1,1,72.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2375,588812,1,1,73.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2376,588812,1,1,73.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2377,588812,1,1,74.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2378,588812,1,1,74.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2379,588812,1,1,75.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2380,588812,1,1,75.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2381,588812,1,1,76.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2382,588812,1,1,76.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2383,588812,1,1,77.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2384,588812,1,1,77.0,17389096,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2385,588812,1,1,78.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2386,588812,1,1,78.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2387,588812,1,1,79.0,17389095,6167,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2388,588812,1,1,79.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2389,588812,1,1,80.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2390,588812,1,1,80.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2391,588812,1,1,81.0,17389095,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2392,588812,1,1,81.0,17389096,6167,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
2393,588813,1,1,,17389095,6167,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2394,588813,1,1,,17389096,6167,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2395,588813,1,1,1.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2396,588813,1,1,1.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2397,588813,1,1,2.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2398,588813,1,1,2.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2399,588813,1,1,3.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2400,588813,1,1,3.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2401,588813,1,1,4.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2402,588813,1,1,4.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2403,588813,1,1,5.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2404,588813,1,1,5.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2405,588813,1,1,6.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2406,588813,1,1,6.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2407,588813,1,1,7.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2408,588813,1,1,7.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2409,588813,1,1,8.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2410,588813,1,1,8.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2411,588813,1,1,9.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2412,588813,1,1,9.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2413,588813,1,1,10.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2414,588813,1,1,10.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2415,588813,1,1,11.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2416,588813,1,1,11.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2417,588813,1,1,12.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2418,588813,1,1,12.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2419,588813,1,1,13.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2420,588813,1,1,13.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2421,588813,1,1,14.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2422,588813,1,1,14.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2423,588813,1,1,15.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2424,588813,1,1,15.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2425,588813,1,1,16.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2426,588813,1,1,16.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2427,588813,1,1,17.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2428,588813,1,1,17.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2429,588813,1,1,18.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2430,588813,1,1,18.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2431,588813,1,1,19.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2432,588813,1,1,19.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2433,588813,1,1,20.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2434,588813,1,1,20.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2435,588813,1,1,21.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2436,588813,1,1,21.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2437,588813,1,1,22.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2438,588813,1,1,22.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2439,588813,1,1,23.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2440,588813,1,1,23.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2441,588813,1,1,24.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2442,588813,1,1,24.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2443,588813,1,1,25.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2444,588813,1,1,25.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2445,588813,1,1,26.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2446,588813,1,1,26.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2447,588813,1,1,27.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2448,588813,1,1,27.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2449,588813,1,1,28.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2450,588813,1,1,28.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2451,588813,1,1,29.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2452,588813,1,1,29.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2453,588813,1,1,30.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2454,588813,1,1,30.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2455,588813,1,1,31.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2456,588813,1,1,31.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2457,588813,1,1,32.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2458,588813,1,1,32.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2459,588813,1,1,33.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2460,588813,1,1,33.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2461,588813,1,1,34.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2462,588813,1,1,34.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2463,588813,1,1,35.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2464,588813,1,1,35.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2465,588813,1,1,36.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2466,588813,1,1,36.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2467,588813,1,1,37.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2468,588813,1,1,37.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2469,588813,1,1,38.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2470,588813,1,1,38.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2471,588813,1,1,39.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2472,588813,1,1,39.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2473,588813,1,1,40.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2474,588813,1,1,40.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2475,588813,1,1,41.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2476,588813,1,1,41.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2477,588813,1,1,42.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2478,588813,1,1,42.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2479,588813,1,1,43.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2480,588813,1,1,43.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2481,588813,1,1,44.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2482,588813,1,1,44.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2483,588813,1,1,45.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2484,588813,1,1,45.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2485,588813,1,1,46.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2486,588813,1,1,46.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2487,588813,1,1,47.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2488,588813,1,1,47.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2489,588813,1,1,48.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2490,588813,1,1,48.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2491,588813,1,1,49.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2492,588813,1,1,49.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2493,588813,1,1,50.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2494,588813,1,1,50.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2495,588813,1,1,51.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2496,588813,1,1,51.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2497,588813,1,1,52.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2498,588813,1,1,52.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2499,588813,1,1,53.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2500,588813,1,1,53.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2501,588813,1,1,54.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2502,588813,1,1,54.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2503,588813,1,1,55.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2504,588813,1,1,55.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2505,588813,1,1,56.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2506,588813,1,1,56.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2507,588813,1,1,57.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2508,588813,1,1,57.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2509,588813,1,1,58.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2510,588813,1,1,58.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2511,588813,1,1,59.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2512,588813,1,1,59.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2513,588813,1,1,60.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2514,588813,1,1,60.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2515,588813,1,1,61.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2516,588813,1,1,61.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2517,588813,1,1,62.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2518,588813,1,1,62.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2519,588813,1,1,63.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2520,588813,1,1,63.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2521,588813,1,1,64.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2522,588813,1,1,64.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2523,588813,1,1,65.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2524,588813,1,1,65.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2525,588813,1,1,66.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2526,588813,1,1,66.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2527,588813,1,1,67.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2528,588813,1,1,67.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2529,588813,1,1,68.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2530,588813,1,1,68.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2531,588813,1,1,69.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2532,588813,1,1,69.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2533,588813,1,1,70.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2534,588813,1,1,70.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2535,588813,1,1,71.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2536,588813,1,1,71.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2537,588813,1,1,72.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2538,588813,1,1,72.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2539,588813,1,1,73.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2540,588813,1,1,73.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2541,588813,1,1,74.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2542,588813,1,1,74.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2543,588813,1,1,75.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2544,588813,1,1,75.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2545,588813,1,1,76.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2546,588813,1,1,76.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2547,588813,1,1,77.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2548,588813,1,1,77.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2549,588813,1,1,78.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2550,588813,1,1,78.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2551,588813,1,1,79.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2552,588813,1,1,79.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2553,588813,1,1,80.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2554,588813,1,1,80.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2555,588813,1,1,81.0,17389095,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2556,588813,1,1,81.0,17389096,6167,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
2557,588814,1,3,,50085974,6167,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
2558,588819,1,4,,50085974,6167,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
2559,588834,2,1,,17389095,6167,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2560,588834,2,1,,17389096,6167,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2561,588834,2,1,,50104821,6167,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2562,588834,2,1,,144204498,6167,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
2563,588850,1,1,,50085974,6167,Inactive,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
2564,588852,1,3,,50085974,6167,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
2565,588855,1,1,,49718107,6167,Inconclusive,18418623.0,4088.0,1.122,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
2566,588856,1,1,,49718107,6167,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
2567,595051,4,2,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Other,21440448.0,
2568,595052,4,2,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Other,21440448.0,
2569,595053,4,3,,103177124,6167,Unspecified,,,,,Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay,Other,21440448.0,
2570,595054,4,2,,103177124,6167,Unspecified,,,,,Inhibition of bovine brain tubulin polymerization after 20 mins by turbidimetry,Other,21440448.0,
2571,595055,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at G2/M phase at 1 ug/ml after 24 hrs by flow cytometry (Rbv = 12.27%),Other,21440448.0,
2572,595057,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at Go/G1 phase at 1 ug/ml after 24 hrs by flow cytometry (Rbv = 66.15%),Other,21440448.0,
2573,595059,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at S phase at 1 ug/ml after 24 hrs by flow cytometry (Rbv = 14.96%),Other,21440448.0,
2574,596136,3,2,,103177124,6167,Active,,,2.68,IC50,Inhibition of pig brain tubulin polymerization by spectrophotometry,Confirmatory,21480626.0,
2575,596138,3,3,,103177124,6167,Active,,,0.04,IC50,Antiproliferative activity against human Bel7402 cells after 72 hrs by sulforhodamine B assay,Confirmatory,21480626.0,
2576,596139,1,4,,103177124,6167,Active,,,0.0532,IC50,Antiproliferative activity against human A431 cells after 72 hrs by sulforhodamine B assay,Confirmatory,21480626.0,
2577,596140,1,4,,103177124,6167,Active,,,0.0712,IC50,Antiproliferative activity against human SKOV3 cells after 72 hrs by sulforhodamine B assay,Confirmatory,21480626.0,
2578,596141,1,4,,103177124,6167,Active,,,0.0219,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by sulforhodamine B assay,Confirmatory,21480626.0,
2579,596142,1,4,,103177124,6167,Active,,,0.0506,IC50,Antiproliferative activity against human NCI-H460 cells after 72 hrs by sulforhodamine B assay,Confirmatory,21480626.0,
2580,596143,1,4,,103177124,6167,Active,,,0.037000000000000005,IC50,Antiproliferative activity against human A549 cells after 72 hrs by sulforhodamine B assay,Confirmatory,21480626.0,
2581,596144,1,4,,103177124,6167,Active,,,0.01,EC50,Cell cycle arrest in human KB cells assessed as accumulation of cells at G2/M phase after 24 hrs by propidium iodide-based FACScan,Confirmatory,21480626.0,
2582,597796,3,2,,103177124,6167,Active,,,0.0172,IC50,Cytotoxicity against human CEM cells after 72 hrs by MTT assay,Confirmatory,21536450.0,
2583,597797,3,2,,103177124,6167,Active,,,0.0073,IC50,Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTT assay,Confirmatory,21536450.0,
2584,597798,3,2,,103177124,6167,Active,,,0.10099999999999999,IC50,Cytotoxicity against human LoVo cells after 72 hrs by MTT assay,Confirmatory,21536450.0,
2585,598212,1,4,,103177124,6167,Active,,,,,Cytotoxicity against human OVCAR3 cells assessed as reduction in viable cells after 24 hrs by trypan blue exclusion assay,Other,21524911.0,
2586,598213,1,4,,103177124,6167,Active,,,,,Cytotoxicity against human OVCAR3 cells assessed as cell death after 24 hrs by trypan blue exclusion assay,Other,21524911.0,
2587,598214,1,4,,103177124,6167,Active,,,,,Cytotoxicity against human OVCAR3 cells assessed as change in cell shape after 24 hrs by trypan blue exclusion assay,Other,21524911.0,
2588,602115,1,4,,103177124,6167,Inactive,,,,,Antimitotic activity in human HeLa cells assessed as visible deffect in microtubule organization at 5 nM after 3 hrs by inverted microscopic analysis,Other,21615090.0,
2589,602123,1,1,,50085974,6167,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
2590,602141,1,1,,50085974,6167,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
2591,602162,1,1,,50085974,6167,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
2592,602163,1,1,,50085974,6167,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
2593,602179,1,2,,49718107,6167,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
2594,602229,1,1,,50085974,6167,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
2595,602233,1,1,,49718107,6167,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
2596,602244,1,2,,50085974,6167,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
2597,602247,1,2,,50085974,6167,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2598,602248,1,2,,50085974,6167,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
2599,602250,1,2,,50085974,6167,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
2600,602252,1,1,,50085974,6167,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2601,602252,1,1,,50085974,6167,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2602,602261,1,1,,50085974,6167,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
2603,602274,1,2,,50085974,6167,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
2604,602281,1,1,,50085974,6167,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2605,602281,1,1,,50085974,6167,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
2606,602310,1,2,,49718107,6167,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
2607,602313,1,1,,49718107,6167,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
2608,602314,1,2,,92123932,6167,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2609,602314,1,2,,92125451,6167,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
2610,602329,1,1,,50085974,6167,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2611,602332,1,1,,11114044,6167,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2612,602332,1,1,,26752175,6167,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2613,602332,1,1,,26752176,6167,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2614,602332,1,1,,49718107,6167,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2615,602332,1,1,,90340644,6167,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
2616,602340,1,2,,50085974,6167,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
2617,602342,2,1,,50085974,6167,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2618,602346,1,1,,50085974,6167,Inconclusive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2619,602363,1,1,,50085974,6167,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
2620,602393,1,1,,50085974,6167,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2621,602396,1,2,,50085974,6167,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
2622,602399,1,2,,50085974,6167,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
2623,602405,1,1,,50085974,6167,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2624,602410,1,1,,50085974,6167,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
2625,602429,1,1,,50085974,6167,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
2626,602438,1,1,,50085974,6167,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
2627,602440,1,1,,50085974,6167,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
2628,602449,1,2,,50085974,6167,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
2629,602481,1,1,,50085974,6167,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2630,602746,1,5,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human K562 cells at 10 uM after 48 hrs by trypan blue assay,Other,21530013.0,
2631,602821,3,2,,103177124,6167,Active,,,0.02,IC50,Growth inhibition of human K562 cells after 48 hrs by trypan blue assay,Confirmatory,21530013.0,
2632,603021,1,3,,103177124,6167,Unspecified,,,,,Inhibition of purified bovine brain tubulin microtubule assembly at 2 uM,Other,21530013.0,
2633,603022,1,3,,103177124,6167,Active,,,,,Inhibition of purified bovine brain tubulin microtubule assembly at 5 to 10 uM,Other,21530013.0,
2634,605715,1,4,,103177124,6167,Active,,,0.22,IC50,Antiproliferative activity against CHO cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2635,605716,1,4,,103177124,6167,Active,,,0.0068,IC50,Antiproliferative activity against human K562 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2636,605717,1,4,,103177124,6167,Active,,,0.0069,IC50,Antiproliferative activity against mouse L1210 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2637,605763,1,5,,103177124,6167,Active,,,0.027999999999999997,IC50,Antiproliferative activity against mouse P388D1 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2638,605764,1,5,,103177124,6167,Active,,,0.013000000000000001,IC50,Antiproliferative activity against mouse B16F0 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2639,605765,1,4,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human DU145 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2640,605766,1,4,,103177124,6167,Active,,,0.0011,IC50,Antiproliferative activity against human HT1080 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2641,605767,1,4,,103177124,6167,Active,,,0.0029,IC50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2642,605768,1,4,,103177124,6167,Active,,,0.0021,IC50,Antiproliferative activity against human SKOV3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2643,605769,1,4,,103177124,6167,Active,,,0.0079,IC50,Antiproliferative activity against human CEM cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2644,605770,1,4,,103177124,6167,Active,,,0.14,IC50,Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2645,605771,1,4,,103177124,6167,Unspecified,,,,,Resistant ratio of IC50 for paclitaxel-resistant CHO-TAX 5-6 cells to IC50 for CHO cells,Other,21604746.0,
2646,605772,1,4,,103177124,6167,Active,,,0.62,IC50,Antiproliferative activity against paclitaxel-resistant CHO-VV 3-2 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2647,605773,1,4,,103177124,6167,Unspecified,,,,,Resistant ratio of IC50 for paclitaxel-resistant CHO-VV 3-2 cells to IC50 for CHO cells,Other,21604746.0,
2648,605774,1,4,,103177124,6167,Active,,,0.36,IC50,Antiproliferative activity against multidrug-resistant human CEM/VLB cells after 48 hrs by sulforhodamine B assay,Confirmatory,21604746.0,
2649,605775,1,4,,103177124,6167,Unspecified,,,,,Resistant ratio of IC50 for multidrug-resistant human CEM-VLB cells to IC50 for human CEM cells,Other,21604746.0,
2650,605843,3,2,,103177124,6167,Active,,,0.027000000000000003,IC50,Antiproliferative activity against human NCI-H460 cells after 48 hrs by alamar blue assay,Confirmatory,21563750.0,
2651,605844,3,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis,Confirmatory,21563750.0,
2652,605845,3,2,,103177124,6167,Active,,,0.028999999999999998,IC50,Antiproliferative activity against human SKOV3 cells after 48 hrs by alamar blue assay,Confirmatory,21563750.0,
2653,605846,3,2,,103177124,6167,Active,,,0.023,IC50,Antiproliferative activity against human BT549 cells after 48 hrs by alamar blue assay,Confirmatory,21563750.0,
2654,605847,3,3,,103177124,6167,Active,,,0.017,IC50,Antiproliferative activity against human 451LU cells after 48 hrs by alamar blue assay,Confirmatory,21563750.0,
2655,605848,3,2,,103177124,6167,Active,,,0.03,IC50,Antiproliferative activity against human SW480 cells after 48 hrs by alamar blue assay,Confirmatory,21563750.0,
2656,605849,3,2,,103177124,6167,Active,,,0.021,IC50,Antiproliferative activity against human COLO205 cells after 48 hrs by alamar blue assay,Confirmatory,21563750.0,
2657,605850,3,2,,103177124,6167,Active,,,0.08900000000000001,IC50,Antiproliferative activity against human DLD1 cells after 48 hrs by alamar blue assay,Confirmatory,21563750.0,
2658,605956,3,2,,103177124,6167,Active,,,1.4,IC50,Inhibition of pig tubulin polymerization determined after 45 mins at 37 degC by turbidimetric analysis,Confirmatory,21563750.0,
2659,605957,1,4,,103177124,6167,Active,,,,,Inhibition of tubulin polymerization in Potorous tridactylus Ptk2 cells assessed as destruction of microtubule network at 5 uM after 1 hr by immunofluorescence assay,Other,21563750.0,
2660,605958,1,4,,103177124,6167,Active,,,,,Cell cycle arrest in human K562 cells assessed as accumulation at G2/M phase at 0.003 to. 1 ug/ml after 24 hrs by flow cytometric analysis,Other,21563750.0,
2661,611264,3,3,,103177124,6167,Unspecified,,,10.0,IC50,Cytotoxicity against ponasterone A-induced human RKOp27 cells with ectopic inducible expression of CDK inhibitor-kip1 after 48 hrs by XTT assay,Confirmatory,21705223.0,
2662,611265,3,3,,103177124,6167,Active,,,0.03,IC50,Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay,Confirmatory,21705223.0,
2663,611266,3,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay,Confirmatory,21705223.0,
2664,611267,3,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer,Confirmatory,21705223.0,
2665,611268,3,3,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against non induced human RKOp27 cells after 48 hrs by XTT assay,Confirmatory,21705223.0,
2666,611269,3,2,,103177124,6167,Active,,,0.07,IC50,Cytotoxicity against human NCI-H460 cells after 48 hrs by XTT assay,Confirmatory,21705223.0,
2667,611270,3,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human SF268 cells after 48 hrs by XTT assay,Confirmatory,21705223.0,
2668,611277,1,4,,103177124,6167,Active,,,0.013999999999999999,EC50,Cell cycle arrest in human KB/HeLa cells assessed as accumulation of cells at G2/M phase after 24 hrs by flow cytometry,Confirmatory,21705223.0,
2669,611278,3,2,,103177124,6167,Active,,,1.4,IC50,Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetry analysis,Confirmatory,21705223.0,
2670,611279,3,2,,103177124,6167,Active,,,1.06,IC50,Displacement of [3H]colchicine from biotinylated pig brain tubulin after 2 hrs by competitive scintillation proximity assay,Confirmatory,21705223.0,
2671,611834,3,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay,Confirmatory,21724404.0,
2672,612171,3,2,,103177124,6167,Active,,,1.9,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,21576023.0,
2673,612257,3,2,,103177124,6167,Active,,,1.9,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,21576023.0,
2674,612315,3,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human A375 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21775150.0,
2675,612316,3,3,,103177124,6167,Active,,,0.03,IC50,Antiproliferative activity against human WM164 cells after 48 hrs by sulforhodamine B assay,Confirmatory,21775150.0,
2676,612317,3,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human LNCAP cells after 96 hrs by sulforhodamine B assay,Confirmatory,21775150.0,
2677,612318,3,2,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human PC3 cells after 96 hrs by sulforhodamine B assay,Confirmatory,21775150.0,
2678,612319,3,2,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human DU145 cells after 96 hrs by sulforhodamine B assay,Confirmatory,21775150.0,
2679,612320,3,3,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human PPC1 cells after 96 hrs by sulforhodamine B assay,Confirmatory,21775150.0,
2680,612339,1,3,,103177124,6167,Active,,,,,Inhibition of bovine brain tubulin polymerization at 20 uM after 15 mins by spectrophotometric analysis,Other,21775150.0,
2681,612421,3,3,,103177124,6167,Unspecified,,,,,Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT based ELISA assay,Other,21783370.0,
2682,612422,3,2,,103177124,6167,Unspecified,,,,,Inhibition of bovine brain tubulin polymerization after 20 mins by turbidimetric analysis,Other,21783370.0,
2683,612423,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at G0/G1 phase at 1 ug/ml after 24 hrs by flow cytometry analysis (Rvb = 48.57%),Other,21783370.0,
2684,612424,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at S phase at 1 ug/ml after 24 hrs by flow cytometry analysis (Rvb = 9.40%),Other,21783370.0,
2685,612425,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at G2/M phase at 1 ug/ml after 24 hrs by flow cytometry analysis (Rvb = 17.03%),Other,21783370.0,
2686,613261,1,5,,103177124,6167,Active,,,0.121,IC50,Antiproliferative activity against human KB-VIN10 cells over-expressing P-gp 170/MDR1 after 72 hrs by methylene blue assay,Confirmatory,21641700.0,
2687,613262,1,4,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human H460 cells after 72 hrs by methylene blue assay,Confirmatory,21641700.0,
2688,613263,1,4,,103177124,6167,Active,,,0.015,IC50,Antiproliferative activity against human HT-29 cells after 72 hrs by methylene blue assay,Confirmatory,21641700.0,
2689,613264,1,5,,103177124,6167,Active,,,0.012,IC50,Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue assay,Confirmatory,21641700.0,
2690,613265,3,2,,103177124,6167,Active,,,4.1,IC50,Inhibition of bovine brain tubulin polymerization after 20 mins by turbidimetry analysis,Confirmatory,21641700.0,
2691,613282,1,4,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay,Confirmatory,21641700.0,
2692,614578,1,4,,103177124,6167,Active,,,0.027000000000000003,EC50,Cytotoxicity against human A549 cells after 24 hrs by MTT assay,Confirmatory,21873068.0,
2693,614580,1,4,,103177124,6167,Active,,,,,Effect on microtubule network in human A549 cells assessed as microtubule depolymerization at 1 uM after 8 hrs by immunofluorescence microscopic analysis,Other,21873068.0,
2694,617075,1,3,,103177124,6167,Unspecified,,,,,Binding affinity to bovine tubulin assessed as half life of compound-tubulin complex,Other,21774499.0,
2695,618908,1,4,,103177124,6167,Active,,,0.017,IC50,Anticancer activity against human OVCAR8 cells after 96 hrs by SRB assay,Confirmatory,21557538.0,
2696,618916,1,5,,103177124,6167,Active,,,1.113,IC50,Anticancer activity against P-gp overexpressing human NCI/ADR-RES cells after 96 hrs by SRB assay,Confirmatory,21557538.0,
2697,618986,1,3,,103177124,6167,Unspecified,,,,,"Resistance factor, ratio of IC50 for human NCI-ADR-RES cells to IC50 for drug-sensitive human OVCAR8 cells",Other,21557538.0,
2698,620717,3,2,,103177124,6167,Active,,,1.96,IC50,Inhibition of bovine tubulin assembly after 1 hr by fluorescence assay,Confirmatory,21851083.0,
2699,620725,1,4,,103177124,6167,Unspecified,,,,,Inhibition of bovine tubulin polymerization at 3 uM after 1 hr by fluorescence assay relative to control,Other,21851083.0,
2700,623870,1,1,,50085974,6167,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2701,623870,1,1,,50085974,6167,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2702,623877,1,1,,50085974,6167,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
2703,623901,1,1,,50085974,6167,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
2704,624030,1,2,,26752176,6167,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
2705,624031,1,2,,26752176,6167,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
2706,624032,1,2,,26752176,6167,Active,8393992.0,24660.0,0.1018,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
2707,624037,1,3,,50085974,6167,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2708,624038,1,3,,50085974,6167,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2709,624040,1,3,,50085974,6167,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
2710,624044,1,2,,26752176,6167,Active,8393992.0,24660.0,0.0891,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
2711,624101,1,2,,85788838,6167,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2712,624125,1,4,,50085974,6167,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2713,624126,1,3,,50085974,6167,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2714,624127,1,2,,50085974,6167,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
2715,624146,1,1,,90340644,6167,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
2716,624147,1,1,,90340644,6167,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
2717,624148,1,2,,90340644,6167,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
2718,624149,1,1,,90340644,6167,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
2719,624156,1,1,,85788838,6167,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
2720,624168,1,1,,50085974,6167,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
2721,624169,1,1,,50085974,6167,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
2722,624170,1,1,,26752176,6167,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2723,624170,1,1,,49718107,6167,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
2724,624171,1,1,,49718107,6167,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
2725,624172,1,1,,26752176,6167,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2726,624172,1,1,,49718107,6167,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
2727,624173,1,3,,26752176,6167,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2728,624173,1,3,,49718107,6167,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
2729,624178,1,1,,49718107,6167,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
2730,624202,1,1,,49718107,6167,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
2731,624204,1,2,,50085974,6167,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
2732,624246,1,1,,49718107,6167,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
2733,624256,1,2,,50085974,6167,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
2734,624263,1,1,,49718107,6167,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2735,624263,1,1,,49718107,6167,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
2736,624267,1,2,,50085974,6167,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2737,624267,1,2,,50085974,6167,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
2738,624268,1,3,,50085974,6167,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
2739,624288,1,1,,49718107,6167,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
2740,624296,1,1,,26752176,6167,Active,7705682.0,51053.0,0.0422,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2741,624296,1,1,,49718107,6167,Inconclusive,7705682.0,51053.0,0.20600000000000002,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
2742,624297,1,1,,26752176,6167,Active,7705682.0,51053.0,0.0531,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2743,624297,1,1,,49718107,6167,Active,7705682.0,51053.0,0.0046,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
2744,624304,1,2,,50085974,6167,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
2745,624330,1,2,,50085974,6167,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
2746,624349,1,2,,92123932,6167,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2747,624349,1,2,,92125451,6167,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2748,624349,1,2,,92307326,6167,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2749,624349,1,2,,121363122,6167,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
2750,624352,1,1,,50085974,6167,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
2751,624354,1,1,,50085974,6167,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
2752,624377,1,1,,50085974,6167,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
2753,624414,1,1,,49718107,6167,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2754,624415,1,2,,49718107,6167,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
2755,624416,1,1,,50085974,6167,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
2756,624417,1,1,,49718107,6167,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
2757,624418,1,1,,49718107,6167,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
2758,624455,1,1,,90340644,6167,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
2759,624463,1,1,,49718107,6167,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
2760,624464,1,1,,49718107,6167,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
2761,624465,1,1,,49718107,6167,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
2762,624466,1,3,,50085974,6167,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2763,624467,1,1,,50085974,6167,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
2764,624483,1,1,,50085974,6167,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
2765,624622,3,1,,103177124,6167,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2766,624623,3,1,,103177124,6167,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
2767,624626,1,9,,103177124,6167,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
2768,624628,1,9,,103177124,6167,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
2769,624629,1,9,,103177124,6167,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
2770,625144,5,5,,103177124,6167,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
2771,625145,4,7,,103177124,6167,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
2772,625146,5,5,,103177124,6167,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
2773,625147,4,7,,103177124,6167,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2774,625148,4,7,,103177124,6167,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2775,625149,4,7,,103177124,6167,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
2776,625150,5,5,,103177124,6167,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
2777,625151,4,7,,103177124,6167,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2778,625152,4,7,,103177124,6167,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2779,625153,4,7,,103177124,6167,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2780,625154,4,7,,103177124,6167,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2781,625155,4,7,,103177124,6167,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
2782,625156,1,9,,103177124,6167,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
2783,625157,6,2,,103177124,6167,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
2784,625158,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
2785,625159,5,5,,103177124,6167,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
2786,625160,1,9,,103177124,6167,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
2787,625161,4,7,,103177124,6167,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
2788,625162,4,7,,103177124,6167,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2789,625163,4,7,,103177124,6167,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
2790,625164,1,6,,103177124,6167,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
2791,625165,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2792,625166,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
2793,625167,5,5,,103177124,6167,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
2794,625168,4,7,,103177124,6167,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
2795,625169,1,6,,103177124,6167,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
2796,625170,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
2797,625171,4,7,,103177124,6167,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
2798,625172,4,7,,103177124,6167,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
2799,625173,5,5,,103177124,6167,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
2800,625174,5,5,,103177124,6167,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
2801,625175,5,5,,103177124,6167,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
2802,625176,1,9,,103177124,6167,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
2803,625177,5,5,,103177124,6167,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2804,625178,5,5,,103177124,6167,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
2805,625179,1,9,,103177124,6167,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
2806,625180,5,5,,103177124,6167,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2807,625181,5,5,,103177124,6167,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2808,625182,5,5,,103177124,6167,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
2809,625183,5,5,,103177124,6167,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
2810,625184,5,5,,103177124,6167,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2811,625185,5,5,,103177124,6167,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2812,625186,5,5,,103177124,6167,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2813,625187,5,5,,103177124,6167,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
2814,625188,1,9,,103177124,6167,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
2815,625189,1,7,,103177124,6167,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
2816,625190,4,5,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
2817,625191,4,7,,103177124,6167,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2818,625192,4,7,,103177124,6167,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
2819,625193,5,5,,103177124,6167,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
2820,625194,4,7,,103177124,6167,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
2821,625195,4,7,,103177124,6167,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
2822,625196,5,6,,103177124,6167,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
2823,625197,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
2824,625198,4,7,,103177124,6167,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2825,625199,4,7,,103177124,6167,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2826,625200,4,7,,103177124,6167,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
2827,625201,4,7,,103177124,6167,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
2828,625202,4,7,,103177124,6167,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
2829,625203,4,7,,103177124,6167,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
2830,625204,4,7,,103177124,6167,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2831,625205,4,7,,103177124,6167,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
2832,625206,4,7,,103177124,6167,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
2833,625207,4,7,,103177124,6167,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2834,625208,5,5,,103177124,6167,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
2835,625209,4,7,,103177124,6167,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
2836,625210,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
2837,625211,1,6,,103177124,6167,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
2838,625212,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
2839,625213,4,7,,103177124,6167,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
2840,625214,1,9,,103177124,6167,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
2841,625215,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
2842,625216,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
2843,625217,4,7,,103177124,6167,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2844,625218,4,7,,103177124,6167,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
2845,625219,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
2846,625220,4,7,,103177124,6167,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
2847,625221,4,7,,103177124,6167,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
2848,625222,4,7,,103177124,6167,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
2849,625223,4,7,,103177124,6167,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
2850,625224,3,4,,103177124,6167,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
2851,625225,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
2852,625226,4,7,,103177124,6167,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
2853,625227,4,7,,103177124,6167,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
2854,625228,4,7,,103177124,6167,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
2855,625229,5,5,,103177124,6167,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
2856,625230,1,6,,103177124,6167,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
2857,625231,4,7,,103177124,6167,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
2858,625232,1,9,,103177124,6167,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
2859,625233,4,7,,103177124,6167,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
2860,625234,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
2861,625235,4,7,,103177124,6167,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
2862,625236,5,5,,103177124,6167,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
2863,625237,4,7,,103177124,6167,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
2864,625238,4,7,,103177124,6167,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
2865,625239,4,7,,103177124,6167,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
2866,625240,1,9,,103177124,6167,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
2867,625241,4,7,,103177124,6167,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
2868,625242,4,7,,103177124,6167,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
2869,625243,5,5,,103177124,6167,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2870,625244,5,5,,103177124,6167,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
2871,625245,5,5,,103177124,6167,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2872,625246,1,9,,103177124,6167,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
2873,625247,5,5,,103177124,6167,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2874,625248,5,5,,103177124,6167,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2875,625249,5,5,,103177124,6167,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2876,625250,5,5,,103177124,6167,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
2877,625251,5,5,,103177124,6167,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
2878,625252,4,7,,103177124,6167,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
2879,625253,4,7,,103177124,6167,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2880,625254,4,7,,103177124,6167,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2881,625255,4,7,,103177124,6167,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
2882,625256,4,7,,103177124,6167,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
2883,625257,4,7,,103177124,6167,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
2884,625258,4,7,,103177124,6167,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2885,625259,4,7,,103177124,6167,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
2886,625260,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
2887,625261,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
2888,625262,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
2889,625263,4,7,,103177124,6167,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
2890,625264,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
2891,625265,1,6,,103177124,6167,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
2892,625266,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
2893,625267,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
2894,625268,4,2,,103177124,6167,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2895,625268,4,2,,103177124,6167,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2896,625268,4,2,,103177124,6167,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2897,625268,4,2,,103177124,6167,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
2898,625269,4,7,,103177124,6167,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
2899,625270,4,7,,103177124,6167,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
2900,625271,5,5,,103177124,6167,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
2901,625272,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
2902,625273,4,6,,103177124,6167,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
2903,625274,1,6,,103177124,6167,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
2904,625275,3,4,,103177124,6167,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
2905,625277,1,3,,103177124,6167,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
2906,625294,1,3,,103177124,6167,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data,Other,22194678.0,
2907,626619,1,4,,103177124,6167,Unspecified,,,,,Ratio of IC50 for paclitaxel-resistant CHO-TAX 5-6 cells to IC50 for CHO cells,Other,21920638.0,
2908,626620,1,4,,103177124,6167,Active,,,0.62,IC50,Antiproliferative activity against colchicine and vinblastine-resistant CHO-VV 3-2 cells after 48 hrs by SRB assay,Confirmatory,21920638.0,
2909,626621,1,4,,103177124,6167,Unspecified,,,,,Ratio of IC50 for colchicine and vinblastine-resistant CHO-VV 3-2 cells to IC50 for CHO cells,Other,21920638.0,
2910,626622,1,3,,103177124,6167,Active,,,0.36,IC50,Antiproliferative activity against human multidrug-resistant CEM/VLB cells after 48 hrs by SRB assay,Confirmatory,21920638.0,
2911,626623,1,4,,103177124,6167,Unspecified,,,,,Ratio of IC50 for human multidrug-resistant CEM/VLB cells to IC50 for human CEM cells,Other,21920638.0,
2912,627395,1,4,,103177124,6167,Active,,,0.22,IC50,Antiproliferative activity against human CHO after 48 hrs by SRB assay,Confirmatory,21920638.0,
2913,627396,1,4,,103177124,6167,Active,,,0.0068,IC50,Antiproliferative activity against human K562 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2914,627397,1,4,,103177124,6167,Active,,,0.0069,IC50,Antiproliferative activity against mouse L1210 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2915,627398,1,3,,103177124,6167,Active,,,0.027999999999999997,IC50,Antiproliferative activity against human P388D1 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2916,627399,1,3,,103177124,6167,Active,,,0.013000000000000001,IC50,Antiproliferative activity against human B16F0 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2917,627400,1,4,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human DU145 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2918,627401,1,4,,103177124,6167,Active,,,0.0011,IC50,Antiproliferative activity against human HT1080 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2919,627402,1,4,,103177124,6167,Active,,,0.0029,IC50,Antiproliferative activity against human MDA-MB-231 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2920,627403,1,4,,103177124,6167,Active,,,0.0021,IC50,Antiproliferative activity against human SKOV3 after 48 hrs by SRB assay,Confirmatory,21920638.0,
2921,627404,1,4,,103177124,6167,Active,,,0.0079,IC50,Antiproliferative activity against human CEM after 48 hrs by SRB assay,Confirmatory,21920638.0,
2922,627405,1,4,,103177124,6167,Active,,,0.14,IC50,Antiproliferative activity against paclitaxel-resistant CHO-TAX 5-6 cells after 48 hrs by SRB assay,Confirmatory,21920638.0,
2923,636070,1,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at Go/G1 phase at 1 ug/ml after 24 hrs by flow cytometry analysis (Rvb = 70.4 %),Other,22192936.0,
2924,636071,1,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at S phase at 1 ug/ml after 24 hrs by flow cytometry analysis (Rvb = 9.97 %),Other,22192936.0,
2925,636072,1,4,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at G2/M phase at 1 ug/ml after 24 hrs by flow cytometry analysis (Rvb = 17.67 %),Other,22192936.0,
2926,636393,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at Go/G1 phase at 1 ug/ml after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 68 %),Other,22189271.0,
2927,636394,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at S phase at 1 ug/ml after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 12 %),Other,22189271.0,
2928,636395,1,5,,103177124,6167,Unspecified,,,,,Cell cycle arrest in mouse B16F10 cells assessed as accumulation at G2/M phase at 1 ug/ml after 24 hrs using propidium iodide staining by flow cytometry (Rvb = 18 %),Other,22189271.0,
2929,637149,3,2,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Other,22261027.0,
2930,637150,3,2,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Other,22261027.0,
2931,637197,3,2,,103177124,6167,Unspecified,,,,,Inhibition of bovine brain tubulin polymerization preincubated for 10 mins measured after 20 mins,Other,22261027.0,
2932,637198,1,4,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 5 ug/ml after 24 hrs by flow cytometric analysis (Rvb = 66%),Other,22261027.0,
2933,637199,1,4,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 5 ug/ml after 24 hrs by flow cytometric analysis (Rvb = 12%),Other,22261027.0,
2934,637200,1,4,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 5 ug/ml after 24 hrs by flow cytometric analysis (Rvb = 18%),Other,22261027.0,
2935,642051,3,2,,103177124,6167,Active,,,3.2,IC50,Inhibition of tubulin polymerization after 15 mins preincubation measured after 20 mins by spectrophotometry,Confirmatory,22044164.0,
2936,642052,1,4,,103177124,6167,Active,,,0.005,IC50,Growth inhibition of human MCF7 cells after 96 hrs,Confirmatory,22044164.0,
2937,642528,5,1,,103177124,6167,Active,,,0.0103,IC50,Growth inhibition of human KB cells after 72 hrs by methylene blue assay,Confirmatory,22060033.0,
2938,642529,1,4,,103177124,6167,Active,,,0.0162,IC50,Growth inhibition of human HT-29 cells after 72 hrs by methylene blue assay,Confirmatory,22060033.0,
2939,642530,1,5,,103177124,6167,Active,,,0.0192,IC50,Growth inhibition of human MKN45 cells after 72 hrs by methylene blue assay,Confirmatory,22060033.0,
2940,645070,3,3,,103177124,6167,Active,,,0.008,IC50,Cytotoxicity against human HT-29 cells after 96 hrs using tetracolor one,Confirmatory,24900316.0,
2941,645071,3,3,,103177124,6167,Active,,,0.054000000000000006,IC50,Cytotoxicity against human A549 cells after 96 hrs using tetracolor one,Confirmatory,24900316.0,
2942,645072,3,3,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human HCT116 cells after 96 hrs using tetracolor one,Confirmatory,24900316.0,
2943,645073,2,1,,103177124,6167,Unspecified,,,,,"Antitumor activity against human HCT116 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 1 mg/kg, ip administered on 1, 3 and 5th day measured on day 21 relative to control",Other,24900316.0,
2944,651550,1,1,,49718107,6167,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
2945,651558,1,1,,49718107,6167,Active,,,0.20600000000000002,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling: Hit Validation in Primary Screen,Confirmatory,,
2946,651560,1,1,,50085974,6167,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
2947,651567,1,1,,49718107,6167,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling: Hit Validation in OCI-Ly3 Assay,Confirmatory,,
2948,651568,1,1,,49718107,6167,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling: Hit Validation in Renilla Reporter Assay,Confirmatory,,
2949,651572,1,2,,50085974,6167,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
2950,651582,1,1,,50085974,6167,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
2951,651602,1,1,,50085974,6167,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2952,651602,1,1,,50085974,6167,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2953,651602,1,1,,50085974,6167,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
2954,651610,2,1,,50085974,6167,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2955,651631,4,1,,144204498,6167,Inconclusive,269849759.0,7157.0,0.1188,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2956,651631,4,1,,144208745,6167,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2957,651631,4,1,,144210899,6167,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
2958,651632,4,1,,144204498,6167,Active,296439460.0,79915.0,0.266,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2959,651632,4,1,,144208745,6167,Active,296439460.0,79915.0,0.048,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2960,651632,4,1,,144210899,6167,Active,296439460.0,79915.0,0.0545,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
2961,651633,4,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2962,651633,4,1,,144208745,6167,Inactive,,,0.0135,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2963,651633,4,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
2964,651634,4,1,,144204498,6167,Active,,,0.3349,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2965,651634,4,1,,144208745,6167,Active,,,0.0096,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2966,651634,4,1,,144210899,6167,Active,,,0.0077,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
2967,651635,1,3,,49718107,6167,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2968,651635,1,3,,90340644,6167,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
2969,651636,1,1,,50085974,6167,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
2970,651640,1,1,,50085974,6167,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
2971,651644,1,1,,49718107,6167,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
2972,651647,1,1,,50085974,6167,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
2973,651654,1,1,,50085974,6167,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2974,651658,1,1,,50085974,6167,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2975,651661,2,1,,50085974,6167,Active,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2976,651687,1,1,,50085974,6167,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2977,651699,1,1,,50085974,6167,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2978,651699,1,1,,50085974,6167,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
2979,651702,1,2,,50085974,6167,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
2980,651704,2,1,,50085974,6167,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2981,651710,1,1,,50085974,6167,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2982,651711,2,1,,50085974,6167,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2983,651718,1,2,,50085974,6167,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
2984,651723,1,1,,50085974,6167,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
2985,651724,1,1,,49718107,6167,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
2986,651725,1,1,,49718107,6167,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
2987,651741,1,1,,17389095,6167,Active,20149576.0,4780.0,0.075,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2988,651741,1,1,,17389096,6167,Inconclusive,20149576.0,4780.0,0.1883,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2989,651741,1,1,,144204498,6167,Inconclusive,20149576.0,4780.0,0.1536,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2990,651743,1,1,,17389095,6167,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2991,651743,1,1,,17389096,6167,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2992,651743,1,1,,144204498,6167,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
2993,651749,1,1,,17389095,6167,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2994,651749,1,1,,17389096,6167,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2995,651749,1,1,,144204498,6167,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
2996,651751,1,1,,17389095,6167,Active,5702233.0,84385.0,15.8489,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2997,651751,1,1,,17389096,6167,Active,5702233.0,84385.0,1.5849,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2998,651751,1,1,,144204498,6167,Active,5702233.0,84385.0,1.5849,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
2999,651754,1,1,,17389095,6167,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
3000,651754,1,1,,17389096,6167,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
3001,651755,1,1,,17389095,6167,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
3002,651755,1,1,,17389096,6167,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
3003,651757,1,1,,17389095,6167,Inconclusive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
3004,651757,1,1,,17389096,6167,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
3005,651758,1,1,,17389095,6167,Active,186368.0,3576.0,0.0531,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
3006,651758,1,1,,17389096,6167,Active,186368.0,3576.0,0.0473,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
3007,651768,1,2,,49718107,6167,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
3008,651777,1,1,,17389095,6167,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3009,651777,1,1,,17389096,6167,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3010,651777,1,1,,144204498,6167,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
3011,651778,1,1,,17389095,6167,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3012,651778,1,1,,17389096,6167,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3013,651778,1,1,,144204498,6167,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
3014,651800,1,1,,50085974,6167,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
3015,651802,1,1,,17389095,6167,Active,49066040.0,6097.0,0.3349,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3016,651802,1,1,,17389096,6167,Active,49066040.0,6097.0,0.1188,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
3017,651819,1,1,,49718107,6167,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
3018,651820,1,1,,49718107,6167,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
3019,651821,2,4,,50085974,6167,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
3020,651828,1,2,,121361086,6167,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
3021,651838,1,1,,17389095,6167,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3022,651838,1,1,,17389096,6167,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3023,651838,1,1,,144204498,6167,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3024,651838,1,1,1.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3025,651838,1,1,1.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3026,651838,1,1,1.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3027,651838,1,1,2.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3028,651838,1,1,2.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3029,651838,1,1,2.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3030,651838,1,1,3.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3031,651838,1,1,3.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3032,651838,1,1,3.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3033,651838,1,1,4.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3034,651838,1,1,4.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3035,651838,1,1,4.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3036,651838,1,1,5.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3037,651838,1,1,5.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3038,651838,1,1,5.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3039,651838,1,1,6.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3040,651838,1,1,6.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3041,651838,1,1,6.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3042,651838,1,1,7.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3043,651838,1,1,7.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3044,651838,1,1,7.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3045,651838,1,1,8.0,17389095,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3046,651838,1,1,8.0,17389096,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3047,651838,1,1,8.0,144204498,6167,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
3048,651957,1,1,,50085974,6167,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
3049,651958,1,1,,50085974,6167,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
3050,651965,1,1,,49718107,6167,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
3051,651999,1,1,,50085974,6167,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
3052,652010,1,1,,50085974,6167,Active,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
3053,652017,1,1,,50085974,6167,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
3054,652025,1,1,,49718107,6167,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
3055,652039,1,1,,50085974,6167,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
3056,652048,1,2,,49718107,6167,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3057,652048,1,2,,144204498,6167,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
3058,652051,1,1,,49718107,6167,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3059,652051,1,1,,144204498,6167,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
3060,652054,1,1,,49718107,6167,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
3061,652067,1,4,,50085974,6167,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
3062,652104,1,1,,49718107,6167,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
3063,652105,1,1,,49718107,6167,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
3064,652106,1,1,,49718107,6167,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3065,652106,1,1,,90340644,6167,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
3066,652115,1,1,,50085974,6167,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
3067,652126,1,3,,50085974,6167,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
3068,652134,1,1,,50085974,6167,Active,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput confirmation assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
3069,652136,1,2,,50085974,6167,Inactive,20070193.0,2516.0,,,"Counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): Luminescence-based cell-based high throughput assay for nonselective inhibitors/assay artifacts using AP2 mutant SF-1 (NR5A1) Transactivation Assay",Screening,,
3070,652154,1,1,,50085974,6167,Active,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3071,652162,2,1,,50085974,6167,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3072,652163,1,1,,50085974,6167,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3073,652197,1,1,,50085974,6167,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3074,652257,1,1,,50085974,6167,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
3075,657575,2,2,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Other,22503741.0,
3076,657576,2,2,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Other,22503741.0,
3077,657577,2,2,,103177124,6167,Unspecified,,,,,Inhibition of bovine tubulin polymerization after 20 mins by spectrophotometry,Other,22503741.0,
3078,657578,1,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation in G0/G1 phase at 5 ug/ml after 24 hrs by flow cytometry (Rvb = 47.79%),Other,22503741.0,
3079,657579,1,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation in S phase at 5 ug/ml after 24 hrs by flow cytometry (Rvb = 8.06%),Other,22503741.0,
3080,657580,1,3,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation in G2/M phase at 5 ug/ml after 24 hrs by flow cytometry (Rvb = 12.99%),Other,22503741.0,
3081,657607,2,2,,103177124,6167,Active,,,0.53,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,22512906.0,
3082,657608,2,2,,103177124,6167,Active,,,0.23,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,22512906.0,
3083,657609,2,2,,103177124,6167,Active,,,0.75,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,22512906.0,
3084,657610,2,2,,103177124,6167,Active,,,1.72,IC50,Inhibition of bovine tubulin polymerization after 20 mins by spectrophotometry,Confirmatory,22512906.0,
3085,658916,2,2,,103177124,6167,Active,,,3.3,Kd,Binding affinity to bovine tubulin after 1 hr by spectrofluorometric analysis,Confirmatory,22185476.0,
3086,658917,1,3,,103177124,6167,Active,,,0.016,IC50,Cytotoxicity against human HT-29 cells after 48 hrs using resazurin by microplate fluorometer analysis,Confirmatory,22185476.0,
3087,658919,2,2,,103177124,6167,Active,,,4.12,IC50,Inhibition of bovine brain tubulin polymerization by thermostatic spectrophotometer,Confirmatory,22185476.0,
3088,658920,1,3,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 10 nM after 18 hrs by propidium iodide based flow cytometric analysis (Rvb = 43.9 %),Other,22185476.0,
3089,658921,1,3,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at S phase at 10 nM after 18 hrs by propidium iodide based flow cytometric analysis (Rvb = 39.9 %),Other,22185476.0,
3090,658922,1,3,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 10 nM after 18 hrs by propidium iodide based flow cytometric analysis (Rvb = 16.2 %),Other,22185476.0,
3091,658923,1,3,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at G0/G1 phase at 30 nM after 18 hrs by propidium iodide based flow cytometric analysis (Rvb = 43.9 %),Other,22185476.0,
3092,659042,1,3,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at S phase at 30 nM after 18 hrs by propidium iodide based flow cytometric analysis (Rvb = 39.9 %),Other,22185476.0,
3093,659043,1,3,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 30 nM after 18 hrs by propidium iodide based flow cytometric analysis (Rvb = 16.2 %),Other,22185476.0,
3094,661636,2,2,,103177124,6167,Active,,,0.01,IC50,Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,22542017.0,
3095,661637,2,2,,103177124,6167,Active,,,0.008,IC50,Cytotoxicity against human HT-29 cells,Confirmatory,22542017.0,
3096,662404,2,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against human HEP7402 cells after 48 hrs by MTT assay,Other,22578453.0,
3097,662405,2,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against mouse B16F10 cells after 48 hrs by MTT assay,Other,22578453.0,
3098,662406,2,2,,103177124,6167,Unspecified,,,,,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Other,22578453.0,
3099,662407,2,3,,103177124,6167,Unspecified,,,,,Cytotoxicity against human TW03 cells after 48 hrs by MTT assay,Other,22578453.0,
3100,663034,1,3,,103177124,6167,Unspecified,,,,,Induction of microtubule depolymerization in rat A10 cells assessed as cellular microtubule loss at 0.5 uM after 18 hrs by immunofluorescence assay,Other,22611477.0,
3101,663036,2,2,,103177124,6167,Active,,,0.016,IC50,Antiproliferative activity against human MDA-MB-435 cells by sulforhodamine B assay,Confirmatory,22611477.0,
3102,665236,1,3,,103177124,6167,Active,,,,,Inhibition of bovine brain tubulin at 2.5 uM after 10 mins by spectrophotometry,Other,22564383.0,
3103,665238,2,2,,103177124,6167,Active,,,0.03,EC50,Induction of mitotic arrest in human HeLa cells assessed as reduction in cell density by immunofluorescence staining,Confirmatory,22564383.0,
3104,665239,1,3,,103177124,6167,Active,,,,,Induction of mitotic arrest in human HeLa cells assessed as nuclear condensation by Hoechst 33342 staining,Other,22564383.0,
3105,665240,1,3,,103177124,6167,Active,,,,,Induction of mitotic arrest in human HeLa cells assessed as reduction in tubulin intensity by Hoechst 33342 staining,Other,22564383.0,
3106,665241,1,3,,103177124,6167,Active,,,,,Induction of mitotic arrest in human HeLa cells assessed as mitotic index measuring phosphohistone H3-positive cells by Hoechst 33342 staining,Other,22564383.0,
3107,668143,2,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human LNCAP cells after 96 hrs by SRB assay,Confirmatory,22608389.0,
3108,668144,2,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human paclitaxel-resistant PC3-TxR cells after 96 hrs by SRB assay,Confirmatory,22608389.0,
3109,668145,2,2,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against human PC3 cells after 96 hrs by SRB assay,Confirmatory,22608389.0,
3110,668214,2,3,,103177124,6167,Active,,,0.03,IC50,Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay,Confirmatory,22608389.0,
3111,668215,2,2,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human A375 cells after 48 hrs by SRB assay,Confirmatory,22608389.0,
3112,670878,2,2,,103177124,6167,Active,,,4.12,IC50,Inhibition of bovine brain microtubule polymerization by spectrophotometric analysis,Confirmatory,22727370.0,
3113,670879,1,3,,103177124,6167,Active,,,0.0506,IC50,Cytotoxicity against human A549 cells after 48 hrs by WST-8 assay,Confirmatory,22727370.0,
3114,670880,2,3,,103177124,6167,Active,,,3.3,Kd,Binding affinity to bovine brain tubulin by spectrophotometric analysis,Confirmatory,22727370.0,
3115,670881,1,3,,103177124,6167,Active,,,0.0093,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by XTT assay,Confirmatory,22727370.0,
3116,670882,1,3,,103177124,6167,Active,,,0.0202,IC50,Cytotoxicity against human HeLa cells after 48 hrs by WST-8 assay,Confirmatory,22727370.0,
3117,670888,1,3,,103177124,6167,Active,,,0.016,IC50,Cytotoxicity against human HT-29 cells after 48 hrs by resazurin assay,Confirmatory,22727370.0,
3118,673731,1,2,,103177124,6167,Active,,,,,Inhibition of microtubule polymerization in human HT1080 cells at 50 nM for 4 hrs by immunocytochemistry analysis,Other,22247791.0,
3119,677620,2,2,,103177124,6167,Active,,,14.0,IC50,Antitrypanosomal activity against bloodstream form of Trypanosoma brucei 427 after 48 hrs by MTS assay,Confirmatory,22850214.0,
3120,677621,2,3,,103177124,6167,Active,,,0.0064,IC50,Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay,Confirmatory,22850214.0,
3121,678712,1,8,,103177124,6167,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
3122,678713,1,8,,103177124,6167,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
3123,678714,1,8,,103177124,6167,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3124,678715,1,8,,103177124,6167,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
3125,678716,1,8,,103177124,6167,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
3126,678717,1,8,,103177124,6167,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
3127,678720,1,5,,103177124,6167,Unspecified,,,,,Metabolic stability in human liver microsomes assessed as low signal/noise ratio (S/N of 1 to 10) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
3128,678722,1,5,,103177124,6167,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
3129,678775,1,8,,103177124,6167,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,10698076.0,
3130,678943,2,7,,103177124,6167,Unspecified,238054374.0,5243.0,1.33,Km,TP_TRANSPORTER: uptake in membranes from CEM/VLB100 cells,Confirmatory,10075817.0,
3131,679098,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Colchicine at a concentration of 25 uM in MDR1-expressing MDCK cells,Other,12948019.0,
3132,679099,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport of Colchicine at a concentration of 25 uM in Caco-2 cells,Other,12948019.0,
3133,679133,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: drug resistance in KB-VIN10 cells,Other,15231674.0,
3134,679134,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: drug resistance in KB-TAX50 cells,Other,15231674.0,
3135,679152,1,8,,103177124,6167,Unspecified,52783101.0,17250.0,,,TP_TRANSPORTER: drug resistance in Mrp1-expressing HEK293 cells,Other,9281595.0,
3136,679469,2,7,,103177124,6167,Unspecified,238054374.0,5243.0,45.0,Km,TP_TRANSPORTER: ATP hydrolysis in reconstituted proteoliposomes,Confirmatory,1356264.0,
3137,679691,1,8,,103177124,6167,Unspecified,1170903.0,24891.0,,,"TP_TRANSPORTER: slot-blot analysis in vivo CF I mouse, liver",Other,7890890.0,
3138,680305,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Colchicine: 100 uM) in MDR1-expressing NIH-3T3 cells",Other,14985103.0,
3139,680331,3,6,,103177124,6167,Unspecified,24212063.0,6581.0,0.12,Ki,TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HEK293 cells,Confirmatory,10196521.0,
3140,681119,3,6,,103177124,6167,Unspecified,239938877.0,18671.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells,Confirmatory,12699389.0,
3141,681120,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells,Other,12699389.0,
3142,681121,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells,Other,11602674.0,
3143,681122,3,6,,103177124,6167,Unspecified,238054374.0,5243.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,Confirmatory,12699389.0,
3144,681128,3,6,,103177124,6167,Unspecified,126927.0,18669.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,Confirmatory,12699389.0,
3145,681130,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells,Other,11602674.0,
3146,681132,1,8,,103177124,6167,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells,Other,11602674.0,
3147,686940,1,1,,50085974,6167,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
3148,686964,1,1,,50085974,6167,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
3149,686970,1,2,,49718107,6167,Inconclusive,49168486.0,3417.0,0.0073,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
3150,686971,1,2,,49718107,6167,Inconclusive,,,0.0082,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
3151,686977,2,1,,49698458,6167,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
3152,686978,1,1,,11114044,6167,Active,79154014.0,55775.0,0.0473,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3153,686978,1,1,,49718107,6167,Inconclusive,79154014.0,55775.0,0.0082,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3154,686978,1,1,,144204498,6167,Active,79154014.0,55775.0,0.1884,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
3155,686979,1,1,,11114044,6167,Active,79154014.0,55775.0,0.0668,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3156,686979,1,1,,49718107,6167,Active,79154014.0,55775.0,0.0164,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3157,686979,1,1,,144204498,6167,Active,79154014.0,55775.0,0.2661,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
3158,686992,2,1,,50085974,6167,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
3159,686996,1,1,,50085974,6167,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
3160,687014,1,1,,50085974,6167,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
3161,687016,1,1,,50085974,6167,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
3162,687017,1,1,,50085974,6167,Inactive,5016090.0,190.0,67.568,IC50,"Luminescence-based cell-based high throughput dose response assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Confirmatory,,
3163,687018,1,1,,50085974,6167,Inactive,20070193.0,2516.0,67.568,IC50,"Counterscreen for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): Luminescence-based cell-based high throughput dose response assay for nonselective inhibitors/assay artifacts using AP2 mutant SF-1 (NR5A1) Transactivation Assay",Confirmatory,,
3164,687027,1,1,,50085974,6167,Active,998701.0,7849.0,0.26,AC50_uM,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
3165,687029,1,1,,50085974,6167,Inactive,998701.0,7849.0,,AC50_uM,PAX8: PAX8-dependent cytoxicity Measured in Cell-Based System Using Plate Reader - 7054-06_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
3166,687032,1,1,,50085974,6167,Inconclusive,998701.0,7849.0,,AC50_uM,SA5-Pax8: Cytotoxicity IOSE-T80 Measured in Cell-Based System Using Plate Reader - 7054-07_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
3167,687035,1,1,,163564264,6167,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
3168,687037,1,3,,163564264,6167,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
3169,695789,2,2,,103177124,6167,Active,,,23.35,IC50,Inhibition of goat brain tubulin polymerization after 30 mins,Confirmatory,23022053.0,
3170,695812,2,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human HepG2 cells after 48 hrs,Confirmatory,23022053.0,
3171,695930,2,2,,103177124,6167,Active,,,0.1,IC50,Cytotoxicity against human HeLa cells after 48 hrs,Confirmatory,23022053.0,
3172,695931,2,2,,103177124,6167,Active,,,0.55,IC50,Cytotoxicity against human K562 cells after 48 hrs,Confirmatory,23022053.0,
3173,695932,2,3,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human SGC7901 cells after 48 hrs,Confirmatory,23022053.0,
3174,696749,2,1,,103177124,6167,Unspecified,,,71.1,LD50,Toxicity against brine shrimp,Confirmatory,23148724.0,
3175,697550,1,2,,103177124,6167,Active,,,0.0112,IC50,Antiproliferative activity against human DU145 cells after 48 hrs by SRB assay,Confirmatory,22783954.0,
3176,697551,1,2,,103177124,6167,Active,,,0.0115,IC50,Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,22783954.0,
3177,697552,1,2,,103177124,6167,Active,,,0.0163,IC50,Antiproliferative activity against human LNCAP cells after 48 hrs by SRB assay,Confirmatory,22783954.0,
3178,697553,1,3,,103177124,6167,Active,,,0.028999999999999998,IC50,Antiproliferative activity against human WM164 cells after 48 hrs by SRB assay,Confirmatory,22783954.0,
3179,697554,1,2,,103177124,6167,Active,,,0.0206,IC50,Antiproliferative activity against human A375 cells after 48 hrs by SRB assay,Confirmatory,22783954.0,
3180,697852,1,7,,103177124,6167,Unspecified,14916521.0,,,,Inhibition of electric eel AChE at 2 mg/ml by Ellman's method,Other,23062825.0,
3181,697853,1,7,,103177124,6167,Unspecified,21362409.0,100033901.0,,,Inhibition of horse BChE at 2 mg/ml by Ellman's method,Other,23062825.0,
3182,699539,1,7,,103177124,6167,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
3183,699540,1,7,,103177124,6167,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3184,699541,1,7,,103177124,6167,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
3185,700072,2,2,,103177124,6167,Unspecified,,,,,Solubility of the compound in presence of 20% serum,Other,23017885.0,
3186,700073,1,3,,103177124,6167,Active,,,2.3,IC50,Immunosuppressant activity in mouse splenocytes by mixed-leukocyte reaction assay,Confirmatory,23017885.0,
3187,711166,1,2,,103177124,6167,Unspecified,,,,,"Resistance factor, ratio of IC50 for human HeLa cells expressing class 3 tubulin to IC50 for human HeLa cells",Other,23176628.0,
3188,711167,1,2,,103177124,6167,Active,,,0.0082,IC50,Cytotoxicity against human HeLa cells after 96 hrs by MTT assay,Confirmatory,23176628.0,
3189,711168,1,2,,103177124,6167,Active,,,0.0097,IC50,Cytotoxicity against human HeLa cells expressing class 3 tubulin after 96 hrs by MTT assay,Confirmatory,23176628.0,
3190,711170,1,2,,103177124,6167,Inactive,,,,,Induction of ABCG2 mRNA expression in human DLD1 cells at 1/10 IC50 to IC50 after 96 hrs by RT-PCR analysis,Other,23176628.0,
3191,711171,1,2,,103177124,6167,Inactive,,,,,Induction of ABCB1 mRNA expression in human DLD1 cells at 1/10 IC50 to IC50 after 96 hrs by RT-PCR analysis,Other,23176628.0,
3192,711172,1,2,,103177124,6167,Active,,,,,Induction of ABCG2 mRNA expression in human HT-29 cells at 1/10 IC50 to IC50 after 96 hrs by RT-PCR analysis,Other,23176628.0,
3193,711173,1,2,,103177124,6167,Active,,,,,Induction of ABCB1 mRNA expression in human HT-29 cells at 1/10 IC50 to IC50 after 96 hrs by RT-PCR analysis,Other,23176628.0,
3194,711174,1,3,,103177124,6167,Active,,,0.0168,IC50,Cytotoxicity against human A2780AD cells expressing p-gp after 96 hrs by MTT assay,Confirmatory,23176628.0,
3195,711175,1,2,,103177124,6167,Active,,,0.0067,IC50,Cytotoxicity against human SW780 cells after 96 hrs by MTT assay,Confirmatory,23176628.0,
3196,711178,1,2,,103177124,6167,Active,,,,,Cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 40 nM after 48 hrs by FACS analysis,Other,23176628.0,
3197,711179,1,2,,103177124,6167,Active,,,,,Cell cycle arrest in human HT-29 cells assessed as accumulation at G2/M phase at 40 nM after 24 hrs by FACS analysis,Other,23176628.0,
3198,711181,1,2,,103177124,6167,Active,,,0.06925,IC50,Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay,Confirmatory,23176628.0,
3199,711182,1,2,,103177124,6167,Active,,,0.037000000000000005,IC50,Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay,Confirmatory,23176628.0,
3200,711183,1,2,,103177124,6167,Active,,,0.0156,IC50,Cytotoxicity against human DLD1 cells after 96 hrs by MTT assay,Confirmatory,23176628.0,
3201,711184,2,2,,103177124,6167,Active,,,7.85,IC50,Binding affinity to pig brain tubulin polymerization measured every 1 mins of 60 mins by fluorescence assay,Confirmatory,23176628.0,
3202,711185,2,3,,103177124,6167,Active,,,0.00161,Ki,Binding affinity to pig brain tubulin,Confirmatory,23176628.0,
3203,711187,1,2,,103177124,6167,Unspecified,,,,,"Resistance factor, ratio of IC50 for human SW780AD cells expressing p-gp to IC50 for human SW780 cells",Other,23176628.0,
3204,712842,1,3,,103177124,6167,Active,,,,,Inhibition of pig neuronal tubulin polymerization at 10 uM by fluorescence analysis,Other,24900431.0,
3205,716401,1,2,,103177124,6167,Active,,,,,Induction of morphological changes in human HaCaT cells assessed as loss of radial distribution of structured microtubules at 10 '-6 M by confocal microscopy,Other,23063401.0,
3206,716402,1,2,,103177124,6167,Active,,,,,Induction of morphological changes in human HaCaT cells assessed as cell detachment at 10 '-6 M by confocal microscopy,Other,23063401.0,
3207,716403,1,2,,103177124,6167,Active,,,,,Induction of morphological changes in human SKv-a cells assessed as loss of radial distribution of structured microtubules at 10 '-6 M by confocal microscopy,Other,23063401.0,
3208,716404,1,2,,103177124,6167,Active,,,,,Induction of morphological changes in human HaCaT cells assessed as cell rounding at 10 '-6 M by confocal microscopy,Other,23063401.0,
3209,716405,1,2,,103177124,6167,Active,,,,,Induction of morphological changes in human SKv-a cells assessed as cell detachment at 10 '-6 M by confocal microscopy,Other,23063401.0,
3210,716406,1,2,,103177124,6167,Active,,,,,Induction of morphological changes in human SKv-a cells assessed as cell rounding at 10 '-6 M by confocal microscopy,Other,23063401.0,
3211,716407,1,2,,103177124,6167,Active,,,,,Induction of microtubule depolymerization in human HaCaT cells at 10 '-6 M by confocal microscopy,Other,23063401.0,
3212,716408,1,2,,103177124,6167,Active,,,,,Induction of microtubule depolymerization in human SKv-a cells at 10 '-6 M by confocal microscopy,Other,23063401.0,
3213,716409,1,2,,103177124,6167,Active,,,0.012,IC50,Antiproliferative activity against human HaCaT cells assessed as cell viability by MTT assay,Confirmatory,23063401.0,
3214,716411,2,2,,103177124,6167,Active,,,1.7,IC50,Inhibition of sheep brain tubulin assembly compound incubated for 10 mins at 37 degC followed by 5 mins incubation at 0 degC by turbidimetry,Confirmatory,23063401.0,
3215,719100,1,2,,103177124,6167,Unspecified,,,,,"Resistance factor, ratio of IC50 for human HeLa cells harboring class 3 beta tubulin mutant to IC50 for human HeLa cells",Other,23103097.0,
3216,719101,2,2,,103177124,6167,Active,,,9.7,IC50,Cytotoxicity against human HeLa cells harboring class 3 beta tubulin mutant assessed as growth inhibition,Confirmatory,23103097.0,
3217,719102,2,2,,103177124,6167,Active,,,8.2,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition,Confirmatory,23103097.0,
3218,719103,1,2,,103177124,6167,Unspecified,,,,,"Resistance factor, ratio of IC50 for multidrug-resistant human A2780AD cells overexpressing p-gp to IC50 for human A2780 cells",Other,23103097.0,
3219,719104,2,3,,103177124,6167,Active,,,16.8,IC50,Cytotoxicity against multidrug-resistant human A2780AD cells overexpressing p-gp assessed as growth inhibition,Confirmatory,23103097.0,
3220,719105,2,2,,103177124,6167,Active,,,6.7,IC50,Cytotoxicity against human A2780 cells assessed as growth inhibition,Confirmatory,23103097.0,
3221,719106,4,1,,103177124,6167,Active,,,0.0455,IC50,Cytotoxicity against human DLD1 cells assessed as growth inhibition,Confirmatory,23103097.0,
3222,720504,1,1,,49718107,6167,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
3223,720508,1,1,,50085974,6167,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3224,720509,1,1,,50085974,6167,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
3225,720511,1,1,,50085974,6167,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
3226,720516,2,1,,144204498,6167,Active,296439460.0,79915.0,0.281796,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3227,720516,2,1,,144208745,6167,Active,296439460.0,79915.0,0.0479658,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3228,720516,2,1,,144210899,6167,Active,296439460.0,79915.0,0.117379,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
3229,720532,1,1,,11114044,6167,Inconclusive,420597.0,,3.1623,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3230,720532,1,1,,26752175,6167,Inconclusive,420597.0,,0.3548,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3231,720532,1,1,,144204498,6167,Inconclusive,420597.0,,3.9811,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
3232,720533,1,1,,11114044,6167,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3233,720533,1,1,,26752175,6167,Inconclusive,,,0.0891,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3234,720533,1,1,,144204498,6167,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
3235,720538,1,2,,90340644,6167,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
3236,720542,1,2,,49718107,6167,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
3237,720543,1,1,,50085974,6167,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
3238,720551,1,2,,49718107,6167,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
3239,720552,2,1,,144204498,6167,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3240,720552,2,1,,144208745,6167,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3241,720552,2,1,,144210899,6167,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
3242,720553,1,2,,49718107,6167,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
3243,720559,1,2,,90340644,6167,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
3244,720572,1,2,,90340644,6167,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
3245,720573,1,2,,90340644,6167,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
3246,720579,2,1,,49718107,6167,Inconclusive,222762.0,3707576.0,0.5012,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
3247,720580,1,1,,49718107,6167,Inconclusive,222762.0,3707576.0,0.5623,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
3248,720582,1,1,,50085974,6167,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
3249,720596,1,1,,50085974,6167,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
3250,720634,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3251,720634,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3252,720634,2,1,,144210899,6167,Inactive,,,8.6349,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
3253,720635,2,1,,144204498,6167,Active,,,3.3491,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3254,720635,2,1,,144208745,6167,Active,,,1.5168,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3255,720635,2,1,,144210899,6167,Active,,,1.3685,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
3256,720636,1,1,,17389095,6167,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3257,720636,1,1,,17389096,6167,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3258,720636,1,1,,144204498,6167,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
3259,720637,2,1,,144204498,6167,Active,,,2.87255,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3260,720637,2,1,,144208745,6167,Inconclusive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3261,720637,2,1,,144210899,6167,Active,,,1.04614,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
3262,720641,1,2,,92307326,6167,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
3263,720647,1,2,,50085974,6167,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
3264,720648,1,1,,50085974,6167,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
3265,720652,1,1,,17389095,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3266,720652,1,1,,17389096,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
3267,720653,1,1,,17389095,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3268,720653,1,1,,17389096,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3269,720653,1,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
3270,720659,1,1,,17389095,6167,Inconclusive,325495557.0,8856.0,0.5012,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3271,720659,1,1,,17389096,6167,Inconclusive,325495557.0,8856.0,0.5623,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3272,720659,1,1,,144204498,6167,Inconclusive,325495557.0,8856.0,0.8913,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
3273,720674,2,2,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3274,720674,2,2,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3275,720674,2,2,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
3276,720675,2,2,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3277,720675,2,2,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3278,720675,2,2,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
3279,720678,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3280,720678,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3281,720678,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
3282,720679,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3283,720679,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3284,720679,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
3285,720680,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3286,720680,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3287,720680,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
3288,720681,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3289,720681,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3290,720681,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
3291,720682,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3292,720682,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3293,720682,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
3294,720683,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3295,720683,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3296,720683,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
3297,720684,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3298,720684,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3299,720684,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
3300,720685,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3301,720685,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3302,720685,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
3303,720686,2,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3304,720686,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3305,720686,2,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
3306,720687,2,2,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3307,720687,2,2,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3308,720687,2,2,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
3309,720691,4,1,,144204498,6167,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3310,720691,4,1,,144208745,6167,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3311,720691,4,1,,144210899,6167,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3312,720692,3,1,,144204498,6167,Inconclusive,311348376.0,2908.0,0.379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3313,720692,3,1,,144208745,6167,Inconclusive,311348376.0,2908.0,0.0684,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3314,720692,3,1,,144210899,6167,Inconclusive,311348376.0,2908.0,0.0309,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
3315,720693,3,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3316,720693,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3317,720693,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
3318,720700,1,4,,50085974,6167,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
3319,720702,1,1,,50085974,6167,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
3320,720704,1,4,,50085974,6167,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
3321,720706,1,2,,50085974,6167,Inactive,,,,,HTS for Bacterial rRNA inhibitors Measured in Microorganism-Based System Using Plate Reader - 7056-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3322,720707,1,2,,49718107,6167,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3323,720708,1,2,,49718107,6167,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
3324,720709,1,2,,49718107,6167,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
3325,720711,1,2,,49718107,6167,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
3326,720717,1,3,,92123932,6167,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3327,720717,1,3,,92125451,6167,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3328,720717,1,3,,92307326,6167,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
3329,720719,2,1,,144204498,6167,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3330,720719,2,1,,144208745,6167,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3331,720719,2,1,,144210899,6167,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3332,720725,2,1,,144204498,6167,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3333,720725,2,1,,144208745,6167,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3334,720725,2,1,,144210899,6167,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
3335,721622,1,2,,103177124,6167,Active,,,1.7,IC50,Inhibition of bovine brain tubulin polymerization by fluorescence assay,Confirmatory,23313639.0,
3336,721873,1,3,,103177124,6167,Active,,,0.32899999999999996,IC50,Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay,Confirmatory,23214452.0,
3337,721875,1,3,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay,Confirmatory,23214452.0,
3338,721876,1,3,,103177124,6167,Inconclusive,,,,IC50,Cytotoxicity against human OVCAR8 cells assessed as growth inhibition by trypan blue exclusion assay,Confirmatory,23214452.0,
3339,721877,1,2,,103177124,6167,Inconclusive,,,,IC50,Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition by trypan blue exclusion assay,Confirmatory,23214452.0,
3340,721878,1,3,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human HCT116 assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay,Confirmatory,23214452.0,
3341,721879,1,3,,103177124,6167,Active,,,0.086,IC50,Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by Celltiter-Glo luminescent assay,Confirmatory,23214452.0,
3342,721880,1,2,,103177124,6167,Active,,,0.018000000000000002,IC50,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23214452.0,
3343,721881,1,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23214452.0,
3344,721883,1,2,,103177124,6167,Active,,,0.027999999999999997,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23214452.0,
3345,721884,1,2,,103177124,6167,Active,,,0.005,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition by trypan blue exclusion assay,Confirmatory,23214452.0,
3346,721885,2,1,,103177124,6167,Active,20455316.0,7278.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3347,721885,2,1,,103177124,6167,Active,20455316.0,113457.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3348,721885,2,1,,103177124,6167,Active,20455322.0,84790.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3349,721885,2,1,,103177124,6167,Active,20455526.0,10381.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3350,721885,2,1,,103177124,6167,Active,55977474.0,10376.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3351,721885,2,1,,103177124,6167,Active,55977476.0,7277.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3352,721885,2,1,,103177124,6167,Active,55977480.0,10383.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3353,721885,2,1,,103177124,6167,Active,55977864.0,7846.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3354,721885,2,1,,103177124,6167,Active,56757569.0,203068.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3355,721885,2,1,,103177124,6167,Active,62903515.0,81027.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3356,721885,2,1,,103177124,6167,Active,68776070.0,84617.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3357,721885,2,1,,103177124,6167,Active,74761283.0,347733.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3358,721885,2,1,,103177124,6167,Active,74762137.0,7280.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3359,721885,2,1,,103177124,6167,Active,93141323.0,10382.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3360,721885,2,1,,103177124,6167,Active,182705285.0,347688.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3361,721885,2,1,,103177124,6167,Active,224471855.0,112714.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 15 mins by spectrophotometry,Confirmatory,23214452.0,
3362,724227,1,2,,103177124,6167,Active,,,0.013000000000000001,IC50,Cytotoxicity against human MCF7 cells by SRB assay,Confirmatory,23220647.0,
3363,729108,1,2,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,23547728.0,
3364,729161,1,3,,103177124,6167,Active,,,0.643,IC50,Cytotoxicity against human MDA-MB-435/LCC6MDR1 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,23547728.0,
3365,729164,1,2,,103177124,6167,Unspecified,,,,,"Resistance index, ratio of IC50 for human MDA-MB-435/LCC6 MDR1 cells to IC50 for human MDA-MB-435 cells",Other,23547728.0,
3366,730201,1,2,,103177124,6167,Active,,,0.00891,IC50,Antiproliferative activity against activated HUVECs after 48 hrs by CCK-8 assay,Confirmatory,23360369.0,
3367,730202,1,2,,103177124,6167,Active,,,0.0076,IC50,Antiproliferative activity against quesicent HUVECs after 48 hrs by CCK-8 assay,Confirmatory,23360369.0,
3368,730203,1,2,,103177124,6167,Unspecified,,,,,Selectivity ratio of IC50 for quesicent HUVECs to IC50 for activated HUVECs,Other,23360369.0,
3369,730204,1,2,,103177124,6167,Active,,,,,Antiangiogenic activity in activated HUVECs assessed as inhibition of capillary tube formation at 0.1 uM after 22 hrs by light microscopic analysis,Other,23360369.0,
3370,730205,1,2,,103177124,6167,Unspecified,,,,,Antiangiogenic activity in quesicent HUVECs assessed as disruption of preformed capillaries at 0.1 uM after 4 hrs by light microscopic analysis (Rvb = 11%),Other,23360369.0,
3371,730213,1,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human A549 cells after 72 hrs by CCK-8 assay,Confirmatory,23360369.0,
3372,730214,1,2,,103177124,6167,Active,,,0.037380000000000004,IC50,Cytotoxicity against human HeLa cells after 72 hrs by CCK-8 assay,Confirmatory,23360369.0,
3373,730215,1,3,,103177124,6167,Active,,,0.015380000000000001,IC50,Cytotoxicity against human HT1080 cells after 72 hrs by CCK-8 assay,Confirmatory,23360369.0,
3374,730216,1,2,,103177124,6167,Active,,,0.04674,IC50,Cytotoxicity against human HepG2 cells after 72 hrs by CCK-8 assay,Confirmatory,23360369.0,
3375,732802,1,3,,103177124,6167,Active,,,0.78,IC50,Cytotoxicity against human SKHEP1 cells assessed as growth inhibition,Confirmatory,23419737.0,
3376,732803,1,3,,103177124,6167,Active,,,1.78,IC50,Cytotoxicity against human CE81T cells assessed as growth inhibition,Confirmatory,23419737.0,
3377,732804,1,2,,103177124,6167,Active,,,3.5,IC50,Cytotoxicity against human SAS cells assessed as growth inhibition,Confirmatory,23419737.0,
3378,732805,1,2,,103177124,6167,Active,,,0.66,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition,Confirmatory,23419737.0,
3379,732806,1,3,,103177124,6167,Active,,,0.06,IC50,Cytotoxicity against human PC3 cells assessed as growth inhibition,Confirmatory,23419737.0,
3380,732807,1,3,,103177124,6167,Active,,,1.45,IC50,Cytotoxicity against human BT-483 cells assessed as growth inhibition,Confirmatory,23419737.0,
3381,732808,1,2,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human AGS cells assessed as growth inhibition,Confirmatory,23419737.0,
3382,732809,1,2,,103177124,6167,Active,,,0.07,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition,Confirmatory,23419737.0,
3383,733780,1,2,,103177124,6167,Unspecified,,,20.0,IC50,Cytotoxicity against taxol-resistant human A2780 cells by MTT assay,Confirmatory,23425970.0,
3384,733782,1,3,,103177124,6167,Active,,,11.8,IC50,Cytotoxicity against taxol-resistant human HCT8 cells by MTT assay,Confirmatory,23425970.0,
3385,733783,1,3,,103177124,6167,Active,,,0.3,IC50,Cytotoxicity against human DU145 cells by MTT assay,Confirmatory,23425970.0,
3386,733784,1,3,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human A2780S cells by MTT assay,Confirmatory,23425970.0,
3387,733785,1,3,,103177124,6167,Active,,,0.04,IC50,Cytotoxicity against human PC3 cells by MTT assay,Confirmatory,23425970.0,
3388,733786,1,3,,103177124,6167,Active,,,0.09,IC50,Cytotoxicity against human ES2 cells by MTT assay,Confirmatory,23425970.0,
3389,733787,1,3,,103177124,6167,Active,,,0.12,IC50,Cytotoxicity against human SKOV3 cells by MTT assay,Confirmatory,23425970.0,
3390,733788,1,3,,103177124,6167,Active,,,0.17,IC50,Cytotoxicity against human SKHEP1 cells by MTT assay,Confirmatory,23425970.0,
3391,733789,1,2,,103177124,6167,Active,,,0.29,IC50,Cytotoxicity against human MCF7 cells by MTT assay,Confirmatory,23425970.0,
3392,733790,1,3,,103177124,6167,Active,,,1.31,IC50,Cytotoxicity against human Bel7402 cells by MTT assay,Confirmatory,23425970.0,
3393,733791,1,3,,103177124,6167,Unspecified,,,80.0,IC50,Cytotoxicity against human SPC-A1 cells by MTT assay,Confirmatory,23425970.0,
3394,733792,1,3,,103177124,6167,Active,,,27.0,IC50,Cytotoxicity against human H460 cells by MTT assay,Confirmatory,23425970.0,
3395,733793,1,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human NCI-H358 cells by MTT assay,Confirmatory,23425970.0,
3396,733794,1,2,,103177124,6167,Active,,,0.02,IC50,Cytotoxicity against human HT-29 cells by MTT assay,Confirmatory,23425970.0,
3397,733795,1,3,,103177124,6167,Active,,,1.72,IC50,Cytotoxicity against mouse C26 cells by MTT assay,Confirmatory,23425970.0,
3398,733796,1,3,,103177124,6167,Active,,,0.08,IC50,Cytotoxicity against human HCT15 cells by MTT assay,Confirmatory,23425970.0,
3399,735021,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in G2/M phase at 8 uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 12.95%),Other,23353745.0,
3400,735022,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in G2/M phase at 4 uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 12.95%),Other,23353745.0,
3401,735023,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in G2/M phase at 2uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 12.95%),Other,23353745.0,
3402,735027,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in S phase at 8 uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 26.17%),Other,23353745.0,
3403,735028,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in S phase at 4 uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 26.17%),Other,23353745.0,
3404,735029,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in S phase at 2uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 26.17%),Other,23353745.0,
3405,735505,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in G0/G1 phase at 8 uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 39.55%),Other,23353745.0,
3406,735506,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in G0/G1 phase at 4 uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 39.55%),Other,23353745.0,
3407,735507,1,2,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human K562 cells assessed as accumulation of cells in G0/G1 phase at 2uM concentration after 24 hrs by propidium iodide staining based cytofluorimetric analysis (Rvb = 39.55%),Other,23353745.0,
3408,736173,1,2,,103177124,6167,Active,,,,,Antiproliferative activity against human HeLa cells assessed as median dose after 24 hrs,Other,23445405.0,
3409,743012,3,1,,144204498,6167,Active,,,0.0668,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3410,743012,3,1,,144208745,6167,Active,,,0.0135,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3411,743012,3,1,,144210899,6167,Active,,,0.0077,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
3412,743014,3,1,,144204498,6167,Active,,,0.0668,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3413,743014,3,1,,144208745,6167,Active,,,0.012,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3414,743014,3,1,,144210899,6167,Active,,,0.0077,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
3415,743015,3,1,,144204498,6167,Active,,,0.0841,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3416,743015,3,1,,144208745,6167,Active,,,0.0107,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3417,743015,3,1,,144210899,6167,Active,,,0.0077,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
3418,743020,1,2,,50085974,6167,Inconclusive,,,,AC50_uM,Counterscreen:CMV reporter Measured in Cell-Based System Using Plate Reader - 7054-04_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
3419,743021,1,2,,50085974,6167,Inactive,,,,AC50_uM,PAX8: non-specific cytotoxicity Measured in Cell-Based System Using Plate Reader - 7054-05_Inhibitor_Dose_DryPowder_Activity,Confirmatory,,
3420,743033,3,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3421,743033,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3422,743033,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
3423,743035,2,1,,144204498,6167,Active,124375976.0,367.0,0.0601,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3424,743035,2,1,,144208745,6167,Inconclusive,124375976.0,367.0,0.0172,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3425,743035,2,1,,144210899,6167,Inconclusive,124375976.0,367.0,0.0062,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3426,743036,2,1,,144204498,6167,Inconclusive,124375976.0,367.0,0.0674,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3427,743036,2,1,,144208745,6167,Inconclusive,124375976.0,367.0,0.0108,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3428,743036,2,1,,144210899,6167,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
3429,743040,3,1,,144204498,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3430,743040,3,1,,144208745,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3431,743040,3,1,,144210899,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3432,743041,3,1,,144204498,6167,Inconclusive,,,0.4946,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3433,743041,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3434,743041,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
3435,743042,3,1,,144204498,6167,Inactive,124375976.0,367.0,0.1883,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3436,743042,3,1,,144208745,6167,Inactive,124375976.0,367.0,0.0303,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3437,743042,3,1,,144210899,6167,Inactive,124375976.0,367.0,0.0086,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
3438,743053,2,1,,144204498,6167,Inconclusive,124375976.0,367.0,0.106822,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3439,743053,2,1,,144208745,6167,Inconclusive,124375976.0,367.0,0.0171721,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3440,743053,2,1,,144210899,6167,Inconclusive,124375976.0,367.0,0.0194938,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3441,743054,2,1,,144204498,6167,Inconclusive,124375976.0,367.0,0.334915,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3442,743054,2,1,,144208745,6167,Inconclusive,124375976.0,367.0,0.0479658,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3443,743054,2,1,,144210899,6167,Inconclusive,124375976.0,367.0,0.0229752,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
3444,743063,2,1,,144204498,6167,Active,124375976.0,367.0,0.0674001,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3445,743063,2,1,,144208745,6167,Active,124375976.0,367.0,0.0171721,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3446,743063,2,1,,144210899,6167,Active,124375976.0,367.0,0.00837973,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
3447,743064,3,1,,144204498,6167,Active,,,1.1883,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3448,743064,3,1,,144208745,6167,Inconclusive,,,67.7534,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3449,743064,3,1,,144210899,6167,Active,,,0.1723,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
3450,743065,3,1,,144204498,6167,Active,399498506.0,24831.0,0.5308,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3451,743065,3,1,,144208745,6167,Active,399498506.0,24831.0,0.1352,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3452,743065,3,1,,144210899,6167,Active,399498506.0,24831.0,0.0969,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3453,743066,3,1,,144204498,6167,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3454,743066,3,1,,144208745,6167,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3455,743066,3,1,,144210899,6167,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
3456,743067,2,1,,144204498,6167,Inconclusive,399498506.0,24831.0,0.55157,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3457,743067,2,1,,144208745,6167,Active,399498506.0,24831.0,0.143196,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3458,743067,2,1,,144210899,6167,Inconclusive,399498506.0,24831.0,0.121972,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
3459,743069,2,1,,144204498,6167,Inconclusive,348019627.0,2099.0,0.0756,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3460,743069,2,1,,144208745,6167,Active,348019627.0,2099.0,0.0153,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3461,743069,2,1,,144210899,6167,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3462,743074,2,1,,144204498,6167,Inconclusive,,,0.0952,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3463,743074,2,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3464,743074,2,1,,144210899,6167,Inconclusive,,,0.0871,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
3465,743075,2,1,,144204498,6167,Inconclusive,348019627.0,2099.0,0.1509,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3466,743075,2,1,,144208745,6167,Inconclusive,348019627.0,2099.0,0.0193,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3467,743075,2,1,,144210899,6167,Inactive,348019627.0,2099.0,0.0436,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
3468,743077,2,1,,144204498,6167,Inconclusive,348019627.0,2099.0,0.212929,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3469,743077,2,1,,144208745,6167,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3470,743077,2,1,,144210899,6167,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3471,743078,2,1,,144204498,6167,Inconclusive,348019627.0,2099.0,0.0756242,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3472,743078,2,1,,144208745,6167,Active,348019627.0,2099.0,0.0128773,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3473,743078,2,1,,144210899,6167,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
3474,743079,3,1,,144204498,6167,Inactive,348019627.0,2099.0,3.7578,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3475,743079,3,1,,144208745,6167,Inconclusive,348019627.0,2099.0,0.7602,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3476,743079,3,1,,144210899,6167,Inactive,348019627.0,2099.0,0.0545,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3477,743080,3,1,,144204498,6167,Active,348019627.0,2099.0,0.1188,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3478,743080,3,1,,144208745,6167,Active,348019627.0,2099.0,0.0427,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3479,743080,3,1,,144210899,6167,Active,348019627.0,2099.0,0.0863,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
3480,743081,3,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3481,743081,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3482,743081,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
3483,743083,3,1,,144204498,6167,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3484,743083,3,1,,144208745,6167,Inactive,119597822.0,1588.0,21.4255,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3485,743083,3,1,,144210899,6167,Inactive,119597822.0,1588.0,43.2771,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
3486,743084,3,1,,144204498,6167,Inconclusive,,,0.3758,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3487,743084,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3488,743084,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
3489,743085,3,1,,144204498,6167,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3490,743085,3,1,,144208745,6167,Inconclusive,51095037.0,196.0,0.0678,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3491,743085,3,1,,144210899,6167,Inconclusive,51095037.0,196.0,13.6854,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
3492,743086,3,1,,144204498,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3493,743086,3,1,,144208745,6167,Inconclusive,,,0.0604,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3494,743086,3,1,,144210899,6167,Inconclusive,,,0.1369,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
3495,743091,2,1,,144204498,6167,Active,348019627.0,2099.0,0.0943918,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3496,743091,2,1,,144208745,6167,Active,348019627.0,2099.0,0.0957043,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3497,743091,2,1,,144210899,6167,Active,348019627.0,2099.0,0.0685896,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
3498,743094,3,1,,144204498,6167,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3499,743094,3,1,,144208745,6167,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3500,743094,3,1,,144210899,6167,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3501,743122,2,1,,144204498,6167,Inconclusive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3502,743122,2,1,,144208745,6167,Inconclusive,51095037.0,196.0,24.0398,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3503,743122,2,1,,144210899,6167,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
3504,743126,1,1,,50085974,6167,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
3505,743139,2,1,,144204498,6167,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3506,743139,2,1,,144208745,6167,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3507,743139,2,1,,144210899,6167,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
3508,743140,2,1,,144204498,6167,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3509,743140,2,1,,144208745,6167,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3510,743140,2,1,,144210899,6167,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3511,743191,3,1,,144208745,6167,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3512,743191,3,1,,144210899,6167,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3513,743191,3,1,,170465011,6167,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
3514,743194,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3515,743194,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3516,743194,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
3517,743199,2,1,,144208745,6167,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3518,743199,2,1,,144210899,6167,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3519,743199,2,1,,170465011,6167,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
3520,743202,4,1,,144208745,6167,Inconclusive,20149576.0,4780.0,0.0427,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3521,743202,4,1,,144210899,6167,Inconclusive,20149576.0,4780.0,0.0193,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3522,743202,4,1,,170465011,6167,Inconclusive,20149576.0,4780.0,0.0237,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
3523,743203,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3524,743203,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3525,743203,3,1,,170465011,6167,Inconclusive,,,0.2371,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
3526,743205,1,1,,90340644,6167,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3527,743205,1,1,,90340644,6167,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
3528,743206,1,1,,90340644,6167,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3529,743206,1,1,,90340644,6167,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
3530,743207,1,1,,90340644,6167,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3531,743207,1,1,,90340644,6167,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
3532,743209,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3533,743209,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3534,743209,3,1,,170465011,6167,Inconclusive,,,0.1188,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
3535,743210,4,1,,144208745,6167,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3536,743210,4,1,,144210899,6167,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3537,743210,4,1,,170465011,6167,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
3538,743211,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3539,743211,3,1,,144210899,6167,Inconclusive,,,0.0275,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3540,743211,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3541,743212,3,1,,144208745,6167,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3542,743212,3,1,,144210899,6167,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3543,743212,3,1,,170465011,6167,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3544,743213,3,1,,144208745,6167,Inconclusive,,,0.0431,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3545,743213,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3546,743213,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
3547,743215,3,1,,144208745,6167,Inconclusive,216409690.0,5467.0,1.0835,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3548,743215,3,1,,144210899,6167,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3549,743215,3,1,,170465011,6167,Inconclusive,216409690.0,5467.0,0.3758,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
3550,743217,3,1,,144208745,6167,Inconclusive,325495553.0,9971.0,0.0684,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3551,743217,3,1,,144210899,6167,Inconclusive,325495553.0,9971.0,0.0062,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3552,743217,3,1,,170465011,6167,Inconclusive,325495553.0,9971.0,0.0106,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3553,743218,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3554,743218,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3555,743218,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3556,743219,3,1,,144208745,6167,Active,20149576.0,4780.0,0.0381006,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3557,743219,3,1,,144210899,6167,Active,20149576.0,4780.0,0.03641319999999999,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3558,743219,3,1,,170465011,6167,Active,20149576.0,4780.0,0.029847000000000002,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
3559,743220,3,1,,144208745,6167,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3560,743220,3,1,,144210899,6167,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3561,743220,3,1,,170465011,6167,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
3562,743221,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3563,743221,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3564,743221,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
3565,743222,3,1,,144208745,6167,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3566,743222,3,1,,144210899,6167,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3567,743222,3,1,,170465011,6167,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3568,743223,3,1,,144208745,6167,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3569,743223,3,1,,144210899,6167,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3570,743223,3,1,,170465011,6167,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
3571,743224,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3572,743224,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3573,743224,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3574,743225,3,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3575,743225,3,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3576,743225,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
3577,743226,2,1,,144208745,6167,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3578,743226,2,1,,144210899,6167,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3579,743226,2,1,,170465011,6167,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3580,743227,2,1,,144208745,6167,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3581,743227,2,1,,144210899,6167,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3582,743227,2,1,,170465011,6167,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
3583,743228,3,1,,144208745,6167,Inconclusive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3584,743228,3,1,,144210899,6167,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3585,743228,3,1,,170465011,6167,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
3586,743238,1,1,,50085974,6167,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
3587,743239,2,1,,144208745,6167,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3588,743239,2,1,,144210899,6167,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3589,743239,2,1,,170465011,6167,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3590,743240,2,1,,144208745,6167,Active,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3591,743240,2,1,,144210899,6167,Active,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3592,743240,2,1,,170465011,6167,Active,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
3593,743241,2,1,,144208745,6167,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3594,743241,2,1,,144210899,6167,Inconclusive,216409708.0,7421.0,4.36412,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3595,743241,2,1,,170465011,6167,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3596,743242,2,1,,144208745,6167,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3597,743242,2,1,,144210899,6167,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3598,743242,2,1,,170465011,6167,Active,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
3599,743244,1,1,,90340644,6167,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3600,743244,1,1,,144204498,6167,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
3601,743247,1,2,,50085974,6167,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3602,743255,1,1,,49718107,6167,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
3603,743266,1,2,,49718107,6167,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
3604,743269,1,1,,50085974,6167,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3605,743269,1,1,,50085974,6167,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
3606,743279,1,2,,49718107,6167,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
3607,743287,1,1,,50085974,6167,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
3608,743288,1,1,,17389095,6167,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3609,743288,1,1,,17389096,6167,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3610,743288,1,1,,144204498,6167,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
3611,743292,1,1,,17389095,6167,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3612,743292,1,1,,17389096,6167,Inconclusive,,,0.0398,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3613,743292,1,1,,144204498,6167,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
3614,743344,1,1,,174007360,6167,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
3615,743345,1,1,,174007360,6167,Inactive,,,10.5839,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
3616,743346,1,1,,174007360,6167,Inactive,,,14.9502,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
3617,743347,1,1,,174007360,6167,Inactive,,,16.7744,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
3618,743397,1,1,,50085974,6167,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
3619,743398,1,1,,50085974,6167,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
3620,744700,1,1,,103177124,6167,Active,,,0.475,IC50,Antimigratory activity against human MDA-MB-231 cells after 6 hrs by Boyden chamber migration assay,Confirmatory,23524161.0,
3621,744701,1,1,,103177124,6167,Unspecified,,,,,Antimigratory activity against human MDA-MB-231 cells at 1 uM after 22 hrs by scratch wound healing assay,Other,23524161.0,
3622,744703,1,1,,103177124,6167,Active,,,,,Antimigratory activity against human MDA-MB-231 cells at 0.5 to 5 uM after 22 hrs by scratch wound healing assay,Other,23524161.0,
3623,744705,1,1,,103177124,6167,Active,,,,,Cell cycle arrest in human HeLa cells assessed as disorganized microtubules at 62 nM after 24 hrs by Hoechst 33342 staining,Other,23524161.0,
3624,744706,1,1,,103177124,6167,Inactive,,,,,Antimitotic activity in human HeLa cells assessed as tubulin staining intensity at 1 nM after 24 hrs by Hoechst 33342 staining,Other,23524161.0,
3625,744707,1,1,,103177124,6167,Active,,,,,Antimitotic activity in human HeLa cells assessed as tubulin staining intensity at 5 nM after 24 hrs by Hoechst 33342 staining,Other,23524161.0,
3626,744708,1,1,,103177124,6167,Unspecified,,,,,Antimitotic activity in human HeLa cells assessed as increase in phosphohistone H3 level after 24 hrs by Hoechst 33342 staining,Other,23524161.0,
3627,744709,1,1,,103177124,6167,Active,,,,,Antimitotic activity in human HeLa cells assessed as tubulin intensity after 24 hrs by Hoechst 33342 staining,Other,23524161.0,
3628,744710,1,1,,103177124,6167,Active,,,0.0325,EC50,Antimitotic activity in human HeLa cells assessed as cell density loss after 24 hrs by Hoechst 33342 staining,Confirmatory,23524161.0,
3629,744711,1,1,,103177124,6167,Active,,,,,Antimitotic activity in human HeLa cells assessed as chromatin condensation after 24 hrs by Hoechst 33342 staining,Other,23524161.0,
3630,744712,1,1,,103177124,6167,Active,,,2.3,IC50,Inhibition of bovine brain tubulin assembly after 20 mins by spectrophotometric analysis,Confirmatory,23524161.0,
3631,744713,1,1,,103177124,6167,Unspecified,,,100.0,IC50,Cytotoxicity against human PBMC cells after 24 hrs by MTT assay,Confirmatory,23524161.0,
3632,744714,1,3,,103177124,6167,Active,,,0.0026,IC50,Cytotoxicity against mouse NIH/3T3 cells after 24 hrs by MTT assay,Confirmatory,23524161.0,
3633,744715,1,1,,103177124,6167,Active,,,0.023,IC50,Cytotoxicity against human HUVEC cells after 24 hrs by MTT assay,Confirmatory,23524161.0,
3634,744716,1,1,,103177124,6167,Active,,,0.0077,IC50,Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay,Confirmatory,23524161.0,
3635,744717,1,1,,103177124,6167,Active,,,0.0095,IC50,Cytotoxicity against human REH cells after 48 hrs by MTT assay,Confirmatory,23524161.0,
3636,744718,1,1,,103177124,6167,Inconclusive,,,,IC50,Cytotoxicity against mouse L1210 cells after 24 hrs by MTT assay,Confirmatory,23524161.0,
3637,749381,1,1,,103177124,6167,Active,,,0.07400000000000001,IC50,Cytotoxicity against human PC3 cells after 72 hrs by MTT assay,Confirmatory,23602523.0,
3638,749382,1,1,,103177124,6167,Active,,,0.017,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23602523.0,
3639,749383,1,1,,103177124,6167,Active,,,0.037000000000000005,IC50,Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay,Confirmatory,23602523.0,
3640,749384,1,1,,103177124,6167,Active,,,0.023,IC50,Cytotoxicity against human A549 cells after 72 hrs by MTT assay,Confirmatory,23602523.0,
3641,749385,1,1,,103177124,6167,Active,,,0.019,IC50,Cytotoxicity against human A431 cells after 72 hrs by MTT assay,Confirmatory,23602523.0,
3642,756578,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3643,756578,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3644,756578,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3645,756578,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3646,756578,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3647,756578,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3648,756578,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3649,756578,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3650,756578,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3651,756578,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3652,756578,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3653,756578,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3654,756578,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3655,756578,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3656,756578,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3657,756578,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of tubulin polymerization in human DU145 cells at 10 nM pretreated with paclitaxel for 24 hrs followed by compound treatment for 4 hrs by Western blotting analysis,Other,23750455.0,
3658,756580,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3659,756580,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3660,756580,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3661,756580,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3662,756580,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3663,756580,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3664,756580,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3665,756580,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3666,756580,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3667,756580,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3668,756580,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3669,756580,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3670,756580,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3671,756580,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3672,756580,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3673,756580,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Inhibition of tubulin polymerization in human DU145 cells after 24 hrs by Western blotting analysis,Other,23750455.0,
3674,758692,1,1,,103177124,6167,Unspecified,,,,,Induction of apoptosis in human HepG2 cells assessed as ratio of apoptotic to dead cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based FACS flow cytometric analysis,Other,23747810.0,
3675,758693,1,1,,103177124,6167,Unspecified,,,,,Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based FACS flow cytometric analysis (Rvb = 0.7 +/- 0.2%),Other,23747810.0,
3676,758695,1,1,,103177124,6167,Unspecified,,,,,Induction of apoptosis in human HepG2 cells assessed as apoptotic cells at 10 uM after 72 hrs by annexin V-FITC/PI staining-based FACS flow cytometric analysis (Rvb = 13.9 +/- 1.2%),Other,23747810.0,
3677,758700,1,1,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by annexin V-FITC/PI staining-based FACS flow cytometric analysis (Rvb = 28.9 +/- 1.3%),Other,23747810.0,
3678,758701,1,1,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation at S phase at 10 uM after 24 hrs by annexin V-FITC/PI staining-based FACS flow cytometric analysis (Rvb = 24 +/- 0.8%),Other,23747810.0,
3679,758702,1,1,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation at G0/G1 phase at 10 uM after 24 hrs by annexin V-FITC/PI staining-based FACS flow cytometric analysis (Rvb = 40 +/- 1.2%),Other,23747810.0,
3680,758703,1,1,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human K562 cells assessed as accumulation at subG1 phase at 10 uM after 24 hrs by annexin V-FITC/PI staining-based FACS flow cytometric analysis (Rvb = 7.1 +/- 1.1%),Other,23747810.0,
3681,758704,1,1,,103177124,6167,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HuDe cells by MTT assay to IC50 for human K562 cells by trypan blue exclusion assay",Other,23747810.0,
3682,758705,1,1,,103177124,6167,Active,,,0.017,IC50,Growth inhibition of human HuDe cells after 72 hrs by MTT assay,Confirmatory,23747810.0,
3683,758706,1,1,,103177124,6167,Active,,,0.07,IC50,Growth inhibition of human HT-29 cells after 72 hrs by MTT assay,Confirmatory,23747810.0,
3684,758707,1,1,,103177124,6167,Unspecified,,,10.0,IC50,Growth inhibition of human HepG2 cells after 72 hrs by MTT assay,Confirmatory,23747810.0,
3685,758708,1,1,,103177124,6167,Active,,,0.71,IC50,Growth inhibition of human NCI-H460 cells after 72 hrs by MTT assay,Confirmatory,23747810.0,
3686,758709,1,1,,103177124,6167,Active,,,0.02,IC50,Growth inhibition of human K562 cells after 24 hrs by trypan blue exclusion assay,Confirmatory,23747810.0,
3687,758711,1,1,,103177124,6167,Unspecified,,,,,Growth inhibition of human HT-29 cells at 10 uM after 72 hrs by MTT assay relative to control,Other,23747810.0,
3688,758712,1,1,,103177124,6167,Unspecified,,,,,Growth inhibition of human MCF7 cells at 10 uM after 72 hrs by MTT assay relative to control,Other,23747810.0,
3689,758713,1,1,,103177124,6167,Unspecified,,,,,Growth inhibition of human K562 cells at 10 uM after 24 hrs by trypan blue exclusion assay relative to control,Other,23747810.0,
3690,758714,1,1,,103177124,6167,Unspecified,,,,,Growth inhibition of human NCI-H460 cells at 10 uM after 72 hrs by MTT assay relative to control,Other,23747810.0,
3691,761194,1,1,,103177124,6167,Active,,,1.8,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23735826.0,
3692,761195,1,1,,103177124,6167,Inconclusive,,,,IC50,Cytotoxicity against human K562 cells assessed as growth inhibition after 48 hrs by MTT assay,Confirmatory,23735826.0,
3693,761835,1,1,,103177124,6167,Active,,,3.2,IC50,Inhibition of bovine brain tubulin polymerization incubated for 15 mins prior to GTP addition measured after 20 mins by spectrophotometry,Confirmatory,23810282.0,
3694,770269,1,1,,103177124,6167,Inactive,,,,,Effect on actin depolymerization in rat REF52 cells assessed as effect on ratio of soluble to insoluble protein fraction at 0.1 uM after 30 mins by Western blot analysis,Other,23947826.0,
3695,770272,1,1,,103177124,6167,Active,,,,,Induction of microtubule depolymerization in rat REF52 cells assessed as decrease in ratio of soluble to insoluble tubulin fraction at 0.1 uM after 30 mins by Western blot analysis,Other,23947826.0,
3696,770279,1,1,,103177124,6167,Active,,,,,Induction of microtubule depolymerization in rat REF52 cells at 0.1 uM after 30 mins by fluorescence assay,Other,23947826.0,
3697,772627,3,1,,103177124,6167,Active,,,0.0302,EC50,Induction of interphase microtubule depolymerization in rat A10 cells after 18 to 24 hrs by DAPI staining-based indirect immunofluorescence assay,Confirmatory,23961916.0,
3698,774671,1,1,,103177124,6167,Active,,,0.009000000000000001,IC50,Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay,Confirmatory,23932339.0,
3699,774673,1,2,,103177124,6167,Active,,,0.022000000000000002,IC50,Cytotoxicity against human H460 cells after 72 hrs by MTT assay,Confirmatory,23932339.0,
3700,774674,1,1,,103177124,6167,Active,,,0.019,IC50,Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,23932339.0,
3701,774675,1,2,,103177124,6167,Active,,,0.018000000000000002,IC50,Cytotoxicity against human KB-3-1 cells after 72 hrs by MTT assay,Confirmatory,23932339.0,
3702,778898,1,1,,103177124,6167,Active,,,,,Inhibition of purified bovine tubulin polymerization preincubated at 2 uM for 2 mins before GTP addition measured every 60 seconds for 60 mins by spectrophotometry,Other,23993668.0,
3703,780967,1,2,,103177124,6167,Active,,,,,Induction of microtubule depolymerization in human KB cells at 1 uM after 6 hrs by immunofluorescence microscopic analysis,Other,24106982.0,
3704,780970,2,1,,103177124,6167,Active,20455316.0,7278.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3705,780970,2,1,,103177124,6167,Active,20455316.0,113457.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3706,780970,2,1,,103177124,6167,Active,20455322.0,84790.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3707,780970,2,1,,103177124,6167,Active,20455526.0,10381.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3708,780970,2,1,,103177124,6167,Active,55977474.0,10376.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3709,780970,2,1,,103177124,6167,Active,55977476.0,7277.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3710,780970,2,1,,103177124,6167,Active,55977480.0,10383.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3711,780970,2,1,,103177124,6167,Active,55977864.0,7846.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3712,780970,2,1,,103177124,6167,Active,56757569.0,203068.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3713,780970,2,1,,103177124,6167,Active,62903515.0,81027.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3714,780970,2,1,,103177124,6167,Active,68776070.0,84617.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3715,780970,2,1,,103177124,6167,Active,74761283.0,347733.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3716,780970,2,1,,103177124,6167,Active,74762137.0,7280.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3717,780970,2,1,,103177124,6167,Active,93141323.0,10382.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3718,780970,2,1,,103177124,6167,Active,182705285.0,347688.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3719,780970,2,1,,103177124,6167,Active,224471855.0,112714.0,2.4,Ki,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Confirmatory,24106982.0,
3720,780971,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3721,780971,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3722,780971,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3723,780971,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3724,780971,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3725,780971,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3726,780971,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3727,780971,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3728,780971,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3729,780971,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3730,780971,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3731,780971,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3732,780971,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3733,780971,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3734,780971,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3735,780971,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3736,780972,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3737,780972,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3738,780972,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3739,780972,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3740,780972,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3741,780972,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3742,780972,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3743,780972,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3744,780972,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3745,780972,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3746,780972,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3747,780972,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3748,780972,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3749,780972,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3750,780972,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3751,780972,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of [3H]-colchicine from biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by scintillation proximity assay relative to control,Other,24106982.0,
3752,780973,1,1,,103177124,6167,Active,,,4.2,IC50,Inhibition of bovine brain MAP-rich tubulin polymerization measured every 30 secs for 30 mins by turbidometric method,Confirmatory,24106982.0,
3753,780975,3,1,,103177124,6167,Active,,,0.0518,IC50,Cytotoxicity against human KB-7d cells overexpressing MRP assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3754,780976,3,1,,103177124,6167,Active,,,0.0354,IC50,Cytotoxicity against human KB-S15 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3755,780977,3,1,,103177124,6167,Active,,,0.122,IC50,Cytotoxicity against human KB-VIN10 cells overexpressing P-gp170/MDR assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3756,780982,1,2,,103177124,6167,Active,,,0.0198,IC50,Cytotoxicity against human H460 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3757,780983,1,1,,103177124,6167,Active,,,0.0115,IC50,Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3758,780984,1,1,,103177124,6167,Active,,,0.0152,IC50,Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3759,780985,3,2,,103177124,6167,Active,,,0.0103,IC50,Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by methylene blue staining-based assay,Confirmatory,24106982.0,
3760,883744,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/6,Other,,
3761,883745,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/6,Other,,
3762,883746,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/6,Other,,
3763,883747,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/7,Other,,
3764,883748,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/7,Other,,
3765,883749,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/7,Other,,
3766,883750,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/7,Other,,
3767,883751,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/7,Other,,
3768,883752,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/7,Other,,
3769,884431,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/7,Other,,
3770,884432,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/7,Other,,
3771,884433,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/7,Other,,
3772,884434,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/7,Other,,
3773,884435,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/7,Other,,
3774,884436,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/7,Other,,
3775,884437,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/7,Other,,
3776,884438,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/7,Other,,
3777,884439,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/7,Other,,
3778,884440,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/7,Other,,
3779,884441,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/7,Other,,
3780,884442,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/7,Other,,
3781,884443,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/7,Other,,
3782,884444,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/7,Other,,
3783,884445,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/7,Other,,
3784,884446,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/8,Other,,
3785,884447,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/8,Other,,
3786,884448,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/8,Other,,
3787,884449,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/8,Other,,
3788,884450,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/8,Other,,
3789,884451,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/8,Other,,
3790,884452,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/8,Other,,
3791,884453,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/8,Other,,
3792,884454,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/8,Other,,
3793,884455,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/8,Other,,
3794,884456,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/8,Other,,
3795,884457,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/8,Other,,
3796,884458,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/8,Other,,
3797,884459,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/8,Other,,
3798,884460,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/8,Other,,
3799,884461,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/8,Other,,
3800,884462,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/8,Other,,
3801,884463,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/8,Other,,
3802,884464,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/8,Other,,
3803,884465,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/8,Other,,
3804,884466,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/8,Other,,
3805,884467,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/9,Other,,
3806,884468,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/9,Other,,
3807,884469,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/9,Other,,
3808,884505,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/16,Other,,
3809,884506,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/16,Other,,
3810,884507,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/16,Other,,
3811,884508,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/16,Other,,
3812,884509,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/16,Other,,
3813,884510,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/16,Other,,
3814,884511,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/16,Other,,
3815,884512,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/16,Other,,
3816,884513,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/16,Other,,
3817,884514,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/16,Other,,
3818,884515,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/16,Other,,
3819,884516,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/16,Other,,
3820,884517,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/16,Other,,
3821,884518,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/16,Other,,
3822,884519,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/16,Other,,
3823,884520,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/16,Other,,
3824,884521,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/16,Other,,
3825,884522,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/16,Other,,
3826,885198,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/16,Other,,
3827,885199,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/16,Other,,
3828,885200,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/16,Other,,
3829,885201,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/5,Other,,
3830,885202,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/5,Other,,
3831,885203,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/5,Other,,
3832,885204,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/5,Other,,
3833,885205,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/5,Other,,
3834,885206,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/5,Other,,
3835,885207,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/5,Other,,
3836,885208,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/5,Other,,
3837,885209,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/5,Other,,
3838,885210,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/5,Other,,
3839,885211,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/5,Other,,
3840,885212,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/5,Other,,
3841,885213,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/5,Other,,
3842,885214,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/5,Other,,
3843,885215,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/5,Other,,
3844,885216,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/5,Other,,
3845,885217,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/5,Other,,
3846,885218,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/5,Other,,
3847,885219,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/5,Other,,
3848,885220,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/5,Other,,
3849,885221,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/5,Other,,
3850,885222,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/6,Other,,
3851,885223,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/6,Other,,
3852,885224,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/6,Other,,
3853,885225,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/6,Other,,
3854,885226,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/6,Other,,
3855,885227,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/6,Other,,
3856,885261,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/12,Other,,
3857,885262,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/13,Other,,
3858,885263,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/13,Other,,
3859,885264,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/13,Other,,
3860,885265,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/13,Other,,
3861,885266,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/13,Other,,
3862,885267,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/13,Other,,
3863,885268,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/13,Other,,
3864,885269,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/13,Other,,
3865,885270,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/13,Other,,
3866,885271,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/13,Other,,
3867,885272,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/13,Other,,
3868,885273,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/13,Other,,
3869,885274,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/13,Other,,
3870,885275,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/13,Other,,
3871,885276,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/13,Other,,
3872,885277,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/13,Other,,
3873,885278,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/13,Other,,
3874,885279,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/13,Other,,
3875,885280,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/13,Other,,
3876,885281,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/13,Other,,
3877,885282,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/13,Other,,
3878,885283,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/14,Other,,
3879,885284,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/14,Other,,
3880,885285,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/14,Other,,
3881,885286,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/14,Other,,
3882,885287,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/14,Other,,
3883,885964,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/14,Other,,
3884,885965,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/14,Other,,
3885,885966,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/14,Other,,
3886,885967,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/14,Other,,
3887,885968,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/14,Other,,
3888,885969,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/14,Other,,
3889,885970,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/14,Other,,
3890,885971,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/14,Other,,
3891,885972,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/14,Other,,
3892,885973,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/14,Other,,
3893,885974,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/14,Other,,
3894,885975,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/14,Other,,
3895,885976,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/14,Other,,
3896,885977,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/14,Other,,
3897,885978,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/14,Other,,
3898,885979,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/14,Other,,
3899,885980,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/15,Other,,
3900,885981,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/15,Other,,
3901,885982,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/15,Other,,
3902,885983,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/15,Other,,
3903,887317,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/9,Other,,
3904,887318,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/9,Other,,
3905,887319,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/9,Other,,
3906,887320,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/9,Other,,
3907,887321,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/9,Other,,
3908,887322,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/9,Other,,
3909,887323,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/9,Other,,
3910,887324,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/9,Other,,
3911,887325,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/9,Other,,
3912,887326,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/9,Other,,
3913,887327,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/9,Other,,
3914,887328,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/9,Other,,
3915,887329,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/9,Other,,
3916,887330,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/9,Other,,
3917,887331,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/9,Other,,
3918,887332,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/9,Other,,
3919,887333,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/9,Other,,
3920,887334,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/9,Other,,
3921,887335,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/10,Other,,
3922,887336,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/10,Other,,
3923,887337,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/10,Other,,
3924,887338,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/10,Other,,
3925,887339,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/10,Other,,
3926,887340,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/10,Other,,
3927,887341,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/10,Other,,
3928,887342,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/10,Other,,
3929,887343,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/10,Other,,
3930,887344,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/10,Other,,
3931,887345,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/10,Other,,
3932,887346,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/10,Other,,
3933,887347,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/10,Other,,
3934,887348,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/10,Other,,
3935,887349,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/10,Other,,
3936,887350,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/10,Other,,
3937,887351,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/10,Other,,
3938,887352,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/10,Other,,
3939,887353,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/10,Other,,
3940,887354,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/10,Other,,
3941,887355,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/10,Other,,
3942,887356,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/11,Other,,
3943,887357,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/11,Other,,
3944,887358,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/11,Other,,
3945,887359,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/11,Other,,
3946,887360,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/11,Other,,
3947,887361,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/11,Other,,
3948,887362,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/11,Other,,
3949,887400,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/6,Other,,
3950,887401,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/6,Other,,
3951,887402,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/6,Other,,
3952,887403,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/6,Other,,
3953,887404,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/6,Other,,
3954,887405,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/6,Other,,
3955,887406,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/6,Other,,
3956,887407,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/6,Other,,
3957,887408,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/6,Other,,
3958,888041,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/11,Other,,
3959,888042,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/11,Other,,
3960,888086,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/6,Other,,
3961,888087,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/6,Other,,
3962,888088,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/6,Other,,
3963,888089,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/6,Other,,
3964,888090,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/6,Other,,
3965,888091,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/6,Other,,
3966,888092,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/7,Other,,
3967,888093,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/7,Other,,
3968,888094,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/7,Other,,
3969,888095,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/7,Other,,
3970,888096,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/7,Other,,
3971,888097,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/7,Other,,
3972,888098,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/7,Other,,
3973,888099,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/7,Other,,
3974,888100,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/7,Other,,
3975,888101,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/7,Other,,
3976,888102,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/7,Other,,
3977,888103,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/7,Other,,
3978,888104,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/7,Other,,
3979,888105,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/7,Other,,
3980,888106,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/7,Other,,
3981,888107,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/7,Other,,
3982,888108,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/7,Other,,
3983,888109,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/7,Other,,
3984,888110,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/7,Other,,
3985,888111,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/7,Other,,
3986,888112,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/7,Other,,
3987,888113,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/8,Other,,
3988,888114,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/8,Other,,
3989,888115,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/8,Other,,
3990,888116,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/8,Other,,
3991,888117,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/8,Other,,
3992,888118,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/8,Other,,
3993,888119,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/8,Other,,
3994,888120,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/8,Other,,
3995,888121,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/8,Other,,
3996,888122,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/8,Other,,
3997,888123,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/8,Other,,
3998,888159,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/15,Other,,
3999,888160,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/15,Other,,
4000,888161,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/15,Other,,
4001,888162,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/15,Other,,
4002,888163,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/15,Other,,
4003,888164,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/15,Other,,
4004,888165,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/15,Other,,
4005,888166,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/15,Other,,
4006,888167,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/15,Other,,
4007,888168,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/15,Other,,
4008,888169,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/15,Other,,
4009,888170,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/15,Other,,
4010,888171,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/15,Other,,
4011,888172,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/15,Other,,
4012,888173,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/15,Other,,
4013,888174,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/15,Other,,
4014,888175,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/15,Other,,
4015,888849,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/16,Other,,
4016,888850,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/16,Other,,
4017,888851,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/16,Other,,
4018,888852,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/16,Other,,
4019,888853,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/16,Other,,
4020,888854,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/16,Other,,
4021,888855,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/16,Other,,
4022,888856,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/16,Other,,
4023,888857,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/16,Other,,
4024,888858,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/16,Other,,
4025,888859,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/16,Other,,
4026,888860,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/16,Other,,
4027,888861,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/16,Other,,
4028,888862,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/16,Other,,
4029,888863,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/16,Other,,
4030,888864,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/16,Other,,
4031,888865,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/16,Other,,
4032,888866,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/16,Other,,
4033,888867,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/16,Other,,
4034,888868,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/16,Other,,
4035,888869,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/16,Other,,
4036,890213,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/11,Other,,
4037,890214,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/11,Other,,
4038,890215,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/11,Other,,
4039,890216,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/11,Other,,
4040,890217,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/11,Other,,
4041,890218,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/11,Other,,
4042,890219,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/11,Other,,
4043,890220,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/11,Other,,
4044,890221,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/11,Other,,
4045,890222,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/11,Other,,
4046,890223,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/11,Other,,
4047,890224,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/11,Other,,
4048,890225,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/12,Other,,
4049,890226,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/12,Other,,
4050,890227,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/12,Other,,
4051,890228,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/12,Other,,
4052,890229,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/12,Other,,
4053,890230,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/12,Other,,
4054,890231,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/12,Other,,
4055,890232,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/12,Other,,
4056,890233,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/12,Other,,
4057,890234,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/12,Other,,
4058,890235,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/12,Other,,
4059,890236,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/12,Other,,
4060,890237,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/12,Other,,
4061,890238,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/12,Other,,
4062,890239,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/12,Other,,
4063,890240,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/12,Other,,
4064,890241,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/12,Other,,
4065,890242,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/12,Other,,
4066,890243,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/12,Other,,
4067,890244,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/12,Other,,
4068,890245,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/12,Other,,
4069,890246,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/13,Other,,
4070,890247,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/13,Other,,
4071,890248,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/13,Other,,
4072,890294,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/8,Other,,
4073,890928,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/13,Other,,
4074,890929,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/13,Other,,
4075,890930,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/13,Other,,
4076,890931,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/13,Other,,
4077,890932,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/13,Other,,
4078,890933,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/13,Other,,
4079,890934,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/13,Other,,
4080,890935,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/13,Other,,
4081,890936,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/13,Other,,
4082,890937,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/13,Other,,
4083,890938,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/13,Other,,
4084,890972,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/13,Other,,
4085,890973,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/8,Other,,
4086,890974,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/8,Other,,
4087,890975,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/8,Other,,
4088,890976,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/8,Other,,
4089,890977,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/8,Other,,
4090,890978,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/8,Other,,
4091,890979,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/8,Other,,
4092,890980,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/8,Other,,
4093,890981,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/8,Other,,
4094,890982,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/9,Other,,
4095,890983,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/9,Other,,
4096,890984,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/9,Other,,
4097,890985,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/9,Other,,
4098,890986,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/9,Other,,
4099,890987,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/9,Other,,
4100,890988,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/9,Other,,
4101,890989,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/9,Other,,
4102,890990,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/9,Other,,
4103,890991,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/9,Other,,
4104,890992,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/9,Other,,
4105,890993,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/9,Other,,
4106,890994,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/9,Other,,
4107,890995,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/9,Other,,
4108,890996,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/9,Other,,
4109,890997,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/9,Other,,
4110,890998,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/9,Other,,
4111,890999,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/9,Other,,
4112,891000,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/9,Other,,
4113,891001,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/9,Other,,
4114,891002,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/9,Other,,
4115,891003,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/10,Other,,
4116,891004,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/10,Other,,
4117,891005,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/10,Other,,
4118,891006,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/10,Other,,
4119,891007,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/10,Other,,
4120,891008,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/10,Other,,
4121,891009,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/10,Other,,
4122,891010,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/10,Other,,
4123,891011,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/10,Other,,
4124,891012,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/10,Other,,
4125,891013,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/10,Other,,
4126,891014,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/10,Other,,
4127,891015,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/10,Other,,
4128,891016,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/10,Other,,
4129,891017,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/10,Other,,
4130,891695,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/10,Other,,
4131,892366,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/5,Other,,
4132,892367,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/5,Other,,
4133,892368,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/5,Other,,
4134,892369,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/5,Other,,
4135,892370,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/5,Other,,
4136,892371,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/5,Other,,
4137,892372,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/5,Other,,
4138,892373,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/5,Other,,
4139,893050,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/5,Other,,
4140,893051,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/5,Other,,
4141,893052,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/5,Other,,
4142,893053,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/5,Other,,
4143,893054,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/5,Other,,
4144,893055,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/5,Other,,
4145,893056,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/5,Other,,
4146,893057,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/5,Other,,
4147,893058,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/5,Other,,
4148,893059,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/5,Other,,
4149,893060,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/5,Other,,
4150,893061,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/5,Other,,
4151,893062,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/5,Other,,
4152,893063,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/6,Other,,
4153,893064,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/6,Other,,
4154,893065,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/6,Other,,
4155,893066,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/6,Other,,
4156,893067,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/6,Other,,
4157,893068,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/6,Other,,
4158,893069,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/6,Other,,
4159,893070,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/6,Other,,
4160,893071,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/6,Other,,
4161,893072,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/6,Other,,
4162,893073,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/6,Other,,
4163,893074,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/6,Other,,
4164,893075,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/6,Other,,
4165,893076,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/6,Other,,
4166,893077,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/6,Other,,
4167,893078,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/6,Other,,
4168,893079,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/6,Other,,
4169,893080,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/6,Other,,
4170,893114,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/13,Other,,
4171,893115,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/13,Other,,
4172,893116,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/13,Other,,
4173,893117,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/13,Other,,
4174,893118,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/13,Other,,
4175,893119,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/13,Other,,
4176,893120,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/14,Other,,
4177,893121,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/14,Other,,
4178,893122,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/14,Other,,
4179,893123,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/14,Other,,
4180,893124,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/14,Other,,
4181,893125,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/14,Other,,
4182,893126,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/14,Other,,
4183,893127,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/14,Other,,
4184,893128,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/14,Other,,
4185,893129,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/14,Other,,
4186,893130,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/14,Other,,
4187,893131,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/14,Other,,
4188,893132,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/14,Other,,
4189,893133,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/14,Other,,
4190,893134,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/14,Other,,
4191,893135,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/14,Other,,
4192,893136,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/14,Other,,
4193,893137,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/14,Other,,
4194,893138,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/14,Other,,
4195,893139,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/14,Other,,
4196,893140,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/14,Other,,
4197,893819,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 501/15,Other,,
4198,893820,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 501/15,Other,,
4199,893821,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 501/15,Other,,
4200,893822,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 501/15,Other,,
4201,893823,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 501/15,Other,,
4202,893824,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 501/15,Other,,
4203,893825,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 501/15,Other,,
4204,893826,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 501/15,Other,,
4205,893827,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 501/15,Other,,
4206,893828,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 501/15,Other,,
4207,893829,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 501/15,Other,,
4208,893830,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 501/15,Other,,
4209,893831,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 501/15,Other,,
4210,893832,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 501/15,Other,,
4211,893833,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 501/15,Other,,
4212,893834,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 501/15,Other,,
4213,893835,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 501/15,Other,,
4214,893836,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 501/15,Other,,
4215,893837,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 501/15,Other,,
4216,893838,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 501/15,Other,,
4217,893839,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 501/15,Other,,
4218,893873,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/10,Other,,
4219,893874,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/10,Other,,
4220,893875,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/10,Other,,
4221,893876,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/10,Other,,
4222,893877,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/10,Other,,
4223,893878,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/11,Other,,
4224,893879,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/11,Other,,
4225,893880,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/11,Other,,
4226,893881,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/11,Other,,
4227,893882,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/11,Other,,
4228,893883,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/11,Other,,
4229,893884,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/11,Other,,
4230,893885,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/11,Other,,
4231,893886,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/11,Other,,
4232,893887,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/11,Other,,
4233,893888,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/11,Other,,
4234,893889,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/11,Other,,
4235,893890,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/11,Other,,
4236,893891,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/11,Other,,
4237,893892,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/11,Other,,
4238,893893,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/11,Other,,
4239,893894,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/11,Other,,
4240,893895,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/11,Other,,
4241,893896,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/11,Other,,
4242,893897,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/11,Other,,
4243,893898,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 502/11,Other,,
4244,893899,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 502/12,Other,,
4245,893900,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 502/12,Other,,
4246,893901,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 502/12,Other,,
4247,893902,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 502/12,Other,,
4248,893903,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 502/12,Other,,
4249,893904,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 502/12,Other,,
4250,893905,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 502/12,Other,,
4251,893906,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 502/12,Other,,
4252,893907,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 502/12,Other,,
4253,893908,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 502/12,Other,,
4254,894586,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 502/12,Other,,
4255,894587,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 502/12,Other,,
4256,894588,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 502/12,Other,,
4257,894589,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 502/12,Other,,
4258,894590,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 502/12,Other,,
4259,894591,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 502/12,Other,,
4260,894592,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 502/12,Other,,
4261,894593,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 502/12,Other,,
4262,894594,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 502/12,Other,,
4263,894595,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 502/12,Other,,
4264,926372,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S030902,Other,,
4265,926373,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S030902,Other,,
4266,926374,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S030902,Other,,
4267,926375,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S030902,Other,,
4268,926376,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S030902,Other,,
4269,926377,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S030902,Other,,
4270,926378,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S030902,Other,,
4271,926379,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S030902,Other,,
4272,926380,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S030902,Other,,
4273,926381,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S030902,Other,,
4274,926382,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S030902,Other,,
4275,926383,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S030902,Other,,
4276,926384,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S030902,Other,,
4277,926385,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S030902,Other,,
4278,926386,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S030902,Other,,
4279,926387,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S030902,Other,,
4280,926388,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S030902,Other,,
4281,926389,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S030902,Other,,
4282,926390,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S030902",Other,,
4283,961850,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S030902,Other,,
4284,961851,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S030902,Other,,
4285,961852,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S030902,Other,,
4286,961853,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S030902,Other,,
4287,961854,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S030902,Other,,
4288,961855,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S030902,Other,,
4289,961856,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S030902,Other,,
4290,961857,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S030902,Other,,
4291,961858,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S030902,Other,,
4292,961859,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S030902,Other,,
4293,961860,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S030902,Other,,
4294,961861,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S030902,Other,,
4295,961862,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S030902,Other,,
4296,961863,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S030902,Other,,
4297,961864,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S030902,Other,,
4298,961865,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S030902,Other,,
4299,961866,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S030902,Other,,
4300,961867,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S030902,Other,,
4301,961868,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S030902,Other,,
4302,977599,1,1,,103177124,6167,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4303,977602,1,2,,103177124,6167,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
4304,977610,3,1,,310263222,6167,Active,,,1.8,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,24530796.0,
4305,977611,3,1,,310262970,6167,Active,,,20.0,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,24272870.0,
4306,1000386,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: S030902,Other,,
4307,1000387,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: S030902",Other,,
4308,1000967,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: S030902",Other,,
4309,1000968,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: S030902",Other,,
4310,1002833,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: S030902",Other,,
4311,1002834,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: S030902",Other,,
4312,1002835,1,3,,103177124,6167,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: S030902,Other,,
4313,1002836,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: S030902",Other,,
4314,1002837,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: S030902",Other,,
4315,1002838,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: S030902",Other,,
4316,1002839,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: S030902",Other,,
4317,1002840,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: S030902",Other,,
4318,1002841,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: S030902",Other,,
4319,1002842,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: S030902",Other,,
4320,1002843,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: S030902",Other,,
4321,1002844,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: S030902",Other,,
4322,1002845,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: S030902",Other,,
4323,1002846,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: S030902",Other,,
4324,1002847,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: S030902",Other,,
4325,1002848,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: S030902",Other,,
4326,1002849,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: S030902",Other,,
4327,1002850,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: S030902",Other,,
4328,1002851,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: S030902",Other,,
4329,1002852,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: S030902",Other,,
4330,1002853,1,3,,103177124,6167,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: S030902",Other,,
4331,1036138,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/5,Other,,
4332,1036139,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/5,Other,,
4333,1036140,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/5,Other,,
4334,1036141,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/5,Other,,
4335,1036809,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/5,Other,,
4336,1036810,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/6,Other,,
4337,1036811,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/6,Other,,
4338,1036812,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/6,Other,,
4339,1036813,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/6,Other,,
4340,1036814,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/6,Other,,
4341,1036815,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/7,Other,,
4342,1036816,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/7,Other,,
4343,1036817,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/7,Other,,
4344,1036818,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/7,Other,,
4345,1036819,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/7,Other,,
4346,1036820,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/8,Other,,
4347,1036821,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/8,Other,,
4348,1036822,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/8,Other,,
4349,1036823,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/8,Other,,
4350,1036824,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/8,Other,,
4351,1036825,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/9,Other,,
4352,1036826,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/9,Other,,
4353,1036827,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/9,Other,,
4354,1036828,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/9,Other,,
4355,1036829,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/9,Other,,
4356,1038972,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/10,Other,,
4357,1038973,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/10,Other,,
4358,1038974,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/10,Other,,
4359,1038975,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/10,Other,,
4360,1038976,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/10,Other,,
4361,1038977,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/11,Other,,
4362,1038978,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/11,Other,,
4363,1038979,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/11,Other,,
4364,1038980,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/11,Other,,
4365,1038981,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/11,Other,,
4366,1038982,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/12,Other,,
4367,1038983,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/12,Other,,
4368,1038984,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/12,Other,,
4369,1038985,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/12,Other,,
4370,1038986,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/12,Other,,
4371,1038987,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/13,Other,,
4372,1038988,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/13,Other,,
4373,1038989,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/13,Other,,
4374,1039658,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/13,Other,,
4375,1039659,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/13,Other,,
4376,1039660,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/14,Other,,
4377,1039661,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/14,Other,,
4378,1039662,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/14,Other,,
4379,1039663,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/14,Other,,
4380,1039664,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/14,Other,,
4381,1039665,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/15,Other,,
4382,1039666,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/15,Other,,
4383,1039667,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/15,Other,,
4384,1039668,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/15,Other,,
4385,1039669,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/15,Other,,
4386,1039670,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 501/16,Other,,
4387,1039671,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 501/16,Other,,
4388,1039672,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 501/16,Other,,
4389,1039673,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 501/16,Other,,
4390,1039674,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 501/16,Other,,
4391,1039675,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/5,Other,,
4392,1039676,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/5,Other,,
4393,1039677,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/5,Other,,
4394,1039678,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/5,Other,,
4395,1039679,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/5,Other,,
4396,1039680,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/6,Other,,
4397,1039681,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/6,Other,,
4398,1039682,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/6,Other,,
4399,1039683,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/6,Other,,
4400,1039684,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/6,Other,,
4401,1039685,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/7,Other,,
4402,1039686,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/7,Other,,
4403,1041833,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/7,Other,,
4404,1041834,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/7,Other,,
4405,1041835,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/7,Other,,
4406,1041836,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/8,Other,,
4407,1041837,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/8,Other,,
4408,1041838,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/8,Other,,
4409,1041839,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/8,Other,,
4410,1041840,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/8,Other,,
4411,1041841,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/9,Other,,
4412,1041842,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/9,Other,,
4413,1042510,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/9,Other,,
4414,1042511,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/9,Other,,
4415,1042512,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/9,Other,,
4416,1042513,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/10,Other,,
4417,1042514,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/10,Other,,
4418,1042515,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/10,Other,,
4419,1042516,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/10,Other,,
4420,1042517,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/10,Other,,
4421,1042518,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/11,Other,,
4422,1042519,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/11,Other,,
4423,1042520,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/11,Other,,
4424,1042521,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/11,Other,,
4425,1042522,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/11,Other,,
4426,1042523,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/12,Other,,
4427,1042524,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/12,Other,,
4428,1042525,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/12,Other,,
4429,1042526,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/12,Other,,
4430,1042527,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/12,Other,,
4431,1042528,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/13,Other,,
4432,1042529,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/13,Other,,
4433,1042530,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/13,Other,,
4434,1042531,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/13,Other,,
4435,1042532,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/13,Other,,
4436,1042533,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/14,Other,,
4437,1042534,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/14,Other,,
4438,1042535,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/14,Other,,
4439,1042536,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/14,Other,,
4440,1042537,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/14,Other,,
4441,1042538,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/15,Other,,
4442,1042539,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/15,Other,,
4443,1042540,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/15,Other,,
4444,1042541,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/15,Other,,
4445,1042542,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/15,Other,,
4446,1042543,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 502/16,Other,,
4447,1042544,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 502/16,Other,,
4448,1042545,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 502/16,Other,,
4449,1044687,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 502/16,Other,,
4450,1044688,1,2,,103177124,6167,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 502/16,Other,,
4451,1053197,1,1,,50085974,6167,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
4452,1058412,1,4,,103177124,6167,Unspecified,116241312.0,1576.0,,,Inhibition of CYP3A4 (unknown origin) at 3 uM,Other,24210503.0,
4453,1058413,1,4,,103177124,6167,Unspecified,84028191.0,1565.0,,,Inhibition of CYP2D6 (unknown origin) at 3 uM,Other,24210503.0,
4454,1058414,1,4,,103177124,6167,Unspecified,6686268.0,1559.0,,,Inhibition of CYP2C9 (unknown origin) at 3 uM,Other,24210503.0,
4455,1058415,1,4,,103177124,6167,Unspecified,117144.0,1544.0,,,Inhibition of CYP1A2 (unknown origin) at 3 uM,Other,24210503.0,
4456,1058416,1,4,,103177124,6167,Unspecified,117225.0,1558.0,,,Inhibition of CYP2C8 (unknown origin) at 3 uM,Other,24210503.0,
4457,1058418,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from apical to basolateral side in RRCK cells,Other,24210503.0,
4458,1058420,1,2,,103177124,6167,Active,,,0.0132,IC50,Cytotoxicity against HUVEC assessed as cell viability after 4 days by MTS assay,Confirmatory,24210503.0,
4459,1058421,1,2,,103177124,6167,Active,,,0.0021,IC50,Cytotoxicity against human MDA-MB-468 cells assessed as cell viability after 4 days by MTS assay,Confirmatory,24210503.0,
4460,1058422,1,2,,103177124,6167,Active,,,0.0054,IC50,Cytotoxicity against human NCI-N87 cells assessed as cell viability after 4 days by MTS assay,Confirmatory,24210503.0,
4461,1058423,1,2,,103177124,6167,Active,,,0.0038,IC50,Cytotoxicity against human BT474 cells assessed as cell viability after 4 days by MTS assay,Confirmatory,24210503.0,
4462,1063554,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4463,1063554,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4464,1063554,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4465,1063554,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4466,1063554,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4467,1063554,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4468,1063554,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4469,1063554,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4470,1063554,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4471,1063554,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4472,1063554,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4473,1063554,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4474,1063554,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4475,1063554,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4476,1063554,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4477,1063554,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of [3H]-colchicine from tubulin (unknown origin) at 20 uM preincubated for 1 hr followed by radioligand addition measured after 30 mins by competitive binding assay,Other,24360827.0,
4478,1063555,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4479,1063555,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4480,1063555,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4481,1063555,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4482,1063555,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4483,1063555,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4484,1063555,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4485,1063555,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4486,1063555,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4487,1063555,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4488,1063555,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4489,1063555,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4490,1063555,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4491,1063555,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4492,1063555,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4493,1063555,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Inhibition of tubulin polymerization (unknown origin) at 20 uM by spectrophotometric analysis,Other,24360827.0,
4494,1075752,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4495,1075752,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4496,1075752,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4497,1075752,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4498,1075752,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4499,1075752,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4500,1075752,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4501,1075752,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4502,1075752,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4503,1075752,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4504,1075752,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4505,1075752,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4506,1075752,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4507,1075752,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4508,1075752,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4509,1075752,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of tubulin polymerization in human A549 cells assessed as disappearance of microtubule network at 100 nM after 24 hrs by Hoechst 33342 staining-based immunocytochemistry relative to control,Other,24502232.0,
4510,1075754,1,2,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase after 24 hrs by propidium iodide staining-based FACS analysis,Other,24502232.0,
4511,1075755,1,2,,103177124,6167,Active,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 300 nM after 24 hrs by propidium iodide staining-based FACS analysis,Other,24502232.0,
4512,1077391,3,1,,103177124,6167,Active,,,0.0302,EC50,Inhibition of microtubule depolymerization in rat A10 cells after 18 hrs by immunofluorescence assay,Confirmatory,23457660.0,
4513,1077392,1,1,,103177124,6167,Active,,,0.016,IC50,Antiproliferative activity against human MDA-MB-431 cells by SRB assay,Confirmatory,23457660.0,
4514,1078104,1,2,,103177124,6167,Active,,,8.12,IC50,Inhibition of tubulin polymerization assessed as reduction in tubulin assembly after 5 mins using pig microtubule protein by spectrophotometry,Confirmatory,,
4515,1078120,1,2,,103177124,6167,Unspecified,,,,,Metabolic stability in BALB/c mouse hepatic microsomes assessed per mg of microsomal protein at 1 umol/L preincubated for 5 mins by LC-MS/MS method,Other,,
4516,1078121,1,2,,103177124,6167,Active,,,0.0106,IC50,Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 96 hrs,Confirmatory,,
4517,1078122,1,2,,103177124,6167,Active,,,0.0082,IC50,Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation after 96 hrs,Confirmatory,,
4518,1078123,1,2,,103177124,6167,Active,,,0.0544,IC50,Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 96 hrs,Confirmatory,,
4519,1079931,1,1,,103177124,6167,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
4520,1079932,1,1,,103177124,6167,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
4521,1079933,1,1,,103177124,6167,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
4522,1079934,1,1,,103177124,6167,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
4523,1079935,1,1,,103177124,6167,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
4524,1079936,1,1,,103177124,6167,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
4525,1079937,1,1,,103177124,6167,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
4526,1079938,1,1,,103177124,6167,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
4527,1079939,1,1,,103177124,6167,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
4528,1079940,1,1,,103177124,6167,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
4529,1079941,1,1,,103177124,6167,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
4530,1079942,1,1,,103177124,6167,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
4531,1079943,1,1,,103177124,6167,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
4532,1079944,1,1,,103177124,6167,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
4533,1079945,1,1,,103177124,6167,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
4534,1079946,1,1,,103177124,6167,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
4535,1079947,1,1,,103177124,6167,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
4536,1079948,1,1,,103177124,6167,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
4537,1079949,1,1,,103177124,6167,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
4538,1110725,1,1,,103177124,6167,Active,,,0.02,EC50,Antitumor activity against Homo sapiens (human) HCT116 cells,Confirmatory,11378362.0,
4539,1110727,2,3,,103177124,6167,Active,2498194.0,280968.0,0.75,EC50,Inhibition of Bos taurus (bovine) brain tubulin polymerization,Confirmatory,11378362.0,
4540,1110729,1,4,,103177124,6167,Active,2498194.0,280968.0,,,Inhibition of Bos taurus (bovine) brain tubulin polymerization at 2 uM,Other,11378362.0,
4541,1110731,1,1,,103177124,6167,Active,,,,,Mitotic arrest in Nicotiana tabacum (tobacco) root suspension-cultured cells assessed as accumulation of cells in metaphase by cytological staining assay,Other,11378362.0,
4542,1110732,1,1,,103177124,6167,Unspecified,,,356.0,EC50,Inhibition of Nicotiana tabacum (tobacco) root growth assessed as inhibition of root elongation,Confirmatory,11378362.0,
4543,1113289,1,2,,103177124,6167,Unspecified,,,,,Elimination half life in healthy Homo sapiens (human),Other,,
4544,1113290,1,2,,103177124,6167,Unspecified,,,,,Renal clearance in healthy Homo sapiens (human),Other,,
4545,1113291,1,2,,103177124,6167,Unspecified,,,,,Volume of distribution in Homo sapiens (human),Other,,
4546,1113292,1,2,,103177124,6167,Unspecified,,,,,Distribution half life in Homo sapiens (human),Other,,
4547,1113293,1,2,,103177124,6167,Unspecified,,,,,Oral bioavailability in older Homo sapiens (human) individuals at 1 mg,Other,,
4548,1113294,1,2,,103177124,6167,Unspecified,,,,,Oral bioavailability in healthy Homo sapiens (human) at 1 mg,Other,,
4549,1116078,1,2,,103177124,6167,Active,,,7.07,IC50,Antimigratory activity against Homo sapiens (human) MDA-MB-231 cells after 24 to 48 hr by microscopic analysis,Confirmatory,,
4550,1116079,1,3,,103177124,6167,Unspecified,20455316.0,7278.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4551,1116079,1,3,,103177124,6167,Unspecified,20455316.0,113457.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4552,1116079,1,3,,103177124,6167,Unspecified,20455322.0,84790.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4553,1116079,1,3,,103177124,6167,Unspecified,20455526.0,10381.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4554,1116079,1,3,,103177124,6167,Unspecified,55977474.0,10376.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4555,1116079,1,3,,103177124,6167,Unspecified,55977476.0,7277.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4556,1116079,1,3,,103177124,6167,Unspecified,55977480.0,10383.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4557,1116079,1,3,,103177124,6167,Unspecified,55977864.0,7846.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4558,1116079,1,3,,103177124,6167,Unspecified,56757569.0,203068.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4559,1116079,1,3,,103177124,6167,Unspecified,62903515.0,81027.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4560,1116079,1,3,,103177124,6167,Unspecified,68776070.0,84617.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4561,1116079,1,3,,103177124,6167,Unspecified,74761283.0,347733.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4562,1116079,1,3,,103177124,6167,Unspecified,74762137.0,7280.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4563,1116079,1,3,,103177124,6167,Unspecified,93141323.0,10382.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4564,1116079,1,3,,103177124,6167,Unspecified,182705285.0,347688.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4565,1116079,1,3,,103177124,6167,Unspecified,224471855.0,112714.0,,,Inhibition of tubulin polymerization in Homo sapiens (human) MDA-MB-231 cells at 10 uM measured every 1 min for 70 min relative to vehicle-treated control,Other,,
4566,1117298,1,2,,170465011,6167,Inactive,,,39.8107,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
4567,1117299,1,2,,170465011,6167,Active,,,0.0968,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 3 green channel",Confirmatory,,
4568,1117300,1,2,,170465011,6167,Active,,,0.1721,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 3 ratio channel",Confirmatory,,
4569,1117301,1,2,,170465011,6167,Active,,,0.3162,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
4570,1117302,1,2,,170465011,6167,Inactive,,,0.3548,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
4571,1117303,1,2,,170465011,6167,Active,,,0.32,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
4572,1117304,1,2,,170465011,6167,Active,,,22.3872,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
4573,1117305,1,2,,170465011,6167,Active,,,0.3162,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
4574,1117306,1,2,,170465011,6167,Active,,,0.1721,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 3 blue channel",Confirmatory,,
4575,1117307,1,1,,170465011,6167,Inactive,,,0.17214100000000002,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 3, blue channel",Confirmatory,,
4576,1117308,1,1,,170465011,6167,Active,,,0.048515800000000005,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, ratio channel",Confirmatory,,
4577,1117309,1,1,,170465011,6167,Inactive,,,0.09680169999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, blue channel",Confirmatory,,
4578,1117310,1,1,,170465011,6167,Inactive,,,0.0385375,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
4579,1117311,1,1,,170465011,6167,Inactive,,,0.316228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
4580,1117312,1,1,,170465011,6167,Inactive,,,0.0432397,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
4581,1117313,1,1,,170465011,6167,Active,,,0.17214100000000002,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 3, ratio channel",Confirmatory,,
4582,1117314,1,1,,170465011,6167,Inactive,,,0.17214100000000002,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
4583,1117315,1,1,,170465011,6167,Inactive,,,0.354813,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
4584,1117316,1,1,,170465011,6167,Inactive,,,1.93145,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 4, green channel",Confirmatory,,
4585,1117317,1,1,,170465011,6167,Inactive,,,0.10861300000000002,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 3, green channel",Confirmatory,,
4586,1117318,1,1,,170465011,6167,Active,,,0.316228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
4587,1117324,1,1,,170465011,6167,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
4588,1117325,1,1,,170465011,6167,Active,,,0.0185,IC50,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
4589,1117326,1,1,,170465011,6167,Active,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
4590,1117327,1,1,,170465011,6167,Active,,,0.0527,IC50,alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
4591,1117328,1,1,,170465011,6167,Inactive,,,,,human p70S6K1 kinase inhibition-screen,Screening,,
4592,1117329,1,1,,170465011,6167,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
4593,1117336,1,1,,170465011,6167,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
4594,1117337,1,1,,170465011,6167,Active,,,0.0112,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
4595,1117340,1,1,,170465011,6167,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
4596,1117341,1,1,,170465011,6167,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
4597,1117342,1,1,,170465011,6167,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
4598,1117343,1,1,,170465011,6167,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
4599,1117346,1,1,,170465011,6167,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
4600,1117347,1,1,,170465011,6167,Active,,,0.0018800000000000002,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
4601,1117348,1,1,,170465011,6167,Inactive,,,0.1,IC50,Increased HeLa cells in S-phase-IC50,Confirmatory,,
4602,1117349,1,1,,170465011,6167,Active,,,0.0017,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
4603,1117350,1,1,,170465011,6167,Active,,,0.00173,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
4604,1117351,1,1,,170465011,6167,Active,,,0.0017100000000000001,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
4605,1117353,1,1,,170465011,6167,Inactive,,,,,human KDR kinase inhibition-screen,Screening,,
4606,1117354,1,1,,170465011,6167,Inactive,,,,,human JAK2 kinase inhibition-screen,Screening,,
4607,1117355,1,1,,170465011,6167,Inactive,,,,,human GSK3B kinase inhibition-screen,Screening,,
4608,1117356,1,1,,170465011,6167,Inactive,,,,,human FLT3 kinase inhibition-screen,Screening,,
4609,1117413,1,2,,103177124,6167,Active,,,0.0103,IC50,Antiproliferative activity against human KB cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay,Confirmatory,,
4610,1117414,1,1,,103177124,6167,Active,,,0.0198,IC50,Antiproliferative activity against human H460 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay,Confirmatory,,
4611,1117415,1,1,,103177124,6167,Active,,,0.0152,IC50,Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay,Confirmatory,,
4612,1117416,1,1,,103177124,6167,Active,,,0.0115,IC50,Antiproliferative activity against human MKN45 cells assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay,Confirmatory,,
4613,1117417,1,1,,103177124,6167,Active,,,0.1212,IC50,Antiproliferative activity against human KB-VIN10 cells overexpressing P-gp 170/MDR assessed as inhibition of cell growth after 72 hrs by methylene blue dye assay,Confirmatory,,
4614,1117418,1,3,,103177124,6167,Active,75053726.0,,4.1,IC50,Inhibition of bovine brain microtubule-associated protein rich tubulin polymerization by turbidimetric assay,Confirmatory,,
4615,1117418,1,3,,103177124,6167,Active,75053735.0,,4.1,IC50,Inhibition of bovine brain microtubule-associated protein rich tubulin polymerization by turbidimetric assay,Confirmatory,,
4616,1117418,1,3,,103177124,6167,Active,118573906.0,281555.0,4.1,IC50,Inhibition of bovine brain microtubule-associated protein rich tubulin polymerization by turbidimetric assay,Confirmatory,,
4617,1121119,3,1,,103177124,6167,Active,,,0.0544,IC50,Cytotoxicity against human A549 cells after 96 hrs by microplate reader analysis,Confirmatory,,
4618,1121120,1,1,,103177124,6167,Active,,,0.0082,IC50,Cytotoxicity against human HT-29 cells after 96 hrs by microplate reader analysis,Confirmatory,,
4619,1121121,1,1,,103177124,6167,Active,,,0.0106,IC50,Cytotoxicity against human HCT116 cells after 96 hrs by microplate reader analysis,Confirmatory,,
4620,1121122,1,2,,103177124,6167,Unspecified,,,,,Metabolic stability in BALB/c mouse liver microsomes at 1 umol/l by LC-MS/MS analysis,Other,,
4621,1121123,1,1,,103177124,6167,Unspecified,,,,,"Antitumor activity against human HCT116 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 0.75 mg/kg/day, iv administered on day 1, 5 and 9 relative to control",Other,,
4622,1121124,1,1,,103177124,6167,Unspecified,,,,,"Antitumor activity against human HCT116 cells xenografted in BALB/c mouse assessed as tumor growth inhibition at 1.5 mg/kg/day, iv administered on day 1, 5 and 9 relative to control",Other,,
4623,1121134,1,1,,103177124,6167,Unspecified,,,,,"Toxicity in BALB/c mouse assessed as mortality at 0.75 mg/kg/day, iv administered on day 1, 5 and 9",Other,,
4624,1121135,1,1,,103177124,6167,Unspecified,,,,,"Toxicity in BALB/c mouse assessed as mortality at 1.5 mg/kg/day, iv administered on day 1, 5 and 9",Other,,
4625,1121740,1,1,,103177124,6167,Active,,,,,Inhibition of microtubule formation in human HT-29 cells at 100 nM using Dm1a tubulin antibodies by confocal microscopy,Other,,
4626,1121809,1,1,,103177124,6167,Active,,,0.008,IC50,Antiproliferative activity against human MDA-MB-231 cells by MTS assay,Confirmatory,,
4627,1121810,1,1,,103177124,6167,Active,,,0.008,IC50,Antiproliferative activity against human HT-29 cells by MTS assay,Confirmatory,,
4628,1124106,1,1,,103177124,6167,Unspecified,,,,,Mitotic arrest in CHO cells assessed as increase in cell accumulation at 0.2 ug/ml,Other,430477.0,
4629,1124107,1,1,,103177124,6167,Unspecified,,,,,Mitotic arrest in CHO cells assessed as increase in cell accumulation at 0.02 ug/ml,Other,430477.0,
4630,1125803,1,2,,103177124,6167,Active,,,0.0124,IC50,Cytotoxicity against human KB cells after 72 hrs by methylene blue assay,Confirmatory,24657567.0,
4631,1125804,1,1,,103177124,6167,Active,,,0.0149,IC50,Cytotoxicity against human MKN45 cells after 72 hrs by methylene blue assay,Confirmatory,24657567.0,
4632,1125805,1,1,,103177124,6167,Active,,,0.0128,IC50,Cytotoxicity against human HT-29 cells after 72 hrs by methylene blue assay,Confirmatory,24657567.0,
4633,1125809,1,3,,103177124,6167,Active,75053726.0,,4.9,IC50,Inhibition of bovine brain tubulin polymerization measured every 30 sec for 30 mins by spectrophotometry,Confirmatory,24657567.0,
4634,1125809,1,3,,103177124,6167,Active,75053735.0,,4.9,IC50,Inhibition of bovine brain tubulin polymerization measured every 30 sec for 30 mins by spectrophotometry,Confirmatory,24657567.0,
4635,1125809,1,3,,103177124,6167,Active,118573906.0,281555.0,4.9,IC50,Inhibition of bovine brain tubulin polymerization measured every 30 sec for 30 mins by spectrophotometry,Confirmatory,24657567.0,
4636,1125810,1,3,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4637,1125810,1,3,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4638,1125810,1,3,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4639,1125810,1,3,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4640,1125810,1,3,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4641,1125810,1,3,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4642,1125810,1,3,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4643,1125810,1,3,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4644,1125810,1,3,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4645,1125810,1,3,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4646,1125810,1,3,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4647,1125810,1,3,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4648,1125810,1,3,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4649,1125810,1,3,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4650,1125810,1,3,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4651,1125810,1,3,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 1 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4652,1125811,1,3,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4653,1125811,1,3,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4654,1125811,1,3,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4655,1125811,1,3,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4656,1125811,1,3,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4657,1125811,1,3,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4658,1125811,1,3,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4659,1125811,1,3,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4660,1125811,1,3,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4661,1125811,1,3,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4662,1125811,1,3,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4663,1125811,1,3,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4664,1125811,1,3,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4665,1125811,1,3,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4666,1125811,1,3,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4667,1125811,1,3,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of [3H]colchicine from tubulin (unknown origin) at 5 uM after 2 hrs by scintillation counting analysis,Other,24657567.0,
4668,1142130,1,1,,103177124,6167,Active,,,0.0038,IC50,Antiproliferative activity against HMEC1 after 4 days by coulter counter analysis,Confirmatory,24773591.0,
4669,1142131,1,1,,103177124,6167,Active,,,0.031,IC50,Antiproliferative activity against MBEC after 3 days by coulter counter analysis,Confirmatory,24773591.0,
4670,1142132,1,1,,103177124,6167,Active,,,0.0069,IC50,Antiproliferative activity against BAEC after 3 days by coulter counter analysis,Confirmatory,24773591.0,
4671,1142133,1,1,,103177124,6167,Active,,,0.01,IC50,Antiproliferative activity against mouse L1210 cells after 48 to 96 hrs by coulter counter analysis,Confirmatory,24773591.0,
4672,1142134,1,1,,103177124,6167,Active,,,0.013000000000000001,IC50,Antiproliferative activity against human CEM cells after 48 to 96 hrs by coulter counter analysis,Confirmatory,24773591.0,
4673,1142135,1,1,,103177124,6167,Active,,,0.0087,IC50,Antiproliferative activity against human HeLa cells after 4 days by coulter counter analysis,Confirmatory,24773591.0,
4674,1142136,1,1,,103177124,6167,Active,,,,,Cell cycle arrest in HMEC1 cells assessed as accumulation at subG1 phase at 0.03 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis,Other,24773591.0,
4675,1142137,1,1,,103177124,6167,Active,,,,,Cell cycle arrest in HMEC1 cells assessed as accumulation at G2/M phase at 0.03 uM after 24 hrs by propidium iodide staining-based flow cytometric analysis,Other,24773591.0,
4676,1142141,1,1,,103177124,6167,Active,,,,,Competitive binding affinity to beta-tubulin in human MDA-MB-231 cells assessed as inhibition of protein-N/N'-ethylene-bis(iodoacetamide) adduct formation at 0.5 uM preincubated for 16 hrs followed by N/N'-ethylene-bis(iodoacetamide) formation measured after 1.5 hrs by Western blot analysis,Other,24773591.0,
4677,1142145,1,3,,103177124,6167,Active,20455316.0,7278.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4678,1142145,1,3,,103177124,6167,Active,20455316.0,113457.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4679,1142145,1,3,,103177124,6167,Active,20455322.0,84790.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4680,1142145,1,3,,103177124,6167,Active,20455526.0,10381.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4681,1142145,1,3,,103177124,6167,Active,55977474.0,10376.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4682,1142145,1,3,,103177124,6167,Active,55977476.0,7277.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4683,1142145,1,3,,103177124,6167,Active,55977480.0,10383.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4684,1142145,1,3,,103177124,6167,Active,55977864.0,7846.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4685,1142145,1,3,,103177124,6167,Active,56757569.0,203068.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4686,1142145,1,3,,103177124,6167,Active,62903515.0,81027.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4687,1142145,1,3,,103177124,6167,Active,68776070.0,84617.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4688,1142145,1,3,,103177124,6167,Active,74761283.0,347733.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4689,1142145,1,3,,103177124,6167,Active,74762137.0,7280.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4690,1142145,1,3,,103177124,6167,Active,93141323.0,10382.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4691,1142145,1,3,,103177124,6167,Active,182705285.0,347688.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4692,1142145,1,3,,103177124,6167,Active,224471855.0,112714.0,,,Binding affinity to tubulin in human MDA-MB-231 cells assessed as inhibition of mitotic spindle formation at 0.1 uM after 8 hrs by DAPI staining-based fluorescence microscopic analysis,Other,24773591.0,
4693,1142147,1,1,,103177124,6167,Active,,,,,Antivascular activity in HMEC1 cells assessed as destruction of cord like structure at 0.3 to 1 uM after 90 mins by matrigel assay,Other,24773591.0,
4694,1142149,1,1,,103177124,6167,Active,,,,,Antimigratory activity against human MDA-MB-231 cells at 0.08 uM after 17 hrs by Transwell assay,Other,24773591.0,
4695,1142150,1,1,,103177124,6167,Active,,,,,Antiinvasive activity against human MDA-MB-231 cells at 0.08 uM after 17 hrs by Transwell assay,Other,24773591.0,
4696,1142153,1,1,,103177124,6167,Active,,,,,Antiproliferative activity against human MDA-MB-231 cells at 0.08 uM after 17 hrs,Other,24773591.0,
4697,1142160,1,3,,103177124,6167,Unspecified,75053726.0,,,,Binding affinity to calf brain tubulin at 37 degC by fluorometric analysis,Other,24773591.0,
4698,1142160,1,3,,103177124,6167,Unspecified,75053735.0,,,,Binding affinity to calf brain tubulin at 37 degC by fluorometric analysis,Other,24773591.0,
4699,1142160,1,3,,103177124,6167,Unspecified,118573906.0,281555.0,,,Binding affinity to calf brain tubulin at 37 degC by fluorometric analysis,Other,24773591.0,
4700,1153765,1,1,,103177124,6167,Active,,,,EC50,Cytotoxicity against HEK293 cells after 48 hrs by MTS assay,Confirmatory,24842619.0,
4701,1153766,1,1,,103177124,6167,Active,,,,EC50,Cytotoxicity against human M38L cells after 48 hrs by MTS assay,Confirmatory,24842619.0,
4702,1153777,1,1,,103177124,6167,Unspecified,,,,,"Potency index, ratio of EC50 for valyl colchicine to EC50 for compound against HEK293 cells after 48 hrs by MTS assay",Other,24842619.0,
4703,1153778,1,1,,103177124,6167,Unspecified,,,,,"Potency index, ratio of EC50 for valyl colchicine to EC50 for compound against human M38L cells after 48 hrs by MTS assay",Other,24842619.0,
4704,1159387,1,2,,103177124,6167,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
4705,1159509,1,1,,144208745,6167,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4706,1159509,1,1,,144210899,6167,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4707,1159509,1,1,,170465011,6167,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
4708,1159515,1,1,,144208745,6167,Inconclusive,,,0.0384,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4709,1159515,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4710,1159515,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
4711,1159516,1,1,,144208745,6167,Inconclusive,119611100.0,22926.0,0.3054,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4712,1159516,1,1,,144210899,6167,Inconclusive,119611100.0,22926.0,0.5494,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4713,1159516,1,1,,170465011,6167,Inconclusive,119611100.0,22926.0,0.0268,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
4714,1159517,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4715,1159517,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4716,1159517,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
4717,1159518,1,1,,144208745,6167,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4718,1159518,1,1,,144210899,6167,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4719,1159518,1,1,,170465011,6167,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
4720,1159519,1,1,,144208745,6167,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4721,1159519,1,1,,144210899,6167,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4722,1159519,1,1,,170465011,6167,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
4723,1159520,1,1,,144208745,6167,Inconclusive,,,21.4255,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4724,1159520,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4725,1159520,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
4726,1159521,1,1,,144208745,6167,Active,15928672.0,19885.0,0.5382,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4727,1159521,1,1,,144210899,6167,Active,15928672.0,19885.0,0.6859,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4728,1159521,1,1,,170465011,6167,Active,15928672.0,19885.0,0.0376,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
4729,1159523,1,1,,144208745,6167,Inconclusive,15928672.0,19885.0,0.652026,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4730,1159523,1,1,,144210899,6167,Active,15928672.0,19885.0,0.71273,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4731,1159523,1,1,,170465011,6167,Active,15928672.0,19885.0,0.101922,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
4732,1159524,1,1,,11114044,6167,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4733,1159524,1,1,,49718107,6167,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
4734,1159525,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4735,1159525,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4736,1159525,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
4737,1159526,1,1,,144208745,6167,Active,119627033.0,3725.0,0.1717,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4738,1159526,1,1,,144210899,6167,Inconclusive,119627033.0,3725.0,0.309,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4739,1159526,1,1,,170465011,6167,Inconclusive,119627033.0,3725.0,0.0425,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
4740,1159527,1,1,,144208745,6167,Inconclusive,325495497.0,6256.0,0.8606,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4741,1159527,1,1,,144210899,6167,Inconclusive,325495497.0,6256.0,0.0155,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4742,1159527,1,1,,170465011,6167,Inconclusive,325495497.0,6256.0,0.0021,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
4743,1159528,1,1,,144208745,6167,Active,119627033.0,3725.0,0.21618400000000002,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4744,1159528,1,1,,144210899,6167,Active,119627033.0,3725.0,0.236173,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4745,1159528,1,1,,170465011,6167,Active,119627033.0,3725.0,0.06007040000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
4746,1159529,1,1,,144208745,6167,Inconclusive,,,0.0384,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4747,1159529,1,1,,144210899,6167,Inconclusive,,,0.977,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4748,1159529,1,1,,170465011,6167,Inconclusive,,,0.0054,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
4749,1159531,1,1,,144208745,6167,Inconclusive,325495497.0,6256.0,0.0171721,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4750,1159531,1,1,,144210899,6167,Inconclusive,325495497.0,6256.0,0.0822047,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4751,1159531,1,1,,170465011,6167,Inconclusive,325495497.0,6256.0,0.0268325,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
4752,1159551,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4753,1159551,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4754,1159551,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
4755,1159552,1,1,,144208745,6167,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4756,1159552,1,1,,144210899,6167,Inconclusive,325495463.0,5914.0,0.2169,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4757,1159552,1,1,,170465011,6167,Inconclusive,325495463.0,5914.0,0.0298,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4758,1159553,2,1,,144208745,6167,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4759,1159553,2,1,,144210899,6167,Inconclusive,325495463.0,5914.0,0.0433,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4760,1159553,2,1,,170465011,6167,Inconclusive,325495463.0,5914.0,0.0335,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
4761,1159555,1,1,,144208745,6167,Inconclusive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4762,1159555,1,1,,144210899,6167,Active,325495463.0,5914.0,0.14777200000000001,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4763,1159555,1,1,,170465011,6167,Active,325495463.0,5914.0,0.0334915,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
4764,1159580,2,1,,268734454,6167,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
4765,1159606,1,1,,50085974,6167,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
4766,1159607,2,1,,312596519,6167,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
4767,1159614,1,2,,170465011,6167,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
4768,1159620,1,1,,103177124,6167,Active,,,,,Summary of drug indications.,Other,,
4769,1163569,1,1,,103177124,6167,Active,,,0.042,IC50,Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4770,1163570,1,1,,103177124,6167,Active,,,0.012,IC50,Antiproliferative activity against human A375 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4771,1163571,1,1,,103177124,6167,Active,,,0.016,IC50,Antiproliferative activity against human K562 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4772,1163572,1,1,,103177124,6167,Active,,,0.344,IC50,Antiproliferative activity against mouse C26 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4773,1163573,1,1,,103177124,6167,Active,,,0.015,IC50,Antiproliferative activity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4774,1163574,1,1,,103177124,6167,Active,,,0.011000000000000001,IC50,Antiproliferative activity against human DLD1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4775,1163575,1,1,,103177124,6167,Active,,,0.016,IC50,Antiproliferative activity against human HCT15 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4776,1163576,1,1,,103177124,6167,Active,,,0.004,IC50,Antiproliferative activity against human NCI-H358 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4777,1163577,1,1,,103177124,6167,Active,,,0.057999999999999996,IC50,Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4778,1163578,1,1,,103177124,6167,Active,,,0.018000000000000002,IC50,Antiproliferative activity against human ES2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4779,1163579,1,1,,103177124,6167,Active,,,0.004,IC50,Antiproliferative activity against human A2780S cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4780,1163580,1,1,,103177124,6167,Active,,,0.009000000000000001,IC50,Antiproliferative activity against human AGS cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4781,1163581,1,1,,103177124,6167,Active,,,0.02,IC50,Antiproliferative activity against human U251 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay,Confirmatory,25208345.0,
4782,1167518,1,1,,103177124,6167,Active,,,0.0038,IC50,Antiproliferative activity against human HMEC1 cells assessed as inhibition of cell proliferation after 4 days by Coulter counter based cell counting method,Confirmatory,25282265.0,
4783,1167519,1,1,,103177124,6167,Active,,,0.031,IC50,Antiproliferative activity against mouse MBEC assessed as inhibition of cell proliferation after 3 days by Coulter counter based cell counting method,Confirmatory,25282265.0,
4784,1167520,1,1,,103177124,6167,Active,,,0.0069,IC50,Antiproliferative activity against BAEC assessed as inhibition of cell proliferation after 3 days by Coulter counter based cell counting method,Confirmatory,25282265.0,
4785,1167521,1,1,,103177124,6167,Active,,,0.013999999999999999,IC50,Antiproliferative activity against mouse L1210 assessed as inhibition of cell proliferation after 48 hrs by Coulter counter based cell counting method,Confirmatory,25282265.0,
4786,1167522,1,1,,103177124,6167,Active,,,0.031,IC50,Antiproliferative activity against human CEM cells assessed as inhibition of cell proliferation after 96 hrs by Coulter counter based cell counting method,Confirmatory,25282265.0,
4787,1167523,1,1,,103177124,6167,Active,,,0.027999999999999997,IC50,Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation after 4 days by Coulter counter based cell counting method,Confirmatory,25282265.0,
4788,1167524,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at subG1 phase at 0.1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 1%),Other,25282265.0,
4789,1167528,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at G1 phase at 0.1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 45%),Other,25282265.0,
4790,1167532,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at S phase at 0.1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 24%),Other,25282265.0,
4791,1167536,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 0.1 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 31%),Other,25282265.0,
4792,1179654,1,1,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Other,24916028.0,
4793,1179655,1,1,,103177124,6167,Unspecified,,,,,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Other,24916028.0,
4794,1179656,1,1,,103177124,6167,Unspecified,,,,,Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay,Other,24916028.0,
4795,1179657,1,2,,103177124,6167,Active,75053726.0,,1.34,IC50,Inhibition of bovine brain tubulin polymerization after 20 mins by turbidimetric method,Confirmatory,24916028.0,
4796,1179657,1,2,,103177124,6167,Active,75053735.0,,1.34,IC50,Inhibition of bovine brain tubulin polymerization after 20 mins by turbidimetric method,Confirmatory,24916028.0,
4797,1179657,1,2,,103177124,6167,Active,118573906.0,281555.0,1.34,IC50,Inhibition of bovine brain tubulin polymerization after 20 mins by turbidimetric method,Confirmatory,24916028.0,
4798,1179659,1,1,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 1 ug/ml after 24 hrs by flow cytometry (Rvb = 62.34 %),Other,24916028.0,
4799,1179660,1,1,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 1 ug/ml after 24 hrs by flow cytometry (Rvb = 13.05 %),Other,24916028.0,
4800,1179661,1,1,,103177124,6167,Unspecified,,,,,Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 1 ug/ml after 24 hrs by flow cytometry (Rvb = 24.61 %),Other,24916028.0,
4801,1183705,1,2,,103177124,6167,Active,20455316.0,7278.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4802,1183705,1,2,,103177124,6167,Active,20455316.0,113457.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4803,1183705,1,2,,103177124,6167,Active,20455322.0,84790.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4804,1183705,1,2,,103177124,6167,Active,20455526.0,10381.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4805,1183705,1,2,,103177124,6167,Active,55977474.0,10376.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4806,1183705,1,2,,103177124,6167,Active,55977476.0,7277.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4807,1183705,1,2,,103177124,6167,Active,55977480.0,10383.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4808,1183705,1,2,,103177124,6167,Active,55977864.0,7846.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4809,1183705,1,2,,103177124,6167,Active,56757569.0,203068.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4810,1183705,1,2,,103177124,6167,Active,62903515.0,81027.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4811,1183705,1,2,,103177124,6167,Active,68776070.0,84617.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4812,1183705,1,2,,103177124,6167,Active,74761283.0,347733.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4813,1183705,1,2,,103177124,6167,Active,74762137.0,7280.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4814,1183705,1,2,,103177124,6167,Active,93141323.0,10382.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4815,1183705,1,2,,103177124,6167,Active,182705285.0,347688.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4816,1183705,1,2,,103177124,6167,Active,224471855.0,112714.0,3.2,IC50,Inhibition of tubulin (unknown origin) polymerization incubated 15 mins prior to GTP addition by spectrophotometry,Confirmatory,25025991.0,
4817,1183706,1,1,,103177124,6167,Active,,,0.005,IC50,Cytotoxicity against human MCF7 cells after 96 hrs by Giemsa staining-based light microscopy,Confirmatory,25025991.0,
4818,1183715,1,1,,103177124,6167,Active,,,0.03,IC50,Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy,Confirmatory,25025991.0,
4819,1183716,1,1,,103177124,6167,Active,,,0.42,IC50,Cytotoxicity against human NCI/ADR-RES cells assessed as growth inhibition after 96 hrs by Giemsa staining-based light microscopy,Confirmatory,25025991.0,
4820,1183717,1,1,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay,Confirmatory,25025991.0,
4821,1183718,1,1,,103177124,6167,Active,,,0.32899999999999996,IC50,Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTitre-Glo assay,Confirmatory,25025991.0,
4822,1185195,1,2,,103177124,6167,Unspecified,75053726.0,,,,Binding affinity to bovine brain tubulin assessed as half life of compound-tubulin complex,Other,25050880.0,
4823,1185195,1,2,,103177124,6167,Unspecified,75053735.0,,,,Binding affinity to bovine brain tubulin assessed as half life of compound-tubulin complex,Other,25050880.0,
4824,1185195,1,2,,103177124,6167,Unspecified,118573906.0,281555.0,,,Binding affinity to bovine brain tubulin assessed as half life of compound-tubulin complex,Other,25050880.0,
4825,1185443,1,2,,103177124,6167,Active,20455316.0,7278.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4826,1185443,1,2,,103177124,6167,Active,20455316.0,113457.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4827,1185443,1,2,,103177124,6167,Active,20455322.0,84790.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4828,1185443,1,2,,103177124,6167,Active,20455526.0,10381.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4829,1185443,1,2,,103177124,6167,Active,55977474.0,10376.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4830,1185443,1,2,,103177124,6167,Active,55977476.0,7277.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4831,1185443,1,2,,103177124,6167,Active,55977480.0,10383.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4832,1185443,1,2,,103177124,6167,Active,55977864.0,7846.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4833,1185443,1,2,,103177124,6167,Active,56757569.0,203068.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4834,1185443,1,2,,103177124,6167,Active,62903515.0,81027.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4835,1185443,1,2,,103177124,6167,Active,68776070.0,84617.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4836,1185443,1,2,,103177124,6167,Active,74761283.0,347733.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4837,1185443,1,2,,103177124,6167,Active,74762137.0,7280.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4838,1185443,1,2,,103177124,6167,Active,93141323.0,10382.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4839,1185443,1,2,,103177124,6167,Active,182705285.0,347688.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4840,1185443,1,2,,103177124,6167,Active,224471855.0,112714.0,5.4,IC50,Inhibition of tubulin (unknown origin) polymerization by spectrophotometry,Confirmatory,25059503.0,
4841,1185444,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4842,1185444,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4843,1185444,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4844,1185444,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4845,1185444,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4846,1185444,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4847,1185444,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4848,1185444,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4849,1185444,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4850,1185444,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4851,1185444,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4852,1185444,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4853,1185444,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4854,1185444,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4855,1185444,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4856,1185444,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 1 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4857,1185459,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4858,1185459,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4859,1185459,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4860,1185459,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4861,1185459,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4862,1185459,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4863,1185459,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4864,1185459,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4865,1185459,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4866,1185459,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4867,1185459,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4868,1185459,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4869,1185459,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4870,1185459,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4871,1185459,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4872,1185459,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of [3H]colchicine from long-chain biotin-labeled tubulin (unknown origin) at 5 uM after 2 hrs by competition-binding scintillation proximity assay,Other,25059503.0,
4873,1186696,1,1,,103177124,6167,Active,,,0.021,IC50,Cytotoxicity against human NCI-H460 cells assessed as growth inhibition by MTT assay,Confirmatory,25091926.0,
4874,1186697,1,2,,103177124,6167,Active,,,0.003,IC50,Cytotoxicity against human COLO205 cells assessed as growth inhibition by MTT assay,Confirmatory,25091926.0,
4875,1186698,1,1,,103177124,6167,Active,,,0.001,IC50,Cytotoxicity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay,Confirmatory,25091926.0,
4876,1186699,1,1,,103177124,6167,Active,,,0.008,IC50,Cytotoxicity against human A431 cells assessed as growth inhibition after 72 hrs by CCK-8 assay,Confirmatory,25091926.0,
4877,1186700,1,1,,103177124,6167,Active,,,1.71,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay,Confirmatory,25091926.0,
4878,1186701,1,1,,103177124,6167,Active,,,0.7040000000000001,IC50,Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay,Confirmatory,25091926.0,
4879,1186702,1,1,,103177124,6167,Active,,,0.006999999999999999,IC50,Cytotoxicity against human MDA-MB-435S cells assessed as growth inhibition after 72 hrs by CCK-8 assay,Confirmatory,25091926.0,
4880,1189141,1,1,,103177124,6167,Active,,,0.05,IC50,Antiproliferative activity against human A549 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4881,1189142,1,1,,103177124,6167,Active,,,0.034,IC50,Antiproliferative activity against human CNE2 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4882,1189143,1,1,,103177124,6167,Active,,,0.033,IC50,Antiproliferative activity against human SW480 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4883,1189144,1,1,,103177124,6167,Active,,,0.16,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4884,1189145,1,1,,103177124,6167,Active,,,0.035,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4885,1189146,1,1,,103177124,6167,Active,,,0.057,IC50,Antiproliferative activity against human A2780 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4886,1189147,1,1,,103177124,6167,Active,,,0.59,IC50,Antiproliferative activity against taxol-resistant human A2780 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4887,1189148,1,1,,103177124,6167,Active,,,0.059000000000000004,IC50,Antiproliferative activity against human HCT8 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4888,1189149,1,1,,103177124,6167,Active,,,1.1,IC50,Antiproliferative activity against vincristine-resistant human HCT8 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4889,1189150,1,1,,103177124,6167,Active,,,0.081,IC50,Antiproliferative activity against cis-platinum-resistant human A549 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4890,1189151,1,1,,103177124,6167,Active,,,3.2,IC50,Antiproliferative activity against doxorubicin-resistant human MCF7 cells after 48 hrs by SRB method,Confirmatory,25061803.0,
4891,1189152,1,1,,103177124,6167,Unspecified,,,,,"Drug resistance index, ratio of IC50 for taxol-resistant human A2780 cells to IC50 for human A2780 cells",Other,25061803.0,
4892,1189153,1,1,,103177124,6167,Unspecified,,,,,"Drug resistance index, ratio of IC50 for vincristine-resistant human HCT8 cells to IC50 for human HCT8 cells",Other,25061803.0,
4893,1189154,1,1,,103177124,6167,Unspecified,,,,,"Drug resistance index, ratio of IC50 for cis-platinum-resistant human A549 cells to IC50 for human A549 cells",Other,25061803.0,
4894,1189155,1,1,,103177124,6167,Unspecified,,,,,"Drug resistance index, ratio of IC50 for doxorubicin-resistant human MCF7 cells to IC50 for human MCF7 cells",Other,25061803.0,
4895,1189158,1,1,,103177124,6167,Active,,,,,Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 31.25 nM after 24 hrs by Hoechst 33342 staining-based ArrayScanVTI analysis,Other,25061803.0,
4896,1189166,1,1,,103177124,6167,Unspecified,,,,,Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 0.25 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.10%),Other,25061803.0,
4897,1189167,1,1,,103177124,6167,Unspecified,,,,,Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 0.25 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.47%),Other,25061803.0,
4898,1189168,1,2,,103177124,6167,Active,20455316.0,7278.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4899,1189168,1,2,,103177124,6167,Active,20455316.0,113457.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4900,1189168,1,2,,103177124,6167,Active,20455322.0,84790.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4901,1189168,1,2,,103177124,6167,Active,20455526.0,10381.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4902,1189168,1,2,,103177124,6167,Active,55977474.0,10376.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4903,1189168,1,2,,103177124,6167,Active,55977476.0,7277.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4904,1189168,1,2,,103177124,6167,Active,55977480.0,10383.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4905,1189168,1,2,,103177124,6167,Active,55977864.0,7846.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4906,1189168,1,2,,103177124,6167,Active,56757569.0,203068.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4907,1189168,1,2,,103177124,6167,Active,62903515.0,81027.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4908,1189168,1,2,,103177124,6167,Active,68776070.0,84617.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4909,1189168,1,2,,103177124,6167,Active,74761283.0,347733.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4910,1189168,1,2,,103177124,6167,Active,74762137.0,7280.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4911,1189168,1,2,,103177124,6167,Active,93141323.0,10382.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4912,1189168,1,2,,103177124,6167,Active,182705285.0,347688.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4913,1189168,1,2,,103177124,6167,Active,224471855.0,112714.0,2.6,IC50,Inhibition of tubulin polymerization (unknown origin) by DAPI staining-based fluorescence microscopy,Confirmatory,25061803.0,
4914,1189182,1,2,,103177124,6167,Active,20455316.0,7278.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4915,1189182,1,2,,103177124,6167,Active,20455316.0,113457.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4916,1189182,1,2,,103177124,6167,Active,20455322.0,84790.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4917,1189182,1,2,,103177124,6167,Active,20455526.0,10381.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4918,1189182,1,2,,103177124,6167,Active,55977474.0,10376.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4919,1189182,1,2,,103177124,6167,Active,55977476.0,7277.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4920,1189182,1,2,,103177124,6167,Active,55977480.0,10383.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4921,1189182,1,2,,103177124,6167,Active,55977864.0,7846.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4922,1189182,1,2,,103177124,6167,Active,56757569.0,203068.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4923,1189182,1,2,,103177124,6167,Active,62903515.0,81027.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4924,1189182,1,2,,103177124,6167,Active,68776070.0,84617.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4925,1189182,1,2,,103177124,6167,Active,74761283.0,347733.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4926,1189182,1,2,,103177124,6167,Active,74762137.0,7280.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4927,1189182,1,2,,103177124,6167,Active,93141323.0,10382.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4928,1189182,1,2,,103177124,6167,Active,182705285.0,347688.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4929,1189182,1,2,,103177124,6167,Active,224471855.0,112714.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) at 20 uM by fluorescence assay",Other,25061803.0,
4930,1189184,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4931,1189184,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4932,1189184,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4933,1189184,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4934,1189184,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4935,1189184,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4936,1189184,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4937,1189184,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4938,1189184,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4939,1189184,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4940,1189184,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4941,1189184,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4942,1189184,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4943,1189184,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4944,1189184,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4945,1189184,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,"Displacement of (E)-3-(4-(Dimethylamino)phenyl)-1-(4'-fluoro[1,1'-biphenyl]-2-yl)prop-2-en-1-one from tubulin (unknown origin) by fluorescence assay",Other,25061803.0,
4946,1189188,1,1,,103177124,6167,Unspecified,,,,,Induction of apoptosis in human A549 cells assessed as necrotic cells at 0.25 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.06%),Other,25061803.0,
4947,1189189,1,1,,103177124,6167,Unspecified,,,,,Induction of apoptosis in human A549 cells assessed as viable cells at 0.25 uM after 48 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 99.37%),Other,25061803.0,
4948,1189586,1,1,,103177124,6167,Active,,,0.05,IC50,Cytotoxicity against human HT-29 cells after 3 days by MTT assay,Confirmatory,25426924.0,
4949,1189587,1,1,,103177124,6167,Active,,,0.012,IC50,Cytotoxicity against human MCF7 cells after 3 days by MTT assay,Confirmatory,25426924.0,
4950,1189588,1,1,,103177124,6167,Active,,,0.005,IC50,Cytotoxicity against human HEK293 cells after 3 days by MTT assay,Confirmatory,25426924.0,
4951,1189589,1,1,,103177124,6167,Unspecified,,,,,Selectivity ratio of IC50 for human HEK293 cells to IC50 for human HT29 cells,Other,25426924.0,
4952,1189590,1,1,,103177124,6167,Unspecified,,,,,Selectivity ratio of IC50 for human HEK293 cells to IC50 for human MCF7 cells,Other,25426924.0,
4953,1189592,1,1,,103177124,6167,Active,,,,,Depolymerization of microtubule cytoskeleton in human A549 cells at 50 nM after 24 hrs by hoechst 33342-based fluorescence microscopy,Other,25426924.0,
4954,1189594,1,1,,103177124,6167,Active,,,,,Depolymerization of microtubule cytoskeleton in human A549 cells assessed as DNA forming a ball without microtubules at 50 nM after 24 hrs by hoechst 33342-based fluorescence microscopy,Other,25426924.0,
4955,1189595,1,1,,103177124,6167,Active,,,,,Depolymerization of microtubule cytoskeleton in human A549 cells assessed as aberrant mitosis at 50 nM after 24 hrs by hoechst 33342-based fluorescence microscopy,Other,25426924.0,
4956,1189597,1,1,,103177124,6167,Active,,,,,Cell cycle arrest at G2/M phase in human A549 cells at 50 nM after 20 hrs,Other,25426924.0,
4957,1189598,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4958,1189598,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4959,1189598,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4960,1189598,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4961,1189598,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4962,1189598,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4963,1189598,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4964,1189598,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4965,1189598,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4966,1189598,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4967,1189598,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4968,1189598,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4969,1189598,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4970,1189598,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4971,1189598,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4972,1189598,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 25 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4973,1189599,1,1,,103177124,6167,Active,,,0.015,IC50,Cytotoxicity against human A2780 cells after 24 hrs by MTT assay,Confirmatory,25426924.0,
4974,1189600,1,1,,103177124,6167,Active,,,0.306,IC50,Cytotoxicity against human A2780AD cells after 24 hrs by MTT assay,Confirmatory,25426924.0,
4975,1189601,1,1,,103177124,6167,Unspecified,,,,,"Resistance factor, ratio of IC50 for human A2780AD cells to IC50 for human A2780 cells",Other,25426924.0,
4976,1189602,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4977,1189602,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4978,1189602,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4979,1189602,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4980,1189602,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4981,1189602,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4982,1189602,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4983,1189602,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4984,1189602,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4985,1189602,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4986,1189602,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4987,1189602,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4988,1189602,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4989,1189602,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4990,1189602,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4991,1189602,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4992,1189603,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4993,1189603,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4994,1189603,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4995,1189603,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4996,1189603,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4997,1189603,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4998,1189603,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
4999,1189603,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5000,1189603,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5001,1189603,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5002,1189603,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5003,1189603,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5004,1189603,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5005,1189603,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5006,1189603,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5007,1189603,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 0.5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5008,1189604,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5009,1189604,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5010,1189604,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5011,1189604,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5012,1189604,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5013,1189604,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5014,1189604,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5015,1189604,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5016,1189604,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5017,1189604,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5018,1189604,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5019,1189604,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5020,1189604,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5021,1189604,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5022,1189604,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5023,1189604,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 1 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5024,1189605,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5025,1189605,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5026,1189605,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5027,1189605,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5028,1189605,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5029,1189605,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5030,1189605,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5031,1189605,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5032,1189605,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5033,1189605,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5034,1189605,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5035,1189605,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5036,1189605,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5037,1189605,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5038,1189605,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5039,1189605,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 5 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5040,1189606,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5041,1189606,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5042,1189606,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5043,1189606,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5044,1189606,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5045,1189606,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5046,1189606,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5047,1189606,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5048,1189606,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5049,1189606,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5050,1189606,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5051,1189606,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5052,1189606,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5053,1189606,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5054,1189606,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5055,1189606,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 10 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5056,1189607,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5057,1189607,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5058,1189607,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5059,1189607,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5060,1189607,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5061,1189607,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5062,1189607,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5063,1189607,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5064,1189607,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5065,1189607,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5066,1189607,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5067,1189607,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5068,1189607,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5069,1189607,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5070,1189607,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5071,1189607,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of purified tubulin (unknown origin) assessed as critical concentration of tubulin required to produce assembly at 30 uM after 30 mins by spectrophotometry (Rvb = 3.3 +/- 0.1 uM),Other,25426924.0,
5072,1189963,1,1,,103177124,6167,Unspecified,,,,,"Toxicity in C57BL/6 mouse assessed as interphase microtubule de-stabilizing activity by measuring leakage of rhodamine through the gut at 1 mg/kg, iv co-administered with rhodamine B by fluorimetry",Other,25496412.0,
5073,1189964,1,1,,103177124,6167,Unspecified,,,,,"Toxicity in C57BL/6 mouse assessed as interphase microtubule de-stabilizing activity by measuring influx of rhodamine in to heart at 1 mg/kg, iv co-administered with rhodamine B by fluorimetry",Other,25496412.0,
5074,1189965,1,2,,103177124,6167,Unspecified,,,,,"Toxicity in C57BL/6 mouse assessed as interphase microtubule de-stabilizing activity by measuring influx of rhodamine in to spleen at 1 mg/kg, iv co-administered with rhodamine B by fluorimetry",Other,25496412.0,
5075,1189966,1,2,,103177124,6167,Unspecified,,,,,Reduction in blood-brain barrier permeability in C57BL/6 mouse endothelial cells,Other,25496412.0,
5076,1191355,1,1,,103177124,6167,Active,,,0.12,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25499929.0,
5077,1191356,1,2,,103177124,6167,Active,,,0.69,IC50,Cytotoxicity against human DU145 cells after 48 hrs by MTT assay,Confirmatory,25499929.0,
5078,1191357,1,1,,103177124,6167,Active,,,0.54,IC50,Cytotoxicity against human HeLa cells after 48 hrs by MTT assay,Confirmatory,25499929.0,
5079,1191358,1,1,,103177124,6167,Active,,,0.07,IC50,Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25499929.0,
5080,1191359,1,2,,103177124,6167,Unspecified,75053726.0,,,,Inhibition of bovine brain tubulin polymerization at 10 uM measured for 1 hr by fluorescence assay,Other,25499929.0,
5081,1191359,1,2,,103177124,6167,Unspecified,75053735.0,,,,Inhibition of bovine brain tubulin polymerization at 10 uM measured for 1 hr by fluorescence assay,Other,25499929.0,
5082,1191359,1,2,,103177124,6167,Unspecified,118573906.0,281555.0,,,Inhibition of bovine brain tubulin polymerization at 10 uM measured for 1 hr by fluorescence assay,Other,25499929.0,
5083,1191360,1,2,,103177124,6167,Active,75053726.0,,1.7,IC50,Inhibition of bovine brain tubulin polymerization measured for 1 hr by fluorescence assay,Confirmatory,25499929.0,
5084,1191360,1,2,,103177124,6167,Active,75053735.0,,1.7,IC50,Inhibition of bovine brain tubulin polymerization measured for 1 hr by fluorescence assay,Confirmatory,25499929.0,
5085,1191360,1,2,,103177124,6167,Active,118573906.0,281555.0,1.7,IC50,Inhibition of bovine brain tubulin polymerization measured for 1 hr by fluorescence assay,Confirmatory,25499929.0,
5086,1193492,1,1,,103177124,6167,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5087,1193493,1,1,,103177124,6167,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5088,1193494,1,1,,103177124,6167,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5089,1193495,1,1,,103177124,6167,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
5090,1193496,1,1,,103177124,6167,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method",Other,25740159.0,
5091,1193497,1,1,,103177124,6167,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method",Other,25740159.0,
5092,1193498,1,1,,103177124,6167,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method",Other,25740159.0,
5093,1193499,1,1,,103177124,6167,Inconclusive,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method",Other,25740159.0,
5094,1194048,1,1,,103177124,6167,Inconclusive,,,,IC50,Antiproliferative activity against human K562 cells after 48 hrs by MTT assay,Confirmatory,25778766.0,
5095,1194049,1,1,,103177124,6167,Active,,,1.8,IC50,Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay,Confirmatory,25778766.0,
5096,1194693,1,1,,103177124,6167,Active,,,0.04,GI50,Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
5097,1194694,1,1,,103177124,6167,Active,,,0.01,GI50,Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
5098,1194695,1,1,,103177124,6167,Active,,,0.01,GI50,Antiproliferative activity against human PANC1 cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
5099,1194696,1,1,,103177124,6167,Active,,,0.03,GI50,Antiproliferative activity against human A549 cells after 48 hrs by SRB assay,Confirmatory,25827522.0,
5100,1198224,1,2,,103177124,6167,Active,20455316.0,7278.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5101,1198224,1,2,,103177124,6167,Active,20455316.0,113457.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5102,1198224,1,2,,103177124,6167,Active,20455322.0,84790.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5103,1198224,1,2,,103177124,6167,Active,20455526.0,10381.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5104,1198224,1,2,,103177124,6167,Active,55977474.0,10376.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5105,1198224,1,2,,103177124,6167,Active,55977476.0,7277.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5106,1198224,1,2,,103177124,6167,Active,55977480.0,10383.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5107,1198224,1,2,,103177124,6167,Active,55977864.0,7846.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5108,1198224,1,2,,103177124,6167,Active,56757569.0,203068.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5109,1198224,1,2,,103177124,6167,Active,62903515.0,81027.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5110,1198224,1,2,,103177124,6167,Active,68776070.0,84617.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5111,1198224,1,2,,103177124,6167,Active,74761283.0,347733.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5112,1198224,1,2,,103177124,6167,Active,74762137.0,7280.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5113,1198224,1,2,,103177124,6167,Active,93141323.0,10382.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5114,1198224,1,2,,103177124,6167,Active,182705285.0,347688.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5115,1198224,1,2,,103177124,6167,Active,224471855.0,112714.0,0.36,IC50,Inhibition of tubulin (unknown origin) polymerization preincubated for 45 mins followed by GTP addition measured after 2 hrs by fluorescence assay,Confirmatory,25659770.0,
5116,1198453,1,1,,103177124,6167,Active,,,0.39,IC50,Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay,Confirmatory,25703297.0,
5117,1198454,1,1,,103177124,6167,Active,,,0.58,IC50,Antiproliferative activity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25703297.0,
5118,1198455,1,1,,103177124,6167,Active,,,0.48,IC50,Antiproliferative activity against mouse B16F10 cells after 48 hrs by MTT assay,Confirmatory,25703297.0,
5119,1198456,1,2,,103177124,6167,Active,75053726.0,,1.34,IC50,Inhibition of bovine brain tubulin polymerization incubated for 20 mins by spectrophotometry,Confirmatory,25703297.0,
5120,1198456,1,2,,103177124,6167,Active,75053735.0,,1.34,IC50,Inhibition of bovine brain tubulin polymerization incubated for 20 mins by spectrophotometry,Confirmatory,25703297.0,
5121,1198456,1,2,,103177124,6167,Active,118573906.0,281555.0,1.34,IC50,Inhibition of bovine brain tubulin polymerization incubated for 20 mins by spectrophotometry,Confirmatory,25703297.0,
5122,1198463,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase after 24 hrs by flow cytometry (Rvb = 59.75%),Other,25703297.0,
5123,1198464,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at S phase after 24 hrs by flow cytometry (Rvb = 14.58%),Other,25703297.0,
5124,1198465,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase after 24 hrs by flow cytometry (Rvb = 25.67%),Other,25703297.0,
5125,1201719,1,2,,103177124,6167,Unspecified,2498443.0,3065.0,,IC50,Inhibition of recombinant human HDAC1 expressed in baculovirus infected insect High5 cells using Ac-Lys-Tyr-Lys (epsilon-acetyl)-AMC as substrate after 24 hrs by fluorescence assay,Confirmatory,25805446.0,
5126,1201720,1,2,,103177124,6167,Unspecified,68068066.0,3066.0,,IC50,Inhibition of recombinant human HDAC2 expressed in baculovirus infected insect High5 cells using Ac-Lys-Tyr-Lys (epsilon-acetyl)-AMC as substrate after 24 hrs by fluorescence assay,Confirmatory,25805446.0,
5127,1201721,1,2,,103177124,6167,Unspecified,3334210.0,8841.0,,IC50,Inhibition of recombinant human HDAC3 expressed in baculovirus infected insect High5 cells using Ac-Lys-Tyr-Lys (epsilon-acetyl)-AMC as substrate after 3 hrs by fluorescence assay,Confirmatory,25805446.0,
5128,1201722,1,1,,103177124,6167,Active,,,,,Cell cycle arrest in human HCT116 cells assessed as accumulation at G2/M phase at 10 to 20 nM after 24 hrs by flow cytometric analysis,Other,25805446.0,
5129,1201723,1,2,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5130,1201723,1,2,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5131,1201723,1,2,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5132,1201723,1,2,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5133,1201723,1,2,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5134,1201723,1,2,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5135,1201723,1,2,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5136,1201723,1,2,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5137,1201723,1,2,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5138,1201723,1,2,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5139,1201723,1,2,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5140,1201723,1,2,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5141,1201723,1,2,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5142,1201723,1,2,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5143,1201723,1,2,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5144,1201723,1,2,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of tubulin (unknown origin) polymerization at 10 uM,Other,25805446.0,
5145,1201724,1,1,,103177124,6167,Active,,,0.105,IC50,Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5146,1201725,1,1,,103177124,6167,Active,,,0.04,IC50,Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5147,1201726,1,2,,103177124,6167,Active,,,0.005,IC50,Cytotoxicity against human SW620 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5148,1201727,1,1,,103177124,6167,Active,,,0.013999999999999999,IC50,Cytotoxicity against human Hep3B cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5149,1201728,1,1,,103177124,6167,Active,,,0.027000000000000003,IC50,Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5150,1201729,1,1,,103177124,6167,Active,,,0.11,IC50,Cytotoxicity against human MHCC97H cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5151,1201730,1,1,,103177124,6167,Active,,,0.034,IC50,Cytotoxicity against human SNU5 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5152,1201731,1,1,,103177124,6167,Active,,,0.005,IC50,Cytotoxicity against human SNU16 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5153,1201732,1,1,,103177124,6167,Active,,,0.002,IC50,Cytotoxicity against human MKN45 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5154,1201733,1,1,,103177124,6167,Active,,,0.021,IC50,Cytotoxicity against human PANC1 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5155,1201734,1,2,,103177124,6167,Active,,,0.008,IC50,Cytotoxicity against human SJSA1 cells assessed as growth inhibition after 72 hrs by MTT assay,Confirmatory,25805446.0,
5156,1202430,1,2,,103177124,6167,Unspecified,20455316.0,7278.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5157,1202430,1,2,,103177124,6167,Unspecified,20455316.0,113457.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5158,1202430,1,2,,103177124,6167,Unspecified,20455322.0,84790.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5159,1202430,1,2,,103177124,6167,Unspecified,20455526.0,10381.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5160,1202430,1,2,,103177124,6167,Unspecified,55977474.0,10376.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5161,1202430,1,2,,103177124,6167,Unspecified,55977476.0,7277.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5162,1202430,1,2,,103177124,6167,Unspecified,55977480.0,10383.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5163,1202430,1,2,,103177124,6167,Unspecified,55977864.0,7846.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5164,1202430,1,2,,103177124,6167,Unspecified,56757569.0,203068.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5165,1202430,1,2,,103177124,6167,Unspecified,62903515.0,81027.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5166,1202430,1,2,,103177124,6167,Unspecified,68776070.0,84617.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5167,1202430,1,2,,103177124,6167,Unspecified,74761283.0,347733.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5168,1202430,1,2,,103177124,6167,Unspecified,74762137.0,7280.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5169,1202430,1,2,,103177124,6167,Unspecified,93141323.0,10382.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5170,1202430,1,2,,103177124,6167,Unspecified,182705285.0,347688.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5171,1202430,1,2,,103177124,6167,Unspecified,224471855.0,112714.0,,,Inhibition of tubulin (unknown origin) at 10 uM measured for 20 mins by turbidity method,Other,25874341.0,
5172,1203383,1,1,,103177124,6167,Unspecified,,,,,Antiproliferative activity in sea urchin embryo assessed as antimitotic activity by measuring cleavage alteration exposed for 8 to 20 mins after fertilization and 45 to 55 mins before first mitotic cycle completion measured 2.5 to 5.5 hrs after fertilization,Other,25768706.0,
5173,1203384,1,1,,103177124,6167,Unspecified,,,,,Antiproliferative activity in sea urchin embryo assessed as antimitotic activity by measuring cleavage arrest exposed for 8 to 20 mins after fertilization and 45 to 55 mins before first mitotic cycle completion measured 2.5 to 5.5 hrs after fertilization,Other,25768706.0,
5174,1203385,1,1,,103177124,6167,Unspecified,,,,,Antiproliferative activity in sea urchin embryo assessed as destabilization of microtubule by measuring embryo spinning after 15 mins to 20 hrs,Other,25768706.0,
5175,1203386,1,1,,103177124,6167,Active,,,,,Antiproliferative activity in sea urchin embryo assessed as destabilization of microtubule by tuberculate eggs after 15 mins to 20 hrs,Other,25768706.0,
5176,1203387,1,1,,103177124,6167,Active,,,0.132,GI50,Cytotoxicity against human NCI60 cells,Confirmatory,25768706.0,
5177,1205821,1,1,,103177124,6167,Active,,,,,Induction of microtubule destabilization in human A549 cells at 45 nM by DAPI-staining-based fluorescence microscopic analysis,Other,25815147.0,
5178,1221956,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
5179,1221957,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
5180,1221958,1,1,,103177124,6167,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis,Other,21051535.0,
5181,1221960,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5182,1221961,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5183,1221962,1,1,,103177124,6167,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5184,1221963,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5185,1221964,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5186,1221965,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979,Other,21051535.0,
5187,1221968,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
5188,1221969,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
5189,1221970,1,1,,103177124,6167,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
5190,1221971,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
5191,1221972,1,1,,103177124,6167,Unspecified,,,,,Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
5192,1221973,1,1,,103177124,6167,Unspecified,,,,,Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
5193,1221974,1,2,,103177124,6167,Unspecified,308153583.0,1244.0,,,Fold activity change at MRP2 ATPase (unknown origin) relative to control,Other,21051535.0,
5194,1221975,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
5195,1221976,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
5196,1221977,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of BCRP inhibitor Ko143,Other,21051535.0,
5197,1221978,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
5198,1221979,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
5199,1221980,1,1,,103177124,6167,Unspecified,,,,,Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK571,Other,21051535.0,
5200,1221982,1,1,,103177124,6167,Unspecified,,,,,Fraction absorbed in human,Other,21051535.0,
5201,1224818,1,1,,312344435,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
5202,1224819,1,1,,312344435,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
5203,1224820,1,1,,312344435,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
5204,1224821,1,1,,312344435,6167,Inactive,325495545.0,2101.0,1.3333,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
5205,1224822,1,1,,312344435,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
5206,1224823,1,1,,312344435,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
5207,1224824,1,1,,174007360,6167,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
5208,1224825,1,1,,174007360,6167,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
5209,1224834,3,1,,144208745,6167,Inconclusive,,,0.048,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5210,1224834,3,1,,144210899,6167,Inconclusive,,,0.0273,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5211,1224834,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
5212,1224835,1,1,,144208745,6167,Inconclusive,160794.0,,62.5391,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5213,1224835,1,1,,144210899,6167,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5214,1224835,1,1,,170465011,6167,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
5215,1224836,1,1,,144208745,6167,Inconclusive,,,0.1352,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5216,1224836,1,1,,144210899,6167,Inconclusive,,,0.2169,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5217,1224836,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5218,1224837,1,1,,144208745,6167,Inconclusive,,,0.1074,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5219,1224837,1,1,,144210899,6167,Inconclusive,,,0.1723,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5220,1224837,1,1,,170465011,6167,Inconclusive,,,0.0168,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
5221,1224838,1,1,,144208745,6167,Active,66775687.0,9970.0,0.0538,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5222,1224838,1,1,,144210899,6167,Active,66775687.0,9970.0,0.0863,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5223,1224838,1,1,,170465011,6167,Active,66775687.0,9970.0,0.0094,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5224,1224839,1,1,,144208745,6167,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5225,1224839,1,1,,144210899,6167,Inactive,66775687.0,9970.0,0.1369,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5226,1224839,1,1,,170465011,6167,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
5227,1224840,3,1,,144208745,6167,Active,,,2.404,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5228,1224840,3,1,,144210899,6167,Inconclusive,,,0.0433,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5229,1224840,3,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
5230,1224841,3,1,,144208745,6167,Inconclusive,325495545.0,2101.0,60.3853,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5231,1224841,3,1,,144210899,6167,Inactive,325495545.0,2101.0,0.1723,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5232,1224841,3,1,,170465011,6167,Inactive,325495545.0,2101.0,0.4731,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5233,1224842,3,1,,144208745,6167,Inactive,325495545.0,2101.0,60.3853,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5234,1224842,3,1,,144210899,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5235,1224842,3,1,,170465011,6167,Active,325495545.0,2101.0,0.3349,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
5236,1224843,1,1,,144208745,6167,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5237,1224843,1,1,,144210899,6167,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5238,1224843,1,1,,170465011,6167,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5239,1224844,1,1,,144208745,6167,Active,,,48.3976,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5240,1224844,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5241,1224844,1,1,,170465011,6167,Inconclusive,,,0.0034,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
5242,1224845,1,1,,144208745,6167,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5243,1224845,1,1,,144210899,6167,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5244,1224845,1,1,,170465011,6167,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
5245,1224846,1,1,,144208745,6167,Inconclusive,11995455.0,3091.0,60.928999999999995,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5246,1224846,1,1,,144210899,6167,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5247,1224846,1,1,,170465011,6167,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
5248,1224847,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5249,1224847,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5250,1224847,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
5251,1224848,3,1,,144208745,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5252,1224848,3,1,,144210899,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5253,1224848,3,1,,170465011,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5254,1224849,3,1,,144208745,6167,Inactive,325495545.0,2101.0,0.0678,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5255,1224849,3,1,,144210899,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5256,1224849,3,1,,170465011,6167,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
5257,1224857,2,1,,170465011,6167,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5258,1224857,2,1,,174007360,6167,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5259,1224857,2,1,,312344435,6167,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
5260,1224859,2,1,,90340644,6167,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5261,1224859,2,1,,170465011,6167,Inactive,,,14.1254,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5262,1224859,2,1,,174007360,6167,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
5263,1224863,1,1,,316919424,6167,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
5264,1224865,1,2,,50085974,6167,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
5265,1224867,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5266,1224867,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5267,1224867,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
5268,1224868,1,1,,144208745,6167,Active,,,0.0243,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5269,1224868,1,1,,144210899,6167,Inconclusive,,,0.0155,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5270,1224868,1,1,,170465011,6167,Inconclusive,,,0.003,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
5271,1224869,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5272,1224869,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5273,1224869,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
5274,1224870,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5275,1224870,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5276,1224870,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
5277,1224871,1,1,,144208745,6167,Active,,,34.2629,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5278,1224871,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5279,1224871,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
5280,1224872,1,1,,144208745,6167,Inconclusive,,,0.0966,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5281,1224872,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5282,1224872,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
5283,1224873,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5284,1224873,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5285,1224873,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
5286,1224874,1,1,,144208745,6167,Active,,,0.0216,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5287,1224874,1,1,,144210899,6167,Inconclusive,,,0.0155,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5288,1224874,1,1,,170465011,6167,Inconclusive,,,0.0027,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
5289,1224875,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5290,1224875,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5291,1224875,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
5292,1224876,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5293,1224876,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5294,1224876,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
5295,1224877,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5296,1224877,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5297,1224877,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
5298,1224878,1,1,,144208745,6167,Inconclusive,,,54.303000000000004,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5299,1224878,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5300,1224878,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
5301,1224879,1,1,,144208745,6167,Active,,,54.303000000000004,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5302,1224879,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5303,1224879,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
5304,1224880,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5305,1224880,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5306,1224880,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
5307,1224881,1,1,,144208745,6167,Inconclusive,,,30.5368,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5308,1224881,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5309,1224881,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
5310,1224882,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5311,1224882,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5312,1224882,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
5313,1224883,1,1,,144208745,6167,Active,,,60.928999999999995,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5314,1224883,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5315,1224883,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
5316,1224884,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5317,1224884,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5318,1224884,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
5319,1224885,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5320,1224885,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5321,1224885,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
5322,1224886,1,1,,144208745,6167,Inconclusive,,,0.0272,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5323,1224886,1,1,,144210899,6167,Inconclusive,,,0.0155,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5324,1224886,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
5325,1224887,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5326,1224887,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5327,1224887,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
5328,1224888,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5329,1224888,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5330,1224888,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
5331,1224889,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5332,1224889,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5333,1224889,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
5334,1224890,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5335,1224890,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5336,1224890,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
5337,1224892,1,1,,144208745,6167,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5338,1224892,1,1,,144210899,6167,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5339,1224892,1,1,,170465011,6167,Inconclusive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5340,1224893,1,1,,144208745,6167,Inconclusive,66775687.0,9970.0,0.0677535,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5341,1224893,1,1,,144210899,6167,Active,66775687.0,9970.0,0.07695880000000001,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5342,1224893,1,1,,170465011,6167,Inconclusive,66775687.0,9970.0,0.0188336,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
5343,1224894,1,1,,144208745,6167,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5344,1224894,1,1,,144210899,6167,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5345,1224894,1,1,,170465011,6167,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
5346,1224895,1,1,,144208745,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5347,1224895,1,1,,144210899,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5348,1224895,1,1,,170465011,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5349,1224896,1,1,,144208745,6167,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5350,1224896,1,1,,144210899,6167,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5351,1224896,1,1,,170465011,6167,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
5352,1224903,1,1,,318172594,6167,Inactive,,,,,Identification of CBX7 inhibitors - Primary Alpha Screen,Screening,,
5353,1224905,2,1,,121361086,6167,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5354,1224905,2,1,,121361086,6167,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
5355,1225534,1,1,,103177124,6167,Active,,,19.4,LD50,Toxicity in brine shrimp assessed as mortality,Confirmatory,25730346.0,
5356,1226622,1,1,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5357,1226622,1,1,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5358,1226622,1,1,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5359,1226622,1,1,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5360,1226622,1,1,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5361,1226622,1,1,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5362,1226622,1,1,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5363,1226622,1,1,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5364,1226622,1,1,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5365,1226622,1,1,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5366,1226622,1,1,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5367,1226622,1,1,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5368,1226622,1,1,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5369,1226622,1,1,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5370,1226622,1,1,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5371,1226622,1,1,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of acetylated tubulin accumulation in human HeLa cells at 30 to 100 nM after 6 hrs by Western blot analysis,Other,25938266.0,
5372,1226626,1,1,,103177124,6167,Active,20455316.0,7278.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5373,1226626,1,1,,103177124,6167,Active,20455316.0,113457.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5374,1226626,1,1,,103177124,6167,Active,20455322.0,84790.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5375,1226626,1,1,,103177124,6167,Active,20455526.0,10381.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5376,1226626,1,1,,103177124,6167,Active,55977474.0,10376.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5377,1226626,1,1,,103177124,6167,Active,55977476.0,7277.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5378,1226626,1,1,,103177124,6167,Active,55977480.0,10383.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5379,1226626,1,1,,103177124,6167,Active,55977864.0,7846.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5380,1226626,1,1,,103177124,6167,Active,56757569.0,203068.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5381,1226626,1,1,,103177124,6167,Active,62903515.0,81027.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5382,1226626,1,1,,103177124,6167,Active,68776070.0,84617.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5383,1226626,1,1,,103177124,6167,Active,74761283.0,347733.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5384,1226626,1,1,,103177124,6167,Active,74762137.0,7280.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5385,1226626,1,1,,103177124,6167,Active,93141323.0,10382.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5386,1226626,1,1,,103177124,6167,Active,182705285.0,347688.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5387,1226626,1,1,,103177124,6167,Active,224471855.0,112714.0,,,Inhibition of tubulin polymerization in human HeLa cells assessed as reduction of microtubule formation at 100 nM after 6 hrs by DAPI staining-based immunofluorescence assay,Other,25938266.0,
5388,1226630,1,1,,103177124,6167,Active,,,,,Cell cycle arrest in human HeLa cells assessed as accumulation at G2/M phase at 100 nM after 24 hrs by propidium iodide staining based flow cytometry,Other,25938266.0,
5389,1227902,1,1,,103177124,6167,Active,135435.0,100135051.0,,,Inhibition of porcine tubulin polymerization at 100 uM incubated for 1 hr by turbidimetry,Other,25685941.0,
5390,1227902,1,1,,103177124,6167,Active,135490.0,,,,Inhibition of porcine tubulin polymerization at 100 uM incubated for 1 hr by turbidimetry,Other,25685941.0,
5391,1229726,1,1,,103177124,6167,Active,,,8.1,LD50,Cytotoxicity in brine shrimp,Confirmatory,26039736.0,
5392,1231337,1,1,,103177124,6167,Active,135435.0,100135051.0,,,Inhibition of porcine brain tubulin polymerization at 3 uM measured for 1 hr by spectrofluorometer analysis,Other,25466200.0,
5393,1231337,1,1,,103177124,6167,Active,135490.0,,,,Inhibition of porcine brain tubulin polymerization at 3 uM measured for 1 hr by spectrofluorometer analysis,Other,25466200.0,
5394,1233599,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human M21 cells assessed as cells accumulation at subG1 phase at 24 nM after 24 hrs by flow cytometry (Rvb = 1.2%),Other,26069928.0,
5395,1233600,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human M21 cells assessed as cells accumulation at G0/G1 phase at 24 nM after 24 hrs by flow cytometry (Rvb = 54.5%),Other,26069928.0,
5396,1233601,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human M21 cells assessed as cells accumulation at S phase at 24 nM after 24 hrs by flow cytometry (Rvb = 22.2%),Other,26069928.0,
5397,1233602,1,1,,103177124,6167,Unspecified,,,,,Induction of cell cycle arrest in human M21 cells assessed as cells accumulation at G2/M phase at 24 nM after 24 hrs by flow cytometry (Rvb = 22.1%),Other,26069928.0,
5398,1233609,1,1,,103177124,6167,Active,,,,,Induction of microtubule depolymerization and cytoskeleton disruption in human M21 cells at 24 nM after 24 hrs by immunofluorescence assay,Other,26069928.0,
5399,1233617,1,1,,103177124,6167,Active,,,4.4,GI50,Growth inhibition of human A549 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay,Confirmatory,26070164.0,
5400,1233618,1,1,,103177124,6167,Active,,,10.5,GI50,Growth inhibition of human HepG2 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay,Confirmatory,26070164.0,
5401,1233619,1,1,,103177124,6167,Active,,,13.5,GI50,Growth inhibition of human MCF7 cells assessed as inhibition of cell proliferation after 24 hrs by MTT assay,Confirmatory,26070164.0,
5402,1233620,1,1,,103177124,6167,Active,75053726.0,,2.62,IC50,Inhibition of bovine brain tubulin polymerization extent after 20 mins by turbidimetrically,Confirmatory,26070164.0,
5403,1233620,1,1,,103177124,6167,Active,118573906.0,281555.0,2.62,IC50,Inhibition of bovine brain tubulin polymerization extent after 20 mins by turbidimetrically,Confirmatory,26070164.0,
5404,1233621,1,1,,103177124,6167,Inconclusive,75053726.0,,,,Displacement of [3H]colchicine from bovine brain tubulin at 5 uM,Other,26070164.0,
5405,1233621,1,1,,103177124,6167,Inconclusive,118573906.0,281555.0,,,Displacement of [3H]colchicine from bovine brain tubulin at 5 uM,Other,26070164.0,
5406,1235359,1,1,,103177124,6167,Active,,,0.0124,IC50,Antiproliferative activity against human KB cells after 72 hrs by methylene blue assay,Confirmatory,26160020.0,
5407,1235360,1,1,,103177124,6167,Active,,,0.0149,IC50,Antiproliferative activity against human MKN45 cells after 72 hrs by methylene blue assay,Confirmatory,26160020.0,
5408,1235363,1,1,,103177124,6167,Active,75053726.0,,1.9,IC50,Inhibition of bovine brain tubulin polymerization after 30 mins,Confirmatory,26160020.0,
5409,1235363,1,1,,103177124,6167,Active,118573906.0,281555.0,1.9,IC50,Inhibition of bovine brain tubulin polymerization after 30 mins,Confirmatory,26160020.0,
5410,1235364,1,1,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5411,1235364,1,1,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5412,1235364,1,1,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5413,1235364,1,1,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5414,1235364,1,1,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5415,1235364,1,1,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5416,1235364,1,1,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5417,1235364,1,1,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5418,1235364,1,1,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5419,1235364,1,1,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5420,1235364,1,1,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5421,1235364,1,1,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5422,1235364,1,1,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5423,1235364,1,1,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5424,1235364,1,1,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5425,1235364,1,1,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of 1 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5426,1235365,1,1,,103177124,6167,Unspecified,20455316.0,7278.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5427,1235365,1,1,,103177124,6167,Unspecified,20455316.0,113457.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5428,1235365,1,1,,103177124,6167,Unspecified,20455322.0,84790.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5429,1235365,1,1,,103177124,6167,Unspecified,20455526.0,10381.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5430,1235365,1,1,,103177124,6167,Unspecified,55977474.0,10376.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5431,1235365,1,1,,103177124,6167,Unspecified,55977476.0,7277.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5432,1235365,1,1,,103177124,6167,Unspecified,55977480.0,10383.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5433,1235365,1,1,,103177124,6167,Unspecified,55977864.0,7846.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5434,1235365,1,1,,103177124,6167,Unspecified,56757569.0,203068.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5435,1235365,1,1,,103177124,6167,Unspecified,62903515.0,81027.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5436,1235365,1,1,,103177124,6167,Unspecified,68776070.0,84617.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5437,1235365,1,1,,103177124,6167,Unspecified,74761283.0,347733.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5438,1235365,1,1,,103177124,6167,Unspecified,74762137.0,7280.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5439,1235365,1,1,,103177124,6167,Unspecified,93141323.0,10382.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5440,1235365,1,1,,103177124,6167,Unspecified,182705285.0,347688.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5441,1235365,1,1,,103177124,6167,Unspecified,224471855.0,112714.0,,,Displacement of 82.8 +/- 0.9 uM of [3H]colchicine from biotin-labeled tubulin (unknown origin) after 2 hrs by scintillation proximity assay,Other,26160020.0,
5442,1236572,1,1,,103177124,6167,Active,,,0.096,IC50,Cytotoxicity against human NCI-ADR-RES cells expressing ABCB1,Confirmatory,25811651.0,
5443,1236573,1,1,,103177124,6167,Active,,,0.00036,IC50,Cytotoxicity against human NCI/ADR cells,Confirmatory,25811651.0,
5444,1236600,1,1,,103177124,6167,Active,,,5.023,IC50,Inhibition of pig microtubule polymerization after 30 mins by turbidimetric assay,Confirmatory,25937236.0,
5445,1236601,1,1,,103177124,6167,Active,20455316.0,7278.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5446,1236601,1,1,,103177124,6167,Active,20455316.0,113457.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5447,1236601,1,1,,103177124,6167,Active,20455322.0,84790.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5448,1236601,1,1,,103177124,6167,Active,20455526.0,10381.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5449,1236601,1,1,,103177124,6167,Active,55977474.0,10376.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5450,1236601,1,1,,103177124,6167,Active,55977476.0,7277.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5451,1236601,1,1,,103177124,6167,Active,55977480.0,10383.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5452,1236601,1,1,,103177124,6167,Active,55977864.0,7846.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5453,1236601,1,1,,103177124,6167,Active,56757569.0,203068.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5454,1236601,1,1,,103177124,6167,Active,62903515.0,81027.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5455,1236601,1,1,,103177124,6167,Active,68776070.0,84617.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5456,1236601,1,1,,103177124,6167,Active,74761283.0,347733.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5457,1236601,1,1,,103177124,6167,Active,74762137.0,7280.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5458,1236601,1,1,,103177124,6167,Active,93141323.0,10382.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5459,1236601,1,1,,103177124,6167,Active,182705285.0,347688.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5460,1236601,1,1,,103177124,6167,Active,224471855.0,112714.0,,,Binding affinity to tubulin in human HepG2 cells at 5 uM after 4 hrs by EBI competition assay,Other,25937236.0,
5461,1237706,1,1,,103177124,6167,Active,20455316.0,7278.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5462,1237706,1,1,,103177124,6167,Active,20455316.0,113457.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5463,1237706,1,1,,103177124,6167,Active,20455322.0,84790.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5464,1237706,1,1,,103177124,6167,Active,20455526.0,10381.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5465,1237706,1,1,,103177124,6167,Active,55977474.0,10376.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5466,1237706,1,1,,103177124,6167,Active,55977476.0,7277.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5467,1237706,1,1,,103177124,6167,Active,55977480.0,10383.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5468,1237706,1,1,,103177124,6167,Active,55977864.0,7846.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5469,1237706,1,1,,103177124,6167,Active,56757569.0,203068.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5470,1237706,1,1,,103177124,6167,Active,62903515.0,81027.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5471,1237706,1,1,,103177124,6167,Active,68776070.0,84617.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5472,1237706,1,1,,103177124,6167,Active,74761283.0,347733.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5473,1237706,1,1,,103177124,6167,Active,74762137.0,7280.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5474,1237706,1,1,,103177124,6167,Active,93141323.0,10382.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5475,1237706,1,1,,103177124,6167,Active,182705285.0,347688.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5476,1237706,1,1,,103177124,6167,Active,224471855.0,112714.0,3.2,IC50,Inhibition of tubulin (unknown origin) assembly preincubated for 15 mins followed by GTP addition measured for 20 mins by spectrophotometric analysis,Confirmatory,26132075.0,
5477,1237707,1,1,,103177124,6167,Active,,,0.005,IC50,Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,26132075.0,
5478,1237723,1,1,,103177124,6167,Active,,,0.03,IC50,Cytotoxicity against human OVCAR8 cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,26132075.0,
5479,1237724,1,1,,103177124,6167,Active,,,0.42,IC50,Cytotoxicity against Pgp overexpressing human NCI-ADR-RES cells assessed as growth inhibition after 48 hrs by SRB assay,Confirmatory,26132075.0,
5480,1237725,1,1,,103177124,6167,Active,,,0.011000000000000001,IC50,Cytotoxicity against human MESSA cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay,Confirmatory,26132075.0,
5481,1237726,1,1,,103177124,6167,Active,,,0.32899999999999996,IC50,Cytotoxicity against human MESSA/DX5 cells assessed as growth inhibition after 72 hrs by CellTiter-Glo assay,Confirmatory,26132075.0,
5482,1238299,1,1,,103177124,6167,Unspecified,,,,,Inhibition of VEGF production in human HT-29 cells assessed as VEGF level at 5 ug/ml incubated for 72 hrs by ELISA method relative to control,Other,26094121.0,
5483,1238300,1,1,,103177124,6167,Unspecified,,,,,Inhibition of VEGF mRNA expression in human HT-29 cells assessed as VEGF mRNA level at 5 ug/ml incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5484,1238301,1,1,,103177124,6167,Unspecified,,,,,Inhibition of hTERT mRNA expression in human HT-29 cells assessed as hTERT mRNA level at 5 ug/ml incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5485,1238302,1,1,,103177124,6167,Unspecified,,,,,Inhibition of Myc mRNA expression in human HT-29 cells assessed as Myc mRNA level at 5 ug/ml incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5486,1238303,1,1,,103177124,6167,Unspecified,,,,,Inhibition of VEGF mRNA expression in human HT-29 cells assessed as VEGF mRNA level at at 10 uM incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5487,1238304,1,1,,103177124,6167,Unspecified,,,,,Inhibition of VEGF mRNA expression in human HT-29 cells assessed as VEGF mRNA level at at 50 nM incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5488,1238305,1,1,,103177124,6167,Unspecified,,,,,Inhibition of hTERT mRNA expression in human HT-29 cells assessed as hTERT mRNA level at at 10 uM incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5489,1238306,1,1,,103177124,6167,Unspecified,,,,,Inhibition of hTERT mRNA expression in human HT-29 cells assessed as hTERT mRNA level at at 50 nM incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5490,1238307,1,1,,103177124,6167,Unspecified,,,,,Inhibition of Myc mRNA expression in human HT-29 cells assessed as Myc mRNA level at at 10 uM incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5491,1238308,1,1,,103177124,6167,Unspecified,,,,,Inhibition of Myc mRNA expression in human HT-29 cells assessed as Myc mRNA level at at 50 nM incubated for 48 hrs by RT-PCR method relative to control,Other,26094121.0,
5492,1239200,1,1,,103177124,6167,Active,20455316.0,7278.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5493,1239200,1,1,,103177124,6167,Active,20455316.0,113457.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5494,1239200,1,1,,103177124,6167,Active,20455322.0,84790.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5495,1239200,1,1,,103177124,6167,Active,20455526.0,10381.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5496,1239200,1,1,,103177124,6167,Active,55977474.0,10376.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5497,1239200,1,1,,103177124,6167,Active,55977476.0,7277.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5498,1239200,1,1,,103177124,6167,Active,55977480.0,10383.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5499,1239200,1,1,,103177124,6167,Active,55977864.0,7846.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5500,1239200,1,1,,103177124,6167,Active,56757569.0,203068.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5501,1239200,1,1,,103177124,6167,Active,62903515.0,81027.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5502,1239200,1,1,,103177124,6167,Active,68776070.0,84617.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5503,1239200,1,1,,103177124,6167,Active,74761283.0,347733.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5504,1239200,1,1,,103177124,6167,Active,74762137.0,7280.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5505,1239200,1,1,,103177124,6167,Active,93141323.0,10382.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5506,1239200,1,1,,103177124,6167,Active,182705285.0,347688.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5507,1239200,1,1,,103177124,6167,Active,224471855.0,112714.0,7.8,IC50,Inhibition of brain tubulin (unknown origin) polymerization measured up to 15 to 30 mins,Confirmatory,26226379.0,
5508,1239260,1,1,,103177124,6167,Active,20455316.0,7278.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5509,1239260,1,1,,103177124,6167,Active,20455316.0,113457.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5510,1239260,1,1,,103177124,6167,Active,20455322.0,84790.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5511,1239260,1,1,,103177124,6167,Active,20455526.0,10381.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5512,1239260,1,1,,103177124,6167,Active,55977474.0,10376.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5513,1239260,1,1,,103177124,6167,Active,55977476.0,7277.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5514,1239260,1,1,,103177124,6167,Active,55977480.0,10383.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5515,1239260,1,1,,103177124,6167,Active,55977864.0,7846.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5516,1239260,1,1,,103177124,6167,Active,56757569.0,203068.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5517,1239260,1,1,,103177124,6167,Active,62903515.0,81027.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5518,1239260,1,1,,103177124,6167,Active,68776070.0,84617.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5519,1239260,1,1,,103177124,6167,Active,74761283.0,347733.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5520,1239260,1,1,,103177124,6167,Active,74762137.0,7280.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5521,1239260,1,1,,103177124,6167,Active,93141323.0,10382.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5522,1239260,1,1,,103177124,6167,Active,182705285.0,347688.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5523,1239260,1,1,,103177124,6167,Active,224471855.0,112714.0,2.21,IC50,Displacement of [3H]-colchicine from tubulin (unknown origin) preincubated with protein for 1 hr followed by [3H]-colchicine addition measured after 3 hrs by scintillation counting analysis,Confirmatory,26241032.0,
5524,1245422,1,1,,103177124,6167,Unspecified,,,,,Growth inhibition of human K562 cells at 10 uM incubated for 24 hrs by trypan blue dye exclusion assay,Other,26344588.0,
5525,1245423,1,1,,103177124,6167,Active,,,0.02,IC50,Growth inhibition of human K562 cells incubated for 24 hrs by trypan blue dye exclusion assay,Confirmatory,26344588.0,
5526,1245424,1,1,,103177124,6167,Active,,,0.017,IC50,Cytotoxicity against human HuDe cells incubated for 72 hrs by MTT assay,Confirmatory,26344588.0,
5527,1245425,1,1,,103177124,6167,Unspecified,,,,,"Selectivity index, ratio of IC50 for human HuDe cells to IC50 human K562 cells",Other,26344588.0,
5528,1259241,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5529,1259241,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5530,1259241,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
5531,1259242,1,1,,144208745,6167,Inconclusive,,,85.2965,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5532,1259242,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5533,1259242,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
5534,1259243,1,1,,144208745,6167,Inconclusive,124375976.0,367.0,67.7534,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5535,1259243,1,1,,144210899,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5536,1259243,1,1,,170465011,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
5537,1259244,1,1,,144208745,6167,Active,348019627.0,2099.0,26.9731,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5538,1259244,1,1,,144210899,6167,Inconclusive,348019627.0,2099.0,0.0545,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5539,1259244,1,1,,170465011,6167,Inconclusive,348019627.0,2099.0,0.0298,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
5540,1259247,1,1,,144208745,6167,Active,124375976.0,367.0,60.3853,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5541,1259247,1,1,,144210899,6167,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5542,1259247,1,1,,170465011,6167,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
5543,1259248,1,1,,144208745,6167,Active,348019627.0,2099.0,25.9576,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5544,1259248,1,1,,144210899,6167,Active,348019627.0,2099.0,2.25385,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5545,1259248,1,1,,170465011,6167,Inconclusive,348019627.0,2099.0,0.0298493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
5546,1259252,1,1,,174007360,6167,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
5547,1259253,1,1,,174007360,6167,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
5548,1259255,1,1,,174007360,6167,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
5549,1259256,1,1,,174007360,6167,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
5550,1259310,1,1,,321946386,6167,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5551,1259310,1,1,,332950377,6167,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5552,1259310,1,1,,332950583,6167,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5553,1259310,1,1,,332950587,6167,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5554,1259310,1,1,,332950612,6167,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5555,1259310,1,1,,333472243,6167,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
5556,1259313,1,1,,49718107,6167,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
5557,1259318,1,1,,50085974,6167,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
5558,1259344,1,1,,144204498,6167,Active,,,0.7079,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
5559,1259354,1,1,,348454491,6167,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
5560,1259355,1,1,,144204498,6167,Inconclusive,,,0.0794,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
5561,1259356,1,1,,144204498,6167,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
5562,1259364,1,1,,144208745,6167,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5563,1259364,1,1,,144210899,6167,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5564,1259364,1,1,,170465011,6167,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
5565,1259365,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5566,1259365,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5567,1259365,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
5568,1259366,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5569,1259366,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5570,1259366,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5571,1259367,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5572,1259367,1,1,,144210899,6167,Active,,,0.0486,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5573,1259367,1,1,,170465011,6167,Active,,,0.3758,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
5574,1259368,1,1,,144208745,6167,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5575,1259368,1,1,,144210899,6167,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5576,1259368,1,1,,170465011,6167,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5577,1259369,1,1,,144208745,6167,Inconclusive,109731339.0,2737.0,0.0135,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5578,1259369,1,1,,144210899,6167,Active,109731339.0,2737.0,0.0017,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5579,1259369,1,1,,170465011,6167,Active,109731339.0,2737.0,0.0024,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
5580,1259370,2,2,,124637733,6167,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5581,1259370,2,2,,124637733,6167,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5582,1259370,2,2,,124637733,6167,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
5583,1259377,1,1,,144208745,6167,Inconclusive,54288833.0,2100.0,30.2644,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5584,1259377,1,1,,144210899,6167,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5585,1259377,1,1,,170465011,6167,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5586,1259378,1,1,,144208745,6167,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5587,1259378,1,1,,144210899,6167,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5588,1259378,1,1,,170465011,6167,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
5589,1259379,1,1,,144208745,6167,Inconclusive,,,0.2404,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5590,1259379,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5591,1259379,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5592,1259380,1,1,,144208745,6167,Active,,,26.9731,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5593,1259380,1,1,,144210899,6167,Inconclusive,,,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5594,1259380,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5595,1259381,1,1,,144208745,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5596,1259381,1,1,,144210899,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5597,1259381,1,1,,170465011,6167,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
5598,1259382,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5599,1259382,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5600,1259382,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
5601,1259383,1,1,,144208745,6167,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5602,1259383,1,1,,144210899,6167,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5603,1259383,1,1,,170465011,6167,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
5604,1259384,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5605,1259384,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5606,1259384,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
5607,1259385,1,1,,144208745,6167,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5608,1259385,1,1,,144210899,6167,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5609,1259385,1,1,,170465011,6167,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
5610,1259386,1,1,,144208745,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5611,1259386,1,1,,144210899,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5612,1259386,1,1,,170465011,6167,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
5613,1259387,1,1,,144208745,6167,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5614,1259387,1,1,,144210899,6167,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5615,1259387,1,1,,170465011,6167,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
5616,1259388,1,1,,144208745,6167,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5617,1259388,1,1,,144210899,6167,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5618,1259388,1,1,,170465011,6167,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
5619,1259389,1,1,,124637733,6167,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
5620,1259390,1,1,,144208745,6167,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5621,1259390,1,1,,144210899,6167,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5622,1259390,1,1,,170465011,6167,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5623,1259391,1,1,,144208745,6167,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5624,1259391,1,1,,144210899,6167,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5625,1259391,1,1,,170465011,6167,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
5626,1259392,1,1,,144208745,6167,Active,109731339.0,2737.0,0.011594799999999999,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5627,1259392,1,1,,144210899,6167,Inconclusive,109731339.0,2737.0,0.00968854,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5628,1259392,1,1,,170465011,6167,Active,109731339.0,2737.0,0.0118832,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
5629,1259393,1,1,,144208745,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5630,1259393,1,1,,144210899,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5631,1259393,1,1,,170465011,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
5632,1259394,1,1,,144208745,6167,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5633,1259394,1,1,,144210899,6167,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5634,1259394,1,1,,170465011,6167,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5635,1259395,1,1,,144208745,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5636,1259395,1,1,,144210899,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5637,1259395,1,1,,170465011,6167,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
5638,1259396,1,1,,144208745,6167,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5639,1259396,1,1,,144210899,6167,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5640,1259396,1,1,,170465011,6167,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
5641,1259400,1,1,,170465011,6167,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
5642,1259401,1,1,,144208745,6167,Inconclusive,325495545.0,2101.0,0.852965,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5643,1259401,1,1,,144210899,6167,Inconclusive,325495545.0,2101.0,0.740614,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5644,1259401,1,1,,170465011,6167,Inconclusive,325495545.0,2101.0,2.87255,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5645,1259402,1,1,,144208745,6167,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5646,1259402,1,1,,144210899,6167,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5647,1259402,1,1,,170465011,6167,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
5648,1259403,1,1,,144208745,6167,Inconclusive,325495545.0,2101.0,53.8185,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5649,1259403,1,1,,144210899,6167,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5650,1259403,1,1,,170465011,6167,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5651,1259404,1,1,,144208745,6167,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5652,1259404,1,1,,144210899,6167,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5653,1259404,1,1,,170465011,6167,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
5654,1259407,1,1,,363898641,6167,Active,,,,,CCRIS mutagenicity studies,Other,,
5655,1259408,1,1,,363894934,6167,Active,,,,,GENE-TOX mutagenicity studies,Other,,
5656,1259415,1,1,,50085974,6167,Active,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
5657,1259416,1,2,,340080858,6167,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5658,1259416,1,2,,375174791,6167,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
5659,1259421,1,1,,340080858,6167,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5660,1259421,1,1,,375174791,6167,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
5661,1259423,1,2,,354782443,6167,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5662,1259423,1,2,,354938904,6167,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
5663,1259423,1,2,,354998418,6167,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
